Total synthesis and study of the antilipoperoxidant peridinin, synthesis of versatile MIDA boronate building blocks, and a general strategy for the synthesis of polyenes by Woerly, Eric
  
 
 
 
TOTAL SYNTHESIS AND STUDY OF THE ANTILIPOPEROXIDANT PERIDININ, 
SYNTHESIS OF VERSATILE MIDA BORONATE BUILDING BLOCKS, 
AND A GENERAL STRATEGY FOR THE SYNTHESIS OF POLYENES 
 
 
 
 
 
BY 
 
ERIC M. WOERLY 
 
 
 
 
 
 
 
DISSERTATION 
 
Submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy in Chemistry 
in the Graduate College of the 
University of Illinois at Urbana-Champaign, 2013 
 
 
 
 
Urbana, Illinois 
 
 
Doctoral Committee: 
 
 Associate Professor Martin D. Burke, Chair 
 Professor John A. Katzenellenbogen 
 Professor John F. Hartwig 
 Professor Jeffery S. Moore 
ii 
 
ABSTRACT 
Taking advantage of the inherent modularity present in the majority of small molecule 
natural products, we envision that a building block based approach involving the iterative cross-
coupling of MIDA boronate containing molecules can be a universal platform for the preparation 
of small molecules. Guided by this strategy we completed an efficient, flexible, and fully 
stereocontrolled synthesis of the carotenoid natural product peridinin. This natural product 
inspired the development of new methodology, including the stereocontrolled Suzuki-Miyaura 
cross-coupling of haloallenes and the transesterification of boronic esters to MIDA boronates and 
MIDA boronates to boronic esters. Utilizing this synthetic material, we probed the 
antilipoperoxidant activity of peridinin in a chemically defined liposome based system and 
discovered that peridinin is far more potent than the leading carotenoid gold standard 
astaxanthin. Detailed mechanistic studies revealed that this superior activity is derived from an 
early quench of chain propagating lipid peroxyl radicals. 
Our work with peridinin demonstrated that synthesis is often the rate determining step in 
studying the function of a molecule. In order to help shift this rate determining step from 
synthesis to a study of function, we are interested in identifying recurring structural motifs 
present in small molecule natural products and transforming these motifs into MIDA boronate 
building blocks. Toward this goal, cis-olefins, 1,1-disubstituted olefins, and the 2-pyridyl moiety 
are three highly recurring motifs. To gain access to these frameworks, we have developed 
scalable routes to three MIDA boronate building blocks: (Z)-2-bromovinyl MIDA boronate, 1-
bromovinyl MIDA boronate, and 2-pyridyl MIDA boronate. We have demonstrated that these 
building blocks can be readily functionalized to provide a diverse range of products. 
Building on this theme, we developed a systematic approach for identifying additional 
recurring structural motifs present in natural products and transform them to a collection of 
MIDA boronate building blocks. As a case study for how this can be achieved, we have 
identified polyene natural products as an excellent opportunity for testing this concept. We 
identified a collection of just 12 bifunctional haloalkenyl MIDA boronate building blocks would 
be required to prepare the polyene motifs found in >75% of all polyene natural products that 
have ever been isolated. Applying this same approach to other classes of small molecule natural 
products, pharmaceuticals, and materials has the potential to provide a roadmap towards a 
universal approach to the synthesis of small molecules and expedite access to their functions. 
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CHAPTER 1 
INTRODUCTION 
 
Eric M. Woerly and Martin D. Burke 
 
1-1 SYNTHESIS OF NATURAL PRODUCTS VIA ITERATIVE PATHWAYS  
Most of the molecules found in living systems are highly modular in their constitution. 
This is because Nature utilizes a common strategy of iterative coupling of bifunctional building 
blocks to assemble the majority of these compounds. For example, polypeptides are made up of 
amino acids, oligonucleotides consist of nucleotide monomers, and oligosaccharides are 
composed of individual sugar units (Figure 1-1).
1
 This iterative approach enables the assembly of 
each of these important classes of biomolecules in a robust fashion, using common starting 
materials and biosynthetic machinery, and with outstanding flexibility. 
 
 
Figure 1-1. Polypeptides, oligonucleotides, and oligosaccharides are all derived from the iterative coupling of 
bifunctional building blocks. 
 
 Interestingly, Nature also uses the iterative coupling of bifunctional building blocks to 
biosynthesize most small molecule natural products. For example, malonyl-CoA or 
methylmalonyl-CoA units are assembled into polyketides,
2
 isopentenyl pyrophosphate or 
dimethylallyl pyrophosphate units are brought together for polyterpenes,
3
 malonyl-CoA units are 
recursively linked to generate fatty acids,
4
 amino acids are iteratively united for nonribosomal 
peptides,
5
 and a variety of other classes of small molecules, such as polyphenylpropanoids, are 
derived from the coupling of building blocks ultimately derived from shikimic acid (Figure 1-2). 
2 
 
The consequence of this shared biosynthetic logic is that, like their polypeptide, 
oligonucleotides, and oligosaccharide counterparts, most small molecule natural products are 
highly modular in their constitution. 
 
 
Figure 1-2. Polyketides, polyterpenes, fatty acids, nonribosomal peptides, and polyphenylpropanoids are similarly 
derived from the iterative coupling of bifunctional building blocks. 
  
Nature’s iterative coupling strategy has been successfully mimicked in the laboratory in a 
general way for the synthetic preparation of polypeptides,
6
 oligonucleotides,
7
 and 
oligosaccharides.
8
 In each case, a suitably protected form of a bifunctional building block is 
coupled to the growing end of the chain and a deprotection sequence is then executed (Figure 1-
3). Such cycles of coupling and deprotection are iterated until the desired molecule is 
synthesized.  
 
3 
 
 
Figure 1-3. A general strategy for the iterative synthesis of small molecule natural products. 
 
For example, in the solid-phase synthesis of polypeptides the C-terminus of a growing 
polypeptide chain is covalently linked to a solid support.
9
 Amino acid building blocks having 
their N-terminus protected, frequently as the Fmoc or Boc derivative, are then coupled to the 
resin supported peptide. A deprotection sequence reveals a free N-terminus, enabling another 
iteration of this process (Figure 1-4, left). Similar procedures have been developed for the 
efficient synthesis of oligonucleotides
10
 (Figure 1-4, middle) and oligosaccharides
11
 (Figure 1-4, 
right). Importantly, as in Nature, these sequences allow for the controlled construction of 
complex molecular frameworks. Due to the powerfully simple nature of this iterative coupling 
approach, these processes are now increasingly performed in a fully automated fashion. With 
peptides and oligonucleotides, such automation has made it possible for nonchemists to routinely 
prepare these types of compounds for a wide range of applications. As a result, the function, not 
the synthesis, of these molecules is the main focus of research in these areas. 
 
 
Figure 1-4. Strategies for the iterative synthesis of peptides, nucleotides, and saccharides. 
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 In stark contrast, it is typical for a synthetic chemist to develop a unique, highly 
customized strategy for each small molecule that is targeted for preparation in the laboratory. As 
a result, the synthesis of small molecules remains a relatively complex, unsystematized, and 
inflexible process that is practiced almost exclusively by highly trained specialists. However, the 
inherent modularity of many small molecule targets suggests that a unified strategy for their 
construction through the iterative assembly of bifunctional building blocks may exist. Taking 
advantage of the common structural motifs that appear in certain polyketide, polyterpene, fatty 
acid, nonribosomal peptide, and polyphenylpropanoid frameworks, customized iterative 
strategies have been developed for the synthesis of these five classes of small molecule natural 
products. This chapter will highlight classic contributions in each of these areas, as well as 
discuss recent advancements seeking to develop a common, general approach for the 
construction of most small molecules via the iterative cross-coupling of bifunctional haloboronic 
acids masked as the corresponding N-methyliminodiacetic acid (MIDA) boronates. This 
introductory chapter will provide background for the projects described in subsequent chapters, 
specifically the use of the MIDA boronate platform to complete a total synthesis of the 
carotenoid natural product peridinin, the preparation and utility of a number of MIDA boronate 
building blocks, and the development of a general strategy for the synthesis of polyenes. Such 
approaches have the potential to help shift the rate limiting step in small molecule science from 
synthesizing these molecules to understanding and maximally harnessing their functional 
potential. 
 
1-2 ITERATIVE STRATEGIES FOR THE SYNTHESIS OF POLYKETIDE NATURAL 
PRODUCTS 
Polyketide based small molecules are highly abundant in Nature.
12
 The structures of these 
compounds include both cyclic and acyclic frameworks (Figure 1-5). A number of polyketide 
based natural products have been identified as important pharmaceutical agents, including 
antibiotics, antifungals, chemotherapies, and immunosuppressants.
13
 As a result, the efficient and 
modular synthesis of polyketide targets is highly desirable. One approach to enable such a goal is 
to identify motifs that are highly conserved amongst numerous polyketides and use these motifs 
as building blocks around which the target can be constructed. Developing synthetic strategies to 
gain access to these building blocks, and demonstrating that these strategies can be utilized in 
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diverse settings for the preparation of polyketide natural products are also important 
considerations. A common substructure that is highly recurring in polyketide natural products is 
the stereotetrad, consisting of four contiguous stereogenic centers in any diastereomeric 
combination.
14
 Example natural products containing the stereotetrad unit are brasilinolide A, 
erythromycin A, and pironetin (Figure 1-5). Numerous strategies have been developed for the 
synthesis of stereotetrads.
15
 Of particular interest are methodologies that allow for the iterative 
assembly of these building blocks, reminiscent of the approach nature takes to the preparation of 
polyketide natural products. Herein, the contributions of Evans and Paterson are highlighted for 
the construction of polypropionate units using iterative, aldol-based approaches and the 
application toward the synthesis of natural and unnatural polyketides. 
 
 
Figure 1-5. Structures of representative cyclic and acyclic polyketide natural products. 
 
Auxiliary based aldol reactions represent a powerful method for the construction of 
carbon-carbon bonds in a stereocontrolled fashion.
16
 The Evans aldol reaction utilizes an 
oxazolidinone based chiral auxiliary to provide syn aldol products with outstanding levels of 
diastereoselectivity.
17
 The absolute stereochemistry of the product is controlled by the identity of 
the chiral auxiliary. Commonly employed auxiliaries are derived from (S)-valinol and (1S,2R)-
norephedrine. Moreover, the Evans aldol reaction has the capacity to be performed in an iterative 
fashion to provide access to polypropionate frameworks with outstanding levels of stereocontrol 
(Figure 1-6). Specifically, enolates can serve as bifunctional building blocks in this iterative 
aldol cycle. These building blocks have two differentiated termini; a reactive, nucleophilic 
enolate and an electrophilic aldehyde masked in the acid oxidation state by the chiral auxiliary. 
6 
 
In such an iterative cycle, first, reaction of the enolate with an aldehyde provides the aldol 
product. Second, reduction of the auxiliary bearing terminus, typically with protection of the 
newly formed hydroxyl group, can regenerate the aldehyde functionality. The newly generated 
aldehyde can then serve as a substrate for subsequent rounds of aldol addition reactions. 
 
 
Figure 1-6. Iterative Evans aldol reaction. 
 
Reggelin and coworkers have demonstrated the synthesis of polyketide frameworks using 
iterative Evans aldol reactions on a solid support.
18
 Specifically, N-propionyloxazolidinone 1.1 
was converted to the Z-enolate 1.2 by treating with Bu2BOTf and Et3N. Then, reaction with a 
resin bound aldehyde 1.3 provided a solid supported aldol product 1.4 (Scheme 1-1). Cleavage of 
the oxazolidinone and conversion to a thioester 1.5 provided an intermediate that could be 
readily protected and converted to a new aldehyde 1.6. The newly generated aldehyde then 
served as a substrate for subsequent rounds of aldol addition reactions. Using this method, 
complex polyketide 1.7 was prepared in highly diastereomerically enriched form. 
 
 
Scheme 1-1. Solid supported iterative Evans aldol reaction. 
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While the above example highlights the preparation of syn-aldol products through the 
Evans aldol reaction, Evans and coworkers have also reported the preparation of anti-aldol 
products using the same chiral auxiliary approach.
19
 In this method, catalytic amounts of MgCl2 
in the presence of Et3N and chlorotrimethylsilane provided the anti-aldol products in high 
diastereoselectivity. As a result, both syn- and anti-aldol products are accessible from the same 
set of N-acyloxazolidinones. The products generated in the Evans aldol reaction are highly 
versatile reagents in small molecule synthesis. Following the aldol reaction, the chiral auxiliary 
can be removed under a variety of conditions, including hydrolysis, transesterification, 
transamination, or reduction.
20
 
Several modifications to the Evans aldol reaction have been reported.
21
 One such 
modification is the thiazolidinethione based aldol reaction developed by Crimmins and 
coworkers.
22
 In comparison to an oxazolidinone, the thiazolidinethione group can easily be 
removed under mild conditions, allowing facile regeneration of the aldehyde functionality in one 
step, thus further enabling iterative coupling cycles. An additional advancement is that this 
method allows for the preparation of both “Evans” or “non-Evans” syn aldol products from a 
common acyloxazolidinethione precursor. Specifically, a titanium derived enolate of an 
acyloxazolidinethione can be used to access these products (Scheme 1-2). This is accomplished 
by choosing the correct stoichiometry of the amine base and titanium reagent to obtain the 
desired product.
23
 For example, acyloxazolidinethione 1.8 can yield the “Evans” syn product 1.9 
using 1.0 equivalents of TiCl4 and 2.5 equivalents of (-)-sparteine. In contrast, the “non-Evans” 
syn product 1.10 is obtained from the same starting material by using 2.0 equivalents of TiCl4 
and 1.0 equivalents of (-)-sparteine. This feature enables the synthesis of a diverse range of aldol 
products from a common auxiliary. 
 
 
Scheme 1-2. Crimmins thiazolidinethione aldol reaction. 
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 Moreover, the modified Evans aldol reactions can also be utilized in an iterative fashion 
for the construction of polyketide fragments. Crimmins and coworkers utilized a combination of 
the “Evans” and “non-Evans” syn titanium enolate derived acyloxazolidinethione aldol reactions 
described above to complete a formal synthesis of the polyketide natural product 6-
deoxyerythronolide B 1.11 (Scheme 1-3).
24
 A “non-Evans” syn aldol reaction between 
acyloxazolidinethione 1.12 and propionaldehyde 1.13 provided aldol product 1.14. Protection of 
the resulting alcohol as the silyl ether and removal of the chiral auxiliary by reductive cleavage 
provided aldehyde 1.15. Another iteration of the aldol reaction cycle in the form of an “Evans” 
syn aldol reaction was then completed between 1.12 and 1.15, providing product 1.16. Protection 
of the resulting alcohol and cleavage of the auxiliary provided aldehyde 1.17. This aldehyde was 
then reacted with 1.12 in a “non-Evans” syn aldol reaction to provide 1.18. This intermediate was 
further elaborated to 1.11. As demonstrated by these examples, iteration of auxiliary based aldol 
reactions can be harnessed to provide rapid access to the stereochemically rich polyketide motifs 
commonly found in many natural and unnatural polyketide frameworks.  
 
 
Scheme 1-3. Crimmins’ synthesis of polyketide natural product 6-deoxyerythronolide B using iterative aldol 
reactions. 
 
 As described above, the iterative Evans aldol reaction consists of a diastereoselective 
aldol reaction followed by auxiliary cleavage and regeneration of an aldehyde for repetition of 
the cycle. An alternative approach to the iteration of this reaction is to perform an extended 
Evans aldol reaction. In particular, oxidation of β-alcohol 1.19 forms β-keto imide 1.20, 
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providing a starting material for the efficient construction of various polypropionate frameworks. 
Enolization of 1.20 under different conditions enables the formation of diastereomeric 
products.
25
 For example, the enolate generated from treating 1.20 with Sn(OTf)2 and Et3N can be 
trapped with propionaldehyde 1.13 to form the anti-syn product 1.21 (Scheme 1-4). In contrast, 
enolization of 1.20 with TiCl4 and 
i
Pr2NEt and trapping with 1.13 provides the syn-syn product 
1.22. Additionally, boron reagents can be utilized to mediate the aldol reaction. The generation 
of a Z- or E-boron enolate from the corresponding ketone starting material is dependent on the 
identity of the electrophilic boron reagent and amine base. As demonstrated in the preparation of 
1.2 and 1.19, less sterically bulky ligands (i.e. n-butyl) on the boron reagent combined with a 
good leaving group (i.e. OTf) and a hindered amine base (i.e. 
i
Pr2NEt) provides the Z-enolate and 
the syn aldol product. In contrast, sterically bulky ligands (i.e. cyclohexyl) on the boron reagent 
combined with a poor leaving group on boron (i.e. Cl) and a small amine base (i.e. Et3N) 
provides access to the E-enolate.
26
 Enolization of 1.20 under these conditions and trapping with 
1.13 provides the anti-anti product 1.23. 
 
 
Scheme 1-4. The extended Evans aldol reaction. 
 
 Furthermore, 1,3-syn and 1,3-anti diols can be prepared from the extended Evans aldol 
products 1.21-1.23. For example, reduction of 1.21 with Zn(BH4)2
27
 or LiBH4
28
 provides the 1,3-
syn diol product 1.24 (Scheme 1-5). In contrast, reduction with Me4NBH(OAc)3 provides the 
1,3-anti diol product 1.25.
29
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Scheme 1-5. Stereoselective reduction to provide 1,3-syn and 1,3-anti diols. 
 
 Evans and Ng employed this methodology to complete a total synthesis of rutamycin B 
1.26 (Scheme 1-6).
30
 In particular, an extended Evans aldol reaction between aldehyde 1.27 and 
1.28 provided product 1.29. A reduction of this β-hydroxy ketone with NaBH(OAc)3 provided 
anti-diol 1.30, which was further elaborated to 1.26. 
 
 
Scheme 1-6. Synthesis of rutamycin B using an extended Evans aldol reaction. 
 
As demonstrated by these examples, removable auxiliary-based aldol reactions represent 
powerful methods for the regio-, diastereo-, and enantioselective construction of new carbon-
carbon bonds.
31
 A complementary approach is to perform an aldol reaction in which the auxiliary 
becomes incorporated into the desired product. The Paterson aldol reaction, which involves the 
boron-mediated aldol reaction between an aldehyde and a chiral ethyl ketone containing a 
stereogenic center bearing a methyl group, which is a very common motif in polyketide natural 
products, is also useful for the synthesis of β-hydroxy carbonyl compounds.32 Iterative 
applications of the Paterson aldol reaction have been used to prepare many natural and unnatural 
polyketide frameworks.
33
 In general, a bifunctional building block consisting of a ketone and a 
masked aldehyde (as a benzyl ether) are reacted with an aldehyde under aldol reaction conditions 
11 
 
(Figure 1-7). Removal of the benzyl ether protecting group and oxidation of the resulting alcohol 
regenerates an aldehyde for another iteration of the cycle.  
 
 
Figure 1-7. The iterative Paterson aldol reaction. 
 
As with the Evans aldol reaction, the generation of Z- or E-boron enolates from the 
corresponding ketone starting material allows access to syn and anti aldol products, respectively. 
In addition, chiral ligands on boron (i.e. Ipc) can be used to differentiate the diastereotopic faces 
of the enolate.
34
 Furthermore, as described above, reductions of the ketones in the resulting 
products provides efficient access to the stereotetrad units commonly found in polyketide natural 
products. These points are highlighted in the Paterson aldol reactions of ketone 1.31 (Scheme 1-
7).  
 
 
Scheme 1-7. The Paterson aldol reaction. 
 
Paterson and coworkers have prepared similar 1,3-polyol motifs on a solid support in an 
iterative fashion.
35
 In this process, E-boron enolate 1.33, generated from ketone 1.32, is reacted 
with resin bound aldehyde 1.34 in a Paterson aldol reaction to provide 1.35 (Scheme 1-8). A syn 
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reduction of the ketone, protection of the resulting diol, and PMB protecting group removal 
yields aldehyde 1.36, which is ready for another iteration of the aldol reaction cycle. A second 
Paterson aldol reaction between 1.36 and 1.33 provides 1.37. In a similar manner, a syn reduction 
provides 1.38, which contains 8 contiguous stereogenic centers. In theory, protection of this 
newly formed diol and regeneration of the aldehyde functionality could enable additional 
iterations of this cycle. This polypropionate framework, containing all of the hydroxyls in an all-
syn relationship and a 1,3-anti methylation pattern, represents a linear, unnatural polyketide 
based motif. Paterson and coworkers have also prepared these motifs in an iterative fashion using 
solution-phase techniques.
36
   
 
 
Scheme 1-8. Iterative solid phase Paterson aldol reactions. 
 
In addition to the oxygenated motif described above for polyketide natural products 
(polypropionate), deoxypropionate natural products are also commonly found, such as (-)-
dolciculide, vittatalactone, and ionomycin (Figure 1-5).
37
 Biosynthetically, these deoxygenated 
compounds are derived from the same bifunctional building blocks as their polypropionate 
counterparts, either malonate or methylmalonate units. In this process, a keto-reductase reduces a 
ketone on the growing propionate chain to a β-hydroxy group.38 Additional condensation 
reactions on this substrate results in polypropionate products. In contrast, if a molecule of water 
is eliminated from the β-hydroxy substrate an α,β-unsaturated ester results. Reduction of this 
olefin gives a saturated compound and provides the framework for deoxypropionate natural 
products. 
 Several synthetic methods have been developed to prepare deoxypropionate motifs in the 
laboratory.
39
 One such reaction, the Myers asymmetric alkylation, involves the alkylation of N-
acylated pseudoephedrine to obtain, upon removal of the pseudoephedrine group, 
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enantiomerically enriched α-alkylated aldehydes, ketones, carboxylic acids, and alcohols.40 A 
variety of alkylating agents can be used in the reaction, including allylic, benzylic, and alkyl 
halides. Moreover, Myers and coworkers report that the asymmetric alkylation can be conducted 
in an iterative fashion (Figure 1-8).
41
 In this process, the N-acylated pseudoephedrine serves as a 
bifunctional building block. After alkylation with a halide, the chiral auxiliary can be cleaved to 
reveal an alcohol. Conversion of the alcohol to a halide regenerates an alkylating agent for a 
second iteration of the process.  
 
 
Figure 1-8. Iterative Myers asymmetric alkylations. 
 
In a specific example, Myers and coworkers have completed the synthesis of 
diastereomeric 1,3,5,n(odd)-polyalkyl-substituted frameworks.
42
 Alkylation of N-acylated 
pseudoephedrine 1.39 followed by auxiliary cleavage and conversion of the resulting alcohol to a 
primary iodide generated 1.40 (Scheme 1-9). Alkylation of 1.39 with 1.40, followed by auxiliary 
cleavage and iodide formation provided an alkylating agent to be used in the completion of a 
third iteration of this cycle to generate 1.41. This same process was followed for the preparation 
of 1.42, 1.43, and 1.44. 
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Scheme 1-9. Iterative Myers asymmetric alkylations. 
 
 This powerful method has been utilized in an iterative fashion in the synthesis of 
deoxypropionate natural products. One example is the synthesis of (-)-borrelidin 1.45 by 
Theodorakis and coworkers.
43
 In this synthesis, alkyl iodide 1.46 was used to alkylate the enolate 
of (+)-pseudoephedrine 1.39 (Scheme 1-10). The auxiliary was cleaved and the resulting alcohol 
was converted to alkyl iodide 1.47, which served as an alkylating agent for the next iteration of 
the cycle. A third Myers asymmetric alkylation provided amide 1.48, which was further 
elaborated to 1.45. 
 
 
Scheme 1-10. Synthesis of (-)-borrelidin. 
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The above examples highlight how one reaction (i.e. the Evans aldol, Paterson aldol, or 
Myers alkylation) can be conducted in an iterative fashion for the preparation of natural and 
unnatural polypropionate frameworks. In contrast to this approach, a powerful strategy for the 
preparation of complex molecular frameworks is to use a combination of these methods in an 
iterative fashion. White and coworkers took such an approach in their total synthesis of 6-
deoxyerythronolide B 1.11.
44
 A Myers alkylation of ent-1.39 followed by auxiliary cleavage and 
oxidation to an aldehyde provides a substrate for an Evans aldol reaction with 1.49 (Scheme 1-
11). Cleavage of the Evans auxiliary and conversion to an aldehyde regenerated the required 
functionality for a second Evans aldol reaction with 1.50. A final cycle of auxiliary cleavage and 
conversion to an alkyl iodide provides an alkylating agent for reaction with ent-1.39. Following 
auxiliary cleavage, this complex fragment was macrocyclized via C-H activation and then 
elaborated to 1.11 to complete the most efficient synthesis to date of this natural product. 
 
 
Scheme 1-11. White synthesis of 6-deoxyerythronolide B. 
 
Polyketide-derived polyene natural products, such as etnangien, roxaticin, and 
ansatrienine A (Figure 1-5) also represent a class of compounds that have been prepared using 
iterative methods.
45
 Several strategies have been developed to synthesize the polyene portions of 
such natural products, including iterative olefination reactions and iterative transition metal 
based reactions. One example of this concept is the iteration of the Horner-Wadsworth-Emmons 
reaction (Figure 1-9).  
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Figure 1-9. Iterative Horner-Wadsworth-Emmons reactions. 
 
The iterative Horner-Wadsworth-Emmons strategy was used by Nicolaou and coworkers 
to complete a total synthesis of amphotericin B 1.51 (Scheme 1-12).
46
 In this process, aldehyde 
1.52 was condensed with phosphonate 1.53 to provide triene 1.54. Reduction of the ester to an 
alcohol, followed by oxidation, provided aldehyde 1.55. A second iteration of this cycle with 
another equivalent of 1.53 provided hexaene 1.56, which was further elaborated to 1.51. 
 
 
Scheme 1-12. Nicolaou synthesis of amphotericin B. 
 
A second example is the iteration of the Wittig olefination reaction, which is the reaction 
of an aldehyde or ketone with a phosphonium ylide to form an alkene. In this process, a 
bifunctional building block consisting of a phosphonium ylide and ester enables the iteration of 
this reaction (Figure 1-10). After formation of the alkene, the ester functionality can be reduced, 
regenerating an aldehyde for another reaction cycle. 
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Figure 1-10. The iterative Wittig reaction. 
 
In a specific example, Pattenden and Patel have used this iterative Wittig approach to 
complete a total synthesis of the polyketide derived polyene natural product citreomontanin 1.57 
(Scheme 1-13).
47
 Reaction of aldehyde 1.58 with ylide 1.59 forms diene 1.60. Reduction of the 
ester with lithium aluminum hydride and oxidation of the resulting alcohol with manganese 
oxide yields 1.61, regenerating an aldehyde for iteration of this process. Reaction with a second 
equivalent of 1.59 provides triene 1.62. A reduction/oxidation sequence produces aldehyde 1.63. 
A final Wittig reaction with 1.64 completed the synthesis of 1.57. 
 
 
Scheme 1-13. Synthesis of polyketide-derived polyene natural product citreomontanin. 
 
 Iterative transition metal mediated reactions are an important class of reactions for both 
the preparation of these natural products, as well as the synthesis of polyterpene natural products. 
This class of reactions will be explored in the polyterpene natural product synthesis section 
below. 
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In addition to the iterative strategies developed for the polypropionate and 
deoxypropionate natural products described above, several iterative strategies have also been 
developed for the preparation of other polyketide natural products.
48
 Notably, several iterative 
methods have been reported for the synthesis of ladder polycyclic ether fragments, which is a 
motif present in a number of highly potent polyketides.
49
 Additionally, the coupling of iterative 
synthesis to other pathways is a powerful strategy for the installation of molecular complexity in 
a rapid, efficient manner. A report by Wulff and coworkers uses this approach of marrying 
iterative synthesis to cascading radical cyclization pathways for the preparation of polycyclic 
ethers.
50
 Regardless of the products that each of these strategies seeks to make, they are united by 
a common approach of bringing together bifunctional building blocks in an iterative fashion. 
 
1-3 ITERATIVE STRATEGIES FOR THE SYNTHESIS OF POLYTERPENE NATURAL 
PRODUCTS 
Polyterpene natural products are common components of living systems and contribute to 
vital higher-order functions, including structural support in cell membranes and light harvesting 
roles in bacteria. Polyterpene natural products also serve important roles as medicines and 
biological probes. While the terpenoids are one of the most structurally varied classes of natural 
products (Figure 1-11), they are united by a common biosynthetic origin; polyterpenes are 
biosynthesized from isoprene based building blocks that are brought together in an iterative 
fashion.
51
 In some cases, the inherent modularity that results from this biosynthetic origin is quite 
evident. In other cases, polycyclizations of initial linear polyunsaturated precursors lead to the 
rapid assembly of complex polycyclic cores. Synthetic access to these motifs has enabled a better 
understanding of the role of polyterpenes in living systems. Several strategies have been 
developed to gain access to these compounds, taking advantage of an iterative-based approach to 
efficiently and rapidly build up molecular complexity. Herein we highlight the contributions of 
Keinan, Negishi, and Katsumura for the construction of linear and cyclic polyterpene units using 
iterative approaches and the application toward the synthesis of natural products. 
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Figure 1-11. Structures of polyterpene natural products. 
  
Transition metal mediated coupling reactions provide a rapid and efficient means for the 
construction of new carbon-carbon bonds. In addition to applications to the synthesis of 
polyterpene natural products, such reactions have found use in the synthesis of polyketide-
derived polyene natural products (introduced above) and organic based materials. Applications to 
the preparation of organic based materials is outside the scope of this chapter, however reviews 
are available on the topic of iterative methods for the preparation of organic based 
materials.
52,53,54
 
One challenge to the synthesis of polyene containing natural products is maintaining the 
desired stereochemical relationship of the olefins throughout the course of the reaction sequence. 
The use of selective reactions and mild reagents is one strategy to accomplish such a goal. Using 
such an approach, Keinan and coworkers developed an early strategy for the iterative synthesis 
of polyterpene natural products.
55
 This strategy involves the regio- and stereoselective palladium 
catalyzed coupling of bifunctional building blocks in an iterative fashion (Figure 1-12). In 
general, geraniol derived bifunctional building blocks containing nucleophilic and masked 
electrophilic termini are utilized. The nucleophilic terminus consists of a methine group bearing 
two electron withdrawing groups, namely methoxycarbonyl and tolylsulfonyl substituents. The 
electrophilic terminus consists of an allylic alcohol that can be activated as a methyl carbonate 
leaving group. In the key bond forming process, π-allylpalladium formation from the allylic 
methyl carbonate followed by addition of the activated methine provides the coupled product. 
Activation of the pendant allyl alcohol allows for a second iteration of this process, providing 
extended intermediates. Removal of the activating groups provides the polyterpene framework.  
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Figure 1-12. Keinan’s iterative polyterpene synthesis. 
 
 Keinan and coworkers utilized this methodology to complete a total synthesis of 
coenzyme Q10 1.65, an important nutritional supplement (Scheme 1-14). Coupling between allyl 
methyl carbonate 1.66 and bifunctional building block 1.67 provided allyl alcohol 1.68. 
Activation of this substrate with methyl chloroformate and diethylaniline, followed by a second 
coupling sequence provided advanced intermediate 1.69. Another such sequence, followed by 
activation and coupling with a capping group 1.70 provided 1.71, the precursor to coenzyme Q10. 
Removal of the activating groups and oxidation of the aromatic ring to provide the quinone 
completed the synthesis of 1.65. Specifically, the methoxycarbonyl substituent was cleaved 
under the action of 4-aminothiophenol and cesium carbonate in DMF,
56
 and the tolylsulfonyl 
group was removed using lithium triethylborohydride and a palladium catalyst in THF.
57
 
 
 
Scheme 1-14. Keinan’s synthesis of coenzyme Q10. 
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 Negishi and coworkers have also completed a total synthesis of coenzyme Q10 using 
transition metal mediated iterative synthesis.
58
 As an alternative to Keinan’s approach, activating 
groups were not required for their synthesis. In Negishi’s approach, (E)-1,4-diiodo-2-methyl-1-
butene serves as a bifunctional building block (Figure 1-13). After a palladium mediated cross-
coupling between the vinyl iodide terminus and a primary zinc halide species, the primary iodide 
is converted to a zinc halide to enable another iteration of the process. Through this sequence, a 
stereocontrolled total synthesis of coenzyme Q10 was completed. 
 
 
Figure 1-13. Negishi’s iterative transition metal mediated coupling cycle. 
 
 Negishi and coworkers have also developed methodology based on the zirconium 
catalyzed carboalumination of alkynes combined with a palladium and zinc catalyzed cross-
coupling reaction to provide the highly stereoselective synthesis of both symmetrical and 
unsymmetrical carotenoids.
59
 This methodology can be conducted in an iterative fashion (Figure 
1-14). Bifunctional building blocks consisting of a vinyl bromide and a protected alkyne are 
coupled to vinyl aluminum intermediates. Removal of the alkyne protecting group reveals a 
terminal alkyne, regenerating the functionality needed for another carboalumination/cross-
coupling cycle. 
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Figure 1-14. Negishi’s iterative synthesis of polyterpenes. 
 
An example of this process is the synthesis of γ-carotene 1.72 (Scheme 1-15). This 
unsymmetrical carotenoid was prepared in a convergent manner from vinyl bromide 1.73 and 
vinyl aluminate 1.74. Each of these building blocks was prepared through an iterative sequence 
of carboalumination and cross-coupling reactions. Specifically, a sequence consisting of a 
zirconium-catalyzed carboalumination of alkyne 1.75, a palladium and zinc catalyzed cross-
coupling with enyne 1.76, and alkyne deprotection provided polyenyne 1.77. A second iteration 
of this sequence provided intermediate 1.78, which upon carboalumination provided building 
block 1.74. In a similar manner, 1.73 was prepared through a series of iterative carboalumination 
and cross-coupling reactions. A final palladium and zinc catalyzed cross-coupling between 1.73 
and 1.74 completed the synthesis of γ-carotene. Importantly, the highly stereoselective 
carboalumination reaction and stereospecific cross-coupling reaction provided this material in 
>99% stereoisomeric purity. 
 
 
Scheme 1-15. Synthesis of γ-carotene. 
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 The methods highlighted above by Keinan and Negishi provide efficient and rapid access 
to linear polyterpene derived frameworks through the iterative assembly of bifunctional building 
blocks. Some potential challenges associated with these specific transition metal mediated 
methods include air sensitivity and unstable building blocks/intermediates.  
Another interesting class of polyterpene natural products is cyclic terpenoids. 
Biosynthetically, these molecules are prepared through enzyme mediated cyclizations of the 
linear precursor. Synthetically, methods have been developed to convert linear polyterpene 
frameworks into cyclized products.
60
 However, an alternative strategy is the direct synthesis of 
these cyclic frameworks through the iteration of a defined set of reactions. Katsumura and 
coworkers have developed such an approach to prepare a series of 1,1,5-trimethyl decalin based 
polyterpene natural products.
61
 Specifically, a bromination-condensation-cyclization sequence of 
an allylic alcohol starting material provides an ester intermediate (Figure 1-15). Phosphonate 
formation, methylation, and ester reduction completes the sequence, regenerating the alcohol 
functionality for another iteration of the process. 
 
 
Figure 1-15. Iterative synthesis of cyclic terpenoids. 
 
Katsumura and coworkers have used this iterative process to complete the synthesis of 
the biologically active target scalarenedial.
62
 Starting from cyclogeraniol 1.79, a three step 
sequence involving a bromination, condensation, and cyclization reaction provided 1.80 (Scheme 
1-16). This bicycle then underwent a three step sequence of phosphonate formation, methylation, 
and ester reduction to convert 1.80 to allyl alcohol 1.81. A second iteration of the bromination, 
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condensation, and cyclization sequence provided tricycle 1.82. Conversion of ester 1.82 to allyl 
alcohol 1.83, followed by a final iteration of the cyclization sequence provided 1.84, which 
serves as a precursor to scalarenedial. 
 
 
Scheme 1-16. Iterative pathway for the synthesis of polycyclic terpenoids. 
 
The methods developed by Keinan, Negishi, and Katsumura highlight the idea that 
iterative synthesis provides an effective strategy for the synthesis of a variety of polyterpene 
based motifs, including repeating linear polyprenoids, polyenes, and polycyclic frameworks. 
Collectively, these methods demonstrate that taking advantage of the inherent modularity of 
small molecule natural products through the power of an iterative synthetic approach can provide 
rapid and efficient access to a variety of molecules. 
 
1-4 ITERATIVE STRATEGIES FOR THE SYNTHESIS OF FATTY ACID NATURAL 
PRODUCTS 
 Fatty acid natural products serve important roles in living systems, including modulation 
of membrane fluidity, serving as chemical energy storage units, and participation in cell 
signaling pathways. While many structurally diverse fatty acid natural products have been 
discovered (Figure 1-16), those containing eighteen carbons are the most commonly occurring. 
Strategies have been developed to synthesize fatty acid natural products, including several 
iterative-based approaches. Herein we highlight the contributions of Kim and Feringa for the 
construction of fatty acids in an iterative fashion. 
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Figure 1-16. Fatty acid natural products. 
 
 Kim and coworkers have developed an iterative strategy for the synthesis of 
unsymmetrical polyynes.
63
 In this process, a trialkylsilylacetylene serves as a bifunctional 
building block (Figure 1-17). Cross-coupling of the terminal alkyne with a bromoalkyne, 
followed by a desilylative bromination enables iteration of this reaction sequence. 
 
 
Figure 1-17. Iterative polyyne synthesis. 
 
 Kim and coworkers have used this iterative method to complete a total synthesis of the 
fatty acid natural product 15,16-dihydrominquartynoic acid 1.85 (Scheme 1-17). Specifically, 
coupling between bromoalkyne 1.86 and TIPS-acetylene 1.87 provided diyne 1.88. A 
desilylative bromination afforded bromodiyne 1.89. A second iteration of this process provided 
triyne 1.90, which was further elaborated to 1.85. 
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Scheme 1-17. Iterative synthesis of 15,16-dihydrominquartynoic acid. 
 
 1,3-polymethyl arrays are also present in fatty acid derived natural products. Feringa and 
coworkers have developed an iterative strategy to synthesize this structural motif.
64
 An iterative 
reaction sequence involving a stereoselective conjugate addition, palladium catalyzed reduction, 
and Wittig reaction regenerates the α,β-unsaturated thioester required for another iteration of this 
process (Figure 1-18). 
 
 
Figure 1-18. Iterative cycle for the synthesis of polymethyl fatty acids. 
 
 Feringa and coworkers have used this iterative approach to complete a total synthesis of 
the fatty acid natural product mycocerosic acid 1.91 (Scheme 1-18). Enantioselective 
methylation of unsaturated thioester 1.92 provided 1.93. Reduction of the thioester to an 
aldehyde followed by a Wittig reaction with ylide 1.94 provided unsaturated thioester 1.95. Two 
additional iterations of this cycle furnished 1.96, which was further elaborated to mycocerosic 
acid. 
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Scheme 1-18. Synthesis of mycocerosic acid. 
 
1-5 ITERATIVE STRATEGIES FOR THE SYNTHESIS OF OTHER NATURAL PRODUCTS 
 In addition to the synthesis of polyketide, polyterpene, and fatty acid derived natural 
products via iterative strategies, nonribosomal peptide, hybrid polyketide/nonribosomal peptide, 
and several other classes of natural products have also been prepared using iterative approaches. 
This section briefly provides examples from each of these areas. 
 Similar to peptide based natural products, nonribosomal peptide derived natural products 
utilize peptide bonds to link unnatural peptide residues. As a result, the iterative peptide 
synthesis strategy (Figure 1-4, left) can be applied to the preparation of these compounds. An 
example of this can be found in Wipf and coworkers synthesis of N
14
-desacetoxytubulysin H 
1.97 (Scheme 1-19).
65
 N-deprotection of unnatural amino acid building block 1.98 followed by 
coupling with 1.99 afforded dipeptide 1.100. A subsequent N-deprotection regenerated the amine 
functionality required for a second iteration of this process. Coupling with Fmoc protected 1.101 
provided tripeptide 1.102, which was further elaborated to 1.97. 
 
 
Scheme 1-19. Synthesis of N
14
-desacetoxytubulysin H. 
 
 Hybrid polyketide/nonribosomal peptide derived natural products, such as phoboxazole B 
1.103, have been prepared using iterative strategies. Zhou, Lin, and coworkers used iterative 
crotylation reactions (Figure 1-19) to prepare the tetrahydropyrane-oxazole segment of 1.103 
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(Scheme 1-20).
66
 Specifically, crotyl addition of boronic ester 1.105 to aldehyde 1.104 provided 
alcohol 1.106. Protection of the alcohol and ozonolysis regenerated the aldehyde functionality 
required for a second iteration of this process. Crotylation of 1.107 provided intermediate 1.108, 
which was a fragment in the synthesis of 1.103. 
 
 
Figure 1-19. Iterative crotylation reactions. 
 
 
Scheme 1-20. Synthesis of tetrahydropyrane-oxazole segment of phorboxazole B. 
 
1-6.1 MIDA BORONATES: A POTENTIALLY GENERAL PLATFORM FOR THE 
ITERATIVE SYNTHESIS OF SMALL MOLECULE NATURAL PRODUCTS 
 As described above, many customized strategies and methods have been developed to 
access specific classes of natural products via the iterative coupling of bifunctional building 
blocks. It is intriguing to consider the possibility that a single platform could prove to be general 
for accessing many different classes of small molecules. Inspired by the building block based 
approach to the laboratory synthesis of polypeptides, oligonucleotides, and oligosaccharides, a 
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strategy for the construction of small molecules in the laboratory by the iterative coupling of 
bifunctional building blocks is attractive. Toward this goal, metal-mediated cross-coupling 
reactions provide a mild and controlled way to form new carbon-carbon and carbon-heteroatom 
bonds that are characteristically found in small molecules.
67
 Harnessing this synthetic potential, 
an idealized form of such an “Iterative Cross-Coupling” (ICC) strategy can be envisioned. In this 
approach, building blocks having all of the required functional groups preinstalled in the correct 
oxidation state and with the desired stereochemical relationships are iteratively united using only 
stereospecific cross-coupling reactions. In addition to being simple, efficient, and potentially 
amenable to automation, the modularity of this approach makes it inherently well-suited for 
generating diverse collections of compounds simply by substituting modified building blocks 
into the same synthesis pathway.
68
 Encouraging progress toward such an ICC strategy was 
reported by Moore and coworkers specifically for the iterative assembly of phenylacetylene 
oligomers.
52
 Also, contemporaneous with the results presented below, Suginome and coworkers 
reported the use of iterative cross-coupling reactions for the preparation of oligoarenes.
53 
 In this regard, N-methyliminodiacetic acid (MIDA) boronates also represent a highly 
promising platform for this type of synthesis strategy (Figure 1-20).
69
 These building blocks are 
remarkably convenient to prepare, analyze, purify, and store.
69,70
 The MIDA boronate functional 
group is inert to anhydrous cross-coupling conditions, yet can be readily transformed into a fully 
reactive boronic acid or ester using exceptionally mild conditions.
69
 As first introduced here and 
elaborated upon in subsequent chapters, these features have enabled the simple, efficient, and 
highly flexible synthesis of a wide range of small molecules, including both pharmaceuticals and 
complex natural products. 
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Figure 1-20. MIDA boronates and Iterative Cross-Coupling (ICC). 
 
1-6.2 DEVELOPMENT OF ICC 
 The routinely automated process of iterative peptide coupling represents an inspiring 
benchmark for a general strategy for making small molecules in the laboratory. Peptides are 
often quite complex in structure. They have many different functional groups with varied 
oxidation states and contain a large number of stereogenic centers. However, the synthesis of 
many peptides simply involves the use of a single reaction to iteratively assemble a collection of 
amino acid building blocks having all of the required functional groups and stereochemistry 
preinstalled. 
 With the goal of developing a process for the laboratory construction of small molecules, 
an analogous strategy was envisioned by my colleague Dr. Eric Gillis using the Suzuki-Miyaura 
reaction
71
 and the ICC of bifunctional “haloboronic acids”.72 To avoid random oligomerization 
of a haloboronic acid under cross-coupling conditions, it is necessary to reversibly attenuate the 
reactivity of one end of this type of bifunctional reagent, in analogy to the use of a protective 
group to control the reactivity of the amine terminus of an amino acid.
73
 Toward this goal, 
controlling the reactivity of the boronic acid functional group is one possible strategy. 
 It is hypothesized that a vacant and Lewis acidic boron p orbital is required for 
transmetalation of a boronic acid under Suzuki-Miyaura cross-coupling conditions.
74
 Consistent 
with this, complexation of boronic acids with electron-donating, Lewis basic ligands is known to 
attenuate their reactivity towards cross-coupling.
75
 This reactivity attenuation can be attributed to 
the decreased Lewis acidity of the boron p orbital as a result of conjugation with the lone pairs of 
the ligand heteroatoms. This approach has been utilized with a variety of divalent heteroatomic 
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ligands, including diols and diamines.
76
 However, there is an inherent limitation with this 
approach that precludes its general utilization for complex small-molecule synthesis. 
Specifically, conjugation between the heteroatom lone pairs and boron p orbital produces 
relatively strong boron-heteroatom bonds, creating both a kinetic and thermodynamic barrier for 
bond cleavage. As a result, removing this type of ligand to regenerate the boronic acid typically 
requires harsh conditions
77
 and/or reagents to destroy the free divalent ligand after to prevent re-
complexation.
78
 These types of conditions can be problematic in the context of small-molecule 
synthesis. 
 Recognizing the inherent limitations of this approach, an alternative strategy was 
envisioned. Specifically, given that the boron p orbital is predicted to be critical for the 
transmetalation of a boronic acid, it was hypothesized that rehybridization of the boron atom 
from sp
2
 to sp
3 
via complexation with a trivalent heteroatomic ligand would eliminate its 
reactivity towards cross-coupling.
79
 Furthermore, it is known that boron-heteroatom bonds in 
tetrahedral adducts are weaker than those in their tricoordinate counterparts.
80
 Thus, relatively 
mild conditions could be used to hydrolyze this type of pyramidalized boronate and regenerate a 
reactive boronic acid. Testing a series of trivalent heteroatomic ligands revealed that N-
methyliminodiacetic acid (MIDA) embodies all of these expectations and represents a powerful 
platform for ICC chemistry.
81
 
 Specifically, in a competition experiment between p-(n-butyl)phenylboronic acid 1.109 
and p-tolyl MIDA boronate 1.110 under Buchwald-type
82
 anhydrous Suzuki-Miyaura cross-
coupling conditions with p-bromoanisaldehyde Dr. Gillis observed a >20:1 ratio of products 
1.111 and 1.112, consistent with a strong preference for cross-coupling of the sp
2
-hybridized 
boronic acid (Scheme 1-21). This B-protection strategy is remarkably general, with the same 
ligand similarly protecting aryl, heteroaryl, alkynyl, alkenyl, and alkyl haloboronic acids, thereby 
enabling the highly selective coupling of the halide terminus of these building blocks. Moreover, 
the MIDA boronates can be hydrolyzed under mild aqueous conditions (1 N aqueous 
NaOH/THF, 23 
o
C, 10 minutes or NaHCO3/MeOH, 23 
o
C, 6 hours) to generate the 
corresponding free boronic acid. 
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Scheme 1-21. A B-selective Suzuki-Miyaura cross-coupling reaction. 
 
Having established that the MIDA ligand can attenuate the reactivity of a boronic acid, a 
collection of bifunctional haloboronic acid building blocks 1.113a-d was prepared to enable the 
ICC strategy (Figure 1-21). These building blocks contain a halide at one terminus that can be 
coupled under Suzuki-Miyaura conditions. The other terminus contains a boronic acid masked as 
a MIDA boronate, which will be unreactive under anhydrous coupling conditions.  
 
 
Figure 1-21. A collection of bifunctional MIDA boronate building blocks. 
 
The potential of the MIDA ligand to enable the selective cross-coupling of these building 
blocks was probed by reacting each with p-tolylboronic acid (Scheme 1-22). Although the 
reactivity of aryl, heteroaryl, vinyl, and alkyl boronic acids can vary dramatically, the same 
protective group was effective with all four classes of nucleophiles, yielding selective cross-
coupling products 1.114a-d. 
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Scheme 1-22. Selective cross-coupling of bifunctional building blocks. 
 
With the ability to selectively couple the halide terminus of a bifunctional MIDA 
boronate building block, and to subsequently deprotect the resulting MIDA boronate to reveal a 
reactive boronic acid, Dr. Gillis utilized the iteration of this process in the synthesis of the natural 
product ratanhine 1.115, a neolignan isolated from the medicinal plant Ratanhiae radix.
83
 First, a 
selective coupling between propenyl boronic acid 1.116 and the halide terminus of heteroaryl 
MIDA boronate 1.117 provided cross-coupled product 1.118 (Scheme 1-23). Deprotection of the 
benzofuranyl boronate to the boronic acid generated an intermediate 1.119 for coupling with 
electron-rich and sterically bulky aryl bromide 1.120, providing 1.121. A final sequence of 
deprotection and cross-coupling, followed by cleavage of protecting groups, completed a total 
synthesis of 1.115 and established ICC as a viable strategy for the synthesis of complex small 
molecules. 
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Scheme 1-23. ICC approach to the synthesis of ratanhine. 
 
1-6.3 PREPARATION OF MIDA BORONATE BUILDING BLOCKS 
 In order to be useful reagents for small molecule synthesis, ready access to a diverse 
range of MIDA boronate building blocks must be available. The MIDA ligand
84
 is nontoxic, 
biodegradable,
85
 and commercially available. It can also be conveniently, efficiently, and 
inexpensively synthesized on a large scale from the commodity chemical iminodiacetic acid.
86
 
Several different methods have been developed for the synthesis of MIDA boronates. 
Many boronic acids can be readily transformed into the corresponding MIDA boronates through 
condensation with MIDA. This can be accomplished under Dean-Stark conditions using a 
mixture of toluene and DMSO as the reaction solvent (Scheme 1-24a).
87
 This strategy is 
compatible with many aryl, heteroaryl, vinyl, and alkyl boronic acids. For example, Seed and 
coworkers used this approach to prepare a substituted aryl MIDA boronate building block.
88
 
Alternatively, Hamann and coworkers report that boronic acids can be heated with MIDA in 
DMF to be converted to MIDA boronates in good yields.
89
 
 Numerous methods have also been developed to access MIDA boronates without the 
intermediacy of a boronic acid. Brice Uno and Dr. Gillis found that haloboranes, accessed 
through hydroboration of alkynes or alkenes with dibromoborane or transmetalation of 
organotrimethylsilanes with boron tribromide, can be converted to MIDA boronates by trapping 
with the disodium salt of MIDA (Scheme 1-24b).
90
 A variety of boronic esters, including 
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catechol esters and pinacol esters, can be converted to MIDA boronates by heating a solution of 
the boronic ester with MIDA (Scheme 1-24c).
91
 This work will be described in greater detail in 
Chapter 2. Alternatively, as demonstrated by Piersanti and coworkers, pinacol ester boronated 
tryptophans can be converted to boronic acids under the action of sodium periodate. This boronic 
acid was then transformed into the corresponding MIDA boronate under the Dean-Stark 
conditions described above.
92
 
 Graham Dick, Dr. David Knapp, and Dr. Gillis have found that Grignard and 
organolithium reagents, which can be prepared from the corresponding halide, can be converted 
to MIDA boronates (Scheme 1-24d).
93
 Trapping of the Grignard or lithium reagent with 
trimethyl or triisopropyl borate followed by transligation with MIDA in a hot solution of DMSO 
is an effective strategy for the preparation of a variety of alkynyl, alkenyl, aryl, and heteroaryl 
MIDA boronates. This work is further described in Chapters 2 and 3. 
 
 
Scheme 1-24. Preparation of MIDA boronate building blocks. 
  
 Moreover, the MIDA boronate functional group is compatible with a wide range of 
reaction conditions and reagents, including oxidants, reductants, electrophiles, soft nucleophiles, 
strong acids, and a wide range of anhydrous bases, allowing MIDA boronate building blocks to 
be prepared through multistep synthesis, starting from MIDA boronate containing reagents.
94
 As 
a demonstration of this, Hamann and coworkers have reported the synthesis of amines through a 
reductive amination reaction of a MIDA boronate building block containing an aldehyde 
followed by an additional functionalization reaction via cross-coupling of the MIDA boronate 
group (Scheme 1-25a).
95
 Additionally, Brice Uno and Dr. Gillis found that cross-metathesis 
between vinyl MIDA boronate 1.122 and a variety of olefins is a useful method for the 
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preparation of trans-alkenyl MIDA boronates (Scheme 1-25b).
96
 Furthermore, cyclopropanation 
and epoxidation of 1.122 provides the cyclopropane and oxiranyl building blocks, respectively 
(Scheme 1-25b). In a similar fashion, Dr. Justin Struble and Dr. Suk Joong Lee reported that 
ethynyl MIDA boronate 1.123 is a versatile precursor for the preparation of MIDA boronate 
containing building blocks (Scheme 1-25c).
97
 For example, Hamann and coworkers have 
demonstrated MIDA boronate functionalized isoxazoles and triazoles can be prepared from 
1.123 through cycloaddition reactions (Scheme 1-25d).
98
 Also, as described in greater detail in 
Scheme 1-30c below, Toste and coworkers have prepared heterocyclic MIDA boronates through 
a coupling/cyclization sequence.
99
 
 
 
Scheme 1-25. Preparation of MIDA boronate building blocks. 
 
 Bifunctional halo MIDA boronates can also serve as starting materials for generating 
MIDA boronate containing building blocks. For example, Dr. Lee, Dr. Kaitlyn Gray, and James 
Paek found that trans-bromo MIDA boronate 1.124 is a versatile cross-coupling partner, 
enabling functionalization of the halide terminus while leaving the MIDA boronate functional 
group intact (Scheme 1-26).
100
 Suzuki-Miyaura, Stille, and Heck couplings provide a variety of 
diene MIDA boronates. A series of bismetalated lynchpin-type reagents can be prepared via 
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Sonagashira coupling, Miyaura borylation, or a metal-selective Negishi coupling. In a similar 
fashion, cis-bromo MIDA boronate 1.125 can be synthesized and functionalized to prepare a 
series of dienyl MIDA boronate building blocks.
101
 This work is described in Chapter 3. 
 
 
Scheme 1-26. Preparation of MIDA boronate building blocks. 
 
 In addition to 1.124 and 1.125, Dr. Lee and Dr. Tom Anderson have developed a series of 
MIDA protected haloalkenylboronic acid building blocks to enable stereospecific access to 
stereochemically complex polyene frameworks via the ICC strategy.
102
 A collection of 
iodopolyenyl MIDA boronates has been prepared by the ICC of iodide-masked bifunctional 
building blocks. This approach involves metal-selective cross-coupling of Sn/Ge bis-metalated 
olefins
103
 to generate polyenylgermanium intermediates, followed by stereospecific 
iododegermylations (Scheme 1-27a).
104
 Iterative cycles of this metal-selective 
coupling/iododegermylation strategy with building blocks 1.126 and 1.127 provided access to 
iodopolyenyl MIDA boronates in all possible stereoisomeric forms (Scheme 1-27b). Moreover, 
harnessing the iterative nature of this strategy, the more advanced trienyl halide 1.128 was also 
readily prepared by simply executing an additional cycle of the metal-selective coupling and 
stereospecific iododegermylation. This strategy and these building blocks are described in 
greater detail in Chapter 4. 
 
38 
 
 
 
Scheme 1-27. Synthesis of iodopolyenyl MIDA boronates. 
 
1-6.4 DIRECT AND SLOW RELEASE CROSS-COUPLING 
 With ready access to MIDA boronate containing reagents and bifunctional boronate 
building blocks, the MIDA boronate functionality can serve as a precursor or surrogate for 
boronic acids in a number of different contexts. One challenge to the use of boronic acids as 
building blocks in the synthesis of small molecules is that many boronic acids are inherently 
unstable. Sensitivity to moisture and oxygen can lead to protodeborylation and/or other 
decomposition pathways, greatly shortening their benchtop storage time.
105
 Furthermore, the 
decomposition of boronic acids can be accelerated by heat, base, and/or palladium catalysts, 
thereby causing the in situ decomposition of boronic acids to compete kinetically with Suzuki-
Miyaura cross-coupling reactions. Many of these challenges can be linked to the vacant and 
Lewis acidic p orbital that is present in boronic acids. Rehybridization of a boronic acid to a sp
3
-
hybridized MIDA boronate provides a solution to both of these problems.  
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 First, MIDA boronates can serve as air-stable surrogates for many unstable boronic acids, 
providing a solution to the instability of boronic acids to benchtop storage. The instability of 2-
heterocyclic,
106
 vinyl,
107
 and cyclopropyl boronic acids
108
 has frequently been discussed 
anecdotally, yet there is very little quantitative data available. Dr. Knapp and Dr. Gillis 
conducted a systematic evaluation of the stability of a collection of such boronic acids stored on 
the benchtop under air for 15 days revealed significant decomposition (Scheme 1-28).
109
 For 
example, with 2-furan, 2-pyrrole, 2-indole, vinyl, and cyclopropyl boronic acids, very little of the 
original material remained after this time. In contrast to these unstable boronic acids, MIDA 
boronates are uniformly stable to benchtop storage. 2-furan, 2-pyrrole, 2-indole, vinyl, and 
cyclopropyl MIDA boronate are indefinitely air-stable, with no decomposition detectable after 
more than 60 days of storage on the benchtop under air. Suginome and coworkers have reported 
that phenyl MIDA boronate is stable for long periods of time in a solution of wet DMSO.
110
 
Furthermore, Knochel and coworkers have demonstrated that MIDA boronate containing 
heterocycles, in comparison to other boron containing heterocycles, are more stable and less 
reactive under electrophilic aromatic substitution conditions.
111
 
 
 
Scheme 1-28. Benchtop stability of boronic acids and MIDA boronates. 
 
 Second, MIDA boronates can also provide a solution to the in situ decomposition of 
unstable boronic acids in several different ways. For example, MIDA boronates can serve as 
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precursors to boronic acids in cross-coupling reactions. The hydrolysis of MIDA boronates with 
aqueous NaOH is fast, typically requiring less than 10 minutes at 23 
o
C. As a result, a MIDA 
boronate can be converted to a boronic acid, enabling cross-coupling under anhydrous or 
aqueous conditions. This strategy has been used in the synthesis of a number of small molecule 
natural products, including ratanhine (Scheme 1-23), all-trans-retinal, β-parinaric acid, (5Z, 8Z, 
10E, 12E, 14Z)-eicosapentaenoate, and (-)-myxalamida A.
112
 However, as described above, 
complex boronic acid intermediates are often difficult to isolate, and can decompose before the 
desired cross-coupling reaction can be conducted. In an alternative approach, Dr. Knapp and Dr. 
Gillis found that MIDA boronates can serve as surrogates for boronic acids in cross-coupling 
reactions. This feature enables the generation of structurally complex MIDA boronates that can 
then be directly cross-coupled with an organic halide. The conditions that are used to deprotect a 
MIDA boronate are fully compatible with the Suzuki-Miyaura cross-coupling reaction, which are 
often conducted under aqueous basic conditions. As a result, instead of generating the boronic 
acid reagent from the MIDA boronate as a separate step, the boronic acid coupling partner can be 
directly released into the reaction solution from the corresponding MIDA boronate. This avoids 
the potential challenge of isolating unstable and structurally complex boronic acids. This strategy 
has been used as the final step in the synthesis of several small molecule natural products, 
including polyenes described in Chapter 4, a total synthesis of the carotenoid natural product 
peridinin (as described in Chapter 2), as well as the carotenoid synechoxanthin 1.129, as reported 
by Seiko Fujii and Stephanie Chang.
113
 In this process, an in situ MIDA boronate 
hydrolysis/two-directional double cross-coupling sequence between two equivalents of MIDA 
boronate 1.130 and trans-1-iodo-2-bromoethylene 1.131 yielded synechoxanthin bismethylester, 
which upon deprotection provided 1.129 (Scheme 1-29). 
 
 
Scheme 1-29. Total synthesis of synechoxanthin. 
 
While the direct release of a boronic acid from a MIDA boronate can be effective in 
many cross-coupling reactions, the in situ stability of unstable boronic acids can often lead to a 
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reduction in yield similar reactions. Specifically, the in situ decomposition of unstable boronic 
acids can occur at a rate that is competitive with cross-coupling reactions, resulting in an 
inefficient coupling process. In contrast to the rapid release of a boronic acid from a MIDA 
boronate using aqueous NaOH (release is complete in <10 min at 23
 o
C), Dr. Knapp and Dr. 
Gillis found that potassium phosphate in 5:1 dioxane/water at 60 
o
C promotes the continuous 
release of boronic acids from the MIDA boronates over ~3 h.
114
 This rate controlled in situ 
hydrolysis of MIDA boronates provides a “slow release” of the corresponding unstable boronic 
acid at a rate that is slower than the desired cross-coupling reaction. Therefore, analogous to the 
use of a syringe pump,
115
 successful coupling can occur before decomposition of the freshly 
generated boronic acid.  
To demonstrate this point, the cross-coupling efficiency of freshly prepared boronic acids 
was compared to the corresponding MIDA boronate. Under identical reaction conditions, the 
coupling of a variety of heteroaryl, vinyl, and alkyl boronic acids proceeded in low to moderate 
yields, while the corresponding MIDA boronates provided the products in uniformly excellent 
yields (Scheme 1-30). Moreover, the high yields obtained when using the MIDA boronate as a 
coupling partner can be replicated through the syringe pump mediated addition of the boronic 
acid over 3 h. 
 
 
Scheme 1-30. Cross-coupling efficiency of boronic acids and the corresponding MIDA boronates. 
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Several applications of the slow-release methodology have been utilized in the synthesis 
of small molecules. Taylor and coworkers have demonstrated that alkenyl MIDA boronates can 
be coupled with alkenyl tosylates under slow-release conditions to prepare a variety of diene 
products (Scheme 1-31a).
116
 Cobb and coworkers have prepared a collection of MIDA boronate 
containing amino acids. They further functionalized these reagents under the slow-release cross-
coupling conditions to prepare a variety of biaryl amino acids (Scheme 1-31b).
117
 Toste and 
coworkers have developed a method for the preparation for heterocyclic MIDA boronates from 
substituted alkynyl MIDA boronates through a gold catalyzed cycloisomerization reaction. 
Subsequently, these substrates were coupled to aryl bromides and chlorides under slow-release 
conditions to yield 2-arylheterocycles (Scheme 1-31c).
118
 Miller and coworkers have utilized 
slow-release cross-coupling in the regioselective cross-coupling of tribrominated biaryls to 
provide efficient access to atropisomerically defined substituted biaryl frameworks (Scheme 1-
31d).
119
 Furthermore, slow-release cross-coupling has been used to prepare intermediates in 
route to the synthesis of natural products and pharmaceutical agents.
120
 
 
 
Scheme 1-31. Applications of slow-release cross-coupling. 
 
Monteiro, Balme, and coworkers have combined slow-release cross-coupling with ICC 
for the synthesis of 3,4-bisaromatic pyrazoles (Scheme 1-32).
121
 In this process, bifunctional 
MIDA boronate 1.132 was first coupled with a series of aromatic and heteroaromatic boronic 
acids under anhydrous Suzuki-Miyaura cross-coupling conditions. In a subsequent reaction, the 
resulting MIDA boronate 1.133 was hydrolyzed in situ under slow-release conditions and 
coupled with a variety of aryl iodides to provide bissubstituted pyrazoles 1.134.  
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Scheme 1-32. ICC approach toward the synthesis of bissubstituted pyrazoles. 
 
 Slow-release cross-coupling with MIDA boronates has also provided the first general 
solution to “the 2-pyridyl problem”.122 This advance is further described in Chapter 3. 
The principles behind the slow-release cross-coupling of MIDA boronates have also 
found applications in organic synthesis, even beyond the Suzuki-Miyaura cross-coupling 
reaction. For example, Ellman and coworkers have developed the asymmetric rhodium-catalyzed 
addition of boronic acids 1.135 and boronates 1.136 to activated imines 1.137 toward the 
synthesis of chiral amines 1.138 (Scheme 1-33).
123
 They note that the efficiency of this process is 
hampered by the in situ decomposition of the boron reagents. Addition of pentenylboronic acid 
1.135 to 1.137 proceeded in low yield, even when using an excess of boronic acid. To address 
this limitation, they utilized the in situ, rate controlled hydrolysis of MIDA boronate 1.136 to 
continuously generate the boronic acid reagent throughout the course of the reaction. This 
strategy greatly improved the yield of the reaction. Further optimization of the reaction solvent 
provided high yields of the desired amine. These same reaction conditions were compatible with 
the addition of a variety of vinyl MIDA boronates to substituted imines. This approach was 
successfully employed in the synthesis of the natural product (-)-aurantioclavine.
124
 
 
 
Scheme 1-33. Preparation of chiral amines using slow release of boronic acids. 
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1-6.5 ICC IN SMALL MOLECULE SYNTHESIS: EFFICIENT ACCESS TO FUNCTIONAL 
MOLEUCLES 
Due to their ease of synthesis, purification, characterization, storage, and reversibly 
attenuated capacity for cross-coupling, MIDA boronates represent a powerful platform for the 
development of iterative synthesis strategies. Building upon the established synthesis strategies 
for the preparation of MIDA boronate building blocks and the ability to couple these reagents 
under slow and fast release conditions, the projects described in this thesis ultimately seek to 
provide a path toward an ICC-based general platform for small molecule synthesis. First, 
Chapter 1 describes the total synthesis and study of the antilipoperoxidant activity of the 
carotenoid natural product peridinin. This project not only inspired and motivated the 
development of new methodology for small molecule synthesis, but also enabled a fundamental 
understanding of carotenoid antilipoperoxidant activity. Second, Chapter 2 describes the 
synthesis and utility of three MIDA boronate building blocks: (Z)-2-bromovinyl MIDA boronate, 
1-bromovinyl MIDA boronate, and 2-pyridyl MIDA boronate. These building blocks represent 
motifs that are highly prevalent in natural products, pharmaceuticals, and materials. Building 
upon these concepts, Chapter 3 describes a generalized strategy for small molecule synthesis and 
its application in a specific test case toward the preparation of polyene motifs. Collectively, the 
overarching goal of these projects is to help shift the rate limiting step in small molecule science 
from synthesizing molecules to understanding and maximally harnessing their functional 
potential. 
 
1-7 SUMMARY 
 The inherent modularity found in many small molecules can be efficiently accessed in the 
laboratory through iterative approaches. Analogous to Nature’s synthesis of peptides, 
oligonucleotides, oligosaccharides, and small molecules, these iterative strategies involve a 
suitably protected form of the constituent monomer that is coupled to the growing end of the 
chain. After executing a deprotection sequence, additional cycles can then be conducted until the 
desired molecule is synthesized. Customized iterative sequences have been developed for the 
synthesis of polyketide, polyterpene, fatty acid, and nonribosomal peptide derived natural 
products. The iterative cross-coupling of pre-assembled bifunctional MIDA boronate building 
blocks represents an evolving platform with the potential for general application to a wide range 
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of complex small molecules of interest. Such an approach aspires to ultimately gain more 
efficient and flexible access to small molecules and thereby help to shift the rate limiting step in 
small molecule science from synthesis to function. 
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CHAPTER 2 
TOTAL SYNTHESIS AND ANTILIPOPEROXIDANT ACTIVITY OF PERIDININ 
 
Eric M. Woerly, Alan H. Cherney, Erin K. Davis, Hannah M. S. Haley, and Martin D. Burke 
 
Carotenoids are promising small molecule antilipoperoxidants. Among this group, 
peridinin is an interesting, atypical carotenoid. Hints in the literature suggest that peridinin may 
have antilipoperoxidant activity. However, isolation of peridinin from its natural source is very 
challenging and inefficient, and thus the underpinnings of its antilipoperoxidant activity have 
been only minimally explored. Seeking to evaluate and understand the potential 
antilipoperoxidant activity of peridinin, we completed the first fully stereocontrolled total 
synthesis of this natural product. 
The development of several important methods enabled the total synthesis of peridinin. 
These include the stereocontrolled Suzuki-Miyaura cross-coupling of haloallenes, which was 
utilized in the last carbon-carbon bond forming step in the total synthesis. Two novel 
transesterification reactions also enabled efficient access to peridinin: the conversion of a boronic 
ester to a MIDA boronate and the conversion of a MIDA boronate to a boronic ester.  
Having secured ready access to peridinin via this total synthesis, the antilipoperoxidant 
activity of this molecule was evaluated. In comparison to the carotenoid gold standard 
astaxanthin, peridinin was a more effective antilipoperoxidant in a chemically defined LUV 
system. Analysis of the carotenoid concentration further revealed that while both peridinin and 
astaxanthin are consumed throughout the lipoperoxidation assay, peridinin is consumed at a 
much slower rate than the less effective antilipoperoxidant astaxanthin. To better understand this 
increased antilipoperoxidant activity but slower consumption, we have explored the role of both 
astaxanthin and peridinin in the lipid peroxidation process. Preliminary results indicate that 
peridinin exhibits this superior activity via the rapid quenching of chain propagating lipid 
peroxyl radicals. 
Alan H. Cherney contributed to the synthesis and coupling of enantioenriched haloallenes 
and the preparation of building blocks for the total synthesis of peridinin. Erin K. Davis 
contributed to the synthesis of enantioenriched haloallenes. Hannah M. S. Haley contributed to 
the biophysical studies of peridinin. 
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Adapted from Woerly, E. M.; Cherney, A. H.; Davis, E. K.; Burke, M. D. J. Am. Chem. Soc. 
2010, 132, 6941-6943. 
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2-1 CAROTENOIDS ARE PROMISING ANTILIPOPEROXIDANTS 
Pathological lipid peroxidation has been linked to cancer, heart disease, and aging, 
among many other conditions.
1
 Deficiencies in antilipoperoxidant proteins increase incidence of 
these diseases in humans.
2
 Small molecules have demonstrated an important role in protecting 
against lipid peroxidation and may serve as functional surrogates for deficient antilipoperoxidant 
proteins, thereby protecting against disease development.
3
   
Evidence suggests that a diet rich in certain fruits and vegetables may help prevent the 
development of cancer and other diseases, presumably by reducing lipid peroxidation.
4
 It has 
been proposed that carotenoids present in these foods are responsible for protecting the lipid 
membrane by interacting with reactive oxygen species (ROS).
5
 As a class of compounds, 
carotenoids are promising small molecule antilipoperoxidants. Among this group, astaxanthin 
(2.1, Figure 2-1) has emerged as a leading candidate for applications in medicine
6
 and is 
considered the current “gold standard”.7 This natural product is available as a dietary 
supplement, generating $200 million in sales per year.
8
 While these advances are highly 
encouraging, two important limitations stand to limit astaxanthin’s impact. First, high 
concentrations of astaxanthin (>5% of total lipid content in in vitro lipid bilayers) are generally 
required to achieve substantial antilipoperoxidant activity.
9
 Second, the mechanism(s) by which 
astaxanthin protects against lipid peroxidation have been proposed to involve free radical 
scavenging
10
 (leading to consumption of the carotenoid) and/or modulation of membrane 
dynamics,
11
 but these mechanisms are not well understood. This lack of clarity has precluded the 
rational optimization of astaxanthin’s activity. Encouraged by the promising activity of 
astaxanthin, we are interested in exploring and understanding the use of carotenoid natural 
products or their derivatives as substitutes for the deficient or dysfunctional antilipoperoxidant 
proteins that underlie human disease.
12
 
 
 
Figure 2-1. Structure of the carotenoid natural products astaxanthin and peridinin. 
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To guide our search for molecules with advanced antilipoperoxidant capacity with the 
goal of better understanding the mechanism of carotenoid antilipoperoxidant activity, we have 
focused on carotenoids produced by organisms that thrive in environments of extreme oxidative 
stress.
13
 In this regard, peridinin
14
 (2.2, Figure 2-1), produced by the photosynthetic 
dinoflagellate responsible for “red tides”,15 represents an attractive candidate. As a key 
component of the peridinin-chlorophyll-protein complex,
16
 peridinin is thought, in part, to 
protect against the extensive reactive oxygen species generated during photosynthesis.
17
 
However, despite being one of the most abundant carotenoids on earth,
18
 isolation of 2.2 from 
dinoflagellates is very challenging and inefficient,
19
 and thus its potential antilipoperoxidant 
activity has been only minimally explored. In vivo, peridinin has demonstrated potent skin 
anticarcinogenic properties in mouse studies
20
 and has been identified as the primary singlet 
oxygen quencher in the marine algae Gonyaulax polyedra.
21
 In vitro, peridinin has demonstrated 
antilipoperoxidant activity, possibly via decreasing membrane permeability to ROS.
22
 While the 
underpinnings of these findings have been only minimally explored, they provide hints that 
peridinin may be an effective antilipoperoxidant. Obviating the challenges associated with 
isolating peridinin, we sought to gain access to this material via a fully stereocontrolled total 
synthesis in order to evaluate and understand its potential antilipoperoxidant activity. 
 
2-2 RETROSYNTHESIS OF PERIDININ 
While four total syntheses of peridinin have been reported,
23
 these syntheses have not 
constructed the polyene core in a stereocontrolled manner (Figure 2-2). For example, the 
syntheses completed by Ito and Katsumura utilized stereoselective Wittig and Julia olefination 
reactions
24
 to construct the polyene core. As a result, a mixture of cis and trans isomers were 
produced and optimized isomerization protocols had to be developed to convert these isomers 
into the desired all-trans framework. Brückner and coworkers completed a synthesis employing 
two stereospecific Stille cross-coupling reactions
25
 in the construction of the polyene core. 
However, the final step in their route was a Julia olefination reaction which resulted in a complex 
mixture of isomers, with the desired all-trans peridinin representing a minor component of the 
mixture. 
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Figure 2-2. Four syntheses of peridinin have been reported. The polyene core was not constructed in a 
stereocontrolled fashion in these syntheses. 
 
Notably, de Lera and coworkers reported an attempted synthesis of peridinin in 2005.
26
  
Their synthetic plan involved a Julia olefination and three Stille cross-coupling reactions, one of 
which was between a vinyl stannane and a chiral haloallene (Scheme 2-1).  The major product 
under optimized reaction conditions
27
 corresponded to net inversion at the allene center (2:1 
inversion:retention) and ultimately led to the synthesis of 6’-epi-peridinin. 
 
 
Scheme 2-1. de Lera synthesis of 6’-epi-peridinin. 
 
In addition to the strategies utilized in the reported syntheses of peridinin, several general 
approaches have been taken to the synthesis of carotenoids. Many of these strategies are aimed at 
the preparation of C2-symmetric carotenoids. Five C2-symmetic carotenoids are produced on an 
industrial scale via a symmetrical double Wittig coupling between a dialdehyde and a 
phosphonium salt.
28
 This approach takes advantage of the inherent symmetry of the carotenoid 
and can provide the carotenoid in high yield. However, the lack of stereocontrol with this method 
often results in a mixture of cis and trans isomers which must be isomerized or separated via 
specialized protocols. Ito has attempted to apply the Wittig methodology to the synthesis of 
peridinin, but found that the reaction conditions were incompatible with the structurally complex 
aldehyde and phosphonium salt building blocks.
29
 In general, the double Wittig strategy is 
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suitable for the large scale production of certain carotenoids, but this strategy can be difficult to 
apply to the laboratory scale production of carotenoids and their targeted derivatives. 
Another strategy for the synthesis of symmetrical carotenoids is the “two-fold Stille 
reaction” developed by de Lera, which involves a double Stille coupling to a central pentenyl 
bisstannane building block.
30
 This methodology was applied to the synthesis of β-carotene and 
zeaxanthin. While this methodology provides an efficient preparation of these carotenoids, the 
synthesis of the required pentenyl bisstannane utilized a Julia olefination reaction and resulted in 
a mixture of isomers. As a result, this strategy does not provide a completely stereocontrolled 
synthesis of these carotenoids. 
As first introduced in Chapter 1, Negishi and coworkers have reported a zirconium 
catalyzed carboalumination followed by palladium and zinc catalyzed cross-coupling strategy for 
the preparation of the C2-symmetric carotenoid β-carotene and the non-C2-symmetric carotenoid 
γ-carotene.31 While this method provides the carotenoids in >99% isomeric purity without the 
need for separations or isomerizations, the functional group compatibility of the 
carboalumination reaction has limited the application of this method to functionally simple 
carotenoids.   
In contrast to the synthetic strategies described above, we aim to prepare peridinin via an 
efficient, modular, flexible, and scalable synthetic plan, using only stereospecific reactions for 
the construction of the polyene core.
32
 Such a modular synthesis will enable the preparation of 
peridinin derivatives to aid in understanding the structure/function relationships that underlie the 
antilipoperoxidant activity of this natural product. 
Toward this end, we recognized that the iterative cross-coupling (ICC) strategy
33
 
introduced in Chapter 1 could be harnessed to enable an efficient total synthesis of peridinin.  
This approach is attractive because the building blocks used in this strategy contain preinstalled 
functionality and stereochemistry which is transferred to the product through the stereospecific 
Suzuki-Miyaura cross-coupling reaction. This eliminates the need for post-coupling 
modifications (e.g. oxidations/reductions, isomerizations), except for global deprotections at the 
end of the synthesis.  At the outset of this project, the application of this strategy to polyenes had 
been highly effective, as demonstrated by the synthesis of one-half of the polyene macrolide 
amphotericin B and polyene natural products all-trans-retinal and β-parinaric acid.34 
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As highlighted by the previous syntheses of peridinin, the many stereochemical issues, 
the complex and sensitive polyene core, and a diverse array of functional groups make peridinin 
a challenging synthetic target. Guided by the ICC strategy, we applied only Suzuki-Miyaura
35
 
transforms to retrosynthesize peridinin into four building blocks, 2.3-2.6, which have all of the 
required functional groups, oxidation states, and stereochemistry preinstalled (Scheme 2-2). We 
recognized, however, that the disconnection between C8’/C9’ corresponded to a stereocontrolled 
Suzuki-Miyaura coupling with a chiral allenyl halide. Albeit potentially very useful in the 
preparation of allene containing natural products,
36
 this was an unprecedented transformation 
that first required development. 
 
 
Scheme 2-2. Retrosynthesis of peridinin into four building blocks. 
 
2-3 METHODOLOGY FOR THE CROSS-COUPLING OF HALOALLENES 
At the start of this project, the Suzuki-Miyaura reaction had not been applied to the cross-
coupling of chiral, unactivated haloallenes. Previous work in this area utilized achiral haloallene 
coupling partners.
37
 However, important precedent lies in the Negishi coupling of 
enantioenriched haloallenes conducted by Vermeer and Elsevier.
38
 In these couplings, it was 
observed that iodoallenes favor coupling with stereoretention, while chloro- and bromoallenes 
favor stereoinversion. A model involving two competing mechanisms, direct oxidative addition 
at C1 or indirect SN2’ oxidative addition
39
 at C3 followed by a suprafacial 1,3-shift of Pd, was 
proposed to rationalize this observation (Figure 2-3).  
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Figure 2-3. Proposed mechanisms in the Negishi cross-coupling of enantioenriched haloallenes. 
 
 Based on this precedent and the assumption that the same mechanistic pathways are 
operative under Suzuki-Miyaura cross-coupling conditions, we generated a series of hypotheses 
to rationally pursue the stereoretentive Suzuki-Miyaura coupling of haloallenes. We reasoned 
that the use of an iodoallene should promote stereoretention via direct oxidative addition. We 
further hypothesized that increased steric bulk at C3 of the haloallene and the use of sterically 
bulky phosphine ligands would both promote stereoretention, by disfavoring SN2’-like attack at 
the more hindered internal site. 
 To test these hypotheses, together with first year graduate student Erin Davis and 
undergraduate Alan Cherney, a series of enantioenriched haloallenes were prepared. Access to 
enantioenriched chloro-, bromo-, and iodoallenes was accomplished through a five step reaction 
sequence (Scheme 2-3). Reaction of bis(trimethylsilyl)acetylene 2.7 with a series of acid 
chlorides 2.8 under Friedel-Craft conditions provided the known trimethylsilyl acetylenic 
ketones 2.9.
40
 A Noyori transfer hydrogenation followed by desilylation provided 
enantioenriched propargyl alcohols 2.10.
41
 Mesylation of the alcohol
42
 provided substrates for 
the cuprate mediated haloallene formation to provide enantioenriched haloallenes 2.11-2.15.
43
  
 
 
Scheme 2-3. Synthesis of enantioenriched haloallenes. 
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 With these substrates in hand, we set out to test our hypotheses for the stereocontrolled 
Suzuki-Miyaura coupling. Consistent with the Negishi coupling precedent, using conditions 
similar to those reported to promote the Suzuki-Miyaura coupling of achiral haloallenes, the 
reaction of PhB(OH)2 with enantioenriched chloro- and bromo allenes (R)-2.11,2.12 
demonstrated net stereoinversion to provide (S)-2.16a as the major product (Table 2-1, entries 1-
2). In contrast, coupling of iodoallene (R)-2.13 yielded (R)-2.16a with a moderate 72% 
stereoretention (entry 3). 
 
 
Table 2-1. Conditions for the Suzuki-Miyaura cross-coupling of enantioenriched haloallenes. 
 
 Building on this starting point, we tested the previously unconfirmed hypothesis
44
 that 
maximized steric bulk at C3 of an allenyl halide could promote stereoretention, presumably by 
disfavoring SN2’-like oxidative addition. Specifically, we evaluated a series of substrates 2.13-
2.15 containing progressively smaller R groups at C3 and indeed observed decreased 
stereoretention (entries 3-5). Finally, we tested our third hypothesis
45
 that bulky phosphine 
ligands
46
 would also promote stereoretentive direct oxidative addition at the less sterically 
hindered C1 by surveying a series of ligands with varying cone angles. In contrast to smaller 
cone angles (entries 3, 6-8), >90% stereoretention was observed for phosphine ligands having 
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cone angles >180
o47
 (entries 9-11). With air-stable XPhos,
48
 optimization of the solvent led to 
>99% stereoretention and 61% isolated yield of 2.16a (entry 12). 
Collectively, these findings revealed that maximized stereoretention in the Suzuki-
Miyaura coupling of chiral allenyl halides can best be accomplished using allenyl iodide 
substrates possessing steric bulk at C3 in combination with sterically bulky phosphine ligands. 
Guided by these principles, we designed building block 2.6 for peridinin to include both an 
allenyl iodide and a sterically bulky silyl protecting group at C5’. Building block 2.6 was 
prepared according to literature precedent with a TBS group at C5’ (see Section 2-5).  
The substrate scope of this coupling reaction was briefly explored. Using the conditions 
identified in entry 11 of Table 1, a variety of aryl, heteroaryl, and alkenyl boronic acids were 
coupled to racemic iodoallene 2.13 (Scheme 2-4). Greater than 95% conversion was observed by 
crude 
1
H-NMR for all couplings. The compatibility of this methodology with a variety of 
boronic acid coupling partners provided encouragement that this cross-coupling reaction may be 
viable in the context of the peridinin synthesis. 
 
 
Scheme 2-4. Substrate scope for the coupling of haloallenes with various boronic acids. 
  
2-4 A MODEL FOR THE HALOALLENE CROSS-COUPLING REACTION IN PERIDININ 
 Before pursuing the preparation of the remaining building blocks for the synthesis of 
peridinin, we wanted to evaluate the coupling of 2.6 using a model vinyl boronic acid to 
determine the stereo outcome of the coupling of our actual building block for the peridinin 
synthesis. With TBS protected iodoallene 2.6 in hand, the coupling with styrenyl boronic acid 
2.17 was evaluated using Pd2(dba)3/XPhos and Ag2O in THF/H2O (Scheme 2-5). The crude 
reaction mixture contained a single cross-coupled product 2.18, which was identified as the 
63 
 
desired retention product through single crystal X-ray analysis. Specifically, desilylation and 
deacylation of 2.18 provided highly crystalline allene 2.19, of which a crystal structure was 
obtained. Furthermore, the importance of a bulky protecting group at C5’ was evaluated. 
Coupling of unprotected iodoallene 2.20 with 2.17 under identical conditions provided a 3:2 d.r. 
favoring the desired retention product. The structure of the inversion product 2.21 was confirmed 
via isolation and single crystal X-ray analysis. We hypothesize that the decreased steric bulk at 
C3 may be responsible for the mixture of diastereomers. Alternatively, coordination of the 
palladium catalyst to the tertiary alcohol in 2.20 may enable the invertive SN2’ mechanism. 
Concurrent with these studies, de Lera and coworkers reported similar findings with the Stille 
coupling of 2.20.
49
 This model study emphasized the importance for a protecting group at C3 to 
favor stereoretention for the final cross-coupling in the peridinin synthesis. 
 
 
Scheme 2-5. A model study for the synthesis of peridinin. 
 
2-5 SYNTHESIS OF THE FOUR BUILDING BLOCKS FOR A TOTAL SYNTHESIS OF 
PERIDININ 
 With the methodology for a stereoretentive Suzuki-Miyaura cross-coupling of haloallenes 
in hand, we next sought to prepare the four building blocks for peridinin 2.3-2.6. Strategically, 
we utilized several guiding principles in the design and synthesis of these building blocks. First, 
we sought short, efficient, and scalable routes to all four molecules. We did not want our total 
synthetic efforts to be hampered by a lack of material and, as a result, pursued routes that could 
easily provide the building blocks on at least a gram scale. Taking advantage of the desirable 
physical properties of MIDA boronates and compatibility with a number of reagents, we 
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envisioned installing boron early in the synthetic routes as the MIDA boronate and carrying it 
through multiple steps to prepare the desired building block. Second, we sought to complete a 
fully stereocontrolled synthesis of peridinin. Employing the ICC strategy and the stereospecific 
Suzuki-Miyaura cross-coupling reaction ensures the building blocks will be united in a 
stereocontrolled fashion. Additionally, in order to achieve this goal, the reactions used to 
synthesize the building blocks need to be highly stereoselective or stereospecific. 
 Building blocks 2.3 and 2.6 were prepared according to literature precedent from a 
common precursor (Scheme 2-6). Specifically, hydroboration
50
 of alkyne 2.22, prepared from    
(-)-actinol 2.23
51
 in seven steps and 40% overall yield, provided pinacol ester 2.24. The structure 
of 2.24 was confirmed through single crystal X-ray analysis. Multiple grams (>5 g) of 2.24 could 
be readily prepared in one batch. Haloallene 2.6 was prepared from 2.22 according to literature 
precedent
52
 and the absolute configuration of the allene was confirmed through single crystal X-
ray analysis (Scheme 2-4). To the best of our knowledge, this was the first example of a crystal 
structure of an iodoallene.
53
 
 
 
 
Scheme 2-6. Synthesis of building blocks 2.24 and 2.6. 
 
 As outlined in Chapter 1, the unique compatibilities of the MIDA boronate functional 
group with a wide range of reaction conditions and chromatography were utilized to prepare the 
final two building blocks. Specifically, commercially available propynyl MIDA boronate 2.25 
underwent highly regio- and stereocontrolled molybdenum-catalyzed hydrostannylation
54
 to 
yield bis-metalated olefin 2.26 (Scheme 2-7). A subsequent metal and halide selective Stille 
coupling between 2.26 and lactone 2.27
55
 provided 2.4 as a single stereoisomer. The structure of 
2.4 was confirmed via single crystal X-ray analysis. Multiple grams (>10 g) of 2.4 could readily 
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be prepared in one batch. The final building block was prepared via initial bromination of 
commercially available 2.28 followed by regio- and stereoselective elimination to generate the 
novel tri-substituted bromoalkenyl MIDA boronate 2.29 as a single stereoisomer. Two cycles of 
stereospecific metal-selective cross-coupling with bis-metalated olefin 2.30
56
 followed by 
stereoretentive iododegermylation,
57
 as discovered by Dr. Suk Joong Lee and described in 
Chapter 1,
58
 provided 2.5. Gram quantities of 2.5 could be readily prepared. 
 
 
Scheme 2-7. Synthesis of building blocks 2.4 and 2.5. 
 
2-6 STEREOCONTROLLED TOTAL SYNTHESIS OF PERIDININ 
 The synthesis of peridinin was completed using only Suzuki-Miyaura coupling to 
iteratively unite the four building blocks. Initial attempts to couple pinacol ester 2.24 directly to 
bifunctional lactone building block 2.4 were met with incomplete conversion (<50%) and the 
generation of inseparable impurities (Scheme 2-8). It was hypothesized that formation of the 
corresponding MIDA boronate of 2.31 would permit mild hydrolysis to the boronic acid 2.32, 
which would allow access to additional reaction conditions for coupling with 2.4. In a novel 
transformation, pinacol ester 2.24 was directly transesterified under mild conditions to form air 
and chromatography stable, crystalline MIDA boronate 2.31.
59
 This direct transesterification 
from a boronic ester to a MIDA boronate avoids the intermediacy of unstable boronic acids, and 
as described in Section 2-7, this methodology has proven to be general for the synthesis of 
MIDA boronates. 
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Scheme 2-8. The coupling of building blocks 2.3 and 2.4 could not be accomplished in high yield. An alternative 
strategy involving the preparation of boronic acid 2.32 was pursued. 
 
 Hydrolysis of 2.31 followed by B-selective cross-coupling with 2.4 provided tetraenyl 
MIDA boronate 2.33 (Scheme 2-9). The corresponding boronic acid proved to be unstable, thus 
a new tactic was developed to promote the next cycle of B-activation and coupling. Specifically, 
in a novel transformation, 2.33 was directly converted into the corresponding pinacol ester, 
which was an effective intermediate for B-selective coupling with 2.5. This transesterification 
reaction has proven to be general and is further described in Section 2-7. The resulting highly 
complex heptaenyl MIDA boronate 2.34 was stable to chromatography and storage. Conversely, 
attempts to isolate the heptaenyl boronic acid derived from 2.34 were not fruitful. To solve this 
challenging problem, we hybridized the principles established above for allenyl halide coupling 
(Table 2-1) with in situ release of the unstable boronic acid
60
 (see Chapter 1) derived from 
MIDA boronate 2.34 to promote the final union with 2.6 in good yield and with complete 
stereoretention. Initially, global desilylation was attempted with both TBAF and HF pyridine. 
However, the sterically hindered tertiary TBS group was not removed. To solve this, building 
block 2.35, which contains a more labile TMS group, was utilized in the final cross-coupling 
reaction. This coupling also proceeded in good yield and with complete stereoretention. Global 
desilylation with HF pyridine concluded the first completely stereocontrolled total synthesis of 
2.2. 
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Scheme 2-9. Total synthesis of peridinin. 
  
 Utilizing this efficient synthesis pathway and drawing inspiration from the proposed 
biosynthesis of peridinin,
61
 Erin Davis has initiated studies probing the importance of key 
functional groups, such as the butenolide and allene, on the molecule’s antilipoperoxidant 
activity.   
 
2-7 THE TRANSESTERIFICATION REACTION 
 As described in Section 2-6, two novel transformations were developed to complete the 
total synthesis of peridinin, a transesterification reaction from a boronic ester to a MIDA 
boronate and a transesterification reaction from a MIDA boronate to a boronic ester. Both of 
these reactions have proven to be general and have found utility beyond the synthesis of 
peridinin. 
 First, the transesterification of a boronic ester to a MIDA boronate was discovered 
because a shelf stable form of building block 2.3 that could be readily converted to a boronic 
acid was sought for the peridinin synthesis. While pinacol ester 2.24 was stable to storage under 
an inert atmosphere at -20
 o
C for two months, long term storage resulted in decomposition. 
Furthermore, attempts to convert 2.24 to boronic acid 2.32 were either sluggish or led to 
desilylation or opening of the epoxide. Alternative approaches to prepare MIDA boronate 2.31, 
including Snieckus hydroboration conditions,
62
 were not fruitful. Therefore, a direct conversion 
of a boronic ester intermediate was attempted. 
 Initially, catechol ester 2.36 was prepared from hydroboration of alkyne 2.22 (Scheme 2-
10). Direct transesterification with an excess of MIDA in DMSO provided a 47% yield of the 
desired MIDA boronate 2.31 on small scale. The reaction provided lower yields on larger scales 
(>0.5 mmol). A major byproduct, identified as desilylated MIDA boronate 2.37, was also 
68 
 
isolated. We hypothesized that the acidic catechol byproduct was leading to cleavage of the silyl 
group and a decreased yield. As a result, transesterification of the pinacol ester intermediate 2.24 
was explored. Optimized conditions revealed that an excess of MIDA (6 eq.) in DMSO at 65 
o
C 
provided a 73% isolated yield of 2.31 after three cycles. Temperatures higher than 65 
o
C led to 
partial cleavage of the TBS group. Additional equivalents of MIDA (> 6 eq.) did not provide a 
large increase in isolated yield. 
 
 
Scheme 2-10. Initial route to building block 2.31. The route suffered from low and irreproducible yields. 
 
 Formation of the MIDA boronate can be favored by using an excess of MIDA or by 
running the reaction at high temperature. For example, conversion of 2.24 to 2.31 was monitored 
with varying equivalents of MIDA (Table 2-2). This data indicates that an excess of MIDA 
provides better conversion. Furthermore, better conversion is observed at higher temperatures 
(50% conversion at 65 
o
C and 65% conversion at 100 
o
C with 6 eq. of MIDA for 7 h). This data 
is consistent with the reaction being under thermodynamic equilibrium. The equilibrium 
concentration of the two boronates can also be established starting from the MIDA boronate. 
Addition of pinacol, MIDA, and DMSO to a MIDA boronate reestablishes the pinacol 
ester:MIDA boronate equilibrium distribution. In an attempt to further drive the reaction toward 
the desired MIDA boronate product, a number of additives were explored. For example, 
destruction or sequestration of the pinacol byproduct would drive the equilibrium toward the 
product. Additives such as NaIO4, CaCl2, molecular sieves, MgSO4, and MgCl2 had no effect on 
the conversion and often led to byproduct formation. Addition of toluene as a cosolvent (to 
precipitate out the MIDA boronate product as it formed) did not improve conversion. Because 
MIDA is an inexpensive and readily available material it was decided to not pursue further 
optimization of this reaction. 
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Table 2-2. Effect of number of equivalents of MIDA on the reaction conversion. 
 
 As first discovered in the context of the peridinin synthesis, a variety of boronic esters 
can be transesterified to MIDA boronates. Because of the decreased thermodynamic stability of 
catechol esters (in comparison to pinacol esters),
63
 full conversion of a catechol ester to a MIDA 
boronate can be accomplished using a slight excess of MIDA (1.5 or 2.0 eq.) under mild heat (40 
o
C) in DMSO. Neopenylglycol esters, ethyleneglycol esters, and diethanolamine esters have also 
been converted to MIDA boronates. 
 This methodology provides the convenient and facile preparation of MIDA boronates. 
Beyond the Burke group, this method has also found use by the Taylor group (Scheme 2-11).
64
 A 
variety of substituted alkynes were hydroborated with catechol borane and directly 
transesterified to provide the MIDA boronates. 
 
 
Scheme 2-11. Synthesis of MIDA boronates via transesterification of catechol esters by the Taylor group. 
 
 Additionally, the conversion of MIDA boronates to pinacol esters is possible. Initial 
screens to convert styrenyl MIDA boronate to styrenyl pinacol ester using an excess of pinacol 
(25 eq.) in a variety of solvents (acetone, THF, ethyl acetate, MeCN, toluene, methylene 
chloride) provided low conversion at 50 
o
C (<5% conversion) and only slightly better conversion 
at elevated temperatures (~10% conversion at 100 
o
C). Because this methodology was to be used 
in the presence of the sensitive polyene core of peridinin, mild conditions were desired. 
Application of methanol as the reaction solvent, however, provided full conversion at 50 
o
C after 
15 h. Additional temperatures were then explored. No conversion was obtained at 23 
o
C or 35
 o
C 
using 5 eq. of pinacol in methanol after 3 h, however 25% conversion was observed at 45 
o
C. 
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This improved to 70% conversion after 9 h. In an attempt to accelerate the reaction, a series of 
basic additives were explored, including NaOMe, NaHCO3, and K3PO4. Full conversion was 
observed using NaHCO3 after 3 h. These conditions (slight excess of pinacol, NaHCO3, 
methanol, 45 
o
C, 3 h) have been established as the standard conditions to convert a MIDA 
boronate to a pinacol ester. Excess pinacol can be removed by stirring the crude reaction mixture 
with CaCl2 in toluene.  
 This methodology provides the convenient and facile preparation of pinacol esters. Other 
boronic esters can also be prepared from this method. For example, catechol esters, 
ethyleneglycol esters, and neopentylglycol esters have been prepared by using the corresponding 
diol. Beyond the synthesis of peridinin, this methodology has also been useful in several other 
contexts (Scheme 2-12). Dr. Kaitlyn Gray used the transesterification reaction in order to 
optimize the yields in route to C35-deoxy amphotericin B 2.38.
65
 Junqi Li used the 
transesterification reaction to convert a PIDA boronate to a pinacol ester in the preparation of a 
pharmaceutical agent 2.39.
66
 Finally, Yudin and coworkers have used the transesterification 
reaction in the preparation of unnatural amino acids 2.40.
67
 
 
 
Scheme 2-12. Application of the transesterification reaction in several different contexts. 
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2-8 THE ANTILIPOPEROXIDANT ACTIVITY OF PERIDININ 
 Having secured ready access to peridinin via a completely stereocontrolled total 
synthesis, we next sought to explore the antilipoperoxidant activity of this molecule. As a 
starting point, we compared the activity of peridinin to the “gold standard” astaxanthin in vitro. 
Roughly 25% of the lipids in a mammalian cell membrane contain polyunsaturated fatty 
acids (PUFA) (LH, Figure 2-4).
68
 Upon exposure to reactive oxygen species, such fatty acids can 
be transformed into a lipid peroxyl radical (LOO•)69 which, in turn, can react with a neighboring 
unsaturated fatty acid to form a lipid hydroperoxide (LOOH) and a carbon-centered radical (L•) 
with a rate constant kp.
70,71
 A subsequent fast reaction with O2 (diffusion-limited when pO2 > 100 
Torr) generates a new lipid peroxyl radical, thus closing the loop for radical chain propagation 
and extensive peroxidation of a lipid bilayer.
72
 The LOO• can alternatively be quenched by an 
antilipoperoxidant with a rate constant kq.
73
 Highly effective carotenoids may quench early in 
this lipoperoxidation process (kq > kp), leading to limited propagation and minimized 
consumption of the carotenoid (when the carotenoid is in excess of LOO•). Alternatively, less 
effective carotenoids may quench later in the lipoperoxidation process (kq < kp), leading to 
extensive propagation and increased consumption of the carotenoid. The mechanistic 
connections between lipid peroxidation and the causation of human diseases remain 
incompletely understood. However, it has been demonstrated that LOO• can decompose to yield 
highly electrophilic breakdown products, such as malondialdehyde (MDA),
74
 which can alkylate 
DNA, proteins, and other biomolecules and thereby cause a wide range of deleterious impacts on 
the cell, including mutagenesis.
75
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Figure 2-4. Proposed mechanism of lipoperoxidation. 
 
This lipid peroxidation process can be replicated in large unilamellar vesicles (LUVs).
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Specifically, as shown in Figure 2-4, when exposed to either Cu
77
 or Fe
78
 salts, pre-existing lipid 
hydroperoxides are broken down to generate LOO• [LUVs prepared using commercial lipid 
mixtures isolated from natural sources, e.g., egg yolk phosphatidylcholine (EYPC), almost 
always contain small quantities of LOOH]. Following this initiation event, radical chain 
propagation can proceed as described above, leading to the progressive formation of MDA, 
which can be precisely quantified in the form of its adduct with thiobarbituric acid via HPLC or 
via UV at 535 nm.
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Employing this established LUV-based assay we discovered that synthetic 2.2 is a much 
more effective antilipoperoxidant than the gold standard 2.1 (Figure 2-5) in EYPC. Consistent 
with literature precedent,
80
 2.1 partially protected against lipid peroxidation when incorporated at 
a concentration of 1.0% of total lipid, but after 48 hours the total lipid peroxidation in the treated 
sample was equivalent to that observed in untreated controls. In stark contrast, a concentration of 
0.9% peridinin resulted in complete protection against lipid peroxidation for more than 30 hours. 
Reducing the concentration to 0.5% caused a substantial loss of activity for astaxanthin, whereas 
peridinin maintained an outstanding level of protection, delaying the time required to achieve 
complete peroxidation by more than 10 hours. 
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Figure 2-5. Evaluating the antilipoperoxidant activity of peridinin and astaxanthin in EYPC. 
 
As described above, evidence in the literature suggests that carotenoids exhibit 
antilipoperoxidant activity through the quenching of propagating LOO•.81 This process would 
predict consumption of the carotenoid throughout the lipoperoxidation assay and more effective 
antilipoperoxidants would experience less rapid consumption. Quantitative HPLC analysis
82
 of 
the carotenoid concentration throughout the course of the assay revealed that both peridinin and 
astaxanthin are consumed throughout the assay, but peridinin is consumed at a much slower rate 
than the less effective antilipoperoxidant astaxanthin (Figure 2-6). To better understand the 
increased antilipoperoxidant activity of peridinin but slower consumption and to probe if 
peridinin is an early quencher, we have further explored the role of both astaxanthin and 
peridinin in the lipid peroxidation process. 
 
 
Figure 2-6. Evaluating the consumption of peridinin and astaxanthin in EYPC. 
 
Toward this end, we recognized that the use of EYPC to prepare LUVs for in vitro 
antilipoperoxidation experiments has several important limitations. First, because it is a natural 
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extract, the composition of EYPC can vary considerably as a function of the commercial supplier 
and/or even the batch number. This makes it very challenging to achieve a high degree of 
reproducibility. Second, because it is obtained as a mixture, it is very difficult to selectively 
remove individual lipid components to determine their roles in the different stages of the lipid 
peroxidation process and/or the consequences of their omission. Finally, while the major 
components of EYPC have been identified and are quantifiable by GC,
83
 there are many minor 
components that are typically unidentified. Thus, it is not possible to rule out potentially 
catalytic/important role(s) for such minor components in the lipid peroxidation process.  
To circumvent all of these limitations, we developed a LUV-based lipid peroxidation 
assay system comprised completely of synthetic lipid components. Specifically, we found that, 
after treatment with the same CuCl2 initiator, LUVs derived from a mixture of synthetic POPC 
(16:0-18:1, 75 mol%) and PUFA (18:0-20:4, 25 mol%) produced a lipid peroxidation profile 
very similar to that observed previously with EYPC LUVs (Figure 2-7). Furthermore, similar to 
the EYPC LUV system, 2.2 is a much more effective antilipoperoxidant than 2.1 in the 
chemically defined LUV system. Moreover, peridinin was also consumed at a slower rate than 
astaxanthin (Figure 2-8). With this very well characterized system in hand, we set out to 
determine the mechanistic underpinnings of the antilipoperoxidant activity of peridinin. 
 
 
Figure 2-7. Evaluating the antilipoperoxidant activity of peridinin and astaxanthin in a chemically defined liposome 
system. 
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Figure 2-8. Evaluating the consumption of peridinin and astaxanthin in a chemically defined liposome system. 
 
To guide our mechanistic studies, we first sought to confirm that LOO• is the component 
of the chemically defined system that is responsible for carotenoid consumption. Incorporation 
of peridinin or astaxanthin into POPC liposomes lacking PUFAs and LOOH and subjection to 
the CuCl2 initiated assay conditions resulted in no consumption of the carotenoids over 26 hours 
(Figure 2-9). Additionally, incorporation of carotenoids into POPC liposomes containing PUFAs 
and LOOH, but lacking CuCl2 also resulted in no consumption of 2.1 or 2.2.  Together these 
results indicate that the initiation components alone are not responsible for carotenoid 
consumption. Carotenoid consumption was not observed in samples containing PUFA and CuCl2 
but lacking LOOH,
84
 indicating that the presence of PUFA alone is not sufficient for carotenoid 
consumption.  Next, we added CuCl2 to the liposomes containing only the carotenoids, POPC, 
and LOOH (13(S)-HpOTrE, 13(S)-hydroperoxy-6Z,9Z,11E-octadecatrienoic acid) and observed 
time dependent consumption of 2.1 and 2.2. This data is consistent with LOO•, generated from 
the reaction between LOOH and CuCl2, being responsible for carotenoid consumption. As 
shown in Figure 2-4, oxygen is needed for the chain propagation process to occur. As a result, it 
can be hypothesized that exclusion of oxygen from the system would result in minimal 
carotenoid consumption because the substrate for reaction with the carotenoid (LOO•) would be 
at a low concentration. To test this hypothesis, the carotenoid concentration was monitored in the 
absence of oxygen. Consistent with this mechanism, and with the importance of LOO• in the 
chain propagation process, only a slight decrease in the concentration of astaxanthin was 
observed. 
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Figure 2-9. Consumption of astaxanthin under various conditions to determine which component of the chemically 
defined liposome system is responsible for carotenoid consumption. 
 
Based on this framework, we have explored two hypotheses for the source of peridinin’s 
superior antilipoperoxidant activity yet minimized chemical reactivity (Figure 2-10): 1) 
peridinin, more effectively than astaxanthin, decreases the lateral diffusion of propagating lipid 
radicals,
85
 thus decreasing both kp and kq and 2) for peridinin, but not for astaxanthin, kq is 
substantially greater than kp, thus both lipid peroxidation and consumption are minimized. 
 
 
Figure 2-10. Hypotheses for the source of peridinin’s superior antilipoperoxidant activity. 
 
To test the first hypothesis, we utilized a liposome-based solution phase NMR assay to 
evaluate the impact of carotenoid incorporation on the rate of lipid lateral diffusion.
86
 The lateral 
diffusion of lipids, including LOO•, effects the rate of propagation in the lipoperoxidation 
process, as well as the rate of carotenoid quenching. A decrease in lipid lateral diffusion would 
result in a decrease of both kp and kq. Changes in the solution phase NMR linewidths of lipid 
molecules contained in liposomes can be correlated to changes in lateral diffusion. Specifically, 
an increase in linewidth indicates a decrease in lipid lateral diffusion. This effect has been 
demonstrated using small molecules such as cholesterol and has been used to rationalize the 
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antilipoperoxidant effect of cholesterol.
87
 We have coupled this NMR assay with the 
antilipoperoxidant assay described above to correlate effects on lipid lateral diffusion to 
antilipoperoxidant activity. Using this strategy, we have demonstrated a concentration dependant 
correlation between cholesterol concentration, antilipoperoxidant activity, and lipid lateral 
diffusion (in EYPC); higher concentrations of cholesterol lead to more effective 
antilipoperoxidant activity and exhibit decreased levels of lipid lateral diffusion (Figure 2-11). 
 
 
 
Figure 2-11. Correlation between lipid lateral diffusion and concentration of cholesterol. Higher concentrations of 
cholesterol lead to more effective antilipoperoxidant activity and decreased levels of lipid lateral diffusion. 
 
We next applied this coupled NMR/antilipoperoxidant assay to probe the role of lipid 
lateral diffusion in the mechanism of carotenoid antilipoperoxidant activity (in EYPC, Figure 2-
12). Similar to cholesterol, astaxanthin decreased lipid lateral diffusion in a dose dependant 
manner. However, inconsistent with our first hypothesis, there was no distinguishable difference 
between the effects on lipid lateral diffusion between cholesterol and astaxanthin. Furthermore, 
incorporation of astaxanthin at the same concentrations as cholesterol revealed far superior 
antilipoperoxidant activity of the carotenoid in comparison to cholesterol, despite a similar effect 
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on lipid lateral diffusion. The same experiments are currently underway with peridinin. Overall, 
this study has revealed that, while polar carotenoids such as astaxanthin decrease lipid lateral 
diffusion, the magnitude of this effect is minimal and inconsistent with the large 
antilipoperoxidant effect that is observed. 
 
 
 
Figure 2-12. Correlation between lipid lateral diffusion and concentration of astaxanthin, in comparison to 
cholesterol. Astaxanthin decreases lipid lateral diffusion but the magnitude of this effect is minimal and inconsistent 
with the large antilipoperoxidant effect that is observed. 
 
The second hypothesis which could explain peridinin’s superior antilipoperoxidant activity 
states that the rate constant for quenching LOO• by peridinin, kq, is both greater than the rate of 
propagation, kp, as well as the rate constant for quenching by astaxanthin. To test the first part of 
this hypothesis, together with Hannah Haley, we have tracked the concentration of PUFA and the 
carotenoid over time. We hypothesized that if kq for peridinin is greater than kp than we would 
observe consumption of peridinin but no consumption of the PUFA. Incorporation of peridinin 
into the chemically defined liposome and tracking the concentration of the carotenoid and PUFA 
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revealed consumption of peridinin and no consumption of the PUFA, consistent with our 
hypothesis and with kq,peri > kp (Figure 2-13).  
 
 
 
Figure 2-13. PUFA and peridinin consumption in a chemically defined liposome system. 
 
Additionally, we hypothesized that astaxanthin is a less effective antilipoperoxidant than 
peridinin because kq for astaxanthin is less than or equal to kp. This hypothesis would predict 
simultaneous consumption of the PUFA and astaxanthin. Incorporation of astaxanthin into the 
chemically defined liposome and tracking the concentration of the carotenoid and PUFA 
revealed consumption of astaxanthin as well as consumption of the PUFA, consistent with our 
hypothesis and with kq,astax ≤ kp (Figure 2-14). 
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Figure 2-14. PUFA and astaxanthin consumption in a chemically defined liposome system. 
 
 Finally, to test if the rate constant for quenching with peridinin (kq,peri) is greater than the 
rate constant for quenching with astaxanthin (kq,astax) we conducted a competition experiment to 
measure the relative rate of carotenoid consumption in the lipoperoxidation assay. Preliminary 
results indicate that incorporation of nearly identical concentrations of peridinin and astaxanthin 
into the same POPC/PUFA liposome followed by CuCl2 mediated initiation leads to preferential 
reaction of peridinin over astaxanthin (Figure 2-15). Consistent with the hypothesis, this result 
demonstrates that the kq for peridinin is greater than the kq for astaxanthin. Currently, additional 
experiments are underway to provide further support for this hypothesis. 
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Figure 2-15. Carotenoid consumption competition experiment conducted in a chemically defined liposome system. 
 
2-9 SUMMARY AND CONCLUSIONS 
 Taking advantage of a building block based strategy for small molecule synthesis, we 
accomplished the first completely stereocontrolled total synthesis of peridinin. This synthesis 
effort inspired the development of several new methodologies, including the stereocontrolled 
Suzuki-Miyaura cross-coupling of haloallenes and transesterification of boronic esters to MIDA 
boronates and MIDA boronates to boronic esters. This flexible and efficient route has enabled 
the preparation of derivatives of peridinin. Furthermore, we have used this synthetic material to 
probe the antilipoperoxidant activity of peridinin. These studies have revealed that peridinin is a 
more effective antilipoperoxidant than the current gold standard, astaxanthin. Mechanistic 
studies in a chemically defined liposome system have revealed that peridinin exhibits this 
excellent activity through the early quenching of lipid peroxyl radicals, quenching these radicals 
at a rate greater than propagation. Collectively, these studies reveal that peridinin can serve as a 
potent probe molecule to further understand the antilipoperoxidant mechanism of carotenoids. 
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CHAPTER 2 
EXPERIMENTAL SECTION 
 
Materials. Commercial reagents were purchased from Sigma-Aldrich, Fisher Scientific, Alfa 
Aesar, TCI America, Strem Chemicals Inc., or Frontier Scientific and were used without further 
purification unless otherwise noted. (-)-Actinol was a generous gift from DSM Nutritional 
Products in Basel, Switzerland. Solvents were purified via passage through packed columns as 
described by Pangborn and coworkers
1
 (THF, Et2O, CH3CN, CH2Cl2: dry neutral alumina; 
hexane, benzene, and toluene: dry neutral alumina and Q5 reactant; DMSO, DMF: activated 
molecular sieves). All water was deionized prior to use. Triethylamine, diisopropylamine, 
pyridine, and 2,6-lutidine were freshly distilled under an atmosphere of nitrogen from CaH2. The 
following compounds were prepared according to known literature procedures: iodoallene 2.6 
and 2.35,
2
 haloallenes 2.11-2.15,
3
 alkyne 2.22,
4
 dibromolactone 2.27,
5
 and vinyl germane 2.30.
6
  
Propynyl MIDA boronate 2.25, vinyl stanane 2.26, isoprenyl MIDA boronate 2.28, and bromide 
2.29 are commercially available from Sigma-Aldrich. 
 
General Experimental Procedures. Unless noted, all reactions were performed in flame-dried 
round bottom or modified Schlenk flasks fitted with rubber septa under a positive pressure of 
argon or nitrogen. Organic solutions were concentrated via rotary evaporation under reduced 
pressure with a bath temperature of 35 – 40 oC. Reactions were monitored by analytical thin 
layer chromatography (TLC) performed using the indicated solvent on E. Merck silica gel 60 
F254 plates (0.25mm). Compounds were visualized by exposure to a UV lamp (λ = 254 nm) 
and/or a solution of basic KMnO4 followed by brief heating using a Varitemp heat gun. MIDA 
boronates are compatible with standard silica gel chromatography, including standard loading 
techniques. Column chromatography was performed using standard methods
7
 or on a Teledyne-
Isco CombiFlash Rf purification system using Merck silica gel grade 9385 60Å (230-400 mesh). 
For loading, compounds were adsorbed onto non acid-washed Celite in vacuo from an acetone 
solution. Specifically, for a 1 g mixture of crude material the sample is dissolved in reagent grade 
acetone (25 to 50 mL) and to the flask is added Celite 454 Filter Aid (5 to 15 g). The mixture is 
then concentrated in vacuo to afford a powder, which is then loaded on top of a silica gel 
90 
column. The procedure is typically repeated with a small amount of acetone (5 mL) and Celite (2 
g) to ensure quantitative transfer. 
 
Structural analysis. 
1
H NMR spectra were recorded at 23 °C on one of the following 
instruments: Varian Unity 400, Varian Unity 500, Varian Unity Inova 500NB. Chemical shifts 
(δ) are reported in parts per million (ppm) downfield from tetramethylsilane and referenced to 
residual protium in the NMR solvent (CHCl3, δ = 7.26; CD2HCN, δ = 1.94, center line; acetone-
d6, δ = 2.05, center line) or to added tetramethylsilane (δ = 0.00). Data are reported as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = 
sextet, sept = septet, m = multiplet, b = broad, app = apparent), coupling constant (J) in Hertz 
(Hz), and integration. 
13
C NMR spectra were recorded at 23 °C on a Varian Unity 400 or Varian 
Unity 500. Chemical shifts (δ) are reported in ppm downfield from tetramethylsilane and 
referenced to carbon resonances in the NMR solvent (CDCl3, δ = 77.0, center line; CD3CN, δ = 
1.30, center line; acetone-d6, δ = 29.80, center line) or to added tetramethylsilane (δ = 0.00). 
Carbons bearing boron substituents were not observed (quadrupolar relaxation). 
11
B NMR were 
recorded at 23 °C on a General Electric GN300WB or a Varian Unity Inova 400 instrument and 
referenced to an external standard of BF3•Et2O. High resolution mass spectra (HRMS) were 
performed by Furong Sun, Dr. Steve Mullen, and Beth Eves at the University of Illinois School 
of Chemical Sciences Mass Spectrometry Laboratory. Infrared spectra were collected from a thin 
film on NaCl plates on a Perkin-Elmer Spectrum BX FT-IR spectrometer, a Mattson Galaxy 
Series FT-IR 5000 spectrometer or a Mattson Infinity Gold FT-IR spectrometer. Absorption 
maxima (νmax) are reported in wavenumbers (cm
-1
). Specific rotations were measured on a Jasco 
DIP-370 Digital Polarimeter. Gas chromatography analysis was conducted on an Agilent 
Technologies 7890A instrument. GC yields are based on a dodecane internal standard using an 
Agilent Technologies HP-5 column (part number 19091J-413). The stereoretention values were 
determined by GC analysis with an Agilent Technologies chiral β-cyclodextrin stationary phase 
(part number 112-2532). X-ray crystallographic analyses were carried out by Dr. Scott Wilson 
and Dr. Danielle Gray at the University of Illinois George L. Clark X-Ray facility. 
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Experimental procedures 
 
Haloallenes 2.11-2.15. 
The general reaction scheme for the synthesis of haloallenes 2.11-2.15 is shown below and 
reaction references are provided (Figure 2-1):
8, 9, 10, 11 
 
 
Figure 2-1.  Synthesis of haloallenes 2.11-2.15. 
 
 
General procedure for the synthesis of haloallenes 2.11-2.15.
3
  
Preparation of LiCuX2: 
The purity of copper (I) iodide was found to be critical to the enantiopurity of the products 2.11-
2.15. High purity (>99.999%) copper (I) iodide was purchased from Strem or prepared by 
recrystallization.
12
 
 
In a glovebox, to a Schlenk flask equipped with a stir bar and charged with copper (I) halide (4 
eq) was added THF (6 M with respect to the copper halide).  Lithium halide (2 eq) and THF (0.6 
M with respect to the lithium halide) were added to a separate vial.  The Schlenk flask and vial 
were sealed, removed from the glovebox, and placed under an argon atmosphere.  The copper (I) 
halide suspension was cooled to -78 C.  The lithium halide solution was cannula transferred into 
the Schlenk flask.  The mixture was stirred at -78 C for 30 minutes and then stirred at 23 oC for 
30 minutes.  The resulting cuprate solution was cooled to 0 C.  A solution of enantioenriched 
mesylate (1 eq) in THF (0.3 M with respect to the mesylate) was added dropwise via cannula to 
the cuprate solution.  The reaction proceeded with stirring at reflux for 1 hr 45 minutes.  After 
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cooling the resulting mixture to 23 
o
C, the solution was transferred to a separatory funnel 
containing 1:1 NH4Cl (sat. aq.):NH4OH (14.8 M) and shaken.  The layers were separated.  The 
aqueous layer was extracted with Et2O.  The combined organic layers were washed with brine, 
dried over magnesium sulfate, filtered, and concentrated in vacuo to afford the crude haloallene.  
This oil was purified via flash chromatography on silica gel (100% petroleum ether) to afford 
haloallenes 2.11-2.15 as oils. 
 
 
(R)-1-chloro-4,4-dimethyl-1,2-pentadiene, (R)-2.11.
3
  The general procedure was followed 
using CuCl (1.37 g, 13.9 mmol) in THF (2 mL), LiCl (0.30 g, 6.9 mmol) in THF (11 mL) and 
(S)-4,4-dimethylpent-1-yn-3-yl methanesulfonate (0.66 g, 3.5 mmol, 99:1 e.r.) in THF (11 mL).  
The work up used NH4Cl:NH4OH (150 mL), Et2O (2 x 125 mL), and brine (15 mL).  Flash 
chromatography (100% petroleum ether) gave chloroallene (R)-2.11 as a clear, pale yellow oil 
(0.075 g, 17%). 
 
TLC (petroleum ether) 
Rf = 0.72, visualized by short wave UV 
 
1
H-NMR (500 MHz, CDCl3) 
δ 6.05 (d, J = 5.5 Hz, 1H), 5.61 (d, J = 5.5 Hz, 1H), 1.09 (s, 9H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 199.5, 113.3, 89.3, 33.0, 29.5 
 
HRMS (EI+) 
Calculated for C7H11Cl: 130.0549 
Found:    130.0543 
 
 24D -139.8 (c 0.9, CHCl3) 
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The e.r. was determined by chiral GC using a Cyclodex B column: 
 tr (major) 2.0 min, tr (minor) 2.2 min; temperature: 80 °C; 6.5 mL/min.: 93.9:6.1 e.r. 
 
 
(R)-1-bromo-4,4-dimethyl-1,2-pentadiene, (R)-2.12.
3
  The general procedure was followed 
using CuBr (1.92 g, 13.3 mmol) in THF (2 mL), LiBr (0.58 g, 6.7 mmol) in THF (11 mL) and 
(S)-4,4-dimethylpent-1-yn-3-yl methanesulfonate (0.64 g, 3.3 mmol, 99:1 e.r.) in THF (11 mL).  
The work up used NH4Cl:NH4OH (150 mL), Et2O (2 x 125 mL), and brine (15 mL).  Flash 
chromatography (100% petroleum ether) gave bromoallene (R)-2.12 as a clear, yellow oil (0.080 
g, 14%). 
 
TLC (petroleum ether) 
Rf = 0.69, visualized by short wave UV  
 
1
H-NMR (500 MHz, CDCl3) 
δ 5.98 (d, J = 5.5 Hz, 1H), 5.36 (d, J = 5.5 Hz, 1H), 1.09 (s, 9H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 199.6, 112.1, 73.1, 32.5, 29.6 
 
HRMS (EI+) 
Calculated for C7H11Br: 174.0044 
Found:    174.0039 
 
 24D -183.0 (c 1.0, CHCl3) 
 
The e.r. was determined by chiral GC using a Cyclodex B column: 
tr (major) 3.2 min, tr (minor) 3.6 min; temperature: 80 °C; 6.5 mL/min.: 94.2:5.8 e.r. 
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(R)-1-iodo-4,4-dimethyl-1,2-pentadiene, (R)-2c.
3
  The general procedure was followed using 
CuI (8.03 g, 42.2 mmol) in THF (7 mL), LiI (2.86 g, 21.4 mmol) in THF (35 mL) and (S)-4,4-
dimethylpent-1-yn-3-yl methanesulfonate (2.0 g, 10.5 mmol, 99:1 e.r.) in THF (35 mL).  The 
work up used NH4Cl:NH4OH (400 mL), Et2O (2 x 100 mL), and brine (100 mL).  Flash 
chromatography (100% petroleum ether) gave iodoallene (R)-2c as a clear, yellow oil (1.98 g, 
85%). 
 
TLC (petroleum ether) 
Rf = 0.74, visualized by short wave UV 
 
1
H-NMR (500 MHz, CDCl3) 
δ 5.71 (d, J = 6 Hz, 1H), 5.06 (d, J = 6 Hz, 1H), 1.08 (s, 9H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 203.3, 107.7, 36.5, 31.8, 29.7  
 
HRMS (EI+) 
Calculated for C7H11I: 221.9906 
Found:    221.9919 
 
 23D -264.2 (c 1.8, CHCl3) 
 
The e.r. was determined by chiral GC using a Cyclodex B column: 
tr (major) 2.7 min, tr (minor) 3.0 min; temperature: 100 °C; 6.5 mL/min.: 89.5:10.5 e.r. 
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(R)-1-iodo-4-ethyl-1,2-hexadiene, (R)-2.14.  The general procedure was followed using CuI 
(7.48 g, 39.3 mmol) in THF (6.5 mL), LiI (2.58 g, 19.3 mmol) in THF (33 mL) and (S)-4-
ethylhex-1-yn-3-yl methanesulfonate (1.98 g, 9.7 mmol, approximately 99:1 e.r.) in THF (33 
mL).  The work up used NH4Cl:NH4OH (400 mL), Et2O (1 x 100 mL), and brine (100 mL).  
Flash chromatography (100% petroleum ether) gave iodoallene (R)-2.14 as a clear, yellow oil 
(2.1 g, 91%). 
 
TLC (petroleum ether) 
Rf = 0.71, visualized by short wave UV 
 
1
H-NMR (500 MHz, CDCl3) 
δ 5.67 (dd, J = 6, 1.5 Hz, 1H), 4.95 (dd, J = 8, 6 Hz, 1H), 2.03 – 1.96 (m, 1H), 1.57 – 
1.43 (m, 2H), 1.41 – 1.29 (m, 2H), 0.92 (t, J = 7.5 Hz, 3H), 0.90 (t, J = 7.5 Hz, 3H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 205.0, 100.1, 42.0, 35.7, 27.4, 27.1, 11.7, 11.5 
 
HRMS (EI+) 
Calculated for C8H13I: 236.0062 
Found:    236.0048 
 
 25D -309.2 (c 0.9, CHCl3) 
 
Absolute stereochemical assignment was made according to the Lowe-Brewster rules
13
 and by 
analogy to known haloallenes 2.11-2.13.
3 
 
The ee was determined by chiral GC using a Cyclodex B column: 
tr (major) 4.2 min, tr (minor) 4.6 min; temperature: 110 °C; 6.5 mL/min.: 91.0:9.0 e.r. 
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(R)-1-iodo-1,2-octadiene, (R)-2.15.
3
  The general procedure was followed using CuI (5.59 g, 
29.4 mmol) in THF (5 mL), LiI (1.97 g, 14.7 mmol) in THF (25 mL) and (S)-oct-1-yn-3-yl 
methanesulfonate (1.50 g, 7.3 mmol, approximately 97:13 e.r.) in THF (12.5 mL).  The work up 
used NH4Cl:NH4OH (300 mL), Et2O (2 x 125 mL), and brine (30 mL).  Flash chromatography 
(100% petroleum ether) gave iodoallene (R)-2e as a clear, yellow oil (1.24 g, 74%). 
 
TLC (petroleum ether) 
Rf = 0.63, visualized by short wave UV  
 
1
H-NMR (500 MHz, CDCl3) 
δ 5.68 (ddd, J = 5.5, 2.5, 2.5 Hz, 1H), 5.11 (dt, J = 7, 6 Hz, 1H), 2.19 – 2.06 (m, 2H), 
1.54 – 1.35 (m, 2H), 1.34 – 1.27 (m, 4H), 0.91 – 0.90 (m, 3H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 205.4, 96.5, 35.5, 31.2, 28.1, 27.5, 22.4, 14.0 
 
HRMS (EI+) 
Calculated for C8H13I: 236.0062 
Found:    236.0045 
 

 
D
23
-166.9 (c 1.6, CHCl3) 
 
The e.r. was determined by chiral GC using a Cyclodex B column: 
tr (major) 5.6 min, tr (minor) 6.2 min; temperature: 110 °C; 6.5 mL/min: 69.8:30.2 e.r. 
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General procedure for cross-coupling reactions in Table 2-1, Entries 1-11 and 13-14: 
 
Preparation of catalyst stock solution.  In a glovebox, to a 7 mL vial equipped with a stir bar and 
charged with phosphine ligand was added a premixed solution of Pd2(dba)3 in THF.  The 
solution was stirred at 23 °C for 20 min. 
 
The freshly prepared catalyst stock solution was used in the following reaction: 
In a glovebox, to a 7 mL vial equipped with a stir bar and charged with base (0.14 mmol) was 
added the reaction solvent (1.2 mL).  A stock solution of PhB(OH)2 (125.4 mg, 1.0 mmol) in 
THF (3.0 mL) was prepared.  An aliquot (0.20 mL, corresponding to 8.4 mg of boronic acid, 
0.069 mmol) of this solution was added to the reaction vial.  A stock solution of 
haloallene:dodecane (2:1 molar ratio) in THF (0.23 M with respect to the haloallene) was 
prepared.  An aliquot (0.20 mL, corresponding to 0.045 mmol haloallene) was added to the 
reaction vial.  An aliquot of the prepared catalyst stock solution (0.20 mL, corresponding to 4 
mol% Pd2(dba)3 and 16 mol% ligand) was added to the reaction vial.  The vial was sealed with a 
septum cap and removed from the glovebox.  Degassed DI H2O (0.15 mL) was added.  The 
solution was stirred at 23 
o
C for 1.5 hr in a subdued light environment.  Activated carbon, Darco 
G-60 (~50 mg) was added to the reaction solution.
14
  The solution was stirred at 23 
o
C under air 
for 20 min.  The solution was dried over MgSO4 and filtered through a plug of Celite.  The 
resulting solution was analyzed by GC. 
 
Entry 1: Synthesis of  (S)-2.16a. 
Following the general procedure, a stock solution of Pd2(dba)3 (68.0 mg, 0.074 mmol) in THF 
(8.0 mL) was prepared and stirred at 23 
o
C for 10 min.  A portion (1.4 mL) of this solution was 
added to a vial containing recrystallized PPh3 (13.8 mg, 0.053 mmol).  This catalyst stock 
solution was stirred at 23 
o
C for 20 min.  Ag2O (32.5 mg, 0.14 mmol) was suspended in THF 
(1.2 mL).  An aliquot (0.20 mL) of the boronic acid stock solution was added.  A stock solution 
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of chloroallene (R)-2.11 (17.6 mg, 0.13 mmol) and dodecane (11.3 mg, 0.066 mmol) in THF 
(0.60 mL) was prepared.  An aliquot (0.20 mL) of this chloroallene stock solution was added to 
the reaction vial.  An aliquot (0.20 mL) of the prepared catalyst stock solution was added and the 
general procedure was followed for the remainder of the experiment. 
 
Based on the average of two runs: 
The e.r. of (R)-2.11 was determined by chiral GC using a Cyclodex B column: 93.9:6.1 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 15.8:84.2 e.r. 
Stereoretention = -78%, (S)-2.16a was the major product, corresponding to net stereoinversion 
GC yield based on the dodecane internal standard = 83% 
 
Entry 2: Synthesis of (S)-2.16a. 
Following the general procedure, a stock solution of Pd2(dba)3 (68.0 mg, 0.074 mmol) in THF 
(8.0 mL) was prepared and stirred at 23 
o
C for 10 min.  A portion (1.4 mL) of this solution was 
added to a vial containing recrystallized PPh3 (13.8 mg, 0.053 mmol).  This catalyst stock 
solution was stirred at 23 
o
C for 20 min.  Ag2O (33.1 mg, 0.14 mmol) was suspended in THF 
(1.2 mL).  An aliquot (0.20 mL) of the boronic acid stock solution was added.  A stock solution 
of bromoallene (R)-2.12 (23.3 mg, 0.13 mmol) and dodecane (11.2 mg, 0.066 mmol) in THF 
(0.60 mL) was prepared.  An aliquot (0.20 mL) of this bromoallene stock solution was added to 
the reaction vial.  An aliquot (0.20 mL) of the prepared catalyst stock solution was added and the 
general procedure was followed for the remainder of the experiment. 
 
Based on the average of two runs: 
The e.r. of (R)-2.12 was determined by chiral GC using a Cyclodex B column: 94.2:5.8 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 15.5:84.5 e.r. 
Stereoretention = -78%, (S)-2.16a was the major product, corresponding to net stereoinversion 
GC yield based on the dodecane internal standard = 61% 
 
Entry 3: Synthesis of (R)-2.16a. 
Following the general procedure, a stock solution of Pd2(dba)3 (68.0 mg, 0.074 mmol) in THF 
(8.0 mL) was prepared and stirred at 23 
o
C for 10 min.  A portion (1.4 mL) of this solution was 
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added to a vial containing recrystallized PPh3 (13.8 mg, 0.053 mmol).  This catalyst stock 
solution was stirred at 23 
o
C for 20 min.  Ag2O (34.1 mg, 0.15 mmol) was suspended in THF 
(1.2 mL).  An aliquot (0.20 mL) of the boronic acid stock solution was added.  A stock solution 
of iodoallene (R)-2.13 (90.7 mg, 0.41 mmol) and dodecane (35.3 mg, 0.21 mmol) in THF (1.8 
mL) was prepared.  An aliquot (0.20 mL) of this iodoallene stock solution was added to the 
reaction vial.  An aliquot (0.20 mL) of the prepared catalyst stock solution was added and the 
general procedure was followed for the remainder of the experiment. 
 
Based on the average of two runs: 
The e.r. of (R)-2.13 was determined by chiral GC using a Cyclodex B column: 89.5:10.5 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 78.4:21.6 e.r. 
Stereoretention = 72%, (R)-2.16a was the major product, corresponding to net stereoretention 
GC yield based on the dodecane internal standard = 49% 
 
Entry 4: Synthesis of (R)-2.16b. 
Following the general procedure, a solution of Pd2(dba)3 (15.5 mg, 0.017 mmol) in THF (2.0 
mL) was prepared and stirred at 23 
o
C for 10 min.  This entire solution was added to a vial 
containing recrystallized PPh3 (18.2 mg, 0.069 mmol).  This catalyst stock solution was stirred at 
23 
o
C for 20 min.  Ag2O (30.1 mg, 0.13 mmol) was suspended in THF (1.2 mL).  An aliquot 
(0.20 mL) of the boronic acid stock solution was added.  A stock solution of iodoallene (R)-2.14 
(36.5 mg, 0.15 mmol) and dodecane (13.4 mg, 0.079 mmol) in THF (0.6 mL) was prepared.  An 
aliquot (0.20 mL) of this iodoallene stock solution was added to the reaction vial.  An aliquot 
(0.20 mL) of the prepared catalyst stock solution was added and the general procedure was 
followed for the remainder of the experiment. 
 
Based on the average of two runs: 
The e.r. of (R)-2.14 was determined by chiral GC using a Cyclodex B column: 91.0:9.0 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 73.8:26.2 e.r. 
Stereoretention = 58%, (R)-2.16b was the major product, corresponding to net stereoretention 
GC yield based on the dodecane internal standard = 16% 
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Entry 5: Synthesis of (R)-2.16c. 
Following the general procedure, a stock solution of Pd2(dba)3 (68.0 mg, 0.074 mmol) in THF 
(8.0 mL) was prepared and stirred at 23 
o
C for 10 min.  A portion (1.4 mL) of this solution was 
added to a vial containing recrystallized PPh3 (13.8 mg, 0.053 mmol).  This catalyst stock 
solution was stirred at 23 
o
C for 20 min.  Ag2O (31.6 mg, 0.14 mmol) was suspended in THF 
(1.2 mL).  An aliquot (0.20 mL) of the boronic acid stock solution was added.  A stock solution 
of iodoallene (R)-2.15 (31.8 mg, 0.13 mmol) and dodecane (11.0 mg, 0.065 mmol) in THF (0.6 
mL) was prepared.  An aliquot (0.20 mL) of this iodoallene stock solution was added to the 
reaction vial.  An aliquot (0.20 mL) of the prepared catalyst stock solution was added and the 
general procedure was followed for the remainder of the experiment. 
 
Based on the average of two runs: 
The e.r. of (R)-2.15 was determined by chiral GC using a Cyclodex B column: 69.8:30.2 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 55:45 e.r. 
Stereoretention = 25%, (R)-2.16c was the major product, corresponding to net stereoretention 
GC yield based on the dodecane internal standard = 10% 
 
Entry 6: Synthesis of (R)-2.16a. 
Following the general procedure, a stock solution of Pd2(dba)3 (69.4 mg, 0.076 mmol) in THF 
(8.0 mL) was prepared and stirred at 23 
o
C for 10 min.  A portion (0.8 mL) of this solution was 
added to a vial containing trifurylphosphine (7.1 mg, 0.031 mmol).  This catalyst stock solution 
was stirred at 23 
o
C for 20 min.  Ag2O (30.9 mg, 0.13 mmol) was suspended in THF (1.2 mL).  
An aliquot (0.20 mL) of the boronic acid stock solution was added.  A stock solution of 
iodoallene (R)-2.13 (113.5 mg, 0.51 mmol) and dodecane (38.2 mg, 0.22 mmol) in THF (2.2 
mL) was prepared.  An aliquot (0.20 mL) of this iodoallene stock solution was added to the 
reaction vial.  An aliquot (0.20 mL) of the prepared catalyst stock solution was added and the 
general procedure was followed for the remainder of the experiment. 
 
Based on the average of two runs: 
The e.r. of (R)-2.13 was determined by chiral GC using a Cyclodex B column: 89.5:10.5 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 81.6:18.4 e.r. 
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Stereoretention = 80%, (R)-2.16a was the major product, corresponding to net stereoretention 
GC yield based on the dodecane internal standard = 59% 
 
Entry 7: Synthesis of (R)-2.16a. 
Following the general procedure, a stock solution of Pd2(dba)3 (68.0 mg, 0.074 mmol) in THF 
(8.0 mL) was prepared and stirred at 23 
o
C for 10 min.  A portion (0.8 mL) of this solution was 
added to a vial containing PCy3 (9.1 mg, 0.032 mmol).  This catalyst stock solution was stirred at 
23 
o
C for 20 min.  Ag2O (33.9 mg, 0.15 mmol) was suspended in THF (1.2 mL).  An aliquot 
(0.20 mL) of the boronic acid stock solution was added.  A stock solution of iodoallene (R)-2.13 
(90.7 mg, 0.41 mmol) and dodecane (35.3 mg, 0.21 mmol) in THF (1.8 mL) was prepared.  An 
aliquot (0.20 mL) of this iodoallene stock solution was added to the reaction vial.  An aliquot 
(0.20 mL) of the prepared catalyst stock solution was added and the general procedure was 
followed for the remainder of the experiment. 
 
Based on the average of two runs: 
The e.r. of (R)-2.13 was determined by chiral GC using a Cyclodex B column: 89.5:10.5 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 69.8:30.2 e.r. 
Stereoretention = 50%, (R)-2.16a was the major product, corresponding to net stereoretention 
GC yield based on the dodecane internal standard = 10% 
 
Entry 8: Synthesis of (R)-2.16a. 
Following the general procedure, a stock solution of Pd2(dba)3 (69.4 mg, 0.076 mmol) in THF 
(8.0 mL) was prepared and stirred at 23 
o
C for 10 min.  A portion (0.8 mL) of this solution was 
added to a vial containing P
t
Bu2Me (6.1 mg, 0.038 mmol).  This catalyst stock solution was 
stirred at 23 
o
C for 20 min.  Ag2O (33.0 mg, 0.14 mmol) was suspended in THF (1.2 mL).  An 
aliquot (0.20 mL) of the boronic acid stock solution was added.  A stock solution of iodoallene 
(R)-2.13 (113.5 mg, 0.51 mmol) and dodecane (38.2 mg, 0.22 mmol) in THF (2.2 mL) was 
prepared.  An aliquot (0.20 mL) of this iodoallene stock solution was added to the reaction vial.  
An aliquot (0.20 mL) of the prepared catalyst stock solution was added and the general 
procedure was followed for the remainder of the experiment. 
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Based on the average of two runs: 
The e.r. of (R)-2.13 was determined by chiral GC using a Cyclodex B column: 89.5:10.5 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 78.0:22.0 e.r. 
Stereoretention = 71%, (R)-2.16a was the major product, corresponding to net stereoretention 
GC yield based on the dodecane internal standard = 15% 
 
Entry 9: Synthesis of (R)-2.16a. 
Following the general procedure, a stock solution of Pd2(dba)3 (68.0 mg, 0.074 mmol) in THF 
(8.0 mL) was prepared and stirred at 23 
o
C for 10 min.  A portion (0.8 mL) of this solution was 
added to a vial containing P(o-tol)3 (8.4 mg, 0.028 mmol).  This catalyst stock solution was 
stirred at 23 
o
C for 20 min.  Ag2O (31.9 mg, 0.14 mmol) was suspended in THF (1.2 mL).  An 
aliquot (0.20 mL) of the boronic acid stock solution was added.  A stock solution of iodoallene 
(R)-2.13 (90.7 mg, 0.41 mmol) and dodecane (35.3 mg, 0.21 mmol) in THF (1.8 mL) was 
prepared.  An aliquot (0.20 mL) of this iodoallene stock solution was added to the reaction vial.  
An aliquot (0.20 mL) of the prepared catalyst stock solution was added and the general 
procedure was followed for the remainder of the experiment. 
 
Based on the average of two runs: 
The e.r. of (R)-2.13 was determined by chiral GC using a Cyclodex B column: 89.5:10.5 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 85.9:14.1 e.r. 
Stereoretention = 91%, (R)-2.16a was the major product, corresponding to net stereoretention 
GC yield based on the dodecane internal standard = 58% 
 
Entry 10: Synthesis of (R)-2.16a. 
Following the general procedure, a stock solution of Pd2(dba)3 (68.0 mg, 0.074 mmol) in THF 
(8.0 mL) was prepared and stirred at 23 
o
C for 10 min.  A portion (0.8 mL) of this solution was 
added to a vial containing P
t
Bu3 (6.7 mg, 0.033 mmol).  This catalyst stock solution was stirred 
at 23 
o
C for 20 min.  Ag2O (31.7 mg, 0.14 mmol) was suspended in THF (1.2 mL).  An aliquot 
(0.20 mL) of the boronic acid stock solution was added.  A stock solution of iodoallene (R)-2.13 
(90.7 mg, 0.41 mmol) and dodecane (35.3 mg, 0.21 mmol) in THF (1.8 mL) was prepared.  An 
aliquot (0.20 mL) of this iodoallene stock solution was added to the reaction vial.  An aliquot 
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(0.20 mL) of the prepared catalyst stock solution was added and the general procedure was 
followed for the remainder of the experiment. 
 
Based on the average of two runs: 
The e.r. of (R)-2.13 was determined by chiral GC using a Cyclodex B column: 89.5:10.5 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 86.7:13.3 e.r. 
Stereoretention = 93%, (R)-2.16a was the major product, corresponding to net stereoretention 
GC yield based on the dodecane internal standard = 38% 
 
Entry 11: Synthesis of (R)-2.16a. 
Following the general procedure, a stock solution of Pd2(dba)3 (68.0 mg, 0.074 mmol) in THF 
(8.0 mL) was prepared and stirred at 23 
o
C for 10 min.  A portion (0.8 mL) of this solution was 
added to a vial containing XPhos
15
 (14.8 mg, 0.031 mmol).  This catalyst stock solution was 
stirred at 23 
o
C for 20 min.  Ag2O (32.2 mg, 0.14 mmol) was suspended in THF (1.2 mL).  An 
aliquot (0.20 mL) of the boronic acid stock solution was added.  A stock solution of iodoallene 
(R)-2.13 (90.7 mg, 0.41 mmol) and dodecane (35.3 mg, 0.21 mmol) in THF (1.8 mL) was 
prepared.  An aliquot (0.20 mL) of this iodoallene stock solution was added to the reaction vial.  
An aliquot (0.20 mL) of the prepared catalyst stock solution was added and the general 
procedure was followed for the remainder of the experiment. 
 
Based on the average of two runs: 
The e.r. of (R)-2.13 was determined by chiral GC using a Cyclodex B column: 89.5:10.5 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 86.0:14.0 e.r. 
Stereoretention = 91%, (R)-2.16a was the major product, corresponding to net stereoretention 
GC yield based on the dodecane internal standard = 42% 
 
Entry 12: Synthesis of (R)-2.16a. 
Preparation of catalyst solution.  In a glovebox, to a 20 mL vial equipped with a stir bar and 
charged with XPhos (133.1 mg, 0.28 mmol) and Pd2(dba)3 (63.4 mg, 0.069 mmol) was added 
THF (7.5 mL). The solution was stirred at 23 °C for 20 min. 
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The freshly prepared catalyst solution was used in the following reaction: 
In a glovebox, to a 100 mL round bottom flask equipped with a stir bar and charged with 
PhB(OH)2 (306.5 mg, 2.5 mmol) and Ag2O (1.16 g, 5.0 mmol) was added iodoallene (R)-2.13 
(334.4 mg, 1.5 mmol) as a solution in hexanes (55 mL).  The prepared catalyst solution was 
added in one portion.  The flask was sealed with a septum and removed from the glovebox.  
Degassed DI H2O (6.0 mL) was added.  The solution was stirred in a subdued light environment 
at 23 
o
C for 1.5 hr.  Activated carbon, Darco G-60 (800 mg) was added to the reaction solution.  
The solution was stirred at 23 
o
C under air for 20 min.  The aqueous layer was removed and the 
organic layer was dried over MgSO4 and filtered through a plug of Celite.  The resulting clear, 
yellow solution was concentrated in vacuo,  and the resulting residue was purified via flash 
chromatography on silica gel (100% petroleum ether) to afford the cross coupled product (R)-3a 
as a pale yellow oil (157.6 mg, 61%). 
 
The e.r. of (R)-2.13 was determined by chiral GC using a Cyclodex B column: 89.5:10.5 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 89.5:10.5 e.r. 
Stereoretention = >99%, (R)-2.16a was the major product, corresponding to net stereoretention 
 
Entry 13: Synthesis of (R)-2.16b. 
Following the general procedure, a solution of Pd2(dba)3 (15.5 mg, 0.017 mmol) in THF (2.0 
mL) was prepared and stirred at 23 
o
C for 10 min.  This entire solution was added to a vial 
containing XPhos (17.0 mg, 0.036 mmol).  This catalyst stock solution was stirred at 23 
o
C for 
20 min.  Ag2O (30.1 mg, 0.13 mmol) was suspended in hexanes (1.2 mL).  An aliquot (0.20 mL) 
of the boronic acid stock solution was added.  A stock solution of iodoallene (R)-2.14 (33.7 mg, 
0.14 mmol) and dodecane (14.2 mg, 0.083 mmol) in hexanes (0.6 mL) was prepared.  An aliquot 
(0.20 mL) of this iodoallene stock solution was added to the reaction vial.  An aliquot (0.20 mL) 
of the prepared catalyst stock solution was added and the general procedure was followed for the 
remainder of the experiment. 
 
Based on the average of two runs: 
The e.r. of (R)-2.14 was determined by chiral GC using a Cyclodex B column: 91.0:9.0 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 91.0:9.0 e.r. 
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Stereoretention = >99%, (R)-2.16b was the major product, corresponding to net stereoretention 
GC yield based on the dodecane internal standard = 64% 
 
Entry 14: Synthesis of (R)-2.16c. 
Following the general procedure, a solution of Pd2(dba)3 (15.5 mg, 0.017 mmol) in THF (2.0 
mL) was prepared and stirred at 23 
o
C for 10 min.  This entire solution was added to a vial 
containing XPhos (17.0 mg, 0.036 mmol).  This catalyst stock solution was stirred at 23 
o
C for 
20 min.  Ag2O (33.6 mg, 0.14 mmol) was suspended in hexanes (1.2 mL).  An aliquot (0.20 mL) 
of the boronic acid stock solution was added.  A stock solution of iodoallene (R)-2.15 (31.6 mg, 
0.13 mmol) and dodecane (13.4 mg, 0.079 mmol) in hexanes (0.6 mL) was prepared.  An aliquot 
(0.20 mL) of this iodoallene stock solution was added to the reaction vial.  An aliquot (0.20 mL) 
of the prepared catalyst stock solution was added and the general procedure was followed for the 
remainder of the experiment. 
 
Based on the average of two runs: 
The e.r. of (R)-2.15 was determined by chiral GC using a Cyclodex B column: 69.8:30.2 e.r. 
The e.r. of the product was determined by chiral GC using a Cyclodex B column: 66.8:33.2 e.r. 
Stereoretention = 85%, (R)-2.16c was the major product, corresponding to net stereoretention 
GC yield based on the dodecane internal standard = 30% 
 
 
(R)-(4,4-dimethylpenta-1,2-dien-1-yl)benzene, (R)-2.16a.
16
 
 
TLC (petroleum ether) 
Rf = 0.55, visualized by short wave UV  
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.35 – 7.28 (m, 4H), 7.19 (tt, J = 6.5, 2 Hz, 1H), 6.27 (d, J = 6.5 Hz, 1H), 5.64 (d, J = 
6.5 Hz, 1H), 1.13 (s, 9H). 
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13
C-NMR (125 MHz, d6-acetone) 
δ 203.1, 136.1, 129.4, 127.5, 127.1, 107.3, 96.8, 33.2, 30.4 
 
HRMS (EI+) 
Calculated for C13H16: 172.1252 
Found:    172.1236 
 
 25D -301.8 (c 1.1, CHCl3) 
 
The e.r. was determined by chiral GC using a Cyclodex B column: 
tr (major) 13.3 min, tr (minor) 14.2 min; temperature: 100 °C; 6.5 mL/min: 89.5:10.5 e.r. 
 
 
(R)-(4-ethylhexa-1,2-dien-1-yl)benzene, (R)-2.16b. 
 
TLC (petroleum ether) 
Rf = 0.49, visualized by short wave UV  
 
1
H-NMR (500 MHz, CDCl3) 
δ 7.32 – 7.27 (m, 4H), 7.20 – 7.15 (m, 1H), 6.14 (dd, J = 6.5, 2 Hz, 1H), 5.40 (dd, J = 7, 
7.5 Hz, 1H), 2.05 – 1.96 (m, 1H), 1.57 – 1.46 (m, 2H), 1.46 – 1.34 (m, 2H), 0.98 (t, J = 
7.5 Hz, 3H), 0.95 (t, J = 7.5, 3H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 204.9, 135.2, 128.5, 126.5, 98.9, 94.5, 94.5, 43.1, 27.7, 27.4, 11.9, 11.7 
 
HRMS (EI+) 
Calculated for C14H18: 186.1409 
Found:    186.1420 
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 25D -169.1 (c 0.6, CHCl3) 
 
Absolute stereochemical assignment was made according to the Lowe-Brewster rules and by 
analogy to known haloallene 2.16a.
16 
 
The e.r. was determined by chiral GC using a Cyclodex B column: 
tr (major) 19.5 min, tr (minor) 20.3 min; temperature: 110 °C; 6.5 mL/min: 73.8:26.2 e.r. 
 
 
(R)-octa-1,2-dien-1-ylbenzene, (R)-2.16c. 
 
TLC (petroleum ether) 
Rf = 0.57, visualized by short wave UV  
 
1
H-NMR (500 MHz, CDCl3) 
δ 7.27 (d, J = 1 Hz, 4H), 7.16 – 7.13 (m, 1H), 6.11 – 6.08 (m, 1H), 5.54 (dd, J = 7, 6.5 
Hz, 1H), 2.12 – 2.08 (m, 2H), 1.50 – 1.44 (m, 2H), 1.36 – 1.27 (m, 4H), 0.88 – 0.85 (m, 
3H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 205.1, 135.2, 128.5, 126.6, 126.6 95.1, 94.5, 31.4, 28.8, 28.7, 22.5, 14.1 
 
HRMS (EI+) 
Calculated for C14H18: 186.1409 
Found:    186.1416 
 
 25D -66.7 (c 1.4, CHCl3) 
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Absolute stereochemical assignment was made according to the Lowe-Brewster rules and by 
analogy to known haloallene 2.16a.
16 
 
The e.r. was determined by chiral GC using a Cyclodex B column: 
tr (major) 26.2 min, tr (minor) 26.9 min; temperature: 110 °C; 6.5 mL/min: 63.0:37.0 e.r. 
 
 
Styrenyl allene 2.18.   
Preparation of catalyst stock solution. In a glove box, to a dry 7 mL vial charged with XPhos, 
(28.7 mg, 0.060 mmol) and Pd2(dba)3 (13.3 mg, 0.014 mmol) was added THF (5 mL). The 
solution was stirred at 65 °C for 30 min to afford a dark orange solution. 
 
The prepared catalyst stock solution was used in the following reaction: 
In a glovebox, to a 20 mL vial charged with Ag2O (206.6 mg, 0.89 mmol) and styrenyl boronic 
acid (65.7 mg, 0.44 mmol) was added a solution of iodoallene 2.6 (134.5 mg, 0.29 mmol) in THF 
(6 mL).  The catalyst solution was added in one portion.  The vial was sealed with a septum cap 
and removed from the glovebox.  To the vial was added degassed H2O (0.87 mL).  The solution 
stirred at 23 
o
C for 6 hr.  The reaction mixture was filtered through a pad of celite and MgSO4, 
and concentrated in vacuo, dry loaded onto celite and purified via column chromatography on 
silica gel (Hexanes:EtOAc 100:0 → 97:3) to afford styrenyl allene 2.18 as a clear, colorless oil 
(89 mg, 70%).   
 
TLC (Hexanes:EtOAc 9.5:0.5) 
Rf = 0.42, visualized by short wave UV 
 
1
H-NMR (500 MHz, CDCl3) 
δ 7.40 (d, J = 7.5 Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 7.22 (t, J = 7.5 Hz, 1H), 6.59 – 6.48 
(m, 2H), 6.08 (d, J = 8.5 Hz, 1H), 5.63 (m, 1H), 2.30 (app ddd, J = 12 Hz, 1H), 2.05 (s, 
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3H), 1.94 (app ddd, J = 12 Hz, 1H), 1.51 – 1.40 (m, 5H), 1.36 (s, 3H), 1.10 (s, 3H), 0.92 
(s, 9H), 0.17 (s, 3H), 0.09 (s, 3H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 204.7, 170.4, 137.3, 129.8, 128.5, 127.2, 126.1, 125.1, 116.0, 97.5, 75.0, 68.2, 47.4, 
45.3, 35.5, 32.3, 30.8, 29.7, 26.1, 21.4, 18.3, -1.7, -2.3 
 
HRMS (ESI+) 
Calculated for C27H40O3SiNa: 463.2644 
Found:     463.2654 
 
IR (thin film, cm
-1
) 
2958, 2929, 2895, 2858, 1936, 1739, 1598, 1471, 1362, 1246, 1159, 1076, 1034, 960, 
883, 835, 775, 690, 579. 
 
 24D -144.0 (c 1.3, CHCl3) 
 
 
Desilylated styrenyl allene 2.18a.  To a solution of styrenyl allene 2.18 (86.0 mg, 0.20 mmol) in 
THF (1 mL) was added a solution of 1.0 M TBAF in THF (1 mL, 1 mmol).  The solution stirred 
at 23 
o
C for 4 hr.  To the resulting mixture was added saturated aqueous NaHCO3 (0.50 mL).  
The solution stirred at 23 
o
C for 1 min.  The organic layer was removed, dried over MgSO4, and 
concentrated in vacuo.  The resulting residue was dry loaded onto celite and purified via column 
chromatography on silica gel (Hexanes:EtOAc 100:0 → 75:25) to afford desilylated styrenyl 
allene 2.18a as a white foam (54 mg, 85%). 
   
TLC (Hexanes:EtOAc 9:1) 
Rf = 0.09, stained by KMnO4 
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1
H-NMR (500 MHz, CDCl3) 
δ 7.39 (d, J = 7.5 Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 7.21 (t, J = 7.5 Hz, 1H), 6.58 – 6.47 
(m, 2H), 6.10 (d, J = 7.5 Hz, 1H), 5.38 (m, 1H), 2.28 (app ddd, J = 12 Hz, 1H), 2.05 (s, 
3H), 1.98 (app ddd, J = 12 Hz, 1H), 1.67 (bs, 1H), 1.59 – 1.34 (m, 8H), 1.11 (s, 3H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 204.2, 170.4, 137.2, 130.2, 128.5, 127.3, 126.1, 124.7, 115.9, 97.9, 72.5, 68.0, 45.2, 
45.0, 35.6, 32.0, 31.1, 29.1, 21.4 
 
HRMS (ESI+) 
Calculated for C21H26O3Na: 349.1780 
Found:    349.1774 
 
IR (thin film, cm
-1
) 
3454, 2966, 2926, 2868, 1934, 1736, 1454, 1367, 1247, 1161, 1072, 1030, 958, 858, 818, 
748, 692, 590, 542. 
 
 25D -16.9 (c 1.3, CHCl3) 
 
 
Deacylated styrenyl allene 2.19.  To a 7 mL vial containing desilylated styrenyl allene 2.18a 
(34.9 mg, 0.11 mmol) and finely group K2CO3 (11.7 mg, 0.085 mmol) was added dry MeOH (1 
mL).  The solution stirred at 23 
o
C for 3.5 hr and was then poured into 10 mL H2O.  The mixture 
was diluted with 10 mL Et2O and shaken.  The layers were separated and the aqueous layer was 
extracted with Et2O (2 x 10 mL).  The combined organic phases were dried over MgSO4, 
filtered, and concentrated in vacuo.  The resulting solid was dry loaded onto celite from an 
acetone solution and purified via column chromatography on silica gel (Hexanes:EtOAc 85:15 
→ 20:80) to afford deacylated styrenyl allene 2.19 as a white solid (26 mg, 87%). 
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TLC (Hexanes:EtOAc 1:1) 
Rf = 0.26, stained by KMnO4 
 
1
H-NMR (500 MHz, CDCl3) 
δ 7.39 (d, J = 7.5 Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 7.21 (t, J = 7.5 Hz, 1H), 6.58 – 6.47 
(m, 2H), 6.09 (d, 8 Hz, 1H), 4.31 (m, 1H), 2.25 (ddd, J =13, 4, 2 Hz, 1H), 1.94 (ddd, J = 
13, 4, 2 Hz, 1H), 1.51 (bs, 1H), 1.47 – 1.35 (m, 5H), 1.34 (s, 3H), 1.10 (s, 3H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 204.3, 137.2, 130.1, 128.6, 127.4, 126.2, 124.8, 116.2, 97.9, 72.9, 64.3, 49.2, 48.7, 35.7, 
32.2, 31.2, 29.3 
 
HRMS (ESI+) 
Calculated for C19H25O2: 285.1855 
Found:    285.1842 
 
IR (thin film, cm
-1
) 
3305, 2972, 2954, 1934, 1454, 1367, 1159, 1070, 1043, 964, 860, 820, 746, 690, 592, 
519, 486. 
 
 24D -57.3 (c 1.0, MeOH) 
 
X-ray quality crystals were grown by layering pentane onto a dissolved solution of 10 in THF.  
After sitting at 23
 o
C for 10 hr, the sample was placed in a -20 
o
C freezer.  Crystals formed 
within 3 hr. 
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Iodoallene 2.35.  Iodoallene 2.35 was prepared as previously described.
2
  X-ray quality crystals 
of the unprotected iodoallene starting material 2.35 were grown by layering hexane onto a 
dissolved solution of the allene in Et2O.  The sample was placed in a -20 
o
C freezer.  Crystals 
formed overnight.  To the best of our knowledge, this is the first reported example of a crystal 
structure of an iodoallene.
17
 
 
 
 
 
 
Pinacol ester 2.24.  In a glovebox, to a 20 mL vial equipped with a stir bar and charged with 
alkyne 2.22 (2.57 g, 8.7 mmol) was added solid dicyclohexylborane
18
 (203.4 mg, 1.1 mmol).
19
  
The vial was sealed with a septum cap and removed from the glovebox.  To the vial was added 
neat pinacol borane (1.4 mL, 9.6 mmol).  The solution was stirred at 23
 o
C for 13 hr.  The 
resulting thick white paste was dissolved in Et2O, dry loaded onto Celite, and purified via flash 
chromatography on silica gel (Hexanes:EtOAc 95:5) to afford pinacol ester 2.24 as a white solid 
(3.0 g, 81%). 
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TLC (Hexanes:EtOAc 9:1) 
Rf = 0.50, stained by KMnO4 
 
1
H-NMR (500 MHz, CDCl3) 
δ 6.68 (d, J = 18 Hz, 1H), 5.54 (d, J = 18 Hz, 1H), 3.72 (m, 1H), 2.09 (ddd, J = 14.5, 5, 1 
Hz, 1H), 1.50 (dd, J = 14.5, 8 Hz, 1H), 1.36 (ddd, J = 13, 3.5, 1Hz, 1H), 1.14 (s, 12H), 
1.10 (m, 1H), 1.03 (s, 3H), 1.02 (s, 3H), 0.81 (s, 3H), 0.75 (s, 9H), -0.090 (s, 3H), -0.094 
(s, 3H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 147.9, 82.9, 70.9, 66.0, 64.5, 46.9, 41.1, 34.5, 29.3, 25.7, 24.7, 24.6, 19.9, 17.9, -4.9,  
-4.9 
 
11
B-NMR (96 MHz, CDCl3) 
δ 31.1 
 
HRMS (ESI+) 
Calculated for C23H44BO4Si: 423.3102 
Found:    423.3120 
 
IR (thin film, cm
-1
) 
2976, 2953, 2926, 2854, 1635, 1462, 1379, 1344, 1321, 1250, 1198, 1144, 1072, 966, 
922, 881, 835, 775, 667, 650, 567. 
 
 27D -75.6 (c 1.1, CHCl3) 
 
X-ray quality crystals were grown by layering pentane onto a dissolved solution of 2.24 in 
acetone.  After the layers slowly mixed, the solvent was allowed to slowly evaporate to yield 
crystals. 
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MIDA boronate 2.31.  To a 250 mL round bottom flask equipped with a stir bar and charged 
with pinacol ester 2.24 (2.54 g, 6.0 mmol) was added N-methyliminodiacetic acid, MIDA, (5.48 
g, 37.2 mmol) and DMSO (60 mL).  The flask was sealed and the reaction stirred at 65 
o
C for 
10.5 hr.  The resulting solution was poured into 500 mL H2O.  The mixture was diluted with 250 
mL EtOAc and shaken.  The layers were separated and the aqueous layer was extracted with 
EtOAc (3 x 150 mL).  The combined organic phases were dried over MgSO4, filtered, and 
concentrated in vacuo.  The resulting residue was dry loaded onto Celite from an acetone 
solution and purified via flash chromatography on silica gel (Et2O:Acetone 100:0 → 40:60) to 
afford MIDA boronate 2.31 as a white solid (1.18 g, 44%) and unreacted starting material (1.18 g 
recovered).  The unreacted starting material was subjected to two additional cycles of the above 
procedure to afford MIDA boronate 2.31 as a white solid (1.98 g total, 73%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.44, stained by KMnO4 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.39 (d, J = 18 Hz, 1H), 5.71 (d, J = 18 Hz, 1H), 4.23 (dd, J = 17, 2 Hz, 2H), 4.06 (dd, J 
= 17, 4 Hz, 2H), 3.88 (m, 1H), 3.01 (s, 3H), 2.21 (ddd, J = 14, 5, 1 Hz, 1H), 1.66 (dd, J = 
14.5, 8.5 Hz, 1H), 1.50 (ddd, J = 14, 5, 1 Hz, 1H), 1.30 – 1.19 (m, 1H), 1.15 (s, 3H), 1.14 
(s, 3H), 0.93 (s, 3H), 0.88 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.0, 140.7, 71.4, 66.5, 65.6, 62.3, 47.9, 47.5, 42.1, 35.4, 29.8, 26.2, 25.4, 20.4, 18.5,  
-4.6, -4.6 
 
11
B-NMR (96 MHz, d6-acetone) 
δ 11.5 
 
HRMS (ESI+) 
Calculated for C22H39BNO6Si: 452.2640 
Found:     452.2657 
 
IR (thin film, cm
-1
) 
2953, 2929, 2856, 1780, 1753, 1637, 1460, 1389, 1340, 1294, 1255, 1090, 1034, 1007, 
953, 881, 858, 837, 773, 681, 588, 513. 
 
 25D -55.7 (c 1.0, CHCl3) 
 
 
Propynyl MIDA boronate 2.25.  To a 300 mL 3-neck round bottom flask equipped with a stir 
bar was added B(OMe)3 (5.9 mL, 53 mmol) and THF (50 mL).  The solution was cooled to -78 
o
C.  Propynylmagnesium bromide (0.5 M in THF, 100 mL, 50 mmol) was added dropwise via 
cannula over 45 min.  The resulting solution was stirred at -78
 o
C for 1.5 hr, followed by stirring 
at 23 
o
C for 2 hr.  In a separate 500 mL 3-neck round bottom flask equipped with a stir bar, 
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internal thermometer, 500 mL addition funnel, and distillation apparatus was added MIDA (15.0 
g, 102 mmol) and DMSO (50 mL).  The solution was heated with an oil bath to an internal 
temperature of 110 - 115 
o
C.
20
  The borate suspension was transferred to the addition funnel and 
was continuously agitated with a stream of nitrogen.  The borate suspension was added dropwise 
to the hot MIDA solution over 2 hr 50 min, keeping the internal temperature between 105 and 
115 
o
C.  After full addition of the borate suspension, the reaction solution was cooled to 60 
o
C 
and placed under vacuum (300 mTorr) to distill the reaction to dryness.  The resulting foam was 
cooled to 23 
o
C and dissolved in 200 mL EtOAc, 50 mL acetone, and 75 mL H2O and poured 
into 200 mL EtOAc:Acetone (1:1) and 75 mL brine.  The mixture was shaken and the aqueous 
layer was removed and extracted with EtOAc (1 x 100 mL).  The combined organic phases were 
washed with brine (2 x 20 mL).  The brine wash was back extracted with EtOAc:Acetone (2:1, 1 
x 75 mL)  The combined organic phases were dried over MgSO4, filtered, and concentrated in 
vacuo.  The resulting yellow solid was dissolved in 100 mL THF and 1000 mL Et2O was added 
to precipitate the product. The resulting solid was collected by vacuum filtration to yield 
propynyl MIDA boronate 2.25 as a white solid (7.48 g, 77%). 
 
TLC (Et2O:Acetone 2:1) 
Rf = 0.28, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 4.22 (d, J = 17 Hz, 2H), 4.05 (d, J = 17 Hz, 2H), 3.18 (s, 3H), 1.83 (s, 3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 168.6, 62.1, 48.2, 41.1, 4.0 
 
11
B-NMR (96 MHz, d6-acetone) 
δ 6.8 
 
HRMS (ESI+) 
Calculated for C8H11BNO4:  196.0781 
Found:     196.0784 
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IR (thin film, cm
-1
) 
3009, 2957, 2203, 1790, 1462, 1342, 1290, 1260, 1192, 1169, 1092, 994, 882, 858, 706. 
 
 
MIDA boronate 2.26.  In a glovebox, to a 500 mL round bottom flask equipped with a stir bar 
and charged with propynyl MIDA boronate 2.25 (5.65 g, 29.0 mmol) was added 
[Mo(allyl)Br(CO)2(CH3CN)2]
21
 (705.4 mg, 1.98 mmol).  The round bottom was sealed with a 
septum, removed from the glovebox, and placed under a nitrogen atmosphere.  THF (140 mL) 
was added and the solution was cooled to 0 
o
C.  To the resulting solution was added Bu3SnH (7.6 
mL, 28.2 mmol) dropwise over 45 min to give a dark brown solution.  The reaction solution was 
recharged with a solution of [Mo(allyl)Br(CO)2(CH3CN)2] (700. mg, 1.97 mmol) in THF (6 mL) 
in one portion, followed by Bu3SnH (7.6 mL, 28.2 mmol) dropwise over 10 min.  The cold bath 
was removed and the reaction solution was stirred at 23 
o
C for 2.5 hr.  The resulting dark brown 
solution was concentrated in vacuo.  The resulting foam was dissolved in hexanes and loaded 
onto a silica gel column.  Purification via flash chromatography (Et2O:MeCN 100:0 → 80:20) 
afforded MIDA boronate 2.26 as a pale yellow foam (11.8 g, 84%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.70, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 5.74 (q, J = 1.5 Hz, 1H), 4.17 (d, J = 17 Hz, 2H), 3.98 (d, J = 17 Hz, 2H), 3.03 (s, 3H), 
2.11 (d, J = 1.5 Hz, 3H), 1.64 – 1.45 (m, 6H), 1.34 (app sext, J = 7.5 Hz, 6H), 1.02 – 0.86 
(m, 15H). 
 
13
C-NMR (100 MHz, d6-acetone) 
δ 168.9, 161.1, 62.1, 46.9, 29.6, 27.7, 24.0, 13.7, 9.4 
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11
B-NMR (96 MHz, d6-acetone) 
δ 10.4 
 
HRMS (ESI+) 
Calculated for C20H39BNO4Sn: 488.2002 
Found:     488.2008 
 
IR (thin film, cm
-1
) 
3002, 2957, 2926, 2872, 2853, 1767, 1587, 1461, 1376, 1337, 1293, 1125, 1022, 922, 
873, 822, 760, 733, 689, 660, 593. 
 
 
MIDA boronate BB2.  In a glovebox, to a 1000 mL round bottom equipped with a stir bar, 
MIDA boronate 2.26 (23.1 g, 47.6 mmol), and dibromolactone 2.27
22
 (13.2 g, 51.9 mmol) was 
added Pd2(dba)3 (1.31 g, 1.4 mmol) and AsPh3 (878.0 mg, 2.9 mmol).  The round bottom was 
sealed with a septum, removed from the glovebox, and placed under a nitrogen atmosphere.  
THF (250 mL) was added and the flask was sealed under a nitrogen atmosphere.  The reaction 
solution was stirred at 60 
o
C for 3 hr and was then cooled to 23 
o
C.  The resulting dark yellow 
solution was concentrated in vacuo.  The resulting solid was dry loaded onto Celite from an 
acetone solution and purified via flash chromatography on silica gel (Et2O:Acetone 100:0 → 
50:50) to afford MIDA boronate 2.4 as a pale yellow solid (13.6 g, 77%). 
  
TLC (Et2O:Acetone 4:1) 
Rf = 0.24, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.96 (d, J = 0.5 Hz, 1H), 6.03 (dd, J = 1, 0.5 Hz, 1H), 5.92 (app quint, J = 1 Hz, 1H), 
4.26 (d, J = 17 Hz, 2H), 4.10 (d, J = 17 Hz, 2H), 3.10 (s, 3H), 2.23 (d, J = 1 Hz, 3H). 
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13
C-NMR (125 MHz, d6-acetone) 
δ 168.8, 166.0, 146.6, 145.8, 145.1, 122.1, 110.6, 62.5, 47.2, 18.6 
 
11
B-NMR (96 MHz, d6-acetone) 
δ 11.2 
 
HRMS (ESI+) 
Calculated for C13H14BBrNO6: 370.0098 
Found:     370.0089 
 
IR (thin film, cm
-1
) 
3011, 2957, 2919, 2229, 1765, 1630, 1590, 1454, 1338, 1292, 1188, 1125, 891, 866, 821, 
751, 710, 563. 
 
X-ray quality crystals were grown by layering Et2O onto a dissolved solution of 2.4 in acetone.  
The layers slowly mixed, forming crystals. 
 
 
 
 
 
 
 
120 
 
Isoprenyl MIDA boronate 2.28.  To a 500 mL 3-neck round bottom flask equipped with a stir 
bar was added B(OMe)3 (12.0 mL, 105 mmol) and THF (100 mL).  The solution was cooled to -
78 
o
C.  Isoprenylmagnesium bromide (0.5 M in THF, 200 mL, 100 mmol) was added dropwise 
via cannula over 2 hr.  The resulting solution was stirred at -78
 o
C for 1.5 hr, followed by stirring 
at 23 
o
C for 2 hr.  To a separate 1000 mL 3-neck round bottom flask equipped with a stir bar, 
internal thermometer, 500 mL addition funnel, and distillation apparatus was added MIDA (29.9 
g, 203 mmol) and DMSO (100 mL).  The solution was heated with an oil bath to an internal 
temperature of 110 - 115 
o
C.
20
  The borate suspension was transferred to the addition funnel and 
was continuously agitated with a stream of nitrogen.  The borate suspension was added dropwise 
to the hot MIDA solution over 2 hr, keeping the internal temperature between 100 and 115 
o
C.  
After full addition of the borate suspension, the reaction solution was cooled to 60 
o
C and placed 
under vacuum (250 mTorr) to distill the reaction to dryness.  The resulting foam was cooled to 
23 
o
C and dissolved in 400 mL EtOAc and 150 mL H2O and poured into 400 mL 
EtOAc:Acetone (1:1) and 150 mL brine.  The mixture was shaken and the aqueous layer was 
removed and extracted with EtOAc (2 x 200 mL).  The combined organic phases were washed 
with brine (2 x 20 mL).  The brine wash was back extracted with EtOAc:Acetone (2:1, 1 x 75 
mL)  The combined organic phases were dried over MgSO4, filtered, and concentrated in vacuo.  
The resulting white solid was suspended in 150 mL THF and 1500 mL of Et2O was added to 
precipitate the product. The resulting solid was collected by vacuum filtration to yield isoprenyl 
MIDA boronate 2.28 as a white solid (15.91 g, 81%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.43, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 5.45 (bs, 1H), 5.32 (d, J = 2.5 Hz, 1H), 4.21 (d, J = 17 Hz, 2H), 4.03 (d, J = 17 Hz, 2H), 
3.00 (s, 3H), 1.78 (s, 3H). 
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13
C-NMR (100 MHz, d6-acetone) 
δ 169.1, 124.4, 62.5, 47.0, 22.0 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.2 
 
HRMS (ESI+) 
Calculated for C8H13BNO4:  198.0938 
Found:     198.0934 
 
IR (thin film, cm
-1
) 
3059, 2999, 2956, 2918, 1757, 1456, 1340, 1294, 1250, 1190, 1149, 1063, 1024, 993, 
966, 926, 860, 741, 710, 638, 592, 567. 
 
 
MIDA Boronate 2.29.  To a 500 mL round bottom flask equipped with a stir bar and charged 
with isoprenyl MIDA boronate 2.28 (11.88 g, 60.3 mmol) was added CH2Cl2 (525 mL).  The 
resulting clear, colorless solution was cooled to 0 
o
C in an ice bath.  Neat bromine (4.7 mL, 91.4 
mmol) was added dropwise over 15 minutes to give a cloudy orange solution.  The solution was 
warmed to 23 
o
C over 1 hr and then heated to reflux for 2 hr.  The resulting orange solution was 
cooled to 23 
o
C and concentrated in vacuo to give a yellow solid.  This solid was azeotroped with 
CH2Cl2 (2 x 100 mL) to remove residual bromine. 
 
The resulting white solid was suspended in MeCN (525 mL).  1,8-Diazabicyclo[5.4.0]undec-7-
ene (DBU, 28 mL, 187.4 mmol) was added in one portion.  The resulting mixture stirred at 23 
o
C 
for 1 hr to give a clear, brown solution.  The solution was poured into a separatory funnel 
containing EtOAc:Acetone (4:1, 1000 mL) and 1 M aq. HCl (600 mL).  After shaking, the layers 
were separated.  The organic layer was washed with saturated aqueous sodium bisulfite:brine 
(3:2, 1 x 210 mL) and then brine (1 x 100 mL).  The organic layer was dried over MgSO4, 
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filtered, and concentrated in vacuo.  The resulting oil was dissolved in 60 mL EtOAc and 20 mL 
acetone.  Et2O was added in 20 mL portions to precipitate the product.  The resulting solid was 
collected by vacuum filtration to afford MIDA boronate 2.29 as a white solid (11.03 g, 67%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.60, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.55 (q, J = 1.5 Hz, 1H), 4.31 (d, J = 17 Hz, 2H), 4.15 (d, J = 17 Hz, 2H), 3.04 (s, 3H), 
1.79 (d, J = 1.5 Hz, 3H). 
 
13
C-NMR (100 MHz, d6-acetone) 
δ 168.7, 115.3, 62.8, 47.3, 18.6 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 10.9 
 
HRMS (ESI+) 
Calculated for C8H12BBrNO4: 276.0043 
Found:     276.0040 
 
IR (thin film, cm
-1
) 
3082, 3012, 2954, 2924, 2858, 1768, 1593, 1454, 1336, 1282, 1182, 1041, 891, 864, 798, 
721, 694, 586. 
 
X-ray quality crystals were grown by layering pentane onto a dissolved solution of 2.29 in 
acetone.  The layers slowly mixed, forming crystals. 
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MIDA Boronate 2.41.
23
  In a glovebox, to a 500 mL round bottom flask equipped with a stir bar 
and charged with MIDA boronate 2.29 (5.35 g, 19.4 mmol) was added trans-
bis(triphenylphosphine)palladium dichloride (680.0 mg, 0.97 mmol).  The round bottom was 
sealed with a septum, removed from the glovebox and placed under nitrogen.  THF (40 mL) and 
DMF (150 mL) were added to give a clear, yellow solution. (E)-triethyl(2-
(tributylstannyl)vinyl)germane 2.30 (11.1 g, 23.3 mmol) was added in one portion.  The round 
bottom was sealed under nitrogen and the solution was stirred at 60 
o
C for 20.5 hr.  The dark 
brown reaction solution was cooled to 23 
o
C and was poured into a separatory funnel containing 
400 mL H2O:brine (1:1) and 250 mL EtOAc.  After shaking, the layers were separated.  The 
aqueous layer was extracted with EtOAc (2 x 150 mL).  The combined organic layers were 
washed with H2O:brine (1:1, 2 x 100 mL). The organic layer was dried over MgSO4, filtered, and 
concentrated in vacuo.  The resulting residue was dry loaded onto Celite from an acetone 
solution and purified by flash chromatography on silica gel (Et2O:MeCN 100:0 → 70:30) to 
afford MIDA boronate 2.41 as a pale yellow solid (5.5 g, 74%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.57, stained by KMnO4 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.95 (dd, J = 18, 10.5 Hz, 1H), 6.38 (d, J = 10.5 Hz, 1H), 6.05 (d, J = 18 Hz, 1H), 4.21 
(d, J = 17 Hz, 2H), 4.05 (d, J = 17 Hz, 2H), 2.99 (s, 3H), 1.82 (d, J = 1 Hz, 3H), 1.05 (t, J 
= 8 Hz, 9H), 0.83 (q, J = 8 Hz, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.2, 141.0, 139.5, 133.3, 62.7, 47.1, 15.1, 9.2, 4.8  
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.7 
 
HRMS (ESI+) 
Calculated for C16H29BGeNO4: 384.1408 
Found:     384.1430 
 
IR (thin film, cm
-1
) 
3006, 2953, 2929, 2908, 2872, 1763, 1564, 1460, 1338, 1294, 1254, 1174, 1026, 991, 
889, 850, 731, 708, 575. 
 
 
MIDA Boronate 2.43.  In a subdued light environment, to a 1000 mL round bottom flask 
equipped with a stir bar and charged with MIDA boronate 2.42 (6.29 g, 16.5 mmol) was added 
MeOH (450 mL) to give a clear, pale yellow solution.  The solution was cooled to -78 
o
C.  A 
solution of iodine (12.57 g, 49.5 mmol) in MeOH (150 mL) was added to the cooled reaction 
solution dropwise via cannula over 45 min.  After stirring at -78 
o
C for 3 hr, 200 mL saturated 
aqueous sodium bisulfite and 150 mL EtOAc were added in one portion to give a clear, yellow 
solution.  The cold bath was removed and replaced with a 23 
o
C water bath.  The reaction 
solution was warmed to 23 
o
C over 30 min.  The solution was poured into a separatory funnel 
containing 500 mL H2O and 500 mL EtOAc.  After shaking, the layers were separated and the 
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aqueous layer was extracted with EtOAc (2 x 250 mL).  The combined organic layers were 
washed with saturated aqueous sodium bisulfite (1 x 150 mL) and brine (1 x 150 mL).  The 
organic layer was dried over MgSO4, filtered, and concentrated in vacuo.  The resulting residue 
was dry loaded onto Celite from an acetone solution and purified by flash chromatography on 
silica gel (Et2O:MeCN 100:0 → 80:20) to afford MIDA boronate 2.43 as a pale yellow solid 
(4.43 g, 77%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.48, visualized by short wave UV 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.48 (dd, J = 14.5, 11 Hz, 1H), 6.59 (d, J = 14.5 Hz, 1H), 6.34 (d, J = 11 Hz, 1H), 4.22 
(d, J = 17 Hz, 2H), 4.05 (d, J = 17 Hz, 2H), 2.98 (s, 3H), 1.77 (s, 3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 142.7, 136.3, 82.1, 62.6, 47.1, 15.3 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.5 
 
HRMS (ESI+) 
Calculated for C10H14BINO4:  350.0061 
Found:     350.0067 
 
IR (thin film, cm
-1
) 
3049, 3008, 2956, 2870, 1766, 1612, 1454, 1336, 1292, 1248, 1227, 1194, 1167, 1119, 
1032, 962, 889, 850, 710. 
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MIDA Boronate 2.44.  In a glovebox, to a 300 mL round bottom flask equipped with a stir bar 
and charged with MIDA boronate 2.43 (4.43 g, 12.6 mmol) was added copper(I) thiophene-2-
carboxylate
24
 (CuTc, 3.60 g, 18.9 mmol) and tetrakis(triphenylphosphine)palladium (735.6 mg, 
0.64 mmol).  The round bottom was sealed with a septum, removed from the glovebox and 
placed under nitrogen.  DMF (120 mL) was added to give a dark green solution.  This solution 
was cooled to 0 
o
C.  (E)-triethyl(2-(tributylstannyl)vinyl)germane 2.30 (7.20 g, 15.1 mmol) was 
added in one portion to give a dark brown solution.  The 0 
o
C bath was removed.  The round 
bottom was sealed under nitrogen and the solution was stirred at 23 
o
C in a subdued light 
environment for 4 hr.  The dark brown reaction solution was poured into a separatory funnel 
containing 400 mL H2O:brine (1:1) and 400 mL EtOAc.  After shaking, the layers were 
separated.  The aqueous layer was extracted with EtOAc (2 x 200 mL).  The combined organic 
layers were washed with H2O (2 x 200 mL) and brine (1 x 150 mL).  The aqueous washes were 
back extracted with EtOAc (1 x 100 mL).  The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo.  The resulting residue was dry loaded onto Celite from an 
acetone solution and purified by flash chromatography on silica gel (Et2O:MeCN 100:0 → 
80:20) to afford MIDA boronate 2.44 as a pale yellow solid (2.94 g, 58%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.52, stained by KMnO4 and visualized by short wave UV 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.72 – 6.63 (m, 2H), 6.42 (d, J = 10.5 Hz, 1H), 6.29 (dd, J = 14.5, 10.5 Hz, 1H), 6.07 
(d, J = 18.5 Hz, 1H), 4.21 (d, J = 17 Hz, 2H), 4.04 (d, J = 17 Hz, 2H), 2.97 (s, 3H), 1.82 
(d, J = 1.5 Hz, 3 H), 1.04 (t, J = 8 Hz, 9H), 0.82 (q, J = 8 Hz, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 145.7, 137.0, 136.6, 133.0, 129.5, 62.6, 47.1, 15.2, 9.1, 4.8 
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11
B-NMR (128 MHz, d6-acetone) 
δ 11.8 
 
HRMS (ESI+) 
Calculated for C18H31BGeNO4: 410.1558 
Found:     410.1567 
 
IR (thin film, cm
-1
) 
3016, 2954, 2906, 2872, 1765, 1599, 1458, 1427, 1338, 1296, 1248, 1174, 1026, 999, 
968, 891, 847, 769, 708, 650, 577. 
 
 
MIDA Boronate 2.5.  In a subdued light environment, to a 500 mL round bottom flask equipped 
with a stir bar and charged with MIDA boronate 2.44 (2.94 g, 7.2 mmol) was added MeOH (180 
mL) to give a cloudy, pale yellow solution.  The solution was cooled to -78 
o
C.  A solution of 
iodine (5.57 g, 21.9 mmol) in MeOH (60 mL) was added to the cooled reaction solution 
dropwise via cannula over 15 min.  After stirring at -78 
o
C for 3 hr, 100 mL saturated aqueous 
sodium bisulfite and 100 mL EtOAc were added in one portion to give a clear, yellow solution.  
The cold bath was removed and replaced with a 23 
o
C water bath.  The reaction solution was 
warmed to 23 
o
C over 30 min.  The solution was poured into a separatory funnel containing 400 
mL H2O and 500 mL EtOAc.  After shaking, the layers were separated and the aqueous layer 
was extracted with EtOAc (2 x 100 mL).  The combined organic layers were washed with 
saturated aqueous sodium bisulfite (1 x 100 mL) and brine (1 x 100 mL).  The organic layer was 
dried over MgSO4, filtered, and concentrated in vacuo.  The resulting residue was dissolved in a 
small amount of acetone and the product was precipitated with Et2O.  The resulting pale yellow 
solid was triturated with Et2O (4 x 100 mL) to afford MIDA boronate 2.5 as a pale yellow solid 
(2.01 g, 75%). 
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TLC (Et2O:MeCN 4:1) 
Rf = 0.50, stained by KMnO4 and visualized by short wave UV 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.23 (ddd, J = 14.5, 11, 0.5 Hz, 1H), 6.75 (dd, J = 15, 11 Hz, 1H), 6.55 (d, J = 14.5 Hz, 
1H), 6.38 (dd, J = 11.5, 1.5 Hz, 1H), 6.28 (dd, J = 15, 11 Hz, 1H), 4.22 (d, J = 17 Hz, 
2H), 4.05 (d, J = 17 Hz, 2H), 2.98 (s, 3H), 1.80 (d, J = 1.5 Hz, 3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 146.8, 136.3, 133.5, 130.4, 79.7, 62.7, 47.1, 15.4 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.7 
 
HRMS (ESI+) 
Calculated for C12H16BINO4:  376.0217 
Found:     376.0213 
 
IR (thin film, cm
-1
) 
3045, 3006, 2956, 2929, 2870, 1768, 1699, 1547, 1454, 1338, 1292, 1250, 1213, 1169, 
1140, 1119, 1036, 989, 889, 862, 843, 710. 
 
 
MIDA boronate 2.33.  To a 20 mL vial equipped with a stir bar and charged with MIDA 
boronate 2.31 (500.7 mg, 1.1 mmol) was added THF (11 mL) and 1M aq. NaOH (3.3 mL). The 
mixture was vigorously stirred at 23 °C for 15 minutes. The reaction mixture was then poured 
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into aqueous sodium phosphate buffer (0.5 M, pH 7.0, 10 mL) and diluted with Et2O (10 mL). 
The mixture was shaken and the layers were separated. The aqueous phase was extracted with 
THF:Et2O (1:1, 2 x 10 mL).  (On some occasions phosphate salts precipitated during the 
extraction process and were redissolved by the addition of water.)  The combined organics were 
dried over MgSO4, filtered, and then concentrated in vacuo. Residual solvent was co-evaporated 
with toluene.  The boronic acid 2.32 was isolated as a white solid (358.5 mg, 95%). 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.82 (m, 3H), 5.65 (d, J = 18 Hz, 1H), 3.87 (m, 1H), 2.21 (ddd, J = 14.5, 5, 1 Hz, 1H), 
1.66 (dd, J = 14.5, 8 Hz, 1H), 1.50 (ddd, J = 13, 4, 1.5 Hz, 1H), 1.30 – 1.18 (m, 1H), 1.16 
(s, 3H), 1.12 (s, 3H), 0.91 (s, 3H), 0.89 (s, 9H), 0.07 (s, 3H), 0.06 (s, 3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 145.9, 71.5, 66.4, 65.6, 47.8, 42.0, 35.3, 29.7, 26.2, 25.4, 20.2, 18.5, -4.6, -4.6 
 
The boronic acid 2.32 was used immediately in the following reaction: 
 
Preparation of catalyst solution. In a glovebox, to a 7 mL vial charged with XPhos (46.3 mg, 
0.10 mmol) and Pd(OAc)2 (11.8 mg, 0.053 mmol) was added THF (2.5 mL). The solution was 
stirred at 23 °C for 20 min to afford a clear, brown solution. 
 
The freshly prepared catalyst solution was used in the following reaction: 
In a glovebox, to a 40 mL vial charged with MIDA boronate 2.4 (285.3 mg, 0.77 mmol) was 
added finely ground anhydrous K3PO4 (481.3 mg, 2.3 mmol).  The prepared boronic acid (358.5 
mg, 1.1 mmol) was added as a solution in THF:Toluene (1:2, 10.0 mL).  The prepared catalyst 
solution was added in one portion.  The vial was sealed with a septum cap and removed from the 
glovebox.  The solution was stirred in a subdued light environment at 45 
o
C for 24.5 hr.  The 
reaction mixture was filtered through a pad of Celite, concentrated in vacuo, dry loaded onto 
Celite from an acetone solution, and purified via flash chromatography on florisil (Et2O:MeCN 
100:0 → 80:20) to afford MIDA boronate 2.33 as a pale yellow solid (358.0 mg, 79%). 
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TLC (Et2O:MeCN 4:1) 
Rf = 0.69, visualized by short wave and long wave UV 
 
1
H-NMR (400 MHz, d6-acetone) 
δ 7.52 (s, 1H), 7.19 (d, J = 15.5 Hz, 1H), 6.40 (d, J = 15.5 Hz, 1H), 5.93 (s, 1H), 5.82 (s, 
1H), 4.26 (d, J = 17 Hz, 2H), 4.10 (d, J = 17 Hz, 2H), 3.89 (m, 1H), 3.09 (s, 3H), 2.28 – 
2.21 (m, 4H), 1.71 (dd, J = 14.5, 8.5 Hz, 1H), 1.53 (ddd, J = 13, 3.5, 1.5 Hz, 1H), 1.35 – 
1.23 (m, 1H), 1.20 (s, 3H), 1.16 (s, 3H), 0.95 (s, 3H), 0.89 (s, 9H), 0.08 (s, 3H), 0.07 (s, 
3H). 
 
13
C-NMR (100 MHz, d6-acetone) 
δ 169.2, 168.8, 147.2, 146.4, 138.7, 134.9, 126.5, 122.3, 121.0, 70.7, 67.7, 65.5, 62.5, 
47.6, 47.2, 42.0, 35.7, 29.6, 26.2, 25.4, 20.1, 18.7, 18.6, -4.6, -4.6 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.1 
 
HRMS (ESI+) 
Calculated for C30H45BNO8Si: 586.3008 
Found:     586.2983 
 
IR (thin film, cm
-1
) 
3003, 2956, 2929, 2856, 1765, 1630, 1591, 1387, 1338, 1292, 1255, 1188, 1155, 1124, 
1089, 1028, 989, 893, 862, 837, 773, 735, 582. 
 
 28D -93.5 (c 0.85, CHCl3) 
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Pinacol ester 2.45.  To a 20 mL vial equipped with a stir bar and charged with MIDA boronate 
2.33 (338.2 mg, 0.58 mmol) was added pinacol (110.3 mg, 0.93 mmol) and solid NaHCO3 
(252.6 mg, 3.0 mmol).  MeOH (5.8 mL) was added and the suspension was stirred in a subdued 
light environment at 45 
o
C for 3 hr.  The mixture was filtered through a pad of Celite, eluting 
with EtOAc (125 mL).  The collected solution was concentrated in vacuo.  The resulting residue 
was azeotroped with toluene (2 x 5 mL) and was then dissolved in toluene (5.8 mL).  To remove 
residual pinacol, finely ground CaCl2 (337.8 mg, 3.0 mmol) and solid NaHCO3 (252.3 mg, 3.0 
mmol) were added.  The suspension was stirred at 23 
o
C for 1.5 hr and was then filtered through 
a pad of Celite, eluting with EtOAc (125 mL).  The collected solution was concentrated in vacuo 
to afford pinacol ester 2.45 as a deep red solid (318.3 mg, 99%). 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.54 (s, 1H), 7.22 (d, J = 15.5 Hz, 1H), 6.42 (d, J = 15.5 Hz, 1H), 5.95 (s, 1H), 5.65 (s, 
1H), 3.90 (m, 1H), 2.36 (s, 3H), 2.25 (ddd, J = 14.5, 5, 1 Hz, 1H), 1.72 (dd, J = 14.5, 8.5 
Hz, 1H), 1.53 (ddd, J = 13, 3.5, 1 Hz, 1H), 1.34 – 1.23 (m, 13 H), 1.20 (s, 3H), 1.17 (s, 
3H), 0.95 (s, 3H), 0.89 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 168.9, 153.0, 148.8, 138.3, 135.5, 127.3, 122.2, 119.2, 83.7, 70.7, 67.7, 65.4, 47.6, 41.9, 
35.6, 29.6, 26.2, 25.4, 25.1, 20.2, 20.1, 18.5, -4.5, -4.6 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 30.9 
 
HRMS (ESI+) 
Calculated for C31H50BO6Si:  557.3470 
Found:     557.3483 
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IR (thin film, cm
-1
) 
2956, 2929, 2858, 1765, 1593, 1371, 1257, 1144, 1080, 1032, 976, 953, 852, 837, 775, 
580. 
 
 25D -24.4 (c 1.1, CHCl3) 
 
 
MIDA boronate 2.34.  In a glovebox, to a 7 mL vial equipped with a stir bar and charged with 
pinacol ester 2.45 (105.7 mg, 0.19 mmol), MIDA boronate 2.5 (100.3 mg, 0.27 mmol), and 
Ag2O (141.2 mg, 0.61 mmol) was added trans-bis(triphenylphosphine)palladium dichloride (9.0 
mg, 0.013 mmol) and DMSO (2.0 mL).  The vial was sealed with a cap and removed from the 
glovebox.  The solution was stirred in a subdued light environment at 45 
o
C for 12 hr.  The 
reaction mixture was poured into a separatory funnel containing EtOAc (30 mL).  The organic 
layer was washed with H2O:brine (5:1, 3 x 15 mL).  The organic layer was dried over MgSO4, 
filtered, and concentrated in vacuo.  The resulting residue was dry loaded onto Celite from an 
acetone solution, and purified via reverse phase flash chromatography on C18 silica gel 
(H2O:MeCN 95:5 → 0:100) to afford MIDA boronate 2.34 as an orange solid (57.6 mg, 45%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.51, visualized by visible light (yellow/orange) 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.50 (s, 1H), 7.16 (d, J = 16 Hz, 1H), 6.81 (dd, J = 14.5, 11.5 Hz, 1H), 6.79 (dd, J = 14, 
12 Hz, 1H), 6.63 (dd, J = 14, 11.5 Hz, 1H), 6.58 (d, J = 12, 1.5 Hz, 1H), 6.52 (d, J = 11 
Hz, 1H), 6.50 (dd, J = 12, 11 Hz, 1H), 6.39 (d, J = 16 Hz, 1H), 6.00 (s, 1H), 4.23 (d, J = 
17 Hz, 2H), 4.06 (d, J = 17 Hz, 2H), 3.90 (m, 1H), 2.98 (s, 3H), 2.25 (ddd, J = 9.5, 5, 1.5 
133 
Hz, 1H), 2.21 (s, 3H), 1.85 (d, J = 1.5 Hz, 3H), 1.71 (dd, J = 14.5, 8 Hz, 1H), 1.52 (ddd, J 
= 13, 3.5, 1.5 Hz, 1H), 1.31 (dd, J = 13, 10 Hz, 1H), 1.20 (s, 3H), 1.17 (s, 3H), 0.95 (s, 
3H), 0.90 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 169.1, 148.0, 138.8, 138.2, 137.9, 137.2, 134.9, 134.5, 134.4, 131.9, 130.3, 
125.4, 122.6, 119.6, 70.8, 67.8, 65.5, 62.7, 47.7, 47.1, 42.0, 35.7, 29.7, 26.2, 25.4, 20.2, 
18.6, 15.5, 15.4, -4.6, -4.6 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 12.0 
 
HRMS (ESI+) 
Calculated for C37H53BNO8Si: 678.3634 
Found:     678.3633 
 
IR (thin film, cm
-1
) 
3016, 2956, 2929, 2856, 1757, 1612, 1529, 1462, 1381, 1342, 1298, 1250, 1184, 1084, 
1036, 989, 837, 775, 586. 
 
 29D -23.2 (c 1.21, CHCl3) 
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Protected peridinin 2.46. 
Preparation of catalyst stock solution. In a glovebox, to a 7 mL vial equipped with a stir bar and 
charged with XPhos  (30.4 mg, 0.064 mmol) and Pd(OAc)2 (7.3 mg, 0.033 mmol) was added 
THF (degassed, inhibited with 250 ppm BHT, 2.0 mL). The solution was stirred at 23 °C for 10 
min to afford a clear, brown solution. 
 
The freshly prepared catalyst stock solution was used in the following reaction: 
In a glovebox, to a 7 mL vial equipped with a stir bar and charged with MIDA boronate 2.34 
(45.2 mg, 0.067 mmol) was added finely ground NaOH (18.7 mg, 0.47 mmol).  Iodoallene 2.35 
(37.2 mg, 0.088 mmol) was added as a solution in THF (degassed, inhibited with 250 ppm BHT, 
2.0 mL).  A portion of the prepared catalyst solution (0.20 mL, which contains 0.0033 mmol 
Pd(OAc)2 and 0.0064 mmol XPhos) was added in one portion.  The vial was sealed with a 
septum cap and removed from the glovebox.  Degassed DI H2O (0.45 mL) was added.  The 
solution was stirred in a subdued light environment at 23 
o
C for 1.5 hr.  The reaction mixture was 
poured into aqueous sodium phosphate buffer (0.25 M, pH 7.0, 10 mL) and diluted with Et2O (20 
mL). The mixture was shaken and the layers were separated. The aqueous phase was extracted 
with Et2O (1 x 10 mL).  The combined organic layers were dried over MgSO4, filtered, and then 
concentrated in vacuo.  The resulting residue was dry loaded onto Celite from an Et2O solution, 
and purified via reverse phase flash chromatography on C18 silica gel (H2O:Acetone 7:3 → 
0:100) to afford protected peridinin 2.46 as a red solid (32.6 mg, 60%). 
 
TLC (Hexane:EtOAc 4:1) 
Rf = 0.56, visualized by visible light (orange) 
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1
H-NMR (500 MHz, CDCl3) 
δ 7.15 (d, J = 15.5 Hz, 1H), 7.01 (s, 1H), 6.61 (dd, J = 14.5, 11.5 Hz, 1H), 6.60 (dd, J = 
14, 11 Hz, 1H), 6.51 (dd, J = 14, 11 Hz, 1H), 6.43 (d, J = 11.5 Hz, 1H), 6.37 (dd, J = 14, 
11 Hz, 1H), 6.34 (d, J = 15.5 Hz, 1H), 6.09 (d, J = 11.5 Hz, 1H), 5.99 (s, 1H), 5.72 (s, 
1H), 5.34 (tt, J = 11.5, 4.5 Hz, 1H), 3.90 – 3.80 (m, 1H), 2.26 (ddd, J = 14.5, 5, 1 Hz, 
1H), 2.23 (s, 3H), 2.03 (s, 3H), 1.96 (ddd, J = 12.5, 4, 2 Hz, 1H), 1.79 (s, 3H), 1.65 (dd, J 
= 14.5, 8 Hz, 1H), 1.50 (ddd, J = 13, 3.5, 1.5 Hz, 1H), 1.40 (m, 1H), 1.36 (s, 3H), 1.33 (s, 
3H), 1.32 – 1.20 (m, 3H), 1.19 (s, 3H), 1.17 (s, 3H),  1.04 (s, 3H), 0.95 (s, 3H), 0.88 (s, 
9H), 0.11 (s, 9H), 0.051 (s, 3H), 0.047 (s, 3H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 202.5, 170.4, 168.7, 146.7, 138.0, 137.2, 136.2, 134.3, 133.9, 133.8, 132.7, 131.6, 
128.8, 127.7, 124.8, 121.6, 119.1, 117.0, 102.7, 74.8, 70.6, 68.3, 67.5, 64.6, 47.7, 47.0, 
45.7, 41.3, 35.8, 35.1, 32.3, 30.3, 29.4, 28.8, 25.9, 25.0, 21.4, 20.0, 18.1, 15.4, 14.1, 2.2,  
-4.7, -4.8 
 
HRMS (ESI+) 
Calculated for C48H73O7Si2:  817.4895 
Found:     817.4895 
 
IR (thin film, cm
-1
) 
2960, 2929, 2858, 1961, 1755, 1630, 1523, 1454, 1377, 1250, 1161, 1120, 1078, 1036, 
987, 839. 
 
 28D -40.3 (c 1.6, CHCl3) 
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Peridinin 2.2.  To a 7 mL polyethylene vial containing a stir bar was added protected peridinin 
2.46 (31.3 mg, 0.038 mmol) as a solution in THF (2.0 mL).  HF•pyridine (70% HF in pyridine, 
0.10 mL, 5.5 mmol) was added in one portion. The solution was stirred in a subdued light 
environment at 23 
oC for 1 hr.  An additional portion of HF•pyridine (70% HF in pyridine, 0.10 
mL, 5.5 mmol) was added.  The solution was stirred at 23 
o
C for an additional 2 hr.  The reaction 
was quenched by slow, dropwise addition of saturated aqueous NaHCO3 until effervescence 
ceased (caution: slow addition is important to avoid uncontrolled effervescence).  The reaction 
solution was then poured into saturated aqueous NaHCO3 (10 mL) and diluted with Et2O (20 
mL).  The mixture was shaken and the layers were separated. The aqueous phase was extracted 
with Et2O (1 x 10 mL).  The combined organics were dried over MgSO4, filtered, and then 
concentrated in vacuo.  The resulting residue was dry loaded onto Celite from an Et2O solution, 
and purified via flash chromatography on florisil (Hexane:EtOAc 100:0 → 0:100) to afford 
peridinin 2.2 as a red solid (15.7 mg, 65%). 
 
TLC (Hexane:Acetone 7:3) 
Rf = 0.20, visualized by visible light (orange) 
 
1
H-NMR (500 MHz, CDCl3) 
δ 7.15 (d, J = 16 Hz, 1H), 7.02 (s, 1H), 6.61 (dd, J = 14, 11.5 Hz, 1H), 6.60 (dd, J = 14, 
11.5 Hz, 1H), 6.51 (dd, J = 14, 10.5 Hz, 1H), 6.43 (d, J = 11.5 Hz, 1H), 6.37 (dd, J = 
14.5, 10.5 Hz, 1H), 6.35 (d, J = 15.5 Hz, 1H), 6.09 (d, J = 11.5 Hz, 1H), 6.05 (s, 1H), 
5.73 (s, 1H), 5.37 (tt, J = 11.5, 4.5 Hz, 1H), 3.90 (m, 1H), 2.38 (ddd, J = 14.5, 5, 1.5 Hz, 
1H), 2.27 (ddd, J = 14, 4, 2 Hz, 1H), 2.22 (s, 3H), 2.03 (s, 3H), 1.98 (ddd, J = 12.5, 4, 2 
Hz, 1H), 1.80 (s, 3H), 1.69 – 1.60 (m, 2H), 1.50 (dd, J = 14, 11 Hz, 1H), 1.40 (m, 1H), 
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1.38 (s, 3H), 1.35 (m, 1H), 1.35 (s, 3H), 1.26 (m, 1H), 1.199 (s, 3H), 1.195 (s, 3H), 1.06 
(s, 3H), 0.97 (s, 3H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 202.6, 170.4, 168.7, 146.7, 138.0, 137.2, 136.3, 134.0, 133.9, 133.6, 133.0, 131.5, 
128.9, 128.1, 124.7, 121.8, 119.2, 117.6, 103.3, 72.6, 70.4, 67.9, 67.5, 64.2, 47.1, 45.4, 
45.2, 40.9, 35.8, 35.3, 32.0, 31.2, 29.5, 29.1, 24.9, 21.4, 19.8, 15.4, 14.0 
 
HRMS (ESI+) 
Calculated for C39H51O7:  631.3635 
Found:     631.3629 
 
IR (thin film, cm
-1
) 
3496, 3016, 2962, 2926, 2856, 1928, 1743, 1635, 1523, 1456, 1365, 1250, 1163, 1124, 
1030, 984, 908, 756. 
 
 28D -22.9 ± 5.7 (c 1.1, MeOH) 
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1H NMR data for peridinin: δH/ppm 
Natural peridinin (literature 
reference
25
; 400 MHz, CDCl3) 
Synthetic peridinin 
(500 MHz, CDCl3) 
7.17 7.15 
7.02 7.02 
6.61 6.61 
6.61 6.60 
6.51 6.51 
6.45 6.43 
6.38  6.37 
6.38  6.35 
6.11  6.09 
6.05  6.05 
5.74  5.73 
5.38  5.37 
3.91  3.90 
2.40  2.38 
2.28  2.27 
2.229  2.22 
2.041  2.03 
2.00  1.98 
1.801  1.80 
1.64  1.69-1.60 
1.63  1.69-1.60 
1.51  1.50 
1.40  1.40 
1.385  1.38 
1.352  1.35 
1.35  1.35 
1.27  1.26 
1.207  1.199 
1.203  1.195 
1.069  1.06 
0.976  0.97 
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13
C NMR data for peridinin: δC/ppm 
Natural peridinin (literature 
reference
25
; 100 MHz, CDCl3) 
Synthetic peridinin  
(125 MHz, CDCl3) 
202.6 202.6 
170.4 170.4 
168.8 168.7 
146.8 146.7 
138.0 138.0 
137.2 137.2 
136.3 136.3 
134.0 134.0 
133.9 133.9 
133.7 133.6 
133.0 133.0 
131.5 131.5 
128.9 128.9 
128.2 128.1 
124.8 124.7 
121.8 121.8 
119.2 119.2 
117.6 117.6 
103.3 103.3 
72.7 72.6 
70.5 70.4 
68.0 67.9 
67.5 67.5 
64.2 64.2 
47.1 47.1 
45.4 45.4 
45.2 45.2 
41.0 40.9 
35.8 35.8 
35.3 35.3 
32.1 32.0 
31.3 31.2 
29.5 29.5 
29.2 29.1 
24.9 24.9 
21.4 21.4 
19.9 19.8 
15.4 15.4 
14.0 14.0 
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General information for lipoperoxidation assays. Egg yolk phosphatidylcholine (EYPC) was 
obtained as a 20 mg/mL solution in CHCl3 from Avanti Polar Lipids (catalog number 840051C-
1g, Alabaster, AL), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (16:0-18:1 PC, POPC) 
was obtained as a 25 mg/mL solution in CHCl3 from Avanti Polar Lipids (catalog number 
850457C), and 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (18:0-20:4 PC, PUFA) 
was obtained as a 10 mg/mL solution in CHCl3 from Avanti Polar Lipids (catalog number 
850469C) and were stored at -20
o
C under an atmosphere of dry nitrogen and used within 1.5 
months. Prior to preparing the lipid film, the solution was warmed to ambient temperature to 
prevent condensation from contaminating the solution. The HPLC purity of cholesterol and 
carotenoids was checked prior to use and confirmed to be >95%. Cholesterol was purchased 
from Sigma Aldrich (catalog number C8667, >99%). Astaxanthin was a generous donation from 
BASF.  Peridinin was synthesized as above and was HPLC purified to >95% prior to use. 
 
Preparation of samples for Figure 2-5. 
 
Blank: 
Preparation of lipid films: To three separate 12x75 mm test tubes was added 1.0 mL EYPC 
solution via Hamilton syringe.  The solvent was removed under a gentle stream of nitrogen and 
the resulting lipid film was stored under high vacuum for a minimum of 12 hours prior to use. 
 
Preparation of liposomes: The lipid film was hydrated with 1 mL 150 mM KCl/0.5 mM HEPES 
pH 7.4 (K buffer) and vortexed vigorously for 1 minute (until the film no longer coated the sides 
of the test tube) to form a suspension of multilamellar vesicles (MLVs).  The resulting lipid 
suspension was pulled into a Hamilton 1 mL gastight syringe and the syringe was placed in an 
Avanti Polar Lipids Mini-Extruder.  The lipid solution was then passed through a 0.20 μm 
Whatman (Kent, UK) polycarbonate filter (supported by a 10 mm filter support on each side, 
Avanti Polar Lipids) 21 times, the newly formed large unilamellar vesicle (LUV) suspension 
being collected in the syringe that did not contain the original suspension of MLVs to prevent the 
carryover of MLVs into the LUV solution.  The LUVs were purified by gel exclusion 
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chromatography with a Sephadex G50-150 column (1 cm column, 1.0 g unswelled resin, swelled 
resin with K buffer, eluted with K buffer). 
 
Astaxanthin samples: 
Preparation of lipid films: To three separate 12x75 mm test tubes was added 1.0 mL EYPC 
solution via Hamilton syringe.  The solvent was removed under a gentle stream of nitrogen and 
the resulting lipid film was stored under high vacuum for a minimum of 12 hours prior to use. 
 
Preparation of liposomes: The lipid film was hydrated with 1 mL 150 mM KCl/0.5 mM HEPES 
pH 7.4 (K buffer) and vortexed vigorously for 1 minute (until the film no longer coated the sides 
of the test tube) to form a suspension of multilamellar vesicles (MLVs).  The resulting lipid 
suspension was pulled into a Hamilton 1 mL gastight syringe and the syringe was placed in an 
Avanti Polar Lipids Mini-Extruder.  The lipid solution was then passed through a 0.20 μm 
Whatman (Kent, UK) polycarbonate filter (supported by a 10 mm filter support on each side, 
Avanti Polar Lipids) 21 times, the newly formed large unilamellar vesicle (LUV) suspension 
being collected in the syringe that did not contain the original suspension of MLVs to prevent the 
carryover of MLVs into the LUV solution.  A 25 mM solution of astaxanthin in uninhibited THF 
was prepared.  To a vortexing solution of the newly formed LUV under a stream of dry nitrogen 
was dropwise added 60 μL of the carotenoid solution.  The carotenoid impregnated LUVs were 
purified by gel exclusion chromatography with a Sephadex G50-150 column (1 cm column, 1.0 g 
unswelled resin, swelled resin with K buffer, eluted with K buffer). 
 
Peridinin samples: 
Preparation of lipid films: To three separate 12x75 mm test tubes was added 1.0 mL EYPC 
solution via Hamilton (Reno, NV) syringe.  The solvent was removed under a gentle stream of 
nitrogen and the resulting lipid film was stored under high vacuum for a minimum of 12 hours 
prior to use. 
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Preparation of liposomes: The lipid film was hydrated with 1 mL 150 mM KCl/0.5 mM HEPES 
pH 7.4 (K buffer) and vortexed vigorously for 1 minute (until the film no longer coated the sides 
of the test tube) to form a suspension of multilamellar vesicles (MLVs).  The resulting lipid 
suspension was pulled into a Hamilton 1 mL gastight syringe and the syringe was placed in an 
Avanti Polar Lipids Mini-Extruder.  The lipid solution was then passed through a 0.20 μm 
Whatman (Kent, UK) polycarbonate filter (supported by a 10 mm filter support on each side, 
Avanti Polar Lipids) 21 times, the newly formed large unilamellar vesicle (LUV) suspension 
being collected in the syringe that did not contain the original suspension of MLVs to prevent the 
carryover of MLVs into the LUV solution.  An 11 mM solution of peridinin in uninhibited THF 
was prepared.  To a vortexing solution of the newly formed LUV under a stream of dry nitrogen 
was dropwise added 46 μL of the carotenoid solution.  The carotenoid impregnated LUVs were 
purified by gel exclusion chromatography with a Sephadex G50-150 column (1 cm column, 1.0 g 
unswelled resin, swelled resin with K buffer, eluted with K buffer). 
 
Determination of phosphorus content and liposome dilution. 
Preparation of a standard curve: To 7 mL vials in triplicate was added the following amount of 
phosphorus standard solution (Sigma Aldrich, catalog number P3869, 0.65 mM phosphorus as 
KH2PO4): 20 μL, 40 μL, 60 μL, 80 μL, 100 μL, and 120 μL.  To these vials and to a separate vial 
containing no phosphorus that was used as a blank, was added 450 μL of 8.9 M aq H2SO4.  The 
samples were incubated open to ambient atmosphere in a 225 
o
C aluminum heating block for 25 
min and then removed to 23 
o
C for 5 min.  To each sample was added 150 μL of 30% w/v 
aqueous hydrogen peroxide and the vials were returned to the 225 
o
C heating block for 30 min 
after which the samples were removed to 23 
o
C for 5 min.  To each sample was added 4.0 mL DI 
H2O.  To each vial was then added 500 μL of 2.5% w/v ammonium molybdate tetrahydrate.  The 
vials were capped and the resulting mixtures were vortexed briefly and vigorously.  
Subsequently, 500 μL of 10% w/v L-(+)-ascorbic acid was added to each vial.  The vials were 
capped and the resulting mixtures were vortexed briefly and vigorously.  The capped vials were 
then placed in a 100 
o
C aluminum heating block for 7 min.  The samples were removed to 23 
o
C 
and cooled for approximately 20 minutes to 23 
o
C prior to analysis by UV/Vis spectroscopy.  
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Total phosphorus was determined by observing the absorbance at 820 nm.  A standard curve was 
prepared by plotting μmoles of phosphorus vs. the absorbance at 820 nm. 
 
Analysis of liposomes: To 7 mL vials in triplicate was added 10 μL of the purified LUV 
suspension.  To these vials and to a separate vial containing no LUVs that was used as a blank, 
was added 450 μL of 8.9 M aq H2SO4.  The samples were incubated open to ambient atmosphere 
in a 225 
o
C aluminum heating block for 25 min and then removed to 23 
o
C for 5 min.  To each 
sample was added 150 μL of 30% w/v aqueous hydrogen peroxide and the vials were returned to 
the 225 
o
C heating block for 30 min after which the samples were removed to 23 
o
C for 5 min.  
To each sample was added 4.0 mL DI H2O.  To each vial was then added 500 μL of 2.5% w/v 
ammonium molybdate tetrahydrate.  The vials were capped and the resulting mixtures were 
vortexed briefly and vigorously.  Subsequently, 500 μL of 10% w/v L-(+)-ascorbic acid was 
added to each vial.  The vials were capped and the resulting mixtures were vortexed briefly and 
vigorously.  The capped vials were then placed in a 100 
o
C aluminum heating block for 7 min.  
The samples were removed to 23 
o
C and cooled for approximately 20 minutes to 23 
o
C prior to 
analysis by UV/Vis spectroscopy.  Total phosphorus was determined by observing the 
absorbance at 820 nm and comparing this value to the standard curve.  The liposome suspension 
was diluted to a concentration of 1 mM. 
 
Determination of carotenoid content: 
To a HPLC vial was added 100 μL of the 1 mM liposome suspension and 200 μL of 4:1:1 
acetone:MeOH:0.2 M BHT in EtOH.  The mixture was shaken to give a clear solution.  The 
samples were analyzed by analytical HPLC and the carotenoid content was determined by 
comparing the peak area to standard curves prepared from carotenoid solutions of known 
concentrations. 
HPLC method: 
Reverse phase, C18 column, inject 75 μL sample, flow 2 mL/min 
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astaxanthin: 90:10 MeOH:H2O; detect at 478 nm 
peridinin: 90:10 MeOH:H2O; detect at 468 nm 
Copper based lipoperoxidation assay: 
To 7 mL vials in triplicate was added 4 mL of the 1 mM liposome suspension.  To each sample 
was added 40 μL of 11 mM CuCl2 in DI H2O.  The vials were capped and incubated in a 37 
o
C 
aluminum heating block.  At four hour increments an aliquot was removed from each sample and 
analyzed for TBARS by one of the following methods: 
(1) TBARS analysis.  At each timepoint, a 100 μL aliquot was removed from the liposome assay 
sample to a 1.5 mL microcentrifuge tube containing 10 μL of 0.2 M BHT in EtOH and 400 μL of 
TBA solution (TBA solution = 0.375% w/v thiobarbituric acid, 0.25 M HCl, 1% Triton X-100 in 
MQ H2O).  The microcentrifuge tube was capped and incubated in a 100 
o
C aluminum heating 
block for 15 minutes.  The samples were removed to 23
 o
C and cooled for approximately 20 
minutes to 23 
o
C prior to analysis UV/Vis spectroscopy.  TBARS formation was determined by 
observing the absorbance at 535 nm. 
Or  
(2) TBARS analysis.  At each timepoint, a 100 μL aliquot was removed from the liposome assay 
sample to a 1.5 mL HPLC vial containing 500 μL of TBA solution (TBA solution = 0.4% w/v 
thiobarbituric acid in 0.1 M NaOAc, pH 3.5).  The vial was capped and incubated in a 100 
o
C 
aluminum heating block for 15 minutes.  The samples were removed to 23
 o
C and cooled for 
approximately 20 minutes to 23 
o
C prior to analysis by HPLC. 
HPLC method: 
Reverse phase, C18 column, inject 75 μL sample, flow 2 mL/min 
TBA/MDA adduct: 72:17:11 50 mM KH2PO4:MeOH:MeCN; detect at 535 nm 
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Analysis of samples for Figure 2-6. 
 
Carotenoid consumption:  At each timepoint, a 100 μL aliquot was removed from the liposome 
assay sample to a HPLC vial.  To each sample vial was added 200 μL of 4:1:1 
acetone:MeOH:0.2 M BHT in EtOH.  The mixture was shaken to give a clear solution.  The 
samples were analyzed by analytical HPLC and the cholesterol and carotenoid consumption was 
determined by measuring changes to the peak area over time. 
HPLC method: 
Reverse phase, C18 column, inject 75 μL sample, flow 2 mL/min 
astaxanthin: 90:10 MeOH:H2O; detect at 478 nm 
peridinin: 90:10 MeOH:H2O; detect at 468 nm 
 
Preparation of samples for Figure 2-7. 
 
A chemically defined blank: 
Preparation of lipid films: To a 12x75 mm test tube was added 0.15 mL POPC solution and 
0.125 mL PUFA solution via Hamilton syringe.  The solvent was removed under a gentle stream 
of nitrogen and the resulting lipid film was stored under high vacuum for a minimum of 12 hours 
prior to use. 
 
Preparation of liposomes: The lipid film was hydrated with 0.3 mL 150 mM KCl/0.5 mM 
HEPES pH 7.4 (K buffer) and vortexed vigorously for 1 minute (until the film no longer coated 
the sides of the test tube) to form a suspension of multilamellar vesicles (MLVs).  The resulting 
lipid suspension was pulled into a Hamilton 1 mL gastight syringe and the syringe was placed in 
an Avanti Polar Lipids Mini-Extruder.  The lipid solution was then passed through a 0.20 μm 
Whatman (Kent, UK) polycarbonate filter (supported by a 10 mm filter support on each side, 
Avanti Polar Lipids) 21 times, the newly formed large unilamellar vesicle (LUV) suspension 
being collected in the syringe that did not contain the original suspension of MLVs to prevent the 
carryover of MLVs into the LUV solution.  The LUVs were purified by gel exclusion 
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chromatography with a Sephadex G50-150 column (1 cm column, 1.0 g unswelled resin, swelled 
resin with K buffer, eluted with K buffer). 
 
A chemically defined astaxanthin sample: 
Preparation of lipid films: To a 12x75 mm test tube was added 0.15 mL POPC solution and 
0.125 mL PUFA solution via Hamilton syringe.  The solvent was removed under a gentle stream 
of nitrogen and the resulting lipid film was stored under high vacuum for a minimum of 12 hours 
prior to use. 
 
Preparation of liposomes: The lipid film was hydrated with 0.3 mL 150 mM KCl/0.5 mM 
HEPES pH 7.4 (K buffer) and vortexed vigorously for 1 minute (until the film no longer coated 
the sides of the test tube) to form a suspension of multilamellar vesicles (MLVs).  The resulting 
lipid suspension was pulled into a Hamilton 1 mL gastight syringe and the syringe was placed in 
an Avanti Polar Lipids Mini-Extruder.  The lipid solution was then passed through a 0.20 μm 
Whatman (Kent, UK) polycarbonate filter (supported by a 10 mm filter support on each side, 
Avanti Polar Lipids) 21 times, the newly formed large unilamellar vesicle (LUV) suspension 
being collected in the syringe that did not contain the original suspension of MLVs to prevent the 
carryover of MLVs into the LUV solution.  A 19 mM solution of astaxanthin in uninhibited THF 
was prepared.  To a vortexing solution of the newly formed LUV under a stream of dry nitrogen 
was dropwise added 33 μL of the carotenoid solution.  The carotenoid impregnated LUVs were 
purified by gel exclusion chromatography with a Sephadex G50-150 column (1 cm column, 1.0 g 
unswelled resin, swelled resin with K buffer, eluted with K buffer). 
 
A chemically defined peridinin sample: 
Preparation of lipid films: To a 12x75 mm test tube was added 0.15 mL POPC solution and 
0.125 mL PUFA solution via Hamilton syringe.  The solvent was removed under a gentle stream 
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of nitrogen and the resulting lipid film was stored under high vacuum for a minimum of 12 hours 
prior to use. 
 
Preparation of liposomes: The lipid film was hydrated with 0.3 mL 150 mM KCl/0.5 mM 
HEPES pH 7.4 (K buffer) and vortexed vigorously for 1 minute (until the film no longer coated 
the sides of the test tube) to form a suspension of multilamellar vesicles (MLVs).  The resulting 
lipid suspension was pulled into a Hamilton 1 mL gastight syringe and the syringe was placed in 
an Avanti Polar Lipids Mini-Extruder.  The lipid solution was then passed through a 0.20 μm 
Whatman (Kent, UK) polycarbonate filter (supported by a 10 mm filter support on each side, 
Avanti Polar Lipids) 21 times, the newly formed large unilamellar vesicle (LUV) suspension 
being collected in the syringe that did not contain the original suspension of MLVs to prevent the 
carryover of MLVs into the LUV solution.  A 9 mM solution of peridinin in uninhibited THF 
was prepared.  To a vortexing solution of the newly formed LUV under a stream of dry nitrogen 
was dropwise added 23 μL of the carotenoid solution.  The carotenoid impregnated LUVs were 
purified by gel exclusion chromatography with a Sephadex G50-150 column (1 cm column, 1.0 g 
unswelled resin, swelled resin with K buffer, eluted with K buffer). 
Phosphorus determination, liposome dilution, carotenoid content measurement, and the copper 
based lipoperoxidation assay were preformed as described above. 
 
Analysis of samples for Figure 2-8. Preformed as described for Figure 2-6. 
 
Preparation of samples for Figure 2-9. 
 
Preparation of lipid films: To 12x75 mm test tubes was added the following via Hamilton 
syringe: 
1) 0.8 mL POPC solution 
2) 0.45 mL POPC solution, 0.375 mL PUFA solution, and 0.16 mL of 13(S)-HpOTre solution 
(0.10 mg in 1 mL EtOH), prepared in triplicate 
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3) 0.45 mL POPC solution, 0.375 mL PUFA solution 
The solvent was removed under a gentle stream of nitrogen and the resulting lipid films were 
stored under high vacuum for a minimum of 12 hours prior to use. 
 
Preparation of liposomes: The lipid films were hydrated with 1.0 mL 150 mM KCl/0.5 mM 
HEPES pH 7.4 (K buffer) and vortexed vigorously for 1 minute (until the film no longer coated 
the sides of the test tube) to form a suspension of multilamellar vesicles (MLVs).  The resulting 
lipid suspensions were pulled into a Hamilton 1 mL gastight syringe and the syringe was placed 
in an Avanti Polar Lipids Mini-Extruder.  The lipid solutions were then passed through a 0.20 
μm Whatman (Kent, UK) polycarbonate filter (supported by a 10 mm filter support on each side, 
Avanti Polar Lipids) 21 times, the newly formed large unilamellar vesicle (LUV) suspension 
being collected in the syringe that did not contain the original suspension of MLVs to prevent the 
carryover of MLVs into the LUV solution.  A 40 mM solution of astaxanthin in uninhibited THF 
was prepared.  To a vortexing solution of the newly formed LUV under a stream of dry nitrogen 
was dropwise added 60 μL of the carotenoid solution.  The carotenoid impregnated LUVs were 
purified by gel exclusion chromatography with a Sephadex G50-150 column (1 cm column, 1.0 g 
unswelled resin, swelled resin with K buffer, eluted with K buffer). 
Phosphorus determination, liposome dilution, carotenoid content measurement, the copper based 
lipoperoxidation assay, and measurement of carotenoid consumption were preformed as 
described above.  
 
Preparation of samples for Figure 2-11 and 2-12. 
 
Preparation of lipid films: To 15 12x75 mm test tube was added 0.40 mL EYPC solution via 
Hamilton syringe.  A solution of 10.5 mg cholesterol in 1.0 mL CHCl3 was prepared. To 8 of 
these EYPC solutions, added the following amounts of this cholesterol solution: 5 μL, 10 μL, 15 
μL, 25 μL, 50 μL, 100 μL, 150 μL, and 200 μL. The solvent was removed under a gentle stream 
of nitrogen and the resulting lipid films were stored under high vacuum for a minimum of 12 
hours prior to use. 
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Preparation of liposomes: The lipid films were hydrated with 0.5 mL D2O and vortexed 
vigorously for 1 minute (until the film no longer coated the sides of the test tube) to form a 
suspension of multilamellar vesicles (MLVs).  The resulting lipid suspensions were pulled into a 
Hamilton 1 mL gastight syringe and the syringe was placed in an Avanti Polar Lipids Mini-
Extruder.  The lipid solutions were then passed through a 0.20 μm Whatman (Kent, UK) 
polycarbonate filter (supported by a 10 mm filter support on each side, Avanti Polar Lipids) 21 
times, the newly formed large unilamellar vesicle (LUV) suspension being collected in the 
syringe that did not contain the original suspension of MLVs to prevent the carryover of MLVs 
into the LUV solution.  A 17 mM solution of astaxanthin in uninhibited THF was prepared.  To a 
vortexing solution of the newly formed blank LUV (i.e. non-cholesterol samples) under a stream 
of dry nitrogen was dropwise added the following amounts of the carotenoid solution: 4 μL, 9 
μL, 17 μL, 26 μL, 44 μL, and 85 μL.  The carotenoid and cholesterol impregnated LUVs were 
purified by gel exclusion chromatography with a Sephadex G50-150 column (1 cm column, 0.75 
g unswelled resin, swelled resin with D2O, eluted with D2O). At this point 15 liposome solutions 
had been prepared and purified: 1 blank liposome, 8 cholesterol liposomes, and 6 astaxanthin 
liposomes. 
 
NMR analysis. The purified liposome solutions were transferred to NMR tubes and each sample 
was analyzed using a Varian Unity Inova 500NB instrument in duplicate. The following 
parameters were used: pw = 4.5; at = 4; d1 = 2; nt = 16. The linewidth at half height of each peak 
(3.1, 1.2, and 0.7 ppm) was measured and averaged for the two runs. Plots of this value vs. 
percent incorporation were prepared. 
 
Following the NMR analysis, phosphorus determination, liposome dilution, carotenoid content 
measurement, and the copper based lipoperoxidation assay were preformed as described above.  
HPLC method: 
Reverse phase, C18 column, inject 75 μL sample, flow 2 mL/min 
Cholesterol: 90:10 MeCN:MeOH; detect at 212 nm 
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Preparation of samples for Figure 2-13. Preformed as described for Figures 2-6 and 2-7. 
 
 
Preparation of samples for Figure 2-13. 
 
A coincorporated (astaxanthin + peridinin) sample: 
Preparation of lipid films: To a 12x75 mm test tube was added 0.15 mL POPC solution and 0.05 
mL PUFA solution (25 mg/mL) via Hamilton syringe.  The solvent was removed under a gentle 
stream of nitrogen and the resulting lipid film was stored under high vacuum for a minimum of 
12 hours prior to use. 
 
Preparation of liposomes: The lipid film was hydrated with 0.3 mL 150 mM KCl/0.5 mM 
HEPES pH 7.4 (K buffer) and vortexed vigorously for 1 minute (until the film no longer coated 
the sides of the test tube) to form a suspension of multilamellar vesicles (MLVs).  The resulting 
lipid suspension was pulled into a Hamilton 1 mL gastight syringe and the syringe was placed in 
an Avanti Polar Lipids Mini-Extruder.  The lipid solution was then passed through a 0.20 μm 
Whatman (Kent, UK) polycarbonate filter (supported by a 10 mm filter support on each side, 
Avanti Polar Lipids) 21 times, the newly formed large unilamellar vesicle (LUV) suspension 
being collected in the syringe that did not contain the original suspension of MLVs to prevent the 
carryover of MLVs into the LUV solution.  A 2 mM stock solution of astaxanthin in uninhibited 
THF was prepared. A 2.8 mM stock solution of peridinin in uninhibited THF was prepared. 15 
μL of the astaxanthin stock solution was added to 35 μL of the peridinin solution. To a vortexing 
solution of the newly formed LUV under a stream of dry nitrogen was dropwise added 50 μL of 
the combined carotenoid solution.  The carotenoid impregnated LUVs were purified by gel 
exclusion chromatography with a Sephadex G50-150 column (1 cm column, 1.0 g unswelled 
resin, swelled resin with K buffer, eluted with K buffer). 
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Phosphorus determination, liposome dilution, carotenoid content measurement, the copper based 
lipoperoxidation assay, and measurement of carotenoid consumption were preformed as 
described above.  
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CHAPTER 3 
SYNTHESIS OF (Z)-2-BROMOVINYL MIDA BORONATE, 1-BROMOVINYL MIDA 
BORONATE, AND 2-PYRIDYL MIDA BORONATE 
 
Eric M. Woerly, Justin R. Struble, Nagarjuna Palyam, Sean P. O’Hara,  
Jonathan E. Miller, Anthony S. Grillo, Graham R. Dick, and Martin D. Burke 
 
 Iterative cross-coupling represents a potentially general approach for the simple, efficient, 
and flexible construction of a wide range of functional small molecules. To advance this 
approach, a collection of MIDA boronate building blocks representing structural motifs 
commonly found in small molecules would be highly enabling. In this vein, cis-olefins, 1,1-
disubstituted olefins, and the 2-pyridyl moiety are three recurring motifs in natural products, 
materials, and pharmaceuticals. To gain access to these frameworks, we have prepared three 
MIDA boronate building blocks: (Z)-2-bromovinyl MIDA boronate, 1-bromovinyl MIDA 
boronate, and 2-pyridyl MIDA boronate. This chapter describes the efficient and scalable 
synthesis of these building blocks as well as their applications in small molecule synthesis. 
 Dr. Justin R. Struble, Dr. Nagarjuna Palyam, and Sean P. O’Hara contributed to the 
synthesis and coupling of (Z)-2-bromovinyl MIDA boronate. Jonathan E. Miller contributed to 
the coupling of 1-bromovinyl MIDA boronate. Anthony S. Grillo contributed to the large scale 
synthesis of 2-pyridyl MIDA boronate. Graham R. Dick contributed to many of the results 
involving 2-pyridyl MIDA boronate, especially the synthesis of 2-pyridyl MIDA boronate, the 
development of general reaction conditions, and exploration of the cross-coupling scope. 
 
Adapted from Woerly, E. M.; Struble, J. R.; Palyam, N.; O’Hara, S. P.; Burke, M. D. 
Tetrahedron 2011, 67, 4333-4343.; Woerly, E. M.; Miller, J. E.; Burke, M. D. Tetrahedron 2013, 
submitted.; and Dick, G. R.; Woerly, E. M. Burke, M. D. Angew. Chem. Int. Ed. 2012, 51, 2667-
2672. 
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3-1 INTRODUCTION 
 As exemplified by the total synthesis of peridinin (Chapter 2), a building block based 
strategy for the synthesis of small molecules is a powerful method for accessing targets and their 
derivatives in an efficient manner. Such a strategy has the potential to shift the rate limiting step 
in small molecule science from the synthesis of molecules to understanding and harnessing their 
functional potential. In general, this approach is aided by accessibility to building blocks that can 
be readily linked using only one reaction iteratively. To further enable this strategy, we aim to 
transform substructures that commonly appear in a broad range of complex natural products, 
pharmaceuticals, and materials into readily accessible and air-stable MIDA boronate building 
blocks that can be united using the Suzuki-Miyaura reaction. In this vein, cis-olefins, 1,1-
disubstituted olefins, and the 2-pyridyl moiety are three motifs that are present in a diverse range 
of small molecules. This chapter describes the synthesis of three building blocks, (Z)-(2-
bromovinyl)-MIDA boronate 3.1, (1-bromovinyl)-MIDA boronate 3.2, and 2-pyridyl MIDA 
boronate 3.3 (Figure 3-1) and their utility in small molecule science. 
 
 
Figure 3-1. Three MIDA boronate building blocks that represent common motifs present in a large number of small 
molecule natural products, pharmaceuticals, and materials. 
 
3-2 (Z)-(2-BROMOVINYL)-MIDA BORONATE 
Cis-olefins are prevalent in small molecules derived from a wide range of biosynthetic 
pathways including polyketides, hybrid peptide/polyketides, polyterpenes, fatty acids, and 
phenylpropanoids (Figure 3-2).
1
 Controlling the stereochemistry during the formation of cis 
double bonds often represents a major challenge in the synthesis of these types of molecules.
2
 
Pre-installation of this stereochemistry into a readily-accessible bifunctional olefin that can be 
iteratively functionalized via sequential stereospecific C-C bond forming reactions represents a 
very attractive goal. 
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Figure 3-2. cis-Olefins are found in natural products derived from all major biosynthetic classes. 
 
Drs. Suk Joong Lee and Tom Anderson recently reported a collection of bifunctional 
iodoalkenyl MIDA boronates in all possible stereoisomeric forms that can provide access to a 
wide range of stereochemically complex polyene frameworks via selective cross-coupling of the 
halide terminus.
3
 An important component of this platform was (Z)-(2-iodovinyl)-MIDA 
boronate, (Z)-I-3.1 (Scheme 3-1). This bifunctional building block contains the olefin geometry 
pre-installed in the cis-configuration to allow for the construction of a wide range of polyene 
motifs containing cis-olefins in a stereocontrolled fashion via stereospecific cross-coupling 
reactions. While the synthetic utility of (Z)-I-3.1 proved to be outstanding, its synthesis was 
cumbersome (requiring multiple rounds of partial reduction and chromatography), low yielding, 
and not scalable. To enable ready access to such a building block for many diverse applications, 
we developed a convenient, practical, and highly scalable synthesis of an analogous reagent, (Z)-
(2-bromovinyl)-MIDA boronate, (Z)-Br-3.1. We further demonstrated that (Z)-Br-3.1 can serve 
as a highly versatile building block for the preparation of a wide range of cis-alkene-containing 
synthetic targets. 
 
 
Scheme 3-1. (Z)-I-3.1 and (Z)-Br-3.1 are both prepared from alkynyl MIDA boronate 3.4. 
 
 Bromination/elimination reactions provide a convenient method for the synthesis of vinyl 
halides. In particular, (E)-alkenylboronic esters can be converted to (Z)-alkenyl halides via this 
type of transformation.
4
 We have recently reported a convenient synthesis of bis-borylated olefin 
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3.5 via the hydroboration of ethynyl MIDA boronate 3.4 (Scheme 3-2).
5
 Given the compatibility 
of MIDA boronates to many common synthetic reagents, we hypothesized that 3.5 would be a 
competent starting material for a bromination/elimination sequence, leading to an efficient 
synthesis of (Z)-Br-3.1. In the event, bromination of 3.5 followed by treatment of the resulting 
vicinal dibromide intermediate with anhydrous K3PO4 in MeCN provides a very convenient 
route to (Z)-Br-3.1 in 73% overall yield. Dr. Justin Struble found that this same building block 
can alternatively be prepared in a one pot procedure by reacting 3.5 with CuBr2 in aqueous 
MeCN. Both of these pathways can be performed on the gram scale and (Z)-Br-3.1 can be 
isolated in pure form without the use of chromatography. Moreover, 3.4, 3.5, and (Z)-Br-3.1 are 
now commercially available.
6
 
 
 
Scheme 3-2. Synthesis of (Z)-Br-3.1. 
 
 With a pair of simple and readily scalable syntheses of (Z)-Br-3.1 in hand, together with 
Drs. Struble and Nagarjuna Palyam, we have preliminarily explored its utility in the preparation 
of a range of new (Z)-alkenyl MIDA boronate building blocks. Like its stereoisomeric 
counterpart (E)-Br-3.1,
7
 (Z)-Br-3.1 is a versatile cross-coupling partner, as shown in Scheme 3-3. 
Specifically, Suzuki-Miyaura (SM) cross-coupling with (E)-styrenylboronic acid 3.6 provided 
(E,Z)-diene 3.7. A Stille coupling between (Z)-Br-3.1 and vinyl stannane 3.8 provided diene 3.9. 
A Heck coupling with methyl acrylate 3.10 under phosphine-free conditions yielded the 
unsaturated methyl ester 3.11 as a single regio- and stereoisomer. Additionally, Sonogashira 
coupling between (Z)-Br-3.1 and TMS-acetylene 3.12 generated enyne 3.13. Finally, Negishi 
cross-coupling with 3.14 yielded MIDA boronate 3.15. Collectively, the diversity of coupling 
reactions compatible with (Z)-Br-3.1 demonstrates that this MIDA boronate possesses substantial 
utility in the synthesis of (Z)-alkenyl boronate building blocks for small molecule synthesis. 
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Scheme 3-3. (Z)-Br-3.1 can participate in Suzuki-Miyaura, Stille, Heck, Sonogashira, and Negishi couplings. 
 
We have further determined that the scope for Suzuki-Miyaura coupling of boronic acids 
with (Z)-Br-3.1 is very good, enabling the preparation of a wide range of (Z)-vinyl MIDA 
boronates (Table 3-1). Specifically, the cross-coupling of electron neutral, rich, and deficient aryl 
boronic acids 3.16a-c (entries 1-3) provide the desired products 3.17a-c. Additionally, (Z)-Br-3.1 
can be coupled with a series of heteroaryl boronic acids, including 2-thiophene 3.16d, 2-
benzofuran 3.16e, and 2-pyrrole 3.16f (entries 4-6). Finally, trans- and cis-pentenyl boronic acid 
3.16g-h can be coupled with (Z)-Br-3.1 for the synthesis of (E,Z) and (Z,Z) dienes 3.17g-h in a 
stereocontrolled fashion (entries 7-8). 
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Table 3-1. Scope for Suzuki-Miyaura coupling with (Z)-Br-3.1. 
 
 Together with undergraduate Sean O’Hara, we further explored the utility of (Z)-Br-3.1 
as a substrate for iterative SM coupling reactions. Stilbenoids are small molecule natural 
products that have been implicated in providing several beneficial effects on human health, 
including protecting against cardiovascular disease and cancer.
8
 (Z)-stilbenoids have 
demonstrated increased anticancer activity in comparison to their corresponding (E)-isomers.
9
 In 
particular, (Z)-3,5,4’-trimethoxystilbene 3.18 has been shown to be an exceptionally potent 
analog of the stilbenoid resveratrol (Scheme 3-4).
10
 We have completed an iterative cross-
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coupling-based synthesis of 3.18 as shown in Scheme 3-4. The in situ hydrolysis of 3.19 
followed by cross-coupling of the resulting boronic acid with aryl bromide 3.20 yielded 3.18 
with complete retention of olefin stereochemistry. 
 
 
Scheme 3-4. Synthesis of stilbenoid 3.18 using (Z)-Br-3.1. 
  
Halopolyenyl MIDA boronates have also proven to be valuable building blocks for the 
iterative cross-coupling-based synthesis of polyene natural products, including β-parinaric acid, 
peridinin, and the polyene motifs of amphotericin B and vacidin A.
3,7,11
 In this vein, Dr. Lee 
recently reported the synthesis of all possible stereoisomeric forms of iododienyl MIDA 
boronates via the metal-selective cross-coupling of Sn/Ge bis-metalated olefins followed by the 
stereospecific iododegermylation of the resulting dienylgermanium intermediates.
3,12,13
 However, 
the overall efficiency of this process was limited by the low yielding preparation of key building 
block (Z)-I-3.1. With the development of the efficient preparation of (Z)-Br-3.1, together with 
Dr. Palyam, we have been able to prepare the dienylgermanium intermediates 3.21 with 
substantially improved overall efficiency (Scheme 3-5). Importantly, all of these products were 
prepared using one common set of general reaction conditions. Specifically, the Stille coupling 
between (Z)-Br-3.1 and (E)-3.20 yields (E,Z)-3.21 and coupling between (Z)-Br-3.1 and (Z)-3.20 
provides (Z,Z)-3.21. In a similar fashion, the coupling of (E)-Br-3.1 with (E)-3.20 and (Z)-3.20 
yields (E,E)-3.21 and (Z,E)-3.21, respectively. Dr. Lee has previously reported that the 
iododegermylation of 3.21 proceeds smoothly with I2 in MeOH to complete the synthesis of all 
possible stereoisomeric forms of the iododienyl MIDA boronate building blocks 3.22.
3
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Scheme 3-5. Synthesis of stereoisomeric iododienyl MIDA boronates. 
 
Thus, (Z)-Br-3.1 and (E)-Br-3.1 represent a powerful pair of bifunctional haloalkenyl 
MIDA boronate building blocks. In addition to being versatile coupling partners themselves, they 
provide ready access to a collection of more complex bifunctional building blocks that have the 
potential to enable the synthesis of a wide range of polyene motifs via ICC. For example, 
iterative cross-coupling of building blocks (E,E)-3.22 and (Z,Z)-3.22 was recently shown by Dr. 
Lee to provide synthetic access to the highly complex (E,E,E,Z,Z,E,E)-heptaene portion of 
vacidin A (Scheme 3-6).
3,14
 
 
 
Scheme 3-6. Synthesis of heptaene portion of vacidin A (ref. 3). 
  
Access to a wide range of bifunctional building blocks representing motifs that 
commonly appear in natural products and pharmaceuticals stands to greatly increase the 
efficiency and flexibility of small molecule synthesis. The cis-olefin represents a very important 
substructure that appears in a wide range of polyenyl natural product motifs. We herein 
described a practical and scalable synthesis of the bifunctional building block (Z)-Br-3.1 and 
demonstrate its utility for the stereocontrolled synthesis of a wide range of cis-alkenes. 
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Collectively, these findings expand the utility of ICC with MIDA boronates as a simple and 
flexible platform for the efficient synthesis of a wide range of functional small molecules. 
 
3-3 (1-BROMOVINYL)-MIDA BORONATE 
1,1-disubstituted olefins are prevalent in small molecule pharmaceuticals
15
 and natural 
products derived from a wide range of biosynthetic pathways (Figure 3-3).
16
 In addition, they are 
useful synthetic intermediates.
17
 Some common strategies for the synthesis of 1,1-disubstituted 
olefins include the Wittig reaction of methyltriphenylphosphonium bromide and a ketone,
18
 the 
Heck reaction of an organohalide or triflate and monosubstituted olefin,
19
 and other metal 
catalyzed couplings between a halide or halide surrogate and an organometallic reagent.
20
 
 
 
Figure 3-3. 1,1-Disubstituted olefins are abundant in pharmaceuticals and natural products. 
 
Of particular interest, the 1,1-disubstituted alkenyl boronate motif is an attractive 
intermediate for the preparation of 1,1-disubstituted olefins because of the versatility of the vinyl 
boron moiety.
21
 While methods for the synthesis of 1,2-disubstituted alkenyl boronates are 
abundant,
22
 the methods for the preparation of 1,1-disubstituted alkenyl boronates have been 
limited.
23
 Recent methods for the preparation of these motifs include the copper catalyzed 
hydroboration of aryl and heteroaryl substituted alkynes.
23a
 Alternatively, aryl substituted vinyl 
boronates can be prepared from the corresponding vinyl halide via a Miyaura borylation
23c
 or a 
lithiation/trap sequence.
23d,23e
 However, the synthesis of the requisite vinyl halide can be 
challenging and often uses conditions that are not compatible with acid-sensitive functionalities. 
To address these challenges, we envision that a B-protected 1,1-disubstituted halo boronate 
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building block would be extremely useful for the modular synthesis of targets containing a 1,1-
disubstituted olefin motif (Scheme 3-7). 
 
 
Scheme 3-7. A 1,1-disubstituted halo boronate building block as a useful reagent for the preparation of 1,1-
disubstituted olefins.  
 
Along these lines, we are developing a platform of N-methyliminodiacetic acid (MIDA) 
boronate building blocks.
24,25,26,27,28,29,30,31,32,33,34,35,36,37,38
 MIDA boronates have many desirable 
properties that render them exceptionally useful as synthetic intermediates. They are uniformly 
air-stable, highly crystalline, and monomeric free-flowing solids that are fully compatible with 
silica gel chromatography. Many methods now exist for preparing MIDA boronates from a wide 
range of different starting materials, including boronic acids,
39
 haloboranes, boronic esters, 
trialkoxyborate salts, organohalides, organolithium reagents, and Grignard reagents. The MIDA 
boronate functional group is inert to anhydrous cross-coupling conditions, yet can be readily 
transformed into a fully reactive boronic acid or ester using mild conditions. These features 
enable the simple, efficient, and highly flexible synthesis of a wide range of complex small 
molecules via iterative cross-coupling of MIDA-protected haloboronic acids. Finally, a large and 
growing collection of MIDA boronates are now commercially available.
40
 Taking advantage of 
all of these properties, we herein report a 1,1-disubstituted halo MIDA boronate building block, 
which upon selective functionalization, allows ready access to a variety of 1,1-disubstituted 
alkenyl boronate motifs with the potential for iterative cross-coupling for the preparation of 1,1-
disubstituted olefins. 
 Bromination-elimination reactions provide a convenient method for the synthesis of vinyl 
halides.
41
 In particular, 1,1-disubstituted olefins can be prepared from terminal alkenes via this 
type of transformation.
42
 With this strategy in mind, vinyl MIDA boronate 3.23 is an attractive 
starting point. This building block can easily be prepared on large scale from inexpensive 
starting materials (Scheme 3-8), and is now commercially available on both the gram and 
kilogram scales.
43
 Bromination of 3.23 followed by treatment of the resulting vicinal dibromide 
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intermediate with DBU in MeCN provides a convenient route to (1-bromovinyl)-MIDA boronate 
3.2 in 67% overall yield. Moreover, 3.2 can be prepared on the decagram scale and isolated in 
pure form without the use of column chromatography. Building block 3.2 is also now 
commercially available.
40 
 
 
Scheme 3-8. Synthesis of (1-bromovinyl)-MIDA boronate 3.2. 
 
With a readily scalable synthesis of 3.2 in hand, we have preliminarily explored its utility 
in the preparation of a range of new 1,1-disubstituted alkenyl boronate building blocks en route 
to 1,1-disubstituted olefins. In this vein, our initial attempt to couple 3.2 with phenyl boronic 
acid under standard anhydrous cross-coupling conditions surprisingly formed a mixture of 
products identified as the desired 1,1-disubstituted boronate 3.24 and the trans-1,2-disubstituted 
product 3.25 in a 1:4 ratio (Scheme 3-9). 
 
 
Scheme 3-9. The unoptimized coupling of building block 3.2 with phenyl boronic acid provides a mixture of 
products. 
 
We hypothesized that 3.25 is formed through a competitive reaction pathway involving 
oxidative addition of the palladium catalyst to 3.2 followed by β-hydride elimination, reinsertion 
of the Pd-H species to form a trans-1,2-disubstituted olefin, transmetalation with the boronic 
acid, and reductive elimination (Figure 3-4, pathway 2). Guided by this hypothesis, we explored 
reaction conditions that could limit the β-hydride elimination pathway (pathway 2) and/or 
accelerate the rate of the desired transmetalation reaction that leads to pathway 1 (Figure 3-4). 
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Figure 3-4. Proposed mechanism for the formation of 1,1-disubstituted product 3.24 and 1,2-disubstituted product 
3.25. 
 
Along these lines, silver salts have been proposed to increase the rate of transmetalation 
in the Suzuki-Miyaura cross-coupling reaction.
44
 To test if this could favor pathway 1 over 
pathway 2, we employed silver oxide as the base (Table 3-2, entry 1) in combination with 
Pd(OAc)2 and tricyclohexylphosphine (Cy3P) and observed 3.24 as the major product (3:1), 
although with low conversion (30%). Alternatively, the use of silver carbonate (entry 2) 
produced 3.24 in a slightly better ratio (4:1) and with greater conversion (60%). As a second 
variable, bidentate ligands, such as 1,1’-bis(diphenylphosphino)ferrocene (dppf), have been used 
to limit β-hydride elimination pathways in cross-coupling reactions.45 Use of PdCl2dppf (entry 3) 
with silver carbonate provided 3.24 as the major product (4:1) with greatly improved conversion 
over previous reaction conditions. A survey of other bidentate phosphine ligands revealed 1,5-
bis(diphenylphosphino)pentane (dppp, entry 4) as a ligand that provided 3.24 in a 10:1 ratio. As 
a final variable, ancillary ligands were investigated. A survey of various palladium sources 
revealed that Pd2dba3 combined with 1,6-bis(diphenylphosphino)hexane (dpph, entry 6) provided 
3.24 in a >20:1 ratio and with excellent conversion. Interestingly, during the course of this study, 
we also found that exclusive formation of the trans product 3.25 can be achieved in 85% 
conversion using Pd(OAc)2, SPhos, and K3PO4 in THF (entry 7). 
 
 
Table 3-2. Optimization studies for the coupling of 3.2. 
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 These optimized conditions for the formation of 1,1-disubstituted boronate 3.24 have 
proven to be scalable. On a 1 mmol scale, cross-coupled product 3.24 was obtained in 61% 
isolated yield as a single isomer (Scheme 3-10). We further explored the utility of 3.2 as a 
substrate for iterative Suzuki-Miyaura coupling reactions. The in situ hydrolysis of 3.24 followed 
by cross-coupling of the resulting boronic acid with aryl iodide 3.26 yielded 3.27 as a single 
isomer. 
 
 
Scheme 3-10. MIDA boronate 3.2 is a substrate for iterative Suzuki-Miyaura coupling reactions.  
 
 We next tested the generality of the optimized cross-coupling conditions with a variety of 
aryl, heteroaryl, and vinyl boronic acids (Table 3-3). Good to moderate conversions were 
observed in all cases. The coupling of boronic acids with electron neutral (entries 1-2), 
withdrawing (entries 3-6), and donating groups (entires 7-8) formed the desired product in all 
cases. Specifically, the coupling of 4-vinylphenylboronic acid 3.28a and m-tolylboronic acid 
3.28b proceeded with excellent selectivity (>20:1), high conversion (>95%), and a 81% isolated 
yield for 3.29a and 90% isolated yield for 3.29b. However, the presence of electron withdrawing 
groups, including 4-methoxycarbonyl, 4-cyano, 4-fluoro, and 4-trifluoromethoxy (entries 3-6), 
resulted in moderate selectivities (10:1 to 4:1) albeit still with good conversions (70-90%). The 
electron withdrawing groups on the boronic acid may reduce the rate of the desired 
transmetalation reaction (Figure 3-4, pathway 1), therefore making the β-hydride elimination 
pathway more competitive (pathway 2). In contrast, electron donating groups, including 3,5-
dimethoxy and 4-dimethylamino (entries 7-8) provided the cross-coupled products with excellent 
selectivity (>20:1) and a 66% isolated yield for 3.29g. Additionally, the coupling of 2-
heterocyclic boronic acids, including 2-benzofuranboronic acid 3.28i and 2-thiopheneboronic 
acid 3.28j produced the 1,1-product in >20:1 in both cases and a 82% isolated yield for 3.29i. 
Finally, the coupling of vinyl boronic acids also produced the 1,1-product in >20:1 and 76% 
isolated yield for 3.29k and 65% isolated yield for 3.29l. 
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Table 3-3. Substrate scope under the optimized reaction conditions. 
 
Similar to (Z)-Br-3.1, these findings expand the utility of ICC with MIDA boronates as a 
simple and flexible platform for the efficient synthesis of a wide range of functional small 
molecules. 
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3-4 2-PYRIDYL MIDA BORONATE 
The 2-pyridyl subunit is one of the most prevalent and therefore important structural 
motifs, being found in a wide range of pharmaceuticals,
46
 natural products,
47 
unnatural 
nucleosides,
48
 fluorescent probes,
49
 materials,
50 
and metal-complexing ligands (Figure 3-5).
51 
Tremendous effort over the past three decades has been dedicated to the development of 2-
pyridyl organometallic reagents that can be efficiently employed in cross-coupling 
reactions.
52,53,54,55,56,57,58,59
 All of these methods, however, suffer from one or more important 
limitations, including lack of air-stability of the 2-pyridyl building blocks,
51,53-57
 use of toxic 
metals,
50
 inability to isolate the building blocks in chemically pure form,
52
 and/or inefficient 
couplings with more challenging halide coupling partners such as deactivated aryl 
chlorides.
52,53,54b-60
 Overcoming all of these limitations, we herein report the first general solution 
for the 2-pyridyl problem. 
 
 
Figure 3-5. The 2-pyridyl unit is found in many different small molecules. 
 
 
168 
 
Typically, the 2-pyridyl-boron bond is exquisitely sensitive to protodeborylation, making 
most 2-pyridyl boranes unstable. In contrast, Drs. Eric Gillis and David Knapp recently 
identified 2-pyridyl MIDA boronate 3.3 (Scheme 3-11A) as the first 2-pyridyl borane that is both 
air stable and can be isolated in a chemically pure form.
60
 Together with Graham Dick and 
Anthony Grillo, we developed an inexpensive, environmentally friendly, and scalable method for 
preparing 3.3 and many of its derivatives (Scheme 3-11B).
61
 Importantly, all of these new 
building blocks are monomeric, highly crystalline, free-flowing solids that can be stored 
indefinitely on the bench top under air without decomposition, and several of them are now 
commercially available.
40
 
 
 
Scheme 3-11. a) 2-pyridyl MIDA boronate 3.3 is the first air-stable 2-pyridyl borane that can be isolated in 
chemically pure form. b) An inexpensive, environmentally friendly, and scalable method for preparing 2-pyridyl 
MIDA boronates. c) A preliminary method for cross-coupling 3.3 with activated aryl chlorides. This method is 
ineffective with more challenging deactivated aryl halides. 
 
Having achieved all of these long sought after features in a collection of 2-pyridyl 
boranes, finding maximally general conditions to promote the cross-coupling of these building 
blocks became the final key goal. Kinetically competitive in situ decomposition usually hinders 
the effective cross-coupling of 2-pyridyl boranes. Because electronically and/or sterically 
deactivated aryl halides tend to react more slowly than their activated counterparts, they are 
especially challenging coupling partners.
62
 To overcome similar challenges with other sensitive 
2-heterocyclic boronic acids, Drs. David Knapp and Eric Gillis introduced the slow-release 
cross-coupling strategy.
60
 Specifically, in the presence of mild bases and water as a co-solvent, 
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air-stable MIDA boronates undergo in situ hydrolysis to liberate the corresponding boronic acids 
at a rate that is slower than catalyst turnover.
60
 Analogous to utilizing a syringe pump, such 
conditions strongly favor cross-coupling over boronic acid decomposition.
60,63
  
 
Presumably due to the extreme lability of the 2-pyridyl-boron bond, even under these 
slow-release conditions the cross-coupling of 2-pyridyl MIDA boronate remained challenging. 
As shown in Scheme 3-11C, modified conditions employing isopropanol (IPA) instead of water 
as co-solvent and Cu(OAc)2 as a substoichiometric additive were somewhat effective with 
activated, electron deficient aryl chlorides such as 3.31a. However, when we attempted to cross-
couple 3.3 with more challenging deactivated aryl chlorides, such as 3.31b, very little of the 
desired cross-coupling product 3.32b was observed. 
In collaboration with Graham Dick, an extensive survey of Pd/ligand combinations,
64
 Cu 
salts,
55,57,58,65
 bases, solvents, temperatures, and reaction times were explored, and resulted in 
conditions that were somewhat more effective, but the yield of 3.32b remained modest (49%, 
Table 3-4, entry 1). Driven by our then working hypothesis that the role of IPA in these reactions 
was to promote initial transligation of 3.3 to the corresponding 2-pyridyl isopropyl boronic ester, 
we investigated a range of different alcohols as additives. However, less (entries 2 and 3) or 
more (entry 4) sterically bulky alcohols were all inferior to IPA, and common diols also provided 
no notable advantage (entries 5-7). In contrast, addition of the trivalent ligand diethanolamine 
(DEA) resulted in the intriguing formation of a royal blue reaction mixture and the formation of 
3.32b in a substantially increased yield of 70% (entry 8). 
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Table 3-4. Cross-coupling of 2-pyridyl MIDA boronate 3.3 with deactived aryl chloride 3.31b. 
 
To enable further optimization of these reaction conditions, we sought to understand the 
mechanistic underpinnings of this DEA-promoted increase in efficiency. Deng and coworkers 
have shown that the cross-coupling of 2-pyridyl boronic esters promoted by copper(I) salts likely 
involves an initial C–B to C–Cu transmetallation to produce an intermediate 2-pyridyl copper 
species which, in turn, undergoes transmetallation with Pd(II).
55a
 Starting with this general 
mechanistic framework, we considered two possible pathways for DEA to promote the 
transformation of 3.3 into a putative 2-pyridyl copper intermediate 3.33 (Scheme 3-12). In 
pathway 1, DEA reacts with the conformationally rigid MIDA boronate 3.3 in a novel 
transligation reaction to form a conformationally flexible and thereby more reactive DEA adduct 
3.34,
26
 which in turn transmetallates with Cu(OAc)2 to form 3.33. In pathway 2, DEA 
alternatively reacts with Cu(OAc)2 to yield a Cu(DEA)n complex
66,67
 and KOAc. The released 
KOAc then reacts with 3.3 to generate a reactive 2-pyridyl boronate intermediate 3.35 (X = 
acetate
68
 and/or other ion), which in turn transmetallates with Cu(DEA)2 to form 3.33. 
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Scheme 3-12. Two possible pathways for the DEA-promoted coupling of 3.3. 
  
To determine whether pathway 1 was operative, we first mixed DEA with 3.3 in the 
presence of K3PO4 in deuterated DMF at 100 ºC and monitored the reaction by 
1
H NMR. 
Seeming to support this mechanism, we observed the slow transligation of 3.3 to 3.34 over the 
course of four hours (Supporting Information) and succeeded in isolating 3.34 as a crystalline 
solid (Scheme 3-13). However, when we attempted to couple to 3.34 to 3.31b with or without 
syringe pump-mediated slow addition of 3.34 over the course of four hours to mimic the rate of 
its in situ formation,
58
 we observed only very low yields of 3.32b (Scheme 3-13). Thus, pathway 
1 cannot account for the beneficial effects of DEA on the coupling of 3.3 and 3.32b. 
 
 
Scheme 3-13. Synthesis of 2-pyridyl DEA boronate and coupling with 3.31a. 
 
To interrogate the possibility of pathway 2, we alternatively combined DEA with 
Cu(OAc)2 in the presence of K3PO4 in DMF at 100 ºC (Scheme 3-14). In less than 15 minutes 
the reaction turned royal blue, and both Cu(DEA)2 and KOAc were formed. After extensive 
experimentation, we developed a new procedure for preparing and purifying Cu(DEA)2 from 
CuCl2, DEA, and K3PO4
 
(Supporting Information).
69
 Strikingly, when we attempted to couple 
3.3 and 3.31b in the presence of purified Cu(DEA)2 and KOAc under our otherwise standard 
conditions we observed an 84% yield of 3.32b (Scheme 3-15, entry 1). Consistent with important 
roles for both of these additives in achieving this result, in the absence of Cu(DEA)2, without or 
with added KOAc, none of this cross-coupling product was observed (entries 2 and 3), 
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Cu(DEA)2 was superior to Cu(OAc)2 (entry 4), and the addition of Cu(DEA)2 but not KOAc 
provided only a modest yield of 3.32b (entry 5).
70
  
 
 
Scheme 3-14. Synthesis of Cu(DEA)2. 
 
 
Scheme 3-15. Exploring the role of the reaction components. 
 
To further probe the role of KOAc in this reaction, we treated 3.3 with K3PO4 in DMF at 
100 ºC with or without adding KOAc and monitored the consumption of 3.3 via 
1
H NMR. In 
both the absence and presence of Cu(DEA)2, the addition of KOAc to otherwise identical 
conditions resulted in substantially accelerated conversion of 3.3 to yield pyridine, presumably 
via protodemetalation of short-lived intermediates 3.35 or 3.33. Although additional studies will 
be needed to characterize this mechanism in further detail, all of these data are consistent with 
pathway 2 (Scheme 3-12). 
Importantly, this mechanism also proved to be predictive for further optimizing this 
cross-coupling system. Specifically, the intermediacy of Cu(DEA)2 predicts that the optimum 
ratio of DEA:Cu(OAc)2 would be 2:1. We tested this hypothesis via systematically varying this 
ratio and found that in fact a 2:1 ratio provided the highest GC yield of 3.32b (Scheme 3-16). 
Employing this rationally optimized ratio of additives on a 1 mmol scale, we were able to obtain 
a 94% isolated yield for this very challenging cross-coupling reaction. 
 
 
Scheme 3-16. The effect of the DEA/Cu(OAc)2 ratio on the cross-coupling yield. 
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With this optimized methodology in hand, Graham Dick explored its scope with respect 
to both the 2-pyridyl MIDA boronate and halide coupling partners. Remarkably, the same set of 
reaction conditions proved to be highly general. For example, as shown in Table 3-5, a series of 
electron-rich and/or sterically bulky aryl chlorides were coupled with 3.3 in typically good to 
excellent yields (entries 1-5). Even the highly deactivated 2,6-dimethoxy chlorobenzene (3.31h) 
was coupled in synthetically useful yield (entry 6). Importantly, the same conditions optimized 
for deactivated substrates were also effective for coupling 3.3 with electronically activated aryl 
chlorides (entries 7-9), and a diverse series of heteroaryl chlorides (entries 10-14). 
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Table 3-5. General cross-coupling of air-stable 2-pyridyl MIDA boronate 3.3 with aryl and heteroaryl chlorides. 
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As shown in Table 3-6, these same conditions were also successfully applied to very 
challenging couplings with a range of other 2-pyridyl MIDA boronate derivatives. Specifically, 
series of both electron rich (3.3a-d) and electron deficient (3.3e-g) 2-pyridyl MIDA boronates, 
representing substructural motifs that appear in a wide variety of pharmaceuticals, materials, 
and/or ligands, were successfully coupled to a representative series of sterically and/or 
electronically deactivated aryl chlorides (entries 1-7). 
 
 
Table 3-6. General cross-coupling of air-stable 2-pyridyl MIDA boronate derivatives with deactivated aryl 
chlorides. 
 
Finally, it is often the case that conditions that are optimized for one class of halides or 
pseudohalides do not transfer to other classes. However, the exact same conditions promote the 
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efficient coupling of 3.3 with a diverse range of electrophilic coupling partners, including 
bromides (3.36a-e), iodides (3.36f-i), and triflates (3.36j-n), with all three classes of 
electrophiles represented as deactivated, activated, and heteroaryl variants (Table 3-7). 
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Table 3-7. General cross-coupling of air-stable 2-pyridyl MIDA boronate 3.3 with aryl and heteroaryl bromides, 
iodides, and triflates. 
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The ubiquity of the 2-pyridyl subunit in a wide range of functional small molecules of 
substantial importance has for decades stimulated the search for an isolable 2-pyridyl borane that 
is both air-stable and can function as a generally effective cross-coupling partner. The 
Cu(DEA)2/KOAc promoted cross-coupling with air-stable 2-pyridyl MIDA boronates described 
herein represents the first general solution to this problem. As the 2-pyridyl motif is in many 
ways the archetype for unstable boronic acids, this discovery has widespread implications for 
many other types of challenging cross-coupling processes. Moreover, this platform stands to 
immediately enable the more effective exploration of the functional potential of 2-pyridyl 
containing small molecules for a wide range of important applications in science and medicine. 
 
3-5 SUMMARY AND CONCLUSIONS 
 Toward shifting the rate limiting step in small molecule science from the synthesis of 
molecules to the study of their function, we have identified three structural motifs that are 
commonly occurring in a variety of natural products, pharmaceuticals, and materials: cis-olefins, 
1,1-disubstituted olefins, and the 2-pyridyl moiety. We have developed efficient and scalable 
syntheses of MIDA boronate building blocks that represent these three motifs. Each of these 
building blocks is now commercially available. Moreover, we have demonstrated that each of 
these building blocks can be functionalized to provide a variety of structural frameworks. 
Specifically, (Z)-(2-bromovinyl)-MIDA boronate 3.1, represeting the cis-olefin motif, can 
undergo Suzuki, Stille, Heck, Sonogashira, and Negishi couplings selectively at the halide 
terminus. Furthermore, 3.1 is a substrate for ICC and can rapidly provide access of molecules 
containing cis-olefins. (1-bromovinyl)-MIDA boronate 3.2, representing the 1,1-disubstituted 
olefin motif, can under Suzuki-Miyaura reactions with a variety of aryl, heteroaryl, and alkenyl 
boronic acids to provide 1,1-disubstituted boronate building blocks that can undergo further 
functionalization to provide small molecules containing the 1,1-disubstituted motif. Finally, 2-
pyridyl MIDA boronate 3.3 can be coupled to a variety of aryl and heteroaryl chlorides, 
bromides, iodides, and triflates using one common set of reaction conditions to provide a diverse 
range of biaryl products. Collectively these three examples stand to enable the more effective 
exploration of the functional potential of small molecules containing these motifs. 
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CHAPTER 3 
EXPERIMENTAL SECTION 
 
Materials. Commercial reagents were purchased from Sigma-Aldrich, Fisher Scientific, Alfa 
Aesar, TCI America, Strem Chemicals Inc., or Frontier Scientific and were used without further 
purification unless otherwise noted. Solvents and amines were dried as noted in Chapter 2. The 
following compounds were prepared according to known literature procedures: ethynyl MIDA 
boronate 3.4,
1
 pinacol ester 3.5,
2
 (E)-(2-bromovinyl)-MIDA boronate (E)-Br-3.1,
3,4
 vinyl boronic 
acid 3.16h,
1
 vinyl stannane (E)-3.20,
1
 vinyl stannane (Z)-3.20.
1 
 
General Experimental Procedures. The general experimental procedures followed in these 
studies are the same as those detailed in Chapter 2, except where noted. Gas chromatography 
analysis was conducted on an Agilent Technologies 7890A instrument. GC yields are based on a 
biphenyl internal standard using an Agilent Technologies HP-5 column (part number 19091J-
413). A standard GC method was used for all analyses: the oven was held at 75 ˚C for 0.5 min 
then heated to 100 ˚C over 3 min followed by heating to 230 ˚C over 9.5 min and held at 230 ˚C 
for 1 min. H2 flow was 30 mL/min; Air flow was 400 mL/min; and N2 flow was 25 mL/min. The 
tr of the biphenyl internal standard 4.96 min; the tr of 2-(4-tertbutoxyphenyl)-pyridine was 8.01 
min; and the tr of 2-(4-acetophenone)-pyridine was 8.03 min. 
 
Structural analysis. Structural analysis was preformed and described as detailed in Chapter 2. 
 
Experimental Procedures. 
 
 
MIDA boronate (Z)-Br-3.1. 
Bromination/elimination procedure: 
A 300 mL round bottom flask equipped with a stir bar was charged with MIDA boronate 3.5 
(3.07g, 9.9 mmol) and CH2Cl2 (100 mL).  To this solution was added dropwise neat bromine 
(0.75 mL, 14.6 mmol).  The resulting solution was stirred at 23 
o
C for 1 h and then concentrated 
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in vacuo to afford a pale yellow solid.  Residual bromine was removed by azeotroping with 
CH2Cl2 (3 x 50 mL).  To the resulting pale yellow solid was added finely ground K3PO4 (20.02 
g, 94.3 mmol) and MeCN (100 mL).  The resulting suspension was stirred at 23 
o
C for 3.5 h.  
The resulting suspension was poured into 200 mL EtOAc, 100 mL pH 7 phosphate buffer (0.5 
M), and 100 mL DI H2O.  The mixture was shaken and the aqueous layer was removed.  The 
organic layer was washed with pH 7 phosphate buffer (0.5 M, 1 x 100 mL).  The combined 
aqueous layers were back extracted with 9:1 EtOAc:Acetone (1 x 200 mL).  The combined 
organic layers were dried over MgSO4, filtered, and concentrated in vacuo.  The resulting residue 
was azeotroped with CH2Cl2 (2 x 50 mL) and then suspended in Et2O (100 mL).  This 
suspension was placed in a sonicator bath for 1 h.  The resulting solid was collected by vacuum 
filtration and rinsed with Et2O (15 mL) to yield MIDA boronate (Z)-Br-3.1 as a colorless solid 
(1.91g, 73%). 
 
One-pot CuBr2 procedure: 
A 500-mL round bottom flask equipped with a stir bar was charged with MIDA boronate 3.5 
(2.00 g, 6.47 mmol), CuBr2 (7.23 g, 32.4 mmol) and CH3CN:H2O (19:1, 100 mL).  The resulting 
solution was stirred at 23 ºC for 1.75 h.  The reaction was poured into a separatory funnel 
containing 1 M aq. HCl (150 mL).  The aqueous layer was extracted with EtOAc (1 x 250 mL, 2 
x 150 mL).  The combined organic layers were sequentially washed with sat. aq. Na2S2O3 (100 
mL), half-saturated brine (100 mL), and brine (100 mL).  The organic solution was vigorously 
stirred with an aq. solution of 2Na
+
 EDTA
2-
 (0.05 M, 150 mL) for 45 min at 23 
o
C. The biphasic 
mixture was transferred to a separatory funnel and the aqueous layer removed.  The organic layer 
was washed with brine (100 mL) and then dried over MgSO4 and decolorized with charcoal.  
Filtration and concentration of the filtrate in vacuo afforded crude (Z)-Br-3.1 as a white solid.  
This solid was suspended in Et2O:Acetone (25:1, ~260 mL) and placed in a sonicator bath for 1 
h.  The resulting solid was collected by vacuum filtration and rinsed with Et2O to yield MIDA 
boronate (Z)-Br-3.1 as a white powder (0.96 g, crop 1).  The filtrate was concentrated in vacuo 
and the sonication process was repeated to afford (Z)-Br-3.1 as a white powder (0.13 g, crop 2; 
1.09 g total, 64%). 
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1
H NMR (500 MHz, d6-acetone) 
δ 7.00 (br d, J = 7.5 Hz, 1H), 6.43 (d, J = 9.0 Hz, 1H), 4.31 (d, J = 17.0 Hz, 2H), 4.10 (d, 
J = 17.0 Hz, 2H), 3.11 (s, 3H).   
 
13
C NMR (125 MHz, d6-acetone)  
δ 168.7, 120.6, 63.7, 47.9.   
 
HRMS (ESI
+
)  
Calculated for C7H10BBrNO4 (M+H)
+
:  261.9886   
Found:      261.9884  
 
IR (thin film, cm
-1
)  
3017, 2953, 1767, 1597, 1453, 1337, 1289, 1249, 1164, 1029, 953, 896, 871.   
 
mp 142-146 
o
C dec, uncorrected.   
 
X-ray quality crystals were grown by vapor diffusion of Et2O into a dissolved solution of (Z)-Br-
3.1 in CH2Cl2.
5
 
 
 
MIDA boronate 3.7. 
Preparation of catalyst solution. In a glovebox, to a 7 mL vial equipped with a stir bar 
and charged with XPhos
6
 (9.6 mg, 0.02 mmol) and Pd(OAc)2 (2.2 mg, 0.01 mmol) was added 
THF (2 mL). The solution was stirred at 23 °C for 10 min. 
The freshly prepared catalyst solution was used in the following reaction:  In a glovebox, 
to a 7 mL vial equipped with a stir bar and charged with MIDA boronate (Z)-Br-3.1 (52.1 mg, 
0.20 mmol) and boronic acid 3.6 (45.4 mg, 0.31 mmol) was added Cs2CO3 (200.2 mg, 0.61 
mmol).  The prepared catalyst solution was added in one portion.  The vial was sealed with a cap 
and removed from the glovebox.  The solution was stirred in a subdued light environment at 23 
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o
C for 23.5 h.  The reaction mixture was filtered through a pad of Celite, concentrated in vacuo, 
dry loaded onto Celite from an acetone solution, and purified via flash chromatography on silica 
gel (Et2O:acetone 100:0 → 3:1) to afford MIDA boronate 3.7 as a pale yellow solid (40.2 mg, 
71%). 
 
1
H NMR (400 MHz, d6-acetone)  
δ 7.46 (m, 3H), 7.34 (t, J = 7.5 Hz, 2H), 7.25 (m, 1H), 6.87 (app t, J = 12.0 Hz, 1H), 6.62 
(d, J = 15.5 Hz, 1H), 5.52 (d, J = 14.0 Hz, 1H), 4.29 (d, J = 17.0 Hz, 2H), 4.09 (d, J = 
17.0 Hz, 2H), 3.07 (s, 3H).   
 
13
C NMR (100 MHz, d6-acetone)  
δ 169.0, 144.3, 138.2, 135.6, 129.4, 128.7, 128.5, 127.3, 62.3, 42.3.   
 
HRMS (ESI
+
)  
Calculated for C15H17BNO4 (M+H)
+
:  286.1251  
Found:      286.1253 
 
General procedure: Stille coupling 
In a glovebox, to a 7 mL vial equipped with a stir bar and charged with (Z)-Br-3.1 or (E)-Br-3.1 
(0.2 mmol) and vinyl stannane 3.8 or 1-triethylgermanium-2-tributyltin ethylene (Z)-3.20 or (E)-
3.20 (0.22 mmol) was added Pd2(dba)3 (0.01 mmol) and Ph3As (0.02 mmol).  The vial was 
sealed with a PTFE-lined septum screw-cap and removed from the glovebox.  At 0 
o
C, under a 
positive pressure of Ar, THF (0.5 mL) and DMF (1.5 mL) were added sequentially via syringe.  
The resulting mixture was stirred in a subdued light environment at 0 
o
C for 2 h and then slowly 
warmed to 23 
o
C and stirred for an additional 8-18 h at 23 
o
C. The reaction mixture was poured 
into brine (5.0 mL) and extracted with EtOAc (2 × 15 mL). The combined organic phases were 
dried over MgSO4, concentrated in vacuo, dry loaded onto Celite from an acetone solution, and 
purified via flash chromatography on silica gel or Florisil to afford the desired compound.
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MIDA boronate 3.9. The general Stille coupling procedure was followed using (Z)-Br-3.1 (39 
mg, 0.15 mmol), vinyl stannane 3.8 (53 mg, 0.17 mmol), Pd2(dba)3 (7.0 mg, 0.01 mmol), Ph3As 
(4.6 mg, 0.02 mmol), THF (0.5 mL) and DMF (1.5 mL). The resulting mixture was stirred at 0 
o
C for 2 h and then slowly warmed to 23 
o
C and stirred for an additional 18 h at 23 
o
C. 
Purification via flash chromatography on Florisil (EtOAc:petroleum ether 1:1 → EtOAc → 
EtOAc:MeCN 9:1) afforded 3.9 as a foam (25 mg, 79%). 
 
1
H NMR (500 MHz, CD3CN)  
6.85 (ddd, J = 17.0, 10.0, 1.0 Hz, 1H), 6.70 (app t, J = 11.0 Hz, 1H), 5.39 (d, J = 13.5 
Hz, 1H), 5.27 (dd, J = 17.0, 2.0 Hz, 1H), 5.23 (ddd, J = 10.0, 2.0, 1.0 Hz, 1H), 3.95 (d, J 
= 17.0 Hz, 2H), 3.79 (d, J = 17.0 Hz, 2H),  2.79 (s, 3H).   
 
13
C NMR (125 MHz, CD3CN)  
 169.1, 145.2, 136.7, 120.6, 62.4, 47.5.   
 
HRMS (ESI
+
)  
Calculated for C9H13BNO4 (M+H)
+
:  210.0938  
Found:      210.0940  
 
IR (thin film, cm
-1
)  
3006, 2954, 2852, 1767, 1577, 1458, 1288, 1022, 997, 866. 
 
 
MIDA boronate 3.11. In a glovebox, to a 7 mL vial equipped with a stir bar and charged with 
MIDA boronate (Z)-Br-3.1 (48.3 mg, 0.18 mmol) was added Pd(OAc)2 (3.4 mg, 0.05 mmol), a 
solution of methyl acrylate 3.10 (0.4 M in DMF, 1.0 mL), and a solution of freshly distilled Et3N 
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(0.4 M in DMF, 1.0 mL).  The vial was sealed with a cap and removed from the glovebox.  The 
solution was stirred in a subdued light environment at 23 
o
C for 46.5 h.  The reaction mixture 
was filtered through a pad of Celite, concentrated in vacuo, dry loaded onto Celite from an 
acetone solution, and purified via flash chromatography on Florisil (Et2O:acetone 100:0 → 2:1) 
to afford MIDA boronate 3.11 as a pale yellow solid (42.4 mg, 86%). 
 
1
H NMR (500 MHz, CD3CN)  
δ 7.78 (dd, J = 11.5, 15.0 Hz, 1H), 6.81 (app t, J = 12.5 Hz, 1H), 5.94 (d, J = 15.0 Hz, 
1H), 5.85 (d, J = 14.0 Hz, 1H), 3.98 (d, J = 17.0 Hz, 2H), 3.83 (d, J = 17.0 Hz, 2H), 3.69 
(s, 3H), 2.82 (s, 3H).   
 
13
C NMR (125 MHz, CD3CN)  
δ 169.0, 168.0, 143.5, 141.4, 124.5, 62.6, 52.1, 47.6.   
 
HRMS (ESI
+
)  
Calculated for C11H15BNO6 (M+H)
+
:  268.0992   
Found:      268.0991 
 
 
MIDA boronate 3.13. In a glovebox, to a 7 mL vial equipped with a stir bar and charged with 
(Z)-Br-3.1 (62.8 mg, 0.24 mmol) was added CuI (2.6 mg, 0.014 mmol) and PdCl2(PPh3)2 (19.5 
mg, 0.028 mmol). The vial was sealed with a PTFE-lined septum screw-cap and removed from 
the glovebox.  Under a positive pressure of Ar, THF (1.2 mL), TMS-acetylene 3.12 (0.050 mL, 
0.36 mmol), and Et3N (0.10 mL, 0.72 mmol) were sequentially added via syringe. The reaction 
was stirred at 23 ºC for 4 h.  The crude reaction was transferred to a separatory funnel containing 
brine (10 mL) and extracted with EtOAc (2 x 15 mL). The combined organic extracts were dried 
over Na2SO4, filtered, dry loaded onto Celite and purified via flash chromatography on Florisil 
(Et2O:EtOAc 3:1  2:1  1:1) to afford MIDA boronate 3.13 as a yellow solid (54 mg, 80 %). 
Colorless crystals could be obtained by recrystallization from Et2O (42 mg, 63 %). 
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1
H NMR (500 MHz, CDCl3)  
 6.27 (d, J = 14.5 Hz, 1H), 6.05 (d, J = 14.5 Hz, 1H), 4.00 (d, J = 16.5 Hz, 2H), 3.87 (d, 
J = 16.5 Hz, 2H), 2.91 (s, 3H), 0.17 (s, 9H).  
 
13
C NMR (125 MHz, CDCl3)  
 167.7, 124.2, 103.8, 101.1, 63.0, 47.4, –0.38.  
 
HRMS (ESI
+
)  
Calculated for C12H19BNO4Si (M+H)
+
:  280.1176  
Found:      280.1170 
 
 
MIDA boronate 3.15. 
(2-methyl-1-propenyl)zinc bromide solution 3.14 was prepared as follows: A 4 mL vial 
equipped with a magnetic stir bar was charged with zinc bromide (68 mg, 0.31 mmol), flushed 
with Ar and sealed with a PTFE-lined septum screw-cap.  THF (1.0 mL) was added and the 
solution was stirred at 0 
o
C for 10 min. 2-methyl-1-propenyl magnesium bromide (0.6 mL, 0.30 
mmol, 0.5 M in THF) and was added and the solution was stirred at 0 
o
C for 30 min.   
The freshly prepared solution of 3.14 was used in the following reaction:  In a glovebox, 
to a 7 mL vial equipped with a magnetic stir bar and charged with (Z)-Br-3.1 (39 mg, 0.15 
mmol) was added Pd(OAc)2 (2 mg, 0.01 mmol) and SPhos (6 mg, 0.02 mmol).  The vial was 
sealed with a PTFE-lined septum screw-cap and removed from the glovebox.  The resulting 
slurry was stirred for 30 min. at 23 
o
C and was then cooled to 0 °C.  The freshly prepared 
solution of 3.14 was added dropwise to the reaction vial. The resulting mixture was stirred in a 
subdued light environment at 0 
o
C for 2 h.   The reaction mixture was poured into brine (5 mL) 
and extracted with EtOAc (2 × 15 mL).  The combined organic phases were dried over MgSO4, 
concentrated in vacuo, dry loaded onto Celite from an acetone solution, and purified via flash 
chromatography on Florisil (EtOAc:petroleum ether 1:1 → EtOAc → EtOAc:MeCN 9:1) to 
afford MIDA boronate 3.15 as a pale yellow solid (33 mg, 92 %). 
192 
 
1
H NMR (500 MHz, CD3CN)  
 6.94 (app t, J = 14.0 Hz, 1H), 6.25 (d, J = 12.0 Hz, 1H), 5.18 (d, J = 14.0 Hz, 1H), 3.94 
(d, J = 17.0 Hz, 2H), 3.77 (d, J = 17.0 Hz, 2H),  2.78 (s, 3H), 1.78 (s, 3H), 1.75 (s, 3H).   
 
13
C NMR (125 MHz, CD3CN)  
 169.2, 140.8, 139.1, 124.7, 62.4, 47.4, 26.5, 17.7.   
 
HRMS (ESI
+
)  
Calculated for C11H17BNO4 (M+H)
+
:  238.1251   
Found:      238.1250   
 
IR (thin film, cm
-1
)  
3001, 2960, 2927, 2854, 1768, 1641, 1585, 1452, 1296, 991, 861.    
 
mp 130-132 
o
C dec, uncorrected. 
 
 
MIDA boronate 3.17a. 
 Preparation of catalyst solution.  In a glovebox, to a 7 mL vial equipped with a stir bar 
and charged with Pd2(dba)3 (9.7 mg, 0.01 mmol) and XPhos (19.2 mg, 0.04 mmol) was added 
THF (2 mL).  The solution was stirred at 23 
o
C for 10 min. 
The freshly prepared catalyst solution was used in the following reaction:  In a glovebox, 
to a 7 mL vial equipped with a stir bar and charged with MIDA boronate (Z)-Br-3.1 (50.5 mg, 
0.19 mmol) and boronic acid 3.16a (37.9 mg, 0.31 mmol) was added finely ground K3PO4 (129.4 
mg, 0.61 mmol).  The prepared catalyst solution was added in one portion.  The vial was sealed 
with a cap and removed from the glovebox.  The solution was stirred in a subdued light 
environment at 35 
o
C for 47.5 h.  The reaction mixture was filtered through a pad of Celite, 
concentrated in vacuo, dry loaded onto Celite from an acetone solution, and purified via flash 
chromatography on silica gel (Et2O:acetone 100:0 → 3:1) to afford MIDA boronate 3.17a as a 
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pale yellow solid.  This solid was triturated with 0.10 mL of acetone to provide a white solid 
(27.5 mg, 55%). 
 
1
H NMR (500 MHz, CD3CN)  
δ 7.36 (d, J = 7.5 Hz, 2H), 7.30 (t, J = 7.5 Hz, 2H), 7.25 (d, J = 7.5 Hz, 1H), 7.18 (br d, J 
= 15.0 Hz, 1H), 5.66 (d, J = 15.0 Hz, 1H), 3.88 (d, J = 17.0 Hz, 2H), 3.66 (d, J = 17.0 Hz, 
2H), 2.86 (s, 3H).   
 
13
C NMR (125 MHz, CD3CN)  
δ 168.9, 145.0, 140.1, 129.4, 128.9, 128.1, 62.6, 47.4.   
 
HRMS (ESI
+
)  
Calculated for C13H15BNO4 (M+H)
+
:  260.1094   
Found:      260.1088 
 
 
MIDA boronate 3.17b. 
 Preparation of catalyst solution.  In a glovebox, to a 7 mL vial equipped with a stir bar 
and charged with Pd2(dba)3 (10.8 mg, 0.01 mmol) and XPhos (20.9 mg, 0.04 mmol) was added 
THF (2 mL).  The solution was stirred at 23 
o
C for 10 min. 
The freshly prepared catalyst solution was used in the following reaction:  In a glovebox, 
to a 7 mL vial equipped with a stir bar and charged with MIDA boronate (Z)-Br-3.1 (50.8 mg, 
0.19 mmol) and boronic acid 3.16b (72.0 mg, 0.40 mmol) was added finely ground K3PO4 
(137.7 mg, 0.65 mmol).  The prepared catalyst solution was added in one portion.  The vial was 
sealed with a cap and removed from the glovebox.  The solution was stirred in a subdued light 
environment at 35 
o
C for 48 h.  The reaction mixture was filtered through a pad of Celite, 
concentrated in vacuo, dry loaded onto Celite from an acetone solution, and purified via flash 
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chromatography on silica gel (Et2O:acetone 100:0 → 3:1) to afford MIDA boronate 3.17b as a 
pale yellow solid (52.6 mg, 85%). 
 
1
H NMR (500 MHz, d6-acetone)  
δ 7.29 (d, J = 2.0 Hz, 1H), 7.07 (d, J = 15.0 Hz, 1H), 6.92 (dd, J = 2.0, 8.0 Hz, 1H), 6.86 
(d, J = 8.0 Hz, 1H), 5.56 (d, J = 15.0 Hz, 1H), 4.18 (d, J = 17.0 Hz, 2H), 3.93 (d, J = 17.0 
Hz, 2H), 3.83 (s, 3H), 3.79 (s, 3H), 3.04 (s, 3H).   
 
13
C NMR (125 MHz, d6-acetone)  
δ 168.8, 149.7, 149.6, 144.7, 132.8, 122.6, 113.0, 112.0, 62.4, 55.9, 55.8, 46.9.   
 
HRMS (ESI
+
)  
Calculated for C15H19BNO6 (M+H)
+
:  320.1305   
Found:      320.1302 
 
 
MIDA boronate 3.17c. 
 Preparation of catalyst solution.  In a glovebox, to a 7 mL vial equipped with a stir bar 
and charged with Pd2(dba)3 (10.6 mg, 0.01 mmol) and XPhos (19.5 mg, 0.04 mmol) was added 
THF (2 mL).  The solution was stirred at 23 
o
C for 10 min. 
The freshly prepared catalyst solution was used in the following reaction:  In a glovebox, 
to a 7 mL vial equipped with a stir bar and charged with MIDA boronate (Z)-Br-3.1 (43.7 mg, 
0.17 mmol) and boronic acid 3.16c (63.8 mg, 0.46 mmol) was added finely ground K3PO4 (136.8 
mg, 0.64 mmol).  The prepared catalyst solution was added in one portion.  The vial was sealed 
with a cap and removed from the glovebox.  The solution was stirred in a subdued light 
environment at 35 
o
C for 48.5 h.  The reaction mixture was filtered through a pad of Celite, 
concentrated in vacuo, dry loaded onto Celite from an acetone solution, and purified via flash 
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chromatography on silica gel (Et2O:acetone 100:0 → 3:1) to afford MIDA boronate 3.17c as a 
pale yellow solid (29.6 mg, 64%). 
 
1
H NMR (400 MHz, d6-acetone)  
δ 7.47 (m, 2H), 7.27 (br d, J = 15.0 Hz, 1H), 7.09 (m, 2H), 5.71 (d, J = 15.0 Hz, 1H), 
4.17 (d, J = 17.0 Hz, 2H), 3.94 (d, J = 17.0 Hz, 2H), 3.11 (s, 3H).   
 
13
C NMR (125 MHz, d6-acetone)  
δ 168.6, 143.3, 137.4, 131.4, 131.3, 115.4, 62.4, 47.0.   
 
HRMS (ESI
+
)  
Calculated for C13H14BFNO4 (M+H)
+
:  278.1000   
Found:      278.1000 
 
 
MIDA boronate 3.17d. 
Preparation of catalyst solution. In a glovebox, to a 7 mL vial equipped with a stir bar 
and charged with P(o-tolyl)3 (12.4 mg, 0.04 mmol) and Pd2(dba)3 (9.8 mg, 0.01 mmol) was 
added THF (2 mL). The solution was stirred at 23 °C for 10 min. 
The freshly prepared catalyst solution was used in the following reaction:  In a glovebox, 
to a 7 mL vial equipped with a stir bar and charged with MIDA boronate (Z)-Br-3.1 (49.8 mg, 
0.19 mmol), boronic acid 3.16d (36.8 mg, 0.29 mmol), and Ag2O (145.0 mg, 0.63 mmol) was 
added the prepared catalyst solution in one portion.  The vial was sealed with a cap and removed 
from the glovebox.  The solution was stirred in a subdued light environment at 23 
o
C for 25 h.  
The reaction mixture was filtered through a pad of Celite, concentrated in vacuo, dry loaded onto 
Celite from an acetone solution, and purified via flash chromatography on silica gel 
(Et2O:acetone 100:0 → 3:1) to afford MIDA boronate 3.17d as a pale yellow solid (36.0 mg, 
72%). 
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1
H NMR (500 MHz, d6-acetone)  
δ 7.40 (m, 1H), 7.24 (m, 1H), 7.19 (br d, J = 15.5 Hz, 1H), 7.00 (dd, J = 3.5, 5.0 Hz, 1H), 
5.54 (d, J = 15.5 Hz, 1H), 4.25 (d, J = 17.0 Hz, 2H), 4.05 (d, J = 17.0 Hz, 2H), 3.08 (s, 
3H).   
 
13
C NMR (125 MHz, d6-acetone)  
δ 168.8, 142.7, 136.3, 129.8, 127.8, 127.3, 62.7, 47.1.   
 
HRMS (ESI
+
)  
Calculated for C11H13BNO4S (M+H)
+
:  266.0658   
Found:      266.0648 
 
 
MIDA boronate 3.17e. 
Preparation of catalyst solution. In a glovebox, to a 7 mL vial equipped with a stir bar 
and charged with P(o-tolyl)3 (11.7 mg, 0.04 mmol) and Pd2(dba)3 (9.3 mg, 0.01 mmol) was 
added THF (2 mL). The solution was stirred at 23 °C for 10 min. 
The freshly prepared catalyst solution was used in the following reaction:  In a glovebox, 
to a 7 mL vial equipped with a stir bar and charged with MIDA boronate (Z)-Br-3.1 (46.6 mg, 
0.18 mmol), boronic acid 3.16e (66.1 mg, 0.41 mmol), and Ag2O (143.5 mg, 0.62 mmol) was 
added the prepared catalyst solution in one portion.  The vial was sealed with a cap and removed 
from the glovebox.  The solution was stirred in a subdued light environment at 23 
o
C for 24 h.  
The reaction mixture was filtered through a pad of Celite, concentrated in vacuo, dry loaded onto 
Celite from an acetone solution, and purified via flash chromatography on silica gel 
(Et2O:acetone 100:0 → 3:1) to afford MIDA boronate 3.17e as a pale yellow solid (49.1 mg, 
92%). 
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1
H NMR (500 MHz, d6-acetone)  
δ 7.58 (d, J = 8.0 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.29 (t, J = 7.5 Hz, 1H), 7.21 (t, J = 
7.5 Hz, 1H), 7.04 (br d, J = 15.5 Hz, 1H), 6.88 (s, 1H), 5.75 (d, J = 15.5 Hz, 1H), 4.38 (d, 
J = 17.0 Hz, 2H), 4.24 (d, J = 17.0 Hz, 2H), 3.11 (s, 3H).   
 
13
C NMR (125 MHz, d6-acetone) 
δ 169.5, 156.1, 155.7, 131.2, 129.4, 125.6, 123.9, 122.0, 112.0, 108.6, 64.4, 48.9.   
 
HRMS (ESI
+
)  
Calculated for C15H15BNO5 (M+H)
+
:  300.1043   
Found:      300.1045 
 
 
MIDA boronate 3.17f. 
 Preparation of catalyst solution.  In a glovebox, to a 7 mL vial equipped with a stir bar 
and charged with Pd(OAc)2 (2.3 mg, 0.01 mmol) and SPhos (9.2 mg, 0.02 mmol) was added 
THF (2 mL).  The solution was stirred at 23 
o
C for 10 min. 
The freshly prepared catalyst solution was used in the following reaction:  In a glovebox, 
to a 7 mL vial equipped with a stir bar and charged with MIDA boronate (Z)-Br-3.1 (43.0 mg, 
0.16 mmol) and boronic acid 3.16f (91.6 mg, 0.40 mmol) was added finely ground K3PO4 (136.7 
mg, 0.64 mmol).  The prepared catalyst solution was added in one portion.  The vial was sealed 
with a cap and removed from the glovebox.  The solution was stirred in a subdued light 
environment at 23 
o
C for 24 h.  The reaction mixture was filtered through a pad of Celite, 
concentrated in vacuo, dry loaded onto Celite from an acetone solution, and purified via flash 
chromatography on silica gel (Et2O:acetone 100:0 → 3:1) to afford MIDA boronate 3.17f as a 
pale yellow solid (39.7 mg, 70%). 
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1
H NMR (500 MHz, d6-acetone)  
δ 7.24 (br d, J = 15.5 Hz, 1H), 7.23 (dd, J = 2.0, 3.5 Hz, 1H), 6.44 (m, 1H), 6.11 (t, J = 
3.5 Hz, 1H), 5.55 (d, J = 15.5 Hz, 1H), 4.13 (d, J = 17.0 Hz, 2H), 3.84 (d, J = 17.0 Hz, 
2H), 3.02 (s, 3H), 1.59 (s, 9H).  
 
13
C NMR (125 MHz, d6-acetone)  
δ 168.8, 150.0, 136.2, 133.7, 122.3, 115.4, 111.3, 84.4, 62.7, 47.2, 28.0.   
 
HRMS (ESI
+
)  
Calculated for C16H22BN2O6 (M+H)
+
:  349.1571   
Found:      349.1575 
 
 
MIDA boronate 3.17g 
Preparation of catalyst solution. In a glovebox, to a 7 mL vial equipped with a stir bar 
and charged with XPhos (8.6 mg, 0.02 mmol) and Pd(OAc)2 (2.1 mg, 0.01 mmol) was added 
THF (2 mL). The solution was stirred at 23 °C for 10 min. 
The freshly prepared catalyst solution was used in the following reaction:  In a glovebox, 
to a 7 mL vial equipped with a stir bar and charged with MIDA boronate (Z)-Br-3.1 (46.5 mg, 
0.18 mmol) and boronic acid 3.16g (53.4 mg, 0.47 mmol) was added Cs2CO3 (209.4 mg, 0.64 
mmol).  The prepared catalyst solution was added in one portion.  The vial was sealed with a cap 
and removed from the glovebox.  The solution was stirred in a subdued light environment at 23 
o
C for 24 h.  The reaction mixture was filtered through a pad of Celite, concentrated in vacuo, 
dry loaded onto Celite from an acetone solution, and purified via flash chromatography on 
Florisil (Et2O:acetone 100:0 → 3:1) to afford MIDA boronate 3.17g as a pale yellow solid (28.5 
mg, 64%).  For characterization of 3.17g see ref. 1. 
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MIDA boronate 3.17h. 
Preparation of catalyst solution. In a glovebox, to a 7 mL vial equipped with a stir bar 
and charged with XPhos (8.6 mg, 0.02 mmol) and Pd(OAc)2 (2.1 mg, 0.01 mmol) was added 
THF (2 mL). The solution was stirred at 23 °C for 10 min. 
The freshly prepared catalyst solution was used in the following reaction:  In a glovebox, 
to a 7 mL vial equipped with a stir bar and charged with MIDA boronate (Z)-Br-3.1 (42.8 mg, 
0.16 mmol) and boronic acid 3.16h (57.5 mg, 0.50 mmol) was added Cs2CO3 (195.8 mg, 0.60 
mmol).  The prepared catalyst solution was added in one portion.  The vial was sealed with a cap 
and removed from the glovebox.  The solution was stirred in a subdued light environment at 23 
o
C for 24 h.  The reaction mixture was filtered through a pad of Celite, concentrated in vacuo, 
dry loaded onto Celite from an acetone solution, and purified via flash chromatography on 
Florisil (Et2O:acetone 100:0 → 3:1) to afford MIDA boronate 3.17h as a pale yellow solid (24.6 
mg, 60%).  For characterization of 3.17h see ref. 1. 
 
 
MIDA boronate 3.19. 
 Preparation of catalyst solution.  In a glovebox, to a 7 mL vial equipped with a stir bar 
and charged with Pd2(dba)3 (9.7 mg, 0.01 mmol) and XPhos (19.2 mg, 0.04 mmol) was added 
THF (2 mL).  The solution was stirred at 23 
o
C for 10 min. 
The freshly prepared catalyst solution was used in the following reaction:  In a glovebox, 
to a 7 mL vial equipped with a stir bar and charged with MIDA boronate (Z)-Br-3.1 (50.0 mg, 
0.19 mmol) and boronic acid (47.2 mg, 0.31 mmol) was added finely ground K3PO4 (131.0 mg, 
0.62 mmol).  The prepared catalyst solution was added in one portion.  The vial was sealed with 
a cap and removed from the glovebox.  The solution was stirred in a subdued light environment 
at 35 
o
C for 47.5 h.  The reaction mixture was filtered through a pad of Celite, concentrated in 
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vacuo, dry loaded onto Celite from an acetone solution, and purified via flash chromatography 
on silica gel (Et2O:acetone 100:0 → 3:1) to afford MIDA boronate 3.19 as a pale yellow solid 
(52.4 mg, 95%). 
 
1
H NMR (500 MHz, CD3CN)  
δ 7.34 (d, J = 8.5 Hz, 2H), 7.08 (br d, J = 15.0 Hz, 1H), 6.85 (d, J = 8.5 Hz, 2H), 5.53 (d, 
J = 15.0 Hz, 1H), 3.89 (d, J = 17.0 Hz, 2H), 3.77 (s, 3H), 3.69 (d, J = 17.0 Hz, 2H), 2.86 
(s, 3H).   
 
13
C NMR (125 MHz, CD3CN)  
δ 169.0, 159.9, 144.5, 132.5, 130.9, 114.2, 62.5, 55.8, 47.3.   
 
HRMS (ESI
+
)  
Calculated for C14H17BNO5 (M+H)
+
:  290.1200   
Found:      290.1201   
 
mp 176-180 
o
C dec, uncorrected. 
 
 
(Z)-3,5,4’-trimethoxystilbene 3.18. 
Preparation of catalyst solution.  In a glovebox, to a 7mL vial charged with SPhos (6.5 
mg, 0.02 mmol) and Pd(OAc)2 (2.1 mg, 0.009 mmol) was added THF (1.4 mL).  The solution 
was stirred at 23 °C for 10 minutes.  
The freshly prepared catalyst solution was used in the following reaction:  In a glovebox, 
to a 7 mL vial equipped with a stir bar and charged with MIDA boronate 3.19 (39.2 mg, 0.14 
mmol) and 1-bromo-3,5-dimethoxybenzene 3.20 (26.1 mg, 0.12) was added the prepared catalyst 
solution in one portion.  The vial was sealed with a PTFE-lined septum screw-cap and removed 
from the glovebox.  Under a positive pressure of Ar, 1 M aq. NaOH (0.40 mL) was added via 
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syringe. The solution was stirred in a subdued light environment at 23 °C for 6 h.  The reaction 
mixture was poured into 1 M aq. phosphate buffer pH 7 (2 mL) and extracted with Et2O (3 x 2 
mL).  The combined organic phases were dried over MgSO4, filtered, and concentrated in vacuo.  
The crude material was dry loaded onto Celite from an acetone solution and purified via flash 
chromatography on Florisil (petroleum ether:CH2Cl2 100:0 → 80:20) to afford the 3.18 as a pale 
yellow oil (28.3 mg, 76%).  Spectral data for 3.18 were consistent with those previously 
reported.
7
 
 
 
MIDA boronate (E,Z)-3.21. The general Stille coupling procedure was followed using (Z)-Br-
3.1 (52 mg, 0.20 mmol), (E)-3.20 (105 mg, 0.22 mmol), Pd2(dba)3 (9.2 mg, 0.01 mmol), Ph3As 
(6.1 mg, 0.02 mmol), THF (0.5 mL), and DMF (1.5 mL). The resulting mixture was stirred at 0 
o
C for 2 h and then slowly warmed to 23 
o
C and stirred for an additional 12 h at 23 
o
C. 
Purification via flash chromatography on Florisil (EtOAc:petroleum ether 1:1 → EtOAc → 
EtOAc:MeCN 9:1) afforded (E,Z)-3.21 as a white solid (59 mg, 81%).  The 
1
H NMR of the 
crude product showed a single stereoisomer.  Spectral data for (E,Z)-3.21 were consistent with 
those previously reported from our laboratories.
1 
 
 
MIDA boronate (Z,Z)-3.21. The general Stille coupling procedure was followed using (Z)-Br-
3.1 (52 mg, 0.20 mmol), (Z)-3.20 (105 mg, 0.22 mmol), Pd2(dba)3 (9.2 mg, 0.01 mmol), Ph3As 
(6.1 mg, 0.02 mmol), THF (0.5 mL), and DMF (1.5 mL). The resulting mixture was stirred at 0 
o
C for 2 h and then slowly warmed to 23 
o
C and stirred for an additional 18 h at 23 
o
C. 
Purification via flash chromatography on Florisil (EtOAc:petroleum ether 1:1 → EtOAc → 
EtOAc:MeCN 9:1) afforded (Z,Z)-3.21 as a pale yellow solid (51.8 mg, 71%).  The 
1
H NMR of 
the crude product indicated 10% (Z,E)- 3.21 as a byproduct which was inseparable by normal 
phase Florisil chromatography.  Spectral data for (Z,Z)- 3.21 were consistent with those 
previously reported from our laboratories.
1 
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MIDA boronate (E,E)-3.21.  The general Stille coupling procedure was followed using (E)-Br-
3.1 (52 mg, 0.20 mmol), (E)-3.20 (105 mg, 0.22 mmol), Pd2(dba)3 (9.2 mg, 0.01 mmol), Ph3As 
(6.1 mg, 0.02 mmol), THF (0.5 mL), and DMF (1.5 mL). The resulting mixture was stirred at 0 
o
C for 2 h and then slowly warmed to 23 
o
C and stirred for an additional 8 h at 23 
o
C. 
Purification via flash chromatography on silica gel (EtOAc:petroleum ether 1:1 → EtOAc → 
EtOAc:MeCN 9:1) afforded (E,E)-3.21 as a white solid (59.5 mg, 81%). The 
1
H NMR of the 
crude product showed a single stereoisomer. Spectral data for (E,E)-3.21 were consistent with 
those previously reported from our laboratories.
1 
 
 
MIDA boronate (Z,E)-3.21. The general Stille coupling procedure was followed using (E)-Br-
3.1 (39 mg, 0.15 mmol), (Z)-3.20 (79 mg, 0.17 mmol), Pd2(dba)3 (7.0 mg, 0.01 mmol), Ph3As 
(4.6 mg, 0.02 mmol), THF (0.5 mL), and DMF (1.5 mL). The resulting mixture was stirred at 0 
o
C for 2 h and then slowly warmed to 23 
o
C and stirred for an additional 12 h at 23 
o
C. 
Purification via flash chromatography on Florisil (EtOAc:petroleum ether 1:1 → EtOAc → 
EtOAc:MeCN 9:1) afforded (Z,E)-3.21 as a pale yellow solid (43 mg, 78%).  The 
1
H NMR of 
the crude product showed a single stereoisomer. Spectral data for (Z,E)-3.21 were consistent with 
those previously reported from our laboratories.
1 
 
 
MIDA boronate 3.23. To a 3 L 3-neck round bottom flask equipped with a stir bar was added 
B(OMe)3 (94 mL, 840 mmol) and THF (600 mL). The solution was cooled to -78 
o
C. 
Vinylmagnesium bromide (1.0 M in THF, 800 mL, 800 mmol) was added dropwise via cannula 
over 2 h 45 min. The resulting solution was stirred at -78
 o
C for 15 min., followed by stirring at 
23 
o
C for 2 h 30 min. In a separate 2 L 3-neck round bottom flask equipped with a stir bar, 
internal thermometer, and distillation apparatus was added dry MIDA (235.0 g, 1.6 mol) and 
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DMSO (600 mL). The solution was heated with an oil bath to an internal temperature of 110 - 
115 
o
C. The borate suspension was added dropwise to the hot MIDA solution via a Teflon 
cannula dropwise over 2 h 10 min, keeping the internal temperature between 105 and 115 
o
C. 
After full addition of the borate solution, the reaction solution was cooled to 23 
o
C. The resulting 
solution was transferred to a separatory funnel containing H2O (1 L), brine (1 L), EtOAc (1.5 L) 
and acetone (1 L). The mixture was shaken and the aqueous layer was removed and extracted 
with EtOAc:acetone (2:1, 2 x 600 mL). The combined organic layers were washed with H2O (2 x 
500 mL). The combined water washes were back extracted with EtOAc:acetone (2:1, 2 x 300 
mL). The combined organic phases were dried over MgSO4, filtered, and concentrated in vacuo. 
The resulting solid was suspended in 300 mL acetone and 4 L Et2O was added to precipitate the 
product. The resulting solid was collected by vacuum filtration to yield vinyl MIDA boronate 
3.23 as a white solid (81.2 g, 55%). Spectral data for 3.23 were consistent with those previously 
reported from our laboratories.
4 
 
 
MIDA boronate 3.2. To a 2 L round bottom flask equipped with a stir bar and charged with 
vinyl MIDA boronate 3.23 (25.0 g, 137 mmol) was added CH2Cl2 (1.2 L). The resulting clear, 
colorless solution was cooled to 0 
o
C in an ice bath. Neat bromine (12.5 mL, 239 mmol) was 
added dropwise over 5 minutes to give a cloudy orange solution. The solution was warmed to 23 
o
C over 30 min. The resulting orange solution was concentrated in vacuo to give a yellow solid. 
Residual bromine was removed by azeotroping with CH2Cl2 (2 x 100 mL). The resulting solid 
was suspended in MeCN (1 L). 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU, 51.0 mL, 342 mmol) 
was added in one portion. The resulting mixture stirred at 23 
o
C for 1 hr. The solution was 
poured into 1 M aq. HCl (1 L) and diluted with EtOAc:acetone (3:1, 1 L). After shaking, the 
layers were separated. The organic layer was washed with saturated aqueous sodium 
bisulfite:brine (3:2, 1 x 500 mL) and brine (1 x 250 mL). The organic layer was dried over 
MgSO4, filtered, and concentrated in vacuo. The resulting residue was passed through a plug of 
silica, eluting with acetone. The resulting solid was suspended in THF (50 mL) onto which Et2O 
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(1.8 L) was layered to precipitate the product. The product was collected by vacuum filtration 
(24.0 g, 67%). 
 
1
H NMR (500 MHz, d6-acetone)  
δ 6.39 (bs, 1H), 6.19 (bs, 1H), 4.37 (d, J = 17.0 Hz, 2H), 4.16 (d, J = 17.0 Hz, 2H), 3.16 
(s, 3H).  
 
13
C NMR (125 MHz, d6-acetone)  
δ 168.4, 129.5, 63.4, 47.2.  
 
X-ray quality crystals were grown by vapor diffusion of Et2O into a dissolved solution of 3.2 in 
acetone. 
 
General procedure for Scheme 3-9 and Table 3-2 
 In a glovebox, to a 7 mL vial containing a stir bar and silver salt (0.4 mmol, 4.0 eq) was 
added a 0.25 mL aliquot of each of the following three stock solutions: 1) 262 mg MIDA 
boronate 3.2 in 2.5 mL THF (0.1 mmol, 1.0 eq of 3.2 added to each reaction); 2) 183 mg 
phenylboronic acid in 2.5 mL THF (0.15 mmol, 1.5 eq of boronic acid added to each reaction); 
3) A solution of 0.05 mmol palladium salt and 0.2 mmol ligand in 2.5 mL THF was prepared and 
stirred at 23 
o
C for 30 min. before adding an aliquot to the reaction vials (0.005 mmol, 0.05 eq of 
palladium added to each reaction and 0.02 mmol, 0.2 eq of ligand added to each reaction). An 
additional 0.25 mL of THF was added to each reaction. The vials were capped, removed from 
the glovebox, and placed in a 40 
o
C heating block with stirring for 24 h. The crude reaction 
mixtures were filtered through a plug of Celite, concentrated in vacuo, and analyzed by 
1
H NMR. 
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MIDA boronate 3.24. 
Preparation of catalyst solution. In a glovebox, to a 7 mL vial charged with dpph (90.9 
mg, 0.20 mmol) and Pd2dba3 (45.8 mg, 0.05 mmol) was added THF (5.0 mL). The solution was 
stirred at 23 °C for 30 min. 
The freshly prepared catalyst solution was used in the following reaction: In a glovebox, 
to a 20 mL vial with stir bar, charged with MIDA boronate 3.2 (261.9 mg, 1.0 mmol) was added 
Ag2CO3 (1.10 g, 4.0 mmol). Phenylboronic acid (182.8 mg, 1.5 mmol) was added as a solution in 
THF (5.0 mL). The prepared catalyst solution was added in one portion. The vial was sealed with 
a septum cap and removed from the glovebox. The solution was stirred at 40 
o
C for 24 h. The 
reaction mixture was filtered through a pad of Celite, concentrated in vacuo, dry loaded onto 
Celite from an acetone solution, and purified via flash chromatography on silica (Et2O:MeCN 
100:0 → 80:20) to afford MIDA boronate 3.24 (158.0 mg, 61%). 
 
1
H NMR (400 MHz, d6-acetone)  
δ 7.42-7.38 (m, 2H), 7.33-7.28 (m, 2H), 7.26-7.21 (m, 1H), 5.73 (bd, J = 3.0 Hz, 1H), 
5.69 (bs, 1H), 4.23 (d, J = 17.0 Hz, 2H), 3.85 (d, J = 17.0 Hz, 2H), 2.82 (s, 3H). 
 
 
1,1-disubstituted olefin 3.27. In a glovebox, to a 20 mL vial with stir bar, charged with MIDA 
boronate 3.24 (100.0 mg, 0.39 mmol, 1.0 eq) was added 4-iodoacetephenone (113.9 mg, 0.46 
mmol, 1.2 eq), 2
nd
 gen. SPhosPd cycle (20.9 mg, 0.029 mmol, 0.075 eq), and THF (3.5 mL). The 
vial was sealed with a septum cap and removed from the glovebox. To the reaction solution was 
added 1 M aq. NaOH via syringe (2.9 mL, 2.9 mmol). The solution was stirred at 23 
o
C for 4 h. 
The reaction mixture was poured into a separatory funnel containing aqueous sodium phosphate 
buffer (0.5 M, pH 7.0, 10 mL) and diluted with Et2O (10 mL). The mixture was shaken and the 
layers were separated. The aqueous phase was extracted with Et2O (2 x 10 mL). The combined 
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organics were dried over MgSO4, filtered, and then concentrated in vacuo. The crude material 
was dry loaded onto Celite from an acetone solution, and purified via flash chromatography on 
silica (hexane:EtOAc 100:0 → 90:10) to afford 1,1-disubstituted olefin 3.27 (63.5 mg, 74%). 
Spectral data for 3.27 were consistent with those previously reported.
8
 
 
General procedure for Table 3-3. 
Preparation of catalyst solution. In a glovebox, to a 20 mL vial charged with dpph (136.4 
mg, 0.30 mmol) and Pd2dba3 (68.7 mg, 0.075 mmol) was added THF (7.5 mL). The solution was 
stirred at 23 °C for 30 min. 
The freshly prepared catalyst solution was used in the following reactions: In a glovebox, 
to a 7 mL vial with stir bar, charged with MIDA boronate 3.2 (26.2 mg, 0.1 mmol) was added 
Ag2CO3 (110.0 mg, 0.4 mmol). Boronic acid (0.15 mmol) was added, followed by THF (0.50 
mL). An aliquot of the prepared catalyst solution (0.50 mL) was added in one portion. The vial 
was sealed with a septum cap and removed from the glovebox. The solution was stirred at 40 
o
C 
for 24 h. The reaction mixture was filtered through a pad of Celite, concentrated in vacuo, and 
analyzed by 
1
H NMR. Select samples were dry loaded onto Celite from an acetone solution, and 
purified via flash chromatography on silica (Et2O:MeCN 100:0 → 80:20) to afford the MIDA 
boronate 3.29. 
 
 
MIDA boronate 3.29a. Based on the crude 
1
H NMR, the reaction proceeded to >95% 
conversion and a >20:1 of 3.29:3.30 was obtained. 3.29a was isolated by column 
chromatography to provide 57.8 mg (0.25 mmol reaction), 81% yield. 
 
TLC (Et2O:MeCN 6:1)  
Rf = 0.44, visualized by short wave UV 
 
1
H NMR (400 MHz, d6-acetone)  
δ 7.71-7.33 (m, 4H), 6.85-6.68 (m, 2H), 5.90-5.68 (m, 2H), 5.29-5.17 (m, 1H), 4.25 (d, J 
= 17.0 Hz, 2H), 3.88 (d, J = 17.0 Hz, 2H), 2.81 (s, 3H). 
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HRMS (ESI
+
)  
Calculated for C15H17BNO4 (M+H)
+
:  286.1251  
Found:      286.1248 
 
 
MIDA boronate 3.29b. Based on the crude 
1
H NMR, the reaction proceeded to >95% 
conversion and a >20:1 of 3.29:3.30 was obtained. 3.29b was isolated by column 
chromatography to provide 61.1 mg (0.25 mmol reaction), 90% yield. 
 
TLC (Et2O:MeCN 6:1)  
Rf = 0.44, visualized by short wave UV 
 
1
H NMR (500 MHz, d6-acetone)  
δ 7.24 (m, 1H), 7.21-7.18 (m, 2H), 7.10-7.05 (m, 1H), 5.73 (bd, J = 3.0 Hz, 1H), 5.68 (bs, 
1H), 4.23 (d, J = 17.0 Hz, 2H), 3.83 (d, J = 17.0 Hz, 2H), 2.83 (s, 3H), 2.31 (s, 3H).  
 
13
C NMR (125 MHz, d6-acetone)  
δ 168.7, 145.2, 138.3, 128.9, 128.8, 127.9, 127.6, 125.3, 62.6, 47.4, 21.4 
 
11
B NMR (128 MHz, d6-acetone)  
δ 11.4 
 
HRMS (ESI
+
)  
Calculated for C14H17BNO4 (M+H)
+
:  274.1251  
Found:      274.1245 
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MIDA boronate 3.29c. Based on the crude 
1
H NMR, the reaction proceeded to 85% conversion 
and a 10:1 of 3.29:3.30 was obtained. 
 
TLC (Et2O:MeCN 6:1)  
Rf = 0.32, visualized by short wave UV 
 
1
H NMR (400 MHz, d6-acetone)  
δ 7.70-7.36 (m, 4H), 5.77 (bd, J = 3.0 Hz, 1H), 5.73 (bs, 1H), 4.25 (d, J = 17.0 Hz, 2H), 
3.91 (d, J = 17.0 Hz, 2H), 3.85 (s, 3H), 2.81 (s, 3H).  
 
HRMS (ESI
+
)  
Calculated for C15H17BNO6 (M+H)
+
:  318.1149 
Found:      318.1143  
 
 
MIDA boronate 3.29d. Based on the crude 
1
H NMR, the reaction proceeded to 70% conversion 
and a 8:1 of 3.29:3.30 was obtained. 
 
TLC (Et2O:MeCN 6:1)  
Rf = 0.32, visualized by short wave UV 
 
1
H NMR (400 MHz, d6-acetone)  
δ 7.79-7.52 (m, 4H), 5.82 (bd, J = 3.0 Hz, 1H), 5.79 (bs, 1H), 4.27 (d, J = 17.0 Hz, 2H), 
3.95 (d, J = 17.0 Hz, 2H), 2.82 (s, 3H).  
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HRMS (ESI
+
)  
Calculated for C14H14BN2O4 (M+H)
+
:  285.1047 
Found:      285.1038  
 
 
MIDA boronate 3.29e. Based on the crude 
1
H NMR, the reaction proceeded to 90% conversion 
and a 4:1 of 3.29:3.30 was obtained. 
 
TLC (Et2O:MeCN 6:1)  
Rf = 0.37, visualized by short wave UV 
 
1
H NMR (400 MHz, d6-acetone)  
δ 7.49-7.00 (m, 4H), 5.70 (bd, J = 3.0 Hz, 1H), 5.67 (bs, 1H), 4.23 (d, J = 17.0 Hz, 2H), 
3.88 (d, J= 17.0 Hz, 2H), 2.80 (s, 3H).  
 
HRMS (ESI
+
)  
Calculated for C13H14BFNO4 (M+H)
+
:  278.1000  
Found:      278.0994 
 
 
MIDA boronate 3.29f. Based on the crude 
1
H NMR, the reaction proceeded to 85% conversion 
and a 10:1 of 3.29:3.30 was obtained. 
 
TLC (Et2O:MeCN 6:1)  
Rf = 0.37, visualized by short wave UV 
 
1
H NMR (400 MHz, d6-acetone)  
δ 7.59-7.20 (m, 4H), 5.75 (bd, J = 3.0 Hz, 1H), 5.73 (bs, 1H), 4.25 (d, J = 17.0 Hz, 2H), 
3.92 (d, J = 17.0 Hz, 2H), 2.82 (s, 3H). 
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MIDA boronate 3.29g. Based on the crude 
1
H NMR, the reaction proceeded to 85% conversion 
and a >20:1 of 3.29:3.30 was obtained. 3.29g was isolated by column chromatography to provide 
21.1 mg (0.1 mmol reaction), 66% yield. 
  
TLC (Et2O:MeCN 6:1)  
Rf = 0.31, visualized by short wave UV 
 
1
H NMR (500 MHz, d6-acetone)  
δ 6.59 (d, J = 2.5 Hz, 2H), 6.38 (t, J = 2.5  Hz, 1H), 5.75 (m, 2H), 4.24 (d, J = 17.0 Hz, 
2H), 3.84 (d, J = 17.0 Hz, 2H), 3.77 (s, 6H), 2.86 (s, 3H).  
 
13
C NMR (125 MHz, d6-acetone)  
δ 169.0, 161.7, 147.4, 127.8, 106.3, 99.7, 62.9, 55.5, 47.6.  
 
11
B NMR (128 MHz, d6-acetone)  
δ 11.3 
 
HRMS (ESI
+
)  
Calculated for C15H19BNO6 (M+H)
+
:  320.1305 
Found:      320.1295  
 
 
MIDA boronate 3.29h. Based on the crude 
1
H NMR, the reaction proceeded to 50% conversion 
and a >20:1 of 3.29:3.30 was obtained. 
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TLC (Et2O:MeCN 6:1)  
Rf = 0.31, visualized by short wave UV 
 
1
H NMR (400 MHz, d6-acetone)  
δ 7.35-7.00 (m, 4H), 5.58 (bs, 1H), 5.55 (bd, J = 3.0 Hz, 1H), 4.18 (d, J = 17.0 Hz, 2H), 
3.79 (d, J = 17.0 Hz, 2H), 3.12 (s, 6H), 2.75 (s, 3H).  
 
HRMS (ESI
+
)  
Calculated for C15H20BN2O4 (M+H)
+
:  303.1516  
Found:      303.1524 
 
 
MIDA boronate 3.29i. Based on the crude 
1
H NMR, the reaction proceeded to 95% conversion 
and a >20:1 of 3.29:3.30 was obtained. 3.29i was isolated by column chromatography to provide 
24.6 mg (0.1 mmol reaction), 82% yield. 
 
1
H NMR (500 MHz, d6-acetone)  
δ 7.59 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 8.0 Hz, 1H), 7.29 (t, J = 7.0 Hz, 1H), 7.21 (t, J = 
7.0 Hz, 1H), 6.92 (s, 1H), 6.45 (s, 1H), 5.80 (d, J = 2.5 Hz, 1H), 4.41 (d, J = 17.0 Hz, 
2H), 4.23 (d, J = 17.0 Hz, 2H), 3.03 (s, 3H).  
 
13
C NMR (125 MHz, d6-acetone)  
δ 168.9, 158.4, 154.8, 129.8, 126.5, 125.0, 123.3, 121.7, 111.2, 104.5, 62.9, 47.7  
 
11
B NMR (128 MHz, d6-acetone)  
δ 11.3 
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MIDA boronate 3.29j. Based on the crude 
1
H NMR, the reaction proceeded to 50% conversion 
and a >20:1 of 3.29:3.30 was obtained. 
 
TLC (Et2O:MeCN 6:1) Rf = 0.39, visualized by short wave UV 
 
1
H NMR (400 MHz, d6-acetone)  
δ 7.80-7.00 (m, 3H), 5.83 (bs, 1H), 5.56 (bs, 1H), 4.30 (d, J = 17.0 Hz, 2H), 4.00 (d, J = 
17.0 Hz, 2H), 3.13 (s, 3H).  
 
HRMS (ESI
+
)  
Calculated for C11H13BNO4S (M+H)
+
:  266.0658  
Found:      266.0647 
 
 
MIDA boronate 3.29k. Based on the crude 
1
H NMR, the reaction proceeded to 90% conversion 
and a >20:1 of 3.29:3.30 was obtained. 3.29k was isolated by column chromatography to provide 
47.7 mg (0.25 mmol reaction), 76% yield. 
 
TLC (Et2O:MeCN 6:1)  
Rf = 0.48, visualized by short wave UV 
 
1
H NMR (500 MHz, d6-acetone)  
δ 6.20 (d, J = 15.0 Hz, 1H), 5.90 (dt, J = 15.0 Hz, 6.5 Hz, 1H), 5.61 (bs, 1H), 5.34 (bd, J 
= 3.5 Hz, 1H), 4.25 (d, J = 17.0 Hz, 2H), 4.01 (d, J = 17.0 Hz, 2H), 2.97 (s, 3H), 2.06 (m, 
2H), 1.41 (s, J = 7.0 Hz, 2H), 0.89 (t, J = 7.0 Hz, 3H).   
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13
C NMR (125 MHz, CDCl3)  
δ 167.3, 132.9, 132.8, 125.9, 61.9, 47.0, 35.4, 22.5, 13.7  
 
11
B NMR (128 MHz, CDCl3)  
δ 10.7  
 
HRMS (ESI
+
)  
Calculated for C12H19BNO4 (M+H)
+
: 252.1407 
Found: 252.1405 
 
 
MIDA boronate 3.29l. Based on the crude 
1
H NMR, the reaction proceeded to 80% conversion 
and a >20:1 of 3.29:3.30 was obtained. 3.29l was isolated by column chromatography to provide 
46.3 mg (0.25 mmol reaction), 65% yield. 
 
TLC (Et2O:MeCN 6:1)  
Rf = 0.36, visualized by short wave UV 
 
1
H NMR (400 MHz, d6-acetone)  
δ 7.47-7.19 (m, 5H), 5.58 (d, J = 2.0 Hz, 1H), 5.31 (d, J = 2.0 Hz, 1H), 5.25 (d, J = 2.0 
Hz, 1H), 5.23 (d, J = 2.0 Hz, 1H), 4.16 (d, J = 17.0 Hz, 2H), 3.91 (d, J = 17.0 Hz, 2H), 
3.05 (s, 3H).  
 
HRMS (ESI
+
)  
Calculated for C15H17BNO4 (M+H)
+
:  286.1251.  
Found:      286.1244.  
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Scheme 3-11C
9
 
Under air to a 40 mL I-CHEM vial was added K2CO3 (691 mg, 5.0 mmol) and 2-pyridyl MIDA 
boronate 3.3 (351 mg, 1.5 mmol). The vial was sealed with a septum cap and backfilled under 
argon. To the vial was then added the aryl chloride (1.0 mmol) via syringe. Into a separate 20 mL 
I-CHEM vial with septum cap and PTFE coated stirbar was added DMF (8 mL). Both vials were 
then brought into a glovebox. To the vial containing the chloride, K2CO3, and 2-pyridyl MIDA 
boronate was added copper (II) acetate (91 mg, 0.5 mmol) and biphenyl (154 mg, 1.0 mmol). To 
the vial containing DMF was added Pd2(dba)3 (14 mg, 0.015 mmol) and XPhos (29 mg, 0.06 
mmol). The vial containing DMF, catalyst, and ligand was removed from the glovebox and 
incubated at 100 ˚C for 5 minutes with stirring and returned to the glovebox. This solution and 
the stirbar were transferred at ~40 ˚C to the 40 mL I-CHEM vial, and the vial was sealed. The 
vial was removed from the glovebox and a needle with a positive pressure of argon was inserted 
into the septum. To the vial by syringe was added isopropanol (2 mL, sparged with argon for 20 
min and dried with 5 Å molecular sieves). The argon needle was removed from the vial and the 
reaction was heated to 100 ˚C with stirring for 4 h. The reaction was then allowed to cool to 
room temperature over 0.5 h. An aliquot was removed and filtered through a pad of silica gel 
washing with acetone into a GC vial and analyzed by gas chromatography using the biphenyl as 
an internal standard. GC yields were determined by the average of three injections. Each reaction 
was run in duplicate and the yields were averaged. 
 
GC Yield for the coupling of 2-pyridyl MIDA boronate (3.3) to 4-chloroacetophenone (3.31a): 
72% 
 
GC Yield for the coupling of 2-pyridyl MIDA boronate (3.3) to 1-(tert-butoxy)-4-chlorobenzene 
(3.31b): 7% 
 
Table 3-4 
 
Cross-coupling of 2-pyridyl MIDA boronate to 1-(tert-butoxy)-4-chlorobenzene utilizing 
various alcohols and diols 
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Under air to a 40 mL I-CHEM vial equipped with PTFE coated stir bar was added XPhos 
Palladacycle, chloro(2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl)[2-(2-
aminoethyl)phenyl] palladium(II) methyl-t-butylether adduct, (37 mg, 0.05 mmol) and 2-pyridyl 
MIDA boronate 3.3 (351 mg, 1.5 mmol). The vial was sealed with a septum cap and back-filled 
with argon. To the vial was added DMF (8 mL) and 1-(tert-butoxy)-4-chlorobenzene 3.31b (174 
µL, 1.00 mmol) by syringe. The vial was brought into a glove box where K3PO4 (1.061 g, 5.0 
mmol), biphenyl (154 mg, 1.00 mmol), and Cu(OAc)2 (91 mg, 0.5 mmol) were added. At this 
point, solid diols with high melting points were added. The vial was sealed with a septum cap 
and removed from the glove box. A needle under positive pressure of argon was inserted into the 
septum and using a syringe, the appropriate liquid or low melting point alcohol was added. The 
syringe was removed and the vial was heated to 100 ˚C with stirring for 24 h. The reaction was 
then allowed to cool to room temperature over 0.5 h. An aliquot was removed and filtered 
through a pad of silica gel washing with acetone into a GC vial and analyzed by gas 
chromatography using the biphenyl as the internal standard. GC yields were determined by the 
average of three injections. Each reaction was run in duplicate and the yields were averaged. 
 
Entry ROH Quantity Equivalents % GC Yield 
1 Isopropanol 229 µL 3 49 
2 Methanol 121 µL 3 36 
3 Ethanol 175 µL 3 39 
4 Tert-butanol 285 µL 3 43 
5 Ethylene Glycol 84 µL 1.5 51 
6 Pinacol 177 mg 1.5 35 
7 Neopentyl Glycol 156 mg 1.5 31 
8 Diethanolamine (DEA) 144 µL 1.5 70 
 
Scheme 3-13 
 
Kinetics of the transligation of 2-pyridyl MIDA boronate with diethanolamine (DEA) 
Under air to a 20 mL I-CHEM vial was added 2-pyridyl MIDA boronate 3.3 (394 mg, 1.69 
mmol). The vial was sealed with a septum cap and back filled under argon. To the vial was 
added by syringe diethanolamine (170 µL, 1.69 mmol), tert-butylbenzene (260 µL, 1.69 mmol), 
and DMF-d7 (9 mL). This vial was brought into a glovebox along with sixteen 2 mL vials with 
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PTFE coated stirbars. Into each 2 mL vial was massed K3PO4 (66 mg, 0.31 mmol) and using a 
pipetman, 500 µL of the MIDA boronate containing stock solution was added to each vial. Each 
vial was then sealed with a PTFE lined cap and the vials were removed from the glovebox. The 
vials were heated to 100 ˚C with stirring. The remaining stock solution was transferred to a NMR 
tube and a 
1
H-NMR was taken (nt = 2, d1 = 30) this represents t = 0. At regular intervals, two 
vials were removed from heating and allowed to cool to 23
 ˚C after which the solution was 
transferred under air into a 
1
H-NMR tube. A 
1
H-NMR was then taken of these duplicate samples. 
The rate of transligation and decomposition of the MIDA boronate were determined by 
integration of the diastereotopic methylene protons of the MIDA boronate (δ 4.55 (d, J = 17 Hz, 
2H)) and of the DEA boronate (δ 3.97 (m, 2H)) and comparing them to the integration of methyl 
protons of the tert-butyl benzene (δ 1.29 (s, 9H)). The major decomposition product was 
determined to be pyridine. 
 
 
 
 
Synthesis of 2-pyridyl DEA boronate 
 
2-pyridyl DEA boronate (3.34). To a 100 mL Schlenk flask with PTFE coated stirbar was 
added 2-pyridyl MIDA boronate 3.3 (1.87 g, 8.00 mmol) and finely ground K3PO4 (8.78 g, 41.4 
mmol) under positive argon pressure. The Schlenk flask was sealed with a septum and to the 
flask was then added acetonitrile (40 mL) and diethanolamine (1.6 mL, 17 mmol). The Schlenk 
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flask was then heated to 80 ˚C with stirring for 7 h. After 7 h while still stirring at 80 ˚C, the 
acetonitrile solution was cannulated into a tared 250 mL round bottom. The acetonitrile was then 
concentrated in vacuo to approximately 20 mL of solution and then allowed to cool to room 
temperature. A stirbar was added to the round bottom and with stirring, 100 mL of Et2O was 
added to the flask over 0.5 h. After the addition was complete, the solution was allowed to stir 
for another 10 min before the stir bar was removed and the solution was decanted. The resulting 
solid was then placed under high vacuum for 10 min. To the round bottom was then added 20 
mL of acetonitrile. The round bottom was sealed with a glass stopper and PTFE tape and heated 
to 80 ˚C for 15-20 min or until the solid completely dissolved. The stirbar was then removed 
from the round bottom and the reaction was allowed to cool to room temperature and sit 
overnight. The acetonitrile solution was decanted and the resulting solid was washed with small 
amounts of diethyl ether. The round bottom was then placed under high vacuum to remove 
residual acetonitrile and diethyl ether affording 3.34 as white spindly crystals (1.00 g, 65%). 
 
 
1
H-NMR (400 MHz, DMSO-d6)  
 δ 8.52 (d, J = 4.0 Hz, 1H), 7.50 (t, J = 6.0 Hz, 1H), 7.40 (d, J = 6.0 Hz, 1H), 7.09 (t, J = 
4.8 Hz, 1H), 7.02 (s, br, 1H), 3.84 (m, 2H), 3.72 (m, 2H), 3.15 (m, 2H), 2.82 (m, 2H). 
 
13
C-NMR (125 MHz, DMSO-d6) 
 δ 148.4, 133.4, 125.8, 120.9, 62.6, 50.8 
 
11
B-NMR (128 MHz, DMSO-d6) 
 δ 9.8 
 
HRMS (ESI+) 
 Calculated for C9H14BN2O2 (M+H)
+
:   193.1148 
 Found:       193.1147 
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Cross-coupling of 2-pyridyl DEA boronate to 1-(tert-butoxy)-4-chlorobenzene 
Under air to a 40 mL I-CHEM vial equipped with a PTFE coated stir bar was added XPhos 
Palladacycle, chloro(2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl)[2-(2-
aminoethyl)phenyl] palladium(II) methyl-t-butylether adduct, (37 mg, 0.05 mmol). The vial was 
sealed with a septum cap and back-filled with argon. To the vial was added DMF (8 mL) and 1-
(tert-butoxy)-4-chlorobenzene 3.31b (174 µL, 1.0 mmol) by syringe. The vial was brought into a 
glove box where K3PO4 (1.061 g, 5.0 mmol), biphenyl (154 mg, 1.0 mmol), Cu(OAc)2 (91 mg, 
0.5 mmol), and 2-pyridyl DEA boronate 3.34 (288 mg, 1.5 mmol) were added. The vial was re-
sealed with the septum cap and removed from the glove box and heated to 100 ˚C with stirring 
for 24 h. The reaction was then allowed to cool to room temperature over 0.5 h. An aliquot was 
removed and filtered through a pad of silica gel washing with acetone into a GC vial and 
analyzed by gas chromatography using the biphenyl as the internal standard. GC yields were 
determined by the average of three injections. Each reaction was run in duplicate and the yields 
were averaged. Based on the biphenyl internal standard, the yield was 9%. 
 
Slow addition cross-coupling of 2-pyridyl DEA boronate to 1-(tert-butoxy)-4-chlorobenzene 
Under air to a 20 mL I-CHEM vial equipped with PTFE coated stir bar was added XPhos 
Palladacycle, chloro(2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl)[2-(2-
aminoethyl)phenyl] palladium(II) methyl-t-butylether adduct, (20 mg, 0.027 mmol). The vial 
was sealed with a septum cap and back-filled with argon. To the vial was added DMF (2 mL) 
and 1-(tert-butoxy)-4-chlorobenzene 3.31b (87 µL, 0.5 mmol) by syringe. Into a second 20 mL I-
CHEM vial with septum cap was added DMF (10 mL). The vials were brought into a glove box 
where K3PO4 (555 mg, 2.61 mmol), and Cu(OAc)2 (46 mg, 0.25 mmol) were added to the vial 
containing the chloride.  2-pyridyl DEA boronate 3.34 (178 mg, 0.93 mmol) was added to the 
vial containing just 10 mL DMF. Both vials were re-sealed with septum caps and removed from 
the glove box. A needle under positive pressure of argon was inserted into both vials and the vial 
containing the catalyst and chloride was heated to 100 ˚C with stirring. A 10 mL syringe with a 
20 gauge steel needle was used to draw up 8 mL of the 2-pyridyl DEA boronate 3.34 solution. 
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This syringe was fitted into a syringe pump and the needle was inserted into the vial containing 
the catalyst and chloride. The 2-pyridyl DEA boronate 3.34 solution was added slowly over 4 h 
15 min. The needles were then removed and the reaction was stirred for a further 20 h at 100 ˚C. 
The reaction was then allowed to cool to room temperature over 0.5 h. The reaction was 
transferred to a 60 mL separatory funnel, diluted with 10 mL of 2N HCl and shaken. The 
reaction was then diluted with 10 mL 2N NaOH and shaken. The resulting aqueous solution was 
extracted twice with 10 mL of diethyl ether. The organic layers were combined and washed with 
5 mL of brine.  The organic layers were dried using Na2SO4, filtered, and concentrated in vacuo. 
The resulting residue was adsorbed onto Celite and subjected to Florisil chromatography 
(EtOAc:Hexanes 5:95 → 20:80) to afford 3.32b as a pale yellow solid (15 mg, 13%). 
 
Scheme 3-14 
 
Preparation of Cu(DEA)2 
To a 100 mL Schlenk flask in the glovebox was added Cu(OAc)2 (229 mg, 1.26 mmol), K3PO4 
(2.49 g, 11.7 mmol) and a PTFE coated stirbar. The Schlenk flask was sealed with a septum and 
removed from the glovebox. The Schlenk flask was attached to a vacuum manifold and placed 
under argon maintenance. To the flask was added diethanolamine (360 µL, 3.75 mmol) and 
DMF (20 mL). The Schlenk flask was then heated at 100 ˚C with stirring for 15 min.  An aliquot 
was removed from the crude reaction mixture and was found to contain Cu(DEA)2 by ESI 
HRMS.  
 
The reaction was then allowed to cool to room temperature and the solids were allowed to settle. 
The DMF solution was decanted and isopropanol (20 mL) was introduced, dissolving the 
product. The reaction was then air-free filtered into a tared 200 mL Schlenk flask. The filtrate 
was concentrated using the vacuum manifold to ¼ of its original volume. With stirring, 20 mL of 
dry, degassed acetone was slowly added precipitating a reddish purple solid. The solution was 
decanted and the solid was washed twice with 5 mL of acetone. The solid was dried on the 
vacuum line for 0.5 h to afford the product as a reddish purple powder with white specks (260 
mg, 76%). 
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A NMR (in CD3OD) was taken of the product which indicated that potassium acetate was 
contaminating the product. 
 
HRMS (ESI+) 
 Calculated for C8H21CuN2O4 (M+H)
+
: 272.0797 
 Found:      272.0793 
 
Synthesis and purification of Cu(DEA)2 
To a 100 mL Schlenk flask in the glovebox was added CuCl2 (840 mg, 6.3 mmol), K3PO4 (6.87g, 
32.4 mmol) and a PTFE coated stirbar. The Schlenk flask was sealed with a septum and removed 
from the glovebox. The Schlenk flask was attached to a vacuum manifold and placed under 
argon maintenance. To the flask was added diethanolamine (3.0 mL, 31.0 mmol) and 
isopropanol (50 mL). The Schlenk flask was then heated at 60 ˚C with stirring for 15 h. The 
reaction was then air-free filtered into a tared 200 mL Schlenk flask. The filtrate was 
concentrated using the vacuum manifold to ½ of its original volume. With stirring, 100 mL of 
dry, degassed acetone was slowly added, precipitating a reddish purple solid. The solution was 
decanted and the solid was washed twice with 20 mL of acetone. The solid was dried on the 
vacuum line for 0.5 h to afford the product as a reddish purple powder (1.38 g, 81%). 
 
 
IR (nujol, cm
-1
) 
ν 3067, 1181, 1115, 1093, 1067, 1043, 1023 
 
CHN/ICP-MS 
 Calculated: C: 35.35%, H: 7.42%, N: 10.31%, Cu: 23.38% 
 Found: C: 35.45%, H: 7.69%, N: 9.96%, Cu: 22.60% 
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HRMS (ESI+) 
 Calculated for C8H21CuN2O4 (M+H)
+
: 272.0797 
 Found:      272.0804 
 
Cross-coupling using Cu(DEA)2 and KOAc. 
Under air to a 40 mL I-CHEM vial equipped with PTFE coated stir bar was added 2-pyridyl 
MIDA boronate 3.3 (351 mg, 1.5 mmol), XPhos Palladacycle, chloro(2-dicyclohexylphosphino-
2',4',6'-tri-i-propyl-1,1'-biphenyl)[2-(2-aminoethyl)phenyl] palladium(II) methyl-t-butylether 
adduct, (37 mg, 0.05 mmol), and KOAc (98 mg, 1.0 mmol). The vial was sealed with a septum 
cap and back-filled with argon. To the vial was added DMF (8 mL) and 1-(tert-butoxy)-4-
chlorobenzene 3.31b (174 µL, 1.0 mmol) by syringe. The vial was brought into a glove box 
where K3PO4 (1.061 g, 5.0 mmol), biphenyl (154 mg, 1.0 mmol), and Cu(DEA)2 (136 mg, 0.5 
mmol) were added. The vial was re-sealed with the septum cap and removed from the glove box 
and heated to 100 ˚C with stirring for 24 h. The reaction was then allowed to cool to room 
temperature over 0.5 h. An aliquot was removed and filtered through a pad of silica gel washing 
with acetone into a GC vial and analyzed by gas chromatography using the biphenyl as the 
internal standard. GC yields were determined by the average of three injections. Each reaction 
was run in duplicate and the yields were averaged. Based on the biphenyl internal standard, the 
yield was 84%. 
 
Cross-coupling using no copper. 
Under air to a 40 mL I-CHEM vial equipped with PTFE stir bar was added 2-pyridyl MIDA 
boronate 3.3 (351 mg, 1.5 mmol) and XPhos Palladacycle, chloro(2-dicyclohexylphosphino-
2',4',6'-tri-i-propyl-1,1'-biphenyl)[2-(2-aminoethyl)phenyl] palladium(II) methyl-t-butylether 
adduct, (37 mg, 0.05 mmol). The vial was sealed with a septum cap and back-filled with argon. 
To the vial was added DMF (8 mL) and 1-(tert-butoxy)-4-chlorobenzene 3.31b (174 µL, 1.0 
mmol) by syringe. The vial was brought into a glove box where K3PO4 (1.061 g, 5.0 mmol) and 
biphenyl (154 mg, 1.0 mmol) were added. The vial was re-sealed with the septum cap and 
removed from the glove box and heated to 100 ˚C with stirring for 24 h. The reaction was then 
allowed to cool to room temperature over 0.5 h. An aliquot was removed and filtered through a 
pad of silica gel washing with acetone into a GC vial and analyzed by gas chromatography using 
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the biphenyl as the internal standard. GC yields were determined by the average of three 
injections. Each reaction was run in duplicate and the yields were averaged. Based on the 
biphenyl internal standard, the yield was <5%. 
 
Cross-coupling using KOAc and no copper. 
Under air to a 40 mL I-CHEM vial equipped with PTFE coated stir bar was added 2-pyridyl 
MIDA boronate 3.3 (351 mg, 1.5 mmol), XPhos Palladacycle, chloro(2-dicyclohexylphosphino-
2',4',6'-tri-i-propyl-1,1'-biphenyl)[2-(2-aminoethyl)phenyl] palladium(II) methyl-t-butylether 
adduct, (37 mg, 0.05 mmol), and KOAc (98 mg, 1.0 mmol). The vial was sealed with a septum 
cap and back-filled with argon. To the vial was added DMF (8 mL) and 1-(tert-butoxy)-4-
chlorobenzene 3.31b (174 µL, 1.0 mmol) by syringe. The vial was brought into a glove box 
where K3PO4 (1.061 g, 5.0 mmol) and biphenyl (154 mg, 1.0 mmol) were added. The vial was 
re-sealed with the septum cap and removed from the glove box and heated to 100 ˚C with stirring 
for 24 h. The reaction was then allowed to cool to room temperature over 0.5 h. An aliquot was 
removed and filtered through a pad of silica gel washing with acetone into a GC vial and 
analyzed by gas chromatography using the biphenyl as the internal standard. GC yields were 
determined by the average of three injections. Each reaction was run in duplicate and the yields 
were averaged. Based on the biphenyl internal standard, the yield was <5%. 
 
Cross-coupling using Cu(OAc)2 and KOAc. 
Under air to a 40 mL I-CHEM vial equipped with PTFE coated stir bar was added 2-pyridyl 
MIDA boronate 3.3 (351 mg, 1.5 mmol), XPhos Palladacycle, chloro(2-dicyclohexylphosphino-
2',4',6'-tri-i-propyl-1,1'-biphenyl)[2-(2-aminoethyl)phenyl] palladium(II) methyl-t-butylether 
adduct, (37 mg, 0.05 mmol), and KOAc (98 mg, 1.0 mmol). The vial was sealed with a septum 
cap and back-filled with argon. To the vial was added DMF (8 mL) and 1-(tert-butoxy)-4-
chlorobenzene 3.31b (174 µL, 1.0 mmol) by syringe. The vial was brought into a glove box 
where K3PO4 (1.061 g, 5.0 mmol), biphenyl (154 mg, 1.0 mmol), and Cu(OAc)2 (91 mg, 0.5 
mmol) were added. The vial was re-sealed with the septum cap and removed from the glove box 
and heated to 100 ˚C with stirring for 24 h. The reaction was then allowed to cool to room 
temperature over 0.5 h. An aliquot was removed and filtered through a pad of silica gel washing 
with acetone into a GC vial and analyzed by gas chromatography using the biphenyl as the 
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internal standard. GC yields were determined by the average of three injections. Each reaction 
was run in duplicate and the yields were averaged. Based on the biphenyl internal standard, the 
yield was 38%. 
 
Cross-coupling using Cu(DEA)2. 
Under air to a 40 mL I-CHEM vial equipped with PTFE coated stir bar was added 2-pyridyl 
MIDA boronate 3.3 (351 mg, 1.5 mmol) and XPhos Palladacycle, chloro(2-
dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl)[2-(2-aminoethyl)phenyl] palladium(II) 
methyl-t-butylether adduct, (37 mg, 0.05 mmol). The vial was sealed with a septum cap and 
back-filled with argon. To the vial was added DMF (8 mL) and 1-(tert-butoxy)-4-chlorobenzene 
3.31b (174 µL, 1.0 mmol) by syringe. The vial was brought into a glove box where K3PO4 
(1.061 g, 5.0 mmol), biphenyl (154 mg, 1.0 mmol), and Cu(DEA)2 (136 mg, 0.5 mmol) were 
added. The vial was re-sealed with the septum cap and removed from the glove box and heated 
to 100 ˚C with stirring for 24 h. The reaction was then allowed to cool to room temperature over 
0.5 h. An aliquot was removed and filtered through a pad of silica gel washing with acetone into 
a GC vial and analyzed by gas chromatography using the biphenyl as the internal standard. GC 
yields were determined by the average of three injections. Each reaction was run in duplicate and 
the yields were averaged. Based on the biphenyl internal standard, the yield was 50%. 
 
2-pyridyl MIDA boronate consumption studies 
Under air, to a 20 mL I-CHEM vial was added 2-pyridyl MIDA boronate 3.3 (623 mg, 2.7 
mmol), tert-butyl benzene (410 μL, 2.7 mmol), and DMF-d7 (14.0 mL).  The vial was sealed 
with a septum cap and backfilled under argon.  This solution was taken into a glovebox.  To six 7 
mL vials containing stir bars was added K3PO4 (80.6 mg each, 0.38 mmol).  To six 7 mL vials 
containing stir bars was added K3PO4 (80.6 mg each, 0.38 mmol) and KOAc (7.5 mg each, 0.076 
mmol).  To five 7 mL vials containing stir bars was added K3PO4 (80.6 mg each, 0.38 mmol) and 
Cu(DEA)2 (10.2 mg each, 0.038 mmol).  To five 7 mL vials containing stir bars was added 
K3PO4 (80.6 mg each, 0.38 mmol), KOAc (7.5 mg each, 0.076 mmol), and Cu(DEA)2 (10.2 mg 
each, 0.038 mmol).  A portion (0.6 mL) of the MIDA boronate containing stock solution was 
added to each of these vials.  The vials were capped, removed from the glovebox, and heated to 
100 
o
C with stirring.  At intervals, a vial from each set was removed and cooled to room 
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temperature.  A 
1
H-NMR was taken of the solutions taking two transients with d1=30.  A 
1
H-
NMR was taken of the initial stock solution.  The quantity of 2-pyridyl MIDA boronate 
remaining was determined by integrating the diastereotopic methylene protons of the MIDA 
boronate (δ 4.55 (d, J = 17 Hz, 2H)) and comparing to the integration of the methyl protons of 
the tert-butyl benzene internal standard (δ 1.28 (s, 9H)). 
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Scheme 3-16 
 
Under air to a 40 mL I-CHEM vial equipped with PTFE coated stir bar was added XPhos 
Palladacycle, chloro(2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl)[2-(2-
aminoethyl)phenyl] palladium(II) methyl-t-butylether adduct, (37 mg, 0.05 mmol) and 2-pyridyl 
MIDA boronate 3.3 (351 mg, 1.5 mmol). The vial was sealed with a septum cap and back-filled 
with argon. To the vial was added DMF (8 mL) and 1-(tert-butoxy)-4-chlorobenzene 3.31b (174 
µL, 1.00 mmol) by syringe. The vial was brought into a glove box where K3PO4 (1.061 g, 5.0 
mmol), biphenyl (154 mg, 1.00 mmol), and Cu(OAc)2 (91 mg, 0.5 mmol) were added. The vial 
was sealed with a septum cap and removed from the glove box. A needle under positive pressure 
of argon was inserted into the septum and using a syringe, the appropriate alcohol was added. 
The syringe was removed and the vial was heated to 100 ˚C with stirring for 24 h. The reaction 
was then allowed to cool to room temperature over 0.5 h. An aliquot was removed and filtered 
through a pad of silica gel washing with acetone into a GC vial and analyzed by gas 
chromatography using the biphenyl as the internal standard. GC yields were determined by the 
average of three injections. Each reaction was run in duplicate and the yields were averaged. 
 
Entry ROH Quantity Equivalents % GC Yield 
1 Diethanolamine (DEA) 144 µL 1.5 70 
2 Diethanolamine (DEA) 96 µL 1 81 
3 Diethanolamine (DEA) 2.4 mL 25 24 
4 Diethanolamine (DEA) 48 µL 0.5 73 
 
Cross-coupling on a 1 mmol scale. 
Under air to a 40 mL I-CHEM vial equipped with PTFE coated stir bar was added XPhos 
Palladacycle, chloro(2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl)[2-(2-
aminoethyl)phenyl] palladium(II) methyl-t-butylether adduct, (42 mg, 0.057 mmol) and 2-
pyridyl MIDA boronate 3.3 (357 mg, 1.53 mmol). The vial was sealed with a septum cap and 
back-filled with argon. To the vial was added DMF (20 mL), 1-(tert-butoxy)-4-chlorobenzene 
3.31b (175 µL, 1.0 mmol), and diethanolamine (95 µL, 0.99 mmol) by syringe. The vial was 
brought into a glove box where K3PO4 (1.086 g, 5.1 mmol) and Cu(OAc)2 (92 mg, 0.51 mmol) 
were added. The vial was sealed with a PTFE lined cap and removed from the glove box. The 
vial was heated to 100 ˚C with stirring for 24 h. The reaction was then allowed to cool to room 
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temperature over 0.5 h. The reaction was transferred to a 60 mL separatory funnel, diluted with 
10 mL of 2N HCl and shaken. The reaction was then diluted with 10 mL 2N NaOH and shaken. 
The resulting aqueous solution was extracted three times with 10 mL of diethyl ether. The 
organic layers were combined and washed with 10 mL of brine.  The organic layers were dried 
using Na2SO4, filtered, and concentrated in vacuo. The resulting residue was adsorbed onto 
Celite and subjected to Florisil chromatography (EtOAc:Hexanes 5:95 → 20:80) to afford 3.32b 
as a pale yellow solid (215 mg, 94%). 
   
Table 3-5. 
 
 
General procedure for the cross-coupling of 2-pyridyl MIDA boronate (Table 3-5, Table 3-
6, and Table 3-7).  
Under air to a flame-dried 40 mL I-CHEM vial equipped with PTFE coated stir bar was added 
halide (1.0 mmol), XPhos Palladacycle, chloro(2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-
biphenyl)[2-(2-aminoethyl)phenyl] palladium(II) methyl-t-butylether adduct, (37 mg, 0.05 
mmol), and 2-pyridyl MIDA boronate 3.3 (351 mg, 1.5 mmol). The vial was sealed with a 
septum cap and back-filled with argon. To the vial was added DMF (8 mL) and diethanolamine 
(96 µL, 1.0 mmol) via syringe. The vial was brought into a glove box where K3PO4 (1.061 g, 5.0 
mmol) and Cu(OAc)2 (91 mg, 0.5 mmol) were added. The vial was sealed with a septum cap and 
removed from the glove box. The vial was heated to 100 ˚C with stirring for 24 h. The vial was 
then cooled to 23 ˚C over 0.5 h. To the vial was added 10 mL of 2N HCl and the resulting 
solution was shaken. To the vial was then added 10 mL of 2N NaOH and the resulting solution 
was shaken and transferred using ~20mL of Et2O to a 100 mL separatory funnel. The mixture 
was shaken and the organic phase was separated. The aqueous phase was extracted twice with 10 
mL of Et2O. The organic fractions were combined, washed with 10 mL of brine, and dried with 
Na2SO4. The solution was then filtered and concentrated in vacuo. The resulting residue was 
adsorbed onto Celite and subjected to column chromatography on SiO2 or Florisil to afford the 
purified product.  
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2-(4-(tert-butoxy)phenyl)pyridine (3.32b). The general procedure was followed using MIDA 
boronate 3.3 (360 mg, 1.54 mmol) and chloride 3.31b (175 µL, 1.00 mmol). The crude product 
was subjected to silica gel chromatography (EtOAc:Hexanes 5:95 → 20:80) to afford 3.32b as a 
pale yellow solid (199 mg, 88%). 
 
TLC (EtOAc:Hexanes 20:80) 
 Rf = 0.4, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, CD3CN)  
 δ 8.61 (d, J = 5.0 Hz, 1H), 7.96 (d, J = 9.0 Hz, 2H), 7.79 (m, 2H), 7.24 (m, 1H), 7.08 (d, J 
= 8.5 Hz, 2H), 1.36 (s, 9H) 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 157.6, 157.3, 150.3, 137.6, 134.9, 128.1, 124.5, 122.6, 120.3, 79.0, 29.1 
 
HRMS (ESI+) 
 Calculated for C15H18NO (M+H)
+
:  228.1388 
 Found:      228.1388 
 
 
2-(4-methoxyphenyl)pyridine (3.32c) [Table 3-5, entry 1]. The general procedure was 
followed using MIDA boronate 3.3 (361 mg, 1.54 mmol) and chloride 3.31c (122.5 µL, 1.00 
mmol). The crude product was subjected to Florisil chromatography (EtOAc:Hexanes 5:95 → 
20:80) to afford 3.32c as an off-white solid (142 mg, 76%). 
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TLC (EtOAc:Hexanes 20:80) 
 Rf = 0.29, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, CD3CN)  
 δ 8.59 (d, J = 4.5 Hz, 1H), 8.00 (d, J = 6.5 Hz, 2H), 7.77 (m, 2H), 7.22 (dt, J = 3.5, 5 Hz, 
1H), 7.02 (d, J = 9.0 Hz, 2H), 3.38 (s, 3H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 161.5, 157.3, 150.3, 137.5, 132.6, 128.7, 122.3, 120.0, 114.7, 55.6 
 
HRMS (ESI+) 
 Calculated for C12H12NO (M+H)
+
:  186.0919 
 Found:      186.0914 
 
 
2-(3-methoxyphenyl)pyridine (3.32d) [Table 3-5, entry 2]. The general procedure was 
followed using MIDA boronate 3.3 (356 mg, 1.52 mmol) and chloride 3.31d (125 µL, 1.02 
mmol). The crude product was subjected to Florisil chromatography (EtOAc:Hexanes 5:95 → 
20:80) to afford 3.32d as a yellow oil (182 mg, 96%). 
 
TLC (EtOAc:Hexanes 20:80) 
 Rf = 0.3, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, acetone-d6)  
 δ 8.65 (d, J = 5.5 Hz, 1H), 7.92 (dt, J = 1.0, 8.0 Hz, 1H), 7.84 (td, J = 2.0, 7.5 Hz, 1H), 
7.71 (t, J = 2.0 Hz, 1H), 7.66 (dt, J = 1.5, 8.0 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.31 (ddd, 
J = 1.0, 5.0, 7.5 Hz, 1H), 6.99 (ddd, J = 0.5, 2.5, 7.5 Hz, 1H), 3.87 (s, 3H). 
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13
C-NMR (125 MHz, acetone-d6) 
 δ 161.0, 157.3, 150.3, 141.6, 137.6, 130.4, 123.2, 121.0, 119.7, 115.4, 112.8, 55.5 
 
HRMS (ESI+) 
 Calculated for C12H12NO (M+H)
+
:  186.0919 
 Found:      186.0920 
 
 
2-(2-methoxyphenyl)pyridine (3.32e) [Table 3-5, entry 3]. The general procedure was 
followed using MIDA boronate 3.3 (365 mg, 1.56 mmol) and chloride 3.31e (130 µL, 1.02 
mmol). The crude product was subjected to Florisil chromatography (EtOAc:Hexanes 5:95 → 
20:80) to afford 3.32e as a yellow oil (142 mg, 75%). 
 
TLC (EtOAc:Hexanes 20:80) 
 Rf = 0.29, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, acetone-d6)  
 δ 8.64 (d, J = 5.0 Hz, 1H), 7.92 (dt, J = 1.0, 8.0 Hz, 1H), 7.85 (dd, J = 2.0, 8.0 Hz, 1H), 
7.75 (td, J = 2.0, 8.0 Hz, 1H), 7.38 (td, J = 2.0, 8.0 Hz, 1H), 7.25 (ddd, J = 1.0, 6.0, 7.5 
Hz, 1H), 7.12 (d, J = 8.0 Hz, 1H), 7.05 (td, J = 1.0, 8.0 Hz, 1H), 3.88 (s, 3H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 158.1, 156.6, 150.1, 136.2, 131.9, 130.7, 129.7, 125.7, 122.4, 121.4, 112.4, 55.9 
 
HRMS (ESI+) 
 Calculated for C12H12NO (M+H)
+
:  186.0919 
 Found:      186.0914 
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2-(o-tolyl)pyridine (3.32f) [Table 3-5, entry 4]. The general procedure was followed using 
MIDA boronate 3.3 (358 mg, 1.53 mmol) and chloride 3.31f (117.5 µL, 1.01 mmol). The crude 
product was subjected to Florisil chromatography (EtOAc:Hexanes 5:95 → 15:85) to afford 
3.32f as a yellow oil (134 mg, 79%). 
 
TLC (EtOAc:Hexanes 17:83) 
 Rf = 0.35, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, acetone-d6)  
 δ 8.65 (d, J = 5.0 Hz, 1H), 7.85 (td, J = 2.0, 8.0 Hz, 1H), 7.48 (dt, J = 1.0, 8.0 Hz, 1H), 
7.39 (d, J = 2.0, 7.0 Hz, 1H), 7.29 (m, 4H), 2.35 (s, 3H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 160.7, 149.8, 141.4, 137.0, 136.5, 131.4, 130.4, 128.8, 126.5, 124.7, 122.5, 20.6 
 
HRMS (ESI+) 
 Calculated for C12H12N (M+H)
+
:  170.0970 
 Found:      170.0962 
 
 
2-(2,5-dimethylphenyl)pyridine (3.32g) [Table 3-5, entry 5]. The general procedure was 
followed using MIDA boronate 3.3 (350 mg, 1.50 mmol) and chloride 3.31g (135 µL, 1.01 
mmol). The crude product was subjected to Florisil chromatography (EtOAc:Hexanes 5:95 → 
15:85) to afford 3.32g as a yellow oil (134 mg, 72%). 
 
TLC (EtOAc:Hexanes 17:83) 
 Rf = 0.32, visualized by UV (λ = 254 nm) 
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1
H-NMR (500 MHz, acetone-d6)  
 δ 8.64 (d, J = 5.0 Hz, 1H), 7.83 (td, J = 2.0, 8.0 Hz, 1H), 7.46 (dt, J = 1.0, 7.5 Hz, 1H), 
7.30 (ddd, J = 1.0, 5.0, 7.5 Hz, 1H), 7.29 (s, 1H), 7.19 (d, J =20 Hz, 1H), 7.10 (dd, J = 
1.0, 8.0 Hz, 1H), 2.32 (s, 3H), 2.30 (s, 3H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 160.9, 149.8, 141.3, 136.9, 135.7, 133.4, 131.4, 131.1, 129.5, 124.7, 122.4, 20.9, 20.1 
 
HRMS (ESI+) 
 Calculated for C13H14N (M+H)
+
:  184.1126 
 Found:      184.1120 
 
 
2-(2,4-dimethoxyphenyl)pyridine (3.32h) [Table 3-5, entry 6]. The general procedure was 
followed using MIDA boronate 3.3 (355 mg, 1.52 mmol), chloride 3.31h (150 µL, 1.01 mmol), 
and running the reaction at 80 ˚C for 24 h. The crude product was subjected to Florisil 
chromatography (EtOAc:Hexanes 50:50) to afford 3.32h as a pale yellow oil (107 mg, 49%). 
 
TLC (EtOAc:Hexanes 50:50) 
 Rf = 0.45, visualized by UV (λ = 254 nm) 
 
1
H-NMR (400 MHz, acetone-d6)  
 δ 8.59 (d, J = 4.8 Hz, 1H), 7.89 (t, J = 9.8 Hz, 2H), 7.71 (td, J = 2.0, 7.4 Hz, 1H), 7.18 
(ddd, J = 1.4, 4.8, 7.4 Hz, 1H), 6.65 (m, 2H), 3.88 (s, 3H), 3.85 (s, 3H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 162.4, 159.3, 156.4, 149.9, 136.2, 132.8, 125.2, 122.3, 121.8, 106.1, 99.3, 55.8, 55.6 
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HRMS (ESI+) 
 Calculated for C13H14NO2 (M+H)
+
:  216.1025 
 Found:      216.1022 
 
 
4-(pyridin-2-yl)benzonitrile (3.32i) [Table 3-5, entry 7]. The general procedure was followed 
using MIDA boronate 3.3 (351 mg, 1.50 mmol) and chloride 3.31i (138 mg, 1.00 mmol). The 
crude product was subjected twice to silica gel chromatography (first Run, EtOAc:Hexanes 
2.5:97.5 → 20:80; second Run, EtOAc:Hexanes 2.5:97.5 → 50:50) to afford 3.32i as a white 
crystalline solid (159 mg, 86%). Characterization was consistent with literature.
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2-(4-fluorophenyl)pyridine (3.32j) [Table 3-5, entry 8]. The general procedure was followed 
using MIDA boronate 3.3 (361 mg, 1.54 mmol) and chloride 3.31j (107.5 µL, 1.01 mmol). The 
crude product was subjected to silica gel chromatography (EtOAc:Hexanes 5:95 → 20:80) to 
afford 3.32j as a pale yellow solid (143 mg, 82%). 
 
TLC (EtOAc:Hexanes 20:80) 
 Rf = 0.42, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, CD3CN)  
 δ 8.63 (d, J = 4.5 Hz, 1H), 8.08 (dq, J = 5.5, 9.0 Hz, 2H), 7.81 (d, J = 3.5 Hz,  2H), 7.28 
(q, J = 4.5, 8.5 Hz 1H), 7.22 (t, J = 9.0 Hz, 2H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 164.3 (d, J = 245 Hz), 156.6, 150.5, 137.8, 136.5, 129.5 (d, J = 8.8 Hz), 123.1, 120.6, 
116.2 (d, J = 22 Hz) 
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HRMS (ESI+) 
 Calculated for C11H9NF (M+H)
+
:  174.0719 
 Found:      174.0717 
 
 
1-(4-(pyridin-2-yl)phenyl)ethanone (3.32a) [Table 3-5, entry 9]. The general procedure was 
followed using MIDA boronate 3.3 (351 mg, 1.50 mmol), chloride 3.31a (130 µL, 1.00 mmol) 
and running the reaction at 80 ˚C for 24 h. The crude product was subjected to silica gel 
chromatography (EtOAc:Hexanes 50:50) to afford 3.32a as an off-white crystalline solid (164 
mg, 83%). Characterization was consistent with literature.
9
 
 
 
2,5-dimethyl-3-(pyridin-2-yl)pyrazine (3.32k) [Table 3-5, entry 10]. The general procedure 
was followed using MIDA boronate 3.3 (359 mg, 1.53 mmol) and chloride 3.31k (120 µL, 1.00 
mmol). The crude product was subjected twice to silica gel chromatography (first Run, 
MeCN:Et2O 10:90; second Run, Acetone:Hexanes (with 1% Triethylamine) 65:35) to afford 
3.32k as a brown oil (141 mg, 77%).  Characterization was consistent with literature.
9 
 
 
2-(pyridin-2-yl)quinoxaline (3.32l) [Table 3-5, entry 11]. The general procedure was followed 
using MIDA boronate 3.3 (352 mg, 1.50 mmol) and chloride 3.31l (166 mg, 1.01 mmol). The 
crude product was subjected to Florisil chromatography (EtOAc:Hexanes 40:60) to afford 3.32l 
as an off-white crystalline solid (166 mg, 80%). Characterization was consistent with literature.
9 
 
 
5-(pyridin-2-yl)-1H-indole (3.32m) [Table 3-5, entry 12]. The general procedure was followed 
using MIDA boronate 3.3 (351 mg, 1.50 mmol) and chloride 3.31m (151 mg, 1.00 mmol. The 
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crude product was subjected to Florisil chromatography (EtOAc:Hexanes 50:50) and silica gel 
chromatography (EtOAc:Hexanes 25:75) to afford 3.32m as a brown crystalline solid (120 mg, 
62%). 
 
TLC (EtOAc:Hexanes 50:50) 
 Rf = 0.36, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, acetone-d6)  
 δ 10.36 (s, 1H), 8.61 (d, J = 3.5 Hz, 1H), 8.36 (s, 1H), 7.93 (ddd, J = 1.5, 8.5, 16.5 Hz, 
2H), 7.79 (td, J = 1.5, 7.0 Hz, 1H), 7.50 (d, J = 8.5 Hz, 1H), 7.37 (t, J = 2.5 Hz, 1H), 7.21 
(ddd, J = 1.0, 5.0, 7.5 Hz, 1H), 6.56 (d, J = 2.0 Hz, 1H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 159.2, 150.1, 137.8, 137.4, 131.6, 129.3, 126.5, 121.8, 121.4, 120.4, 119.8, 112.2, 103.2 
 
HRMS (ESI+) 
 Calculated for C13H11N2 (M+H)
+
:  195.0922 
 Found:      195.0918 
 
 
2-(pyridin-2-yl)quinoxaline (3.32n) [Table 3-5, entry 13]. The general procedure was followed 
using MIDA boronate 3.3 (350 mg, 1.50 mmol) and chloride 3.31n (168 mg, 1.02 mmol). The 
crude product was subjected to silica gel chromatography (EtOAc:Hexanes 70:30) and Florisil 
chromatography (EtOAc:Hexanes 30:70 → 100:0) to afford 3.32n as an amber oil (135 mg, 
64%). Characterization was consistent with literature.
9
 
 
 
2-methyl-5-(pyridin-2-yl)benzo[d]oxazole (3.32o) [Table 3-5, Entry 14]. The general 
procedure was followed using MIDA boronate 3.3 (360 mg, 1.54 mmol) and chloride 3.31o (168 
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mg, 1.00 mmol. The crude product was subjected to silica gel chromatography (EtOAc:Hexanes 
5:95 → 75:25) to afford 3.32o as an off-white crystalline solid (173 mg, 82%). 
 
TLC (EtOAc:Hexanes 75:25) 
 Rf = 0.38, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, CD3CN)  
 δ 8.65 (d, J = 4.0 Hz, 1H), 8.26 (d, J = 1.5 Hz, 1H), 8.06 (dd, J = 1.5, 8.5 Hz, 1H), 7.89 
(dt, J = 1.0, 8.0 Hz, 1H), 7.83 (td, J = 2.0, 7.5 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.29 
(ddd, J = 1.0, 5.0, 7.5 Hz, 1H), 2.60 (s, 3H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 165.4, 157.3, 152.4, 150.4, 143.3, 137.7, 136.7, 124.3, 122.9, 120.9, 118.3, 110.8, 14.3 
 
HRMS (ESI+) 
 Calculated for C13H11N2O (M+H)
+
:  211.0871 
 Found:      211.0874 
 
Table 3-6 
 
 
2-(4-(tertbutoxy)phenyl)-6-methylpyridine (3.32p) [Table 3-6, entry 1]. The general 
procedure was followed using MIDA boronate 3.3a (376 mg, 1.52 mmol) and chloride 3.31b 
(175 µL, 1.00 mmol). The crude product was subjected to Florisil chromatography 
(EtOAc:Hexanes 10:90). The mixed fractions were reconstituted and subject to a second Florisil 
column (EtOAc:Hexanes 10:90) to afford 3.32p as an amber solid (174 mg, 72%). 
 
TLC (EtOAc: Hexanes 10:90) 
 Rf = 0.36, visualized by UV (λ = 254 nm) 
 
236 
 
1
H-NMR (400 MHz, acetone-d6)  
 δ 8.03 (d, J = 8.4 Hz, 2H), 7.67 (m, 2H), 7.13 (d, J = 7.4 Hz, 1H), 7.07 (d, J = 8.8 Hz, 
2H), 2.53 (s, 3H), 1.37 (s, 9H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 158.7, 157.4, 156.5, 137.8, 135.0, 128.1, 124.4, 121.8, 117.2, 78.9, 29.1, 24.7 
 
HRMS (ESI+) 
 Calculated for C16H20NO (M+H)
+
:  242.1545 
 Found:      242.1539 
 
 
2-(4-(tertbutoxy)phenyl)-5-methylpyridine (3.32q) [Table 3-6, entry 2]. The general 
procedure was followed using MIDA boronate 3.3b (375 mg, 1.51 mmol) and chloride 3.31b 
(175 µL, 1.00 mmol). The crude product was subjected to Florisil chromatography 
(EtOAc:Hexanes 10:90) to afford 3.32q as an amber solid (197 mg, 81%). 
 
TLC (EtOAc: Hexanes 20:80) 
 Rf = 0.36, visualized by UV (λ = 254 nm) 
 
1
H-NMR (400 MHz, acetone-d6)  
 δ 8.46 (s, 1H), 8.01 (d, J = 8.8 Hz, 2H), 7.76 (d, J = 8.0 Hz, 1H), 7.63 (dd, J = 1.8, 8.4 
Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 2.33 (s, 3H), 1.36 (s, 9H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 157.2, 154.6, 150.6, 137.9, 134.9, 131.8, 127.8, 124.4, 119.7, 78.8, 29.1, 18.0 
 
HRMS (ESI+) 
 Calculated for C16H20NO (M+H)
+
:  242.1545 
 Found:      242.1539 
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2-(4-(tertbutoxy)phenyl)-4-methylpyridine (3.32r) [Table 3-6, entry 3]. The general 
procedure was followed using MIDA boronate 3.3c (374 mg, 1.51 mmol) and chloride 3.31b 
(175 µL, 1.00 mmol). The crude product was subjected to Florisil chromatography 
(EtOAc:Hexanes 10:90) to afford 3.32r as an amber oil (197 mg, 81%). 
 
TLC (EtOAc: Hexanes 10:90) 
 Rf = 0.22, visualized by UV (λ = 254 nm) 
 
1
H-NMR (400 MHz, acetone-d6)  
 δ 8.46 (d, J = 5.0 Hz, 1H), 8.03 (d, J = 8.8 Hz, 2H), 7.71 (s, 1H), 7.08 (m, 3H), 2.39 (s, 
3H), 1.36 (s, 9H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 157.5, 157.2, 150.0, 148.4, 135.0, 128.1, 124.4, 123.4, 121.1, 78.9, 29.1, 21.0 
 
HRMS (ESI+) 
 Calculated for C16H20NO (M+H)
+
:  242.1545 
 Found:      242.1539 
 
 
2-(2,4-dimethoxyphenyl)-6-methoxypyridine (3.32s) [Table 3-6, entry 4]. The general 
procedure was followed using MIDA boronate 3.3d (340 mg, 1.29 mmol) and chloride 3.31h 
(127.5 µL, 0.86 mmol). The crude product was subjected to Florisil chromatography 
(EtOAc:Hexanes 10:90). The mixed fractions were reconstituted and subjected to silica gel 
chromatography (EtOAc:Hexanes 10:90) to afford 3.32s as an amber oil (162 mg, 77%). 
 
 
238 
 
TLC (EtOAc: Hexanes 10:90) 
 Rf = 0.3, visualized by UV (λ = 254 nm) 
 
1
H-NMR (400 MHz, acetone-d6)  
 δ 8.01 (d, J = 8.4 Hz, 1H), 7.61 (dt, J = 8.0, 16.0 Hz, 2H), 6.63 (m, 3H), 3.93 (s, 3H), 
3.90 (s, 3H), 3.85 (s, 3H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 164.1, 162.3, 159.5, 153.5, 139.4, 132.5, 121.8, 117.9, 108.6, 106.1, 99.3, 55.9, 55.6, 
53.1 
 
HRMS (ESI+) 
 Calculated for C14H16NO3 (M+H)
+
:  246.1130 
 Found:      246.1130 
 
 
2-(4-(tertbutoxy)phenyl)-6-trifluoromethylpyridine (3.32t) [Table 3-6, entry 5]. The general 
procedure was followed using MIDA boronate 3.3e (454 mg, 1.50 mmol) and chloride 3.31b 
(175 µL, 1.00 mmol). The crude product was subjected to Florisil chromatography 
(EtOAc:Hexanes 5:95). The mixed fractions were reconstituted and subject to a second Florisil 
column (EtOAc:Hexanes 5:95) to afford 3.32t as an amber solid (258 mg, 87%). 
 
TLC (EtOAc: Hexanes 5:95) 
 Rf = 0.3, visualized by UV (λ = 254 nm) 
 
1
H-NMR (400 MHz, acetone-d6)  
 δ 8.12 (m, 4H), 7.74 (d, J = 7.4 Hz, 1H), 7.14 (d, J = 8.8 Hz, 2H), 1.39 (s, 9H). 
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13
C-NMR (125 MHz, acetone-d6) 
 δ 158.6, 158.0, 148.2 (q, J = 34 Hz), 139.7, 132.9, 128.6, 124.4, 123.4, 122.7 (q, J = 272 
Hz), 119.0 (d, J = 3 Hz), 79.3, 29.1 
 
HRMS (ESI+) 
 Calculated for C16H17F3NO (M+H)
+
:   296.1262 
 Found:       296.1254 
 
 
2-(4-methoxyphenyl)-5-trifluoromethylpyridine (3.32u) [Table 3-6, entry 6]. The general 
procedure was followed using MIDA boronate 3.3f (229 mg, 0.76 mmol) and chloride 3.31c (61 
µL, 0.5 mmol). The crude product was subjected to Florisil chromatography (Et2O:Hexanes 
5:95). The mixed fractions were recombined and subject to a second Florisil column 
(Et2O:Hexanes 5:95) to afford 3.32u as an off white crystalline solid (99 mg, 78%). 
 
TLC (Et2O: Hexanes 10:90) 
 Rf = 0.39, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, acetone-d6)  
 δ 8.92 (s, 1H), 8.17 (m, 3H), 8.08 (d, J = 8.5 Hz, 1H), 7.07 (d, J = 8.5 Hz, 2H), 3.88 (s, 
3H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 162.5, 161.0, 147.0 (d, J = 4 Hz), 134.9 (d, J = 4 Hz), 131.0, 129.5, 125.1 (q, J = 269 
Hz), 124.3 (q, J = 32 Hz), 115.1, 55.7 
 
HRMS (ESI+) 
 Calculated for C13H11F3NO (M+H)
+
:   254.0793 
 Found:       254.0791 
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2-(4-(tertbutoxy)phenyl)-4-trifluoromethylpyridine (3.32v) [Table 3-6, entry 7]. The general 
procedure was followed using MIDA boronate 3.3g (464 mg, 1.54 mmol) and chloride 3.31b 
(175 µL, 1.00 mmol). The crude product was subjected first to florisil chromatography 
(EtOAc:Hexanes 2.5:97.5) and then to silica gel chromatography (EtOAc:Hexanes 5:95) to 
afford 3.32v as an amber oil (251 mg, 85%). 
 
TLC (EtOAc: Hexanes 10:90) 
 Rf = 0.4, visualized by UV (λ = 254 nm) 
 
1
H-NMR (400 MHz, acetone-d6)  
 δ 8.89 (d, J = 5.4 Hz, 1H), 8.15 (d, J = 8.8 Hz, 3H), 7.59 (d, J = 5.4 Hz, 1H), 7.13 (d, J = 
8.8 Hz, 2H), 1.39 (s, 9H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 158.9, 158.6, 151.7, 139.3 (q, J = 33 Hz), 133.2, 128.6, 124.4, 124.2 (q, J = 271 Hz), 
117.8 (q, J = 4 Hz), 115.7 (q, J = 4 Hz), 79.3, 29.1 
 
HRMS (ESI+) 
 Calculated for C16H17F3NO (M+H)
+
:   296.1262 
 Found:       296.1258 
 
Table 3-7 
 
 
2-(p-tolyl)pyridine (3.32w) [Table 3-7, entry 1]. The general procedure was followed using 
MIDA boronate 3.3 (355 mg, 1.52 mmol) and bromide 3.36a (122.5 µL, 1.00 mmol. The crude 
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product was subjected to silica gel chromatography (EtOAc:Hexanes 5:95 → 15:85) to afford 
3.32w as yellow liquid (140 mg, 83%). 
 
TLC (EtOAc:Hexanes 17:83) 
 Rf = 0.45, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, CD3CN)  
 δ 8.62 (d, J = 4.5 Hz, 1H), 7.94 (d, J = 8.5 Hz, 2H), 7.80 (m, 2H), 7.29 (d, J = 8.0 Hz, 
2H), 7.52 (ddd, J = 2.0, 5.0, 6.5 Hz, 1H), 2.38 (s, 3H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 157.6, 150.3, 139.5, 137.5, 137.4, 130.1, 127.4, 122.8, 120.4, 21.2 
 
HRMS (ESI+) 
 Calculated for C1H12N (M+H)
+
:  170.0970 
 Found:      170.0966 
 
 
2-(4-methoxyphenyl)pyridine (3.32c) [Table 3-7, entry 2]. The general procedure was 
followed using MIDA boronate 3.3 (356 mg, 1.52 mmol) and bromide 3.36b (125 µL, 1.00 
mmol). The crude product was subjected to silica gel chromatography (EtOAc:Hexanes 5:95 → 
20:80) to afford 3.32c as a orange solid (146 mg, 79%). Characterization was consistent with 
previous data. 
 
 
2-(4-fluorophenyl)pyridine (3.32j) [Table 3-7, entry 3]. The general procedure was followed 
using MIDA boronate 3.3 (358 mg, 1.53 mmol) and bromide 3.36c (110 µL, 1.01 mmol). The 
crude product was subjected to silica gel chromatography (EtOAc:Hexanes 5:95 → 20:80) to 
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afford 3.32j as a pale yellow solid (145 mg, 84%). Characterization was consistent with previous 
data. 
 
 
5-(pyridin-2-yl)pyrimidine (3.32x) [Table 3-7, entry 4]. The general procedure was followed 
using MIDA boronate 3.3 (353 mg, 1.51 mmol) and bromide 3.36d (159 mg, 1.00 mmol). The 
crude product was subjected to silica gel chromatography (EtOAc) to afford 3.32x as a white 
crystalline solid (74 mg, 47%). 
 
TLC (EtOAc) 
 Rf = 0.27, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, CD3CN)  
 δ 9.34 (s, 2H), 9.18 (s, 1H), 8.72 (d, J = 4.5 Hz, 1H), 7.92 (m, 2H), 7.41 (ddd, J = 2.0, 
5.0, 7.0 Hz, 1H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 159.3, 155.7, 152.8, 151.1, 138.2, 133.1, 124.6, 121.5 
 
HRMS (ESI+) 
 Calculated for C9H8N3 (M+H)
+
:  158.0718 
 Found:      158.0719 
 
 
1-methyl-5-(pyridin-2-yl)-1H-indole (3.32y) [Table 3-7, entry 5]. The general procedure was 
followed using MIDA boronate 3.3 (356 mg, 1.52 mmol) and bromide 3.36e (213 mg, 1.01 
mmol). The crude product was subjected to silica gel chromatography (EtOAc:Hexanes 5:95 
→30:70) to afford 3.32y as a brown crystalline solid (117 mg, 55%). 
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TLC (EtOAc: Hexanes, 33:67) 
 Rf = 0.4, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, acetone-d6)  
 δ 8.62 (d, J = 5.0 Hz, 1H), 8.34 (t, J = 1.0 Hz, 1H), 8.00 (dd, J = 2.0, 9.0 Hz, 1H), 7.92 
(dt, J = 1.0, 8.0 Hz, 1H), 7.79 (m, 1H), 7.47 (d, J = 8.5 Hz, 1H), 7.26 (d, J = 3.0 Hz, 1H), 
7.21 (ddd, J = 1.0, 5.0, 7.5 Hz, 1H), 6.52, (dd, J = 1.0, 3.0 Hz, 1H), 3.86 (s, 3H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 159.1, 150.2, 138.3, 137.3, 131.5, 130.8, 129.8, 121.8, 121.3, 120.3, 120.0, 110.2, 
102.3, 32.9 
 
HRMS (ESI+) 
 Calculated for C14H13N2 (M+H)
+
:  209.1079 
 Found:      209.1079 
 
 
2-(p-tolyl)pyridine (3.32w) [Table 3-7, entry 6]. The general procedure was followed using 
MIDA boronate 3.3 (354 mg, 1.52 mmol) and iodide 3.36f (130 µL, 1.02 mmol. The crude 
product was subjected to silica gel chromatography (EtOAc:Hexanes 5:95 → 15:85) to afford 
3.32w as yellow liquid (129 mg, 75%). Characterization was consistent with previous data. 
 
 
2-(4-methoxyphenyl)pyridine (3.32c) [Table 3-7, entry 7]. The general procedure was 
followed using MIDA boronate 3.3 (355 mg, 1.52 mmol) and iodide 3.36g (235 mg, 1.00 mmol). 
The crude product was subjected to silica gel chromatography (EtOAc:Hexanes 5:95 → 20:80) 
to afford 3.32c as a orange solid (139 mg, 75%). Characterization was consistent with previous 
data. 
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2-(4-fluorophenyl)pyridine (3.32j) [Table 3-7, entry 8]. The general procedure was followed 
using MIDA boronate 3.3 (360 mg, 1.54 mmol) and iodide 3.36h (115 µL, 0.995 mmol). The 
crude product was subjected to silica gel chromatography (EtOAc:Hexanes 5:95 → 20:80) to 
afford 3.32j as a pale yellow solid (139 mg, 81%). Characterization was consistent with previous 
data. 
 
 
tert-butyl 5-(pyridin-2-yl)-1H-indole-1-carboxylate (3.32z) [Table 3-7, entry 9]. The general 
procedure was followed using MIDA boronate 3.3 (355 mg, 1.52 mmol), iodide 3.36i (346 mg, 
1.01 mmol), and heating the reaction to 80 ˚C for 24 h. The crude product was subjected to silica 
gel chromatography (EtOAc:Hexanes 5:95 → 20:80) to afford 3.32z as a brown oil (199 mg, 
67%). 
 
TLC (EtOAc: Hexanes 20:80) 
 Rf = 0.42, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, CD3CN)  
 δ 8.64 (d, J = 5.0 Hz, 1H), 8.28 (d, J = 1.5 Hz, 1H), 8.20 (d, J = 8.5 Hz, 1H), 8.04 (dd, J = 
2.0, 8.5 Hz, 1H), 7.89 (dt, J = 1.0, 8.0 Hz, 1H), 7.83 (td, J = 1.5, 8.0 Hz, 1H), 7.67 (d, J = 
3.5 Hz, 1H), 7.27 (ddd, J = 1.5, 5.0, 7.5 Hz, 1H), 6.71 (d, J = 3.5 Hz, 1H), 1.66 (s, 9H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 157.9, 150.3, 150.1, 137.5, 136.5, 134.9, 131.8, 127.4, 123.8, 122.6, 120.7, 120.2, 
115.8, 108.5, 84.5, 28.2 
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HRMS (ESI+) 
 Calculated for C18H19N2O2 (M+H)
+
:  295.1447 
 Found:      295.1446 
 
 
2-(p-tolyl)pyridine (3.32w) [Table 3-7, entry 10]. The general procedure was followed using 
MIDA boronate 3.3 (357 mg, 1.53 mmol) and triflate 3.36j (180 µL, 1.01 mmol. The crude 
product was subjected to silica gel chromatography (EtOAc:Hexanes 5:95 → 15:85) to afford 
3.32w as yellow liquid (138 mg, 81%). Characterization was consistent with previous data. 
 
 
2-(3,5-dimethoxyphenyl)pyridine (3.32aa) [Table 3-7, entry 11]. The general procedure was 
followed using MIDA boronate 3.3 (352 mg, 1.50 mmol) and triflate 3.36k (202.5 µL, 1.00 
mmol). The crude product was subjected to silica gel chromatography (EtOAc:Hexanes 5:95 → 
30:70) to afford 3.32aa as an amber oil (187 mg, 87%). 
 
TLC (EtOAc: Hexanes 20:80) 
 Rf = 0.21, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, CD3CN)  
 δ 8.63 (d, J = 4.0 Hz, 1H), 7.83 (m, 2H), 7.29 (t, J = 8.5 Hz, 1H), 7.20 (d, J = 2.0 Hz, 
2H), 6.55 (t, J = 2.5 Hz, 1H), 3.84 (s, 6H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 162.1, 157.2, 150.2, 142.2, 137.6, 123.3, 121.1, 105.4, 101.7, 55.6 
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HRMS (ESI+) 
 Calculated for C13H14NO2 (M+H)
+
:  216.1025 
 Found:      216.1023 
 
 
1-(4-(pyridin-2-yl)phenyl)ethanone (3.32a) [Table 3-7, entry 12]. The general procedure was 
followed using MIDA boronate 3.3 (353 mg, 1.51 mmol), triflate 3.36l (190 µL, 1.00 mmol) and 
running the reaction at 80 ˚C for 24 h. The crude product was subjected to Florisil 
chromatography (EtOAc:Hexanes 5:95 → 50:50) to afford 3.32a as an off-white crystalline solid 
(103 mg, 52%). Characterization was consistent with literature.
9
 
 
 
2-(naphthalen-2-yl)pyridine (3.32bb) [Table 3-7, entry 13]. The general procedure was 
followed using MIDA boronate 3.3 (353 mg, 1.51 mmol) and triflate 3.36m (276 mg, 1.00 
mmol). The crude product was subjected to silica gel chromatography (EtOAc:Hexanes 0:100 → 
10:90) to afford 3.32bb as an off-white crystalline solid (185 mg, 90%). 
 
TLC (EtOAc: Hexanes 10:90) 
 Rf = 0.27, visualized by UV (λ = 254 nm) 
 
1
H-NMR (400 MHz, acetone-d6)  
 δ 8.71 (d, J = 4.0 Hz, 1H), 8.65 (s, 1H), 8.30 (dd, J = 2, 7.4 Hz, 1H), 8.10 (d, J = 8.0 Hz, 
1H), 8.02 (m, 2H), 7.92 (m, 2H), 7.54 (m, 2H), 7.35 (ddd, J = 1.4, 5.0, 7.4 Hz, 1H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 157.4, 150.5, 137.7, 137.5, 134.6, 134.4, 129.5, 129.0, 128.4, 127.4, 127.1, 126.8, 
125.3, 123.2, 121.1 
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HRMS (ESI+) 
 Calculated for C15H12N (M+H)
+
:  206.0970 
 Found:      206.0967 
 
 
6-(pyridin-2-yl)quinoline (3.32cc) [Table 3-7, entry 14]. The general procedure was followed 
using MIDA boronate 3.3 (350 mg, 1.50 mmol) and triflate 3.36n (277 mg, 1.00 mmol). The 
crude product was subjected to Florisil chromatography (EtOAc:Hexanes 5:95 → 70:30). The 
appropriate fractions were concentrated and transferred washing with 20 mL Et2O to a 60 mL 
separatory funnel. The solution was diluted with 5 mL 2N HCl and shaken. The organic layer 
was separated and discarded. The aqueous layer was extracted w/ 20 mL Et2O and the organic 
layer was again discarded. The aqueous layer was diluted with 10 mL 2N NaOH and shaken. The 
aqueous layer was then extracted twice with 20 mL Et2O. The organic fractions were combined 
and dried with Na2SO4. The solution was filtered and the filtrate was concentrated to afford 
3.32cc as an off-white crystalline solid (166 mg, 80%). 
 
TLC (EtOAc: Hexanes 30:70) 
 Rf = 0.25, visualized by UV (λ = 254 nm) 
 
1
H-NMR (500 MHz, acetone-d6)  
 δ 8.92 (dd, J = 1.5, 4.0 Hz, 1H), 8.74 (d, J = 5.0 Hz, 1H), 8.69 (d, J = 2.0 Hz, 1H), 8.55 
(dd, J = 2.0, 8.5 Hz, 1H), 8.43 (d, J = 8 Hz, 1H), 8.13 (m, 2H), 7.93 (td, J = 1.5, 7.5 Hz, 
1H), 7.54 (dd, J = 4.0, 8.5 Hz, 1H), 7.38 (ddd, J = 1.0, 5.0, 7.5 Hz, 1H). 
 
13
C-NMR (125 MHz, acetone-d6) 
 δ 156.6, 151.7, 150.5, 149.4, 137.8, 137.2, 130.4, 129.0, 128.6, 126.7, 123.4, 122.4, 
121.2, 121.2 
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HRMS (ESI+) 
 Calculated for C14H11N2 (M+H)
+
:  207.0922 
 Found:      207.0923 
 
Cross-coupling of 2-pyridyl MIDA boronate without a glovebox 
 
This procedure was used for the coupling of 2-pyridyl MIDA boronate 3.3 to 4-chloro-
tertbutoxybenzene 3.31b. 
 
Under air to a 40 mL I-CHEM vial equipped with PTFE coated stir bar was added Cu(OAc)2 (91 
mg, 0.50 mmol), 2-pyridyl MIDA boronate 3.3 (351 mg, 1.50 mmol), Xphos Palladacycle, 
chloro(2-dicyclohexylphosphino-2',4',6'-tri-i-propyl-1,1'-biphenyl)[2-(2-aminoethyl)phenyl] 
palladium(II) methyl-t-butylether adduct, (42 mg, 0.057 mmol) and K3PO4 (1.061g, 5.0 mmol). 
To the vial was added a PTFE coated stirbar. The vial was sealed with a septum cap and back-
filled with argon using a 22.5 gauge needle with a gas adapter connecting to a schlenk line. To 
the vial was added DMF (8 mL), 1-(tert-butoxy)-4-chlorobenzene 3.31b (174 µL, 1.00 mmol), 
and diethanolamine (96 µL, 1.00 mmol) by syringe using 22 or greater gauge needles. The argon 
line was then removed from the septum and the vial was heated to 100˚C with stirring for 24 h. 
The reaction was then allowed to cool to room temperature over 0.5 h. The reaction was 
transferred to a 60 mL separatory funnel, diluted with 10 mL of 2N HCl and shaken. The 
reaction was then diluted with 10 mL 2N NaOH and shaken. The resulting aqueous solution was 
extracted three times with 10 mL of diethyl ether. The organic layers were combined and washed 
with 10 mL of brine.  The organic layers were dried using Na2SO4, filtered, and concentrated in 
vacuo. The resulting residue was adsorbed onto Celite and subjected to Florisil chromatography 
(EtOAc:Hexanes 5:95 → 20:80) to afford 3.32b as a pale yellow solid. This procedure was 
performed twice obtaining yields of 200 mg (88%), and 197 mg (87%). 
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Large scale synthesis of 2-pyridyl MIDA boronate 
 
 
2-Pyridylboronic acid MIDA ester (3.3). An oven-dried, 2-L three-necked, round-
bottomed flask equipped with a 1.5” PTFE-coated football-shaped magnetic stir bar is allowed to 
cool to 23 °C under an inert nitrogen atmosphere (Note 1). In order, the flask is charged with 
anhydrous tetrahydrofuran (500 mL) (Note 2), 2-bromopyridine (25.5 mL, 42.25 g, 267.4 mmol, 
1.1 eq) (Note 3), and triisopropylborate (54.2 mL, 44.17 g, 234.9 mmol, 1.0 eq) (Note 4). The 
resulting clear, colorless solution is cooled to -78 °C in a dry ice/acetone bath with stirring (600 
rpm). To the cooled solution is slowly added via cannula n-butyllithium (100.0 mL, 2.50 M in 
hexanes, 250.0 mmol, 1.1 eq) dropwise over 2 hours (~0.8 mL/min) with stirring (Note 5). The 
opaque, brown suspension (Note 6) is stirred for an additional 1.5 hours at -78 °C. It is then 
removed from the dry ice bath and allowed to warm to 23 °C and stirred under nitrogen for an 
additional 18 hours giving an opaque, green suspension (Note 7).  
An oven-dried, 2-L three-necked, round-bottomed flask equipped with a 1.5” PTFE-
coated football-shaped magnetic stir bar is cooled to 23 °C under an inert nitrogen atmosphere 
(Note 1). The flask is charged with dry N-methyliminodiacetic acid (MIDA) (70.60 g, 479.8 
mmol, 2.0 eq) (Note 8) and then anhydrous DMSO (500 mL) (Note 9). The flask is placed in a 
heating mantle and fitted with a water-cooled distillation train connected to an oven-dried 1-L 
round-bottomed flask in one side neck, and a thermometer in the other side neck via a PTFE-
coated thermometer adapter. With stirring (600 rpm), the contents are heated to an internal 
temperature of 120 °C to give a clear, pale yellow solution (Note 10). The prepared borate 
suspension is then transferred dropwise via cannula to the hot MIDA/DMSO solution over 1 
hour (~10 mL/min), maintaining the internal temperature between 115°C and 120°C (Note 11). 
A dark brown suspension results (Note 12). Additional anhydrous tetrahydrofuran (2 x 50 mL) is 
used to quantitatively transfer the borate suspension to the MIDA/DMSO solution. After 
addition, the suspension is removed from the heating mantle and allowed to cool to 23 °C with 
stirring (2 hours). The suspension is filtered through a pad of Celite (Note 13), and the filter cake 
Caution! The heating of DMSO at high temperatures can lead to 
uncontrollable exothermic decomposition and possibly explosion. 
Heating DMSO should be performed by individuals trained in its proper 
and safe usage and necessary precautions should be taken. 
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is washed with DMSO (2 x 125 mL, then 1 x 50 mL). To the combined filtrate is added freshly 
ground, oven-dried, anhydrous potassium phosphate tribasic (200.0 g, 942.2 mmol, 4.0 eq) (Note 
14), and the suspension is stirred (700 rpm) for 1.5 hours at 23 °C. The suspension is then 
filtered through a pad of Celite (Note 15) into a 2-L round-bottomed flask. The filter cake is 
rinsed with anhydrous acetonitrile (3 x 200 mL) (Note 16). The acetonitrile is then removed in 
vacuo (Note 17) and the flask is equipped with a 1.5” PTFE-coated football-shaped magnetic stir 
bar. A water-cooled distillation train connected to a 1-L round-bottomed flask is attached to the 
flask, and the DMSO is removed by vacuum distillation (Note 18) at 60 °C (Note 19) with 
stirring (600 rpm) over 16 hours.  
To the resulting thick, brown oil is added acetonitrile (200 mL) and Celite (10 g) (Note 
20). The suspension is filtered through a pad of silica gel and Celite (Note 21), and the filter cake 
is washed with additional acetonitrile (2 x 200 mL, then 1 x 50 mL) to ensure quantitative 
transfer (Note 22). The solvent is removed in vacuo (Note 17) yielding a dark brown oil. This oil 
is dissolved in anhydrous acetonitrile (70 mL), and transferred to a 4-L Erlenmeyer flask 
equipped with a 3” PTFE-coated octagonal stir bar. Additional acetonitrile (70 mL) and 
dichloromethane (2 x 200 mL) is used to transfer the oil. Diethyl ether (1.9 L) is added dropwise 
over 12 hours (~2.6 mL/min) with stirring (300 rpm) (Note 23). The suspension is stirred (700 
rpm) for an additional 12 hours after Et2O addition. The resulting solid is collected by vacuum 
filtration, rinsed with diethyl ether (3 x 200 mL), and residual solvent is removed from the 
collected solid under high vacuum (200 mTorr) for 4 hours. The obtained solid is transferred to a 
500-mL Erlenmeyer flask equipped with a 1.5” PTFE-coated octagonal stir bar. Anhydrous 
acetonitrile (300 mL) is added to give a tan suspension, to which activated carbon (1.0 g) (Note 
24) is added. The suspension is stirred (400 rpm) for 10 minutes at 23 °C, and then filtered over a 
pad of silica gel (Note 25) into a tared 1-L round-bottomed flask. The filter cake is rinsed with 
additional acetonitrile (3 x 100 mL) into the same flask. The solution is concentrated in vacuo 
(Note 17), azeotroped with acetone (2 x 100 mL) (Note 17), and residual solvent is removed 
under high vacuum (200 mTorr) at 23 °C for 16 hours to yield 2-pyridylboronic acid MIDA ester 
(3.3) as an off-white, free-flowing solid (26.01 g, 111.1 mmol, 47.2% yield, >95% pure) (Notes 
26-30). 
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Notes 
1.  The glassware is dried in a 120 °C oven for 16 hours. The three-necked flask is 
capped with a gas inlet adapter in one side neck, a thermometer and PTFE-coated thermometer 
adapter in the second neck, a rubber septum in the remaining neck, and cooled under a stream of 
nitrogen for 30 minutes venting through an 18-gauge needle. 
2.  Tetrahydrofuran was obtained from a Solvent Delivery System, purified via passage 
through packed dry neutral alumina columns as described by Pangborn and coworkers. It is 
added under nitrogen via cannula from an oven-dried, 1-L round-bottomed flask. 
3.  2-Bromopyridine (1, 99%) was obtained from Sigma-Aldrich (Cat. No. B80100, Lot 
No. 06596LMV) and used as received. It is added via an anhydrous 60-mL polypropylene 
syringe.   
4.  Triisopropylborate (≥98%) was obtained from Sigma-Aldrich (Cat. No. 197335, Lot 
No. SHBB2938V) and used as received. It is added via an anhydrous 60-mL polypropylene 
syringe. 
5.  n-Butyllithium (2.50 M in hexanes) was obtained from Sigma-Aldrich (Cat. No. 
230707, Lot No. SHBB8936V) and used as received. It is important to keep the internal 
temperature below -70 °C. 
6. During the addition, the solution first turns yellow then becomes a strong 
yellow/orange and finally brown. 
7. The suspension may be brown.
 
8. N-methyliminodiacetic acid (MIDA) is commercially available (Sigma-Aldrich 
M51008), or can be prepared according to Dick et al. MIDA is a snow-white, free-flowing 
powder. MIDA (500 g) can be recrystallized by dissolving in water (500 mL) and precipitating 
by adding acetone (4 L) with stirring at 23 °C. It is dried in a vacuum oven (15 Torr, 150 °C) for 
24 hours immediately prior to use. The use of pure, dry MIDA is crucial to the success of this 
procedure. The use of impure or wet MIDA will result in impure product with diminished yields. 
The MIDA used in this procedure was prepared by the submitters according to Dick et al., and 
was consistent with physical and spectral data as described by Ballmer et al.
 
9. DMSO was obtained from a Solvent Delivery System, purified by passage through 
packed molecular sieves as described by Pangborn and coworkers. It is added under nitrogen via 
cannula through an oven-dried 1-L round-bottomed flask.  
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10. The use of pure MIDA will result in a clear, colorless or pale yellow solution. The use 
of impure MIDA will result in a dark yellow or brown solution. This has led to the product with 
reduced yields. 
11. The borate suspension is added via large bore PTFE cannula (1/4” ID x 1/32” W) at a 
constant rate to control the internal temperature of the solution. The distillation train and 
collection flask are left open to atmospheric pressure. Nitrogen pressure is used to cannulate the 
borate suspension. Careful control of the internal temperature is important. It should not exceed 
120 °C.
3
 Distillation is continuously observed throughout addition of the borate suspension. 
Heating is continued until completion of the THF (2 x 50 mL) transfer. An image displaying the 
distillation setup can be found at the end of this document. 
12. The clear, colorless distillate contains THF, isopropanol, hexanes, and 2-
bromopyridine. The crude product remains in the three-necked flask. 
13. Celite 545 filter aid (non-acid washed) is used throughout this procedure. A 600-mL 
glass fritted funnel is packed with 50 g of Celite. The filtrate is collected via vacuum filtration 
into a 2-L Erlenmeyer flask equipped with a 3” PTFE-coated octagonal stir bar. 
14. Anhydrous potassium phosphate tribasic (≥98%) was obtained from Sigma-Aldrich 
(Cat. No. P5629, Lot No. 031M0077V). It is freshly ground with mortar and pestle to a very fine 
powder and dried at 120°C for 3 hours directly prior to use. 
15. A 600-mL glass fritted funnel is packed with 50 g of Celite. 
16. Anhydrous acetonitrile was obtained from Sigma-Aldrich (Lot No. 68996APV) and 
used as received. The sure-seal is removed directly prior to use. 
17. The solvent is removed by rotary evaporation at 40 °C and 30 Torr. The vacuum 
pressure is monitored to avoid vigorous bumping. 
18. Vacuum distillation occurs at 150 mTorr with stirring (600 rpm). Two dry ice/acetone 
traps were placed in line between the flask and the vacuum pump. The solvent levels in these 
traps were monitored and emptied periodically. All ground glass joints were sealed with Apiezon 
H high vacuum grease and secured with Keck clips. The vacuum pressure was monitored to 
avoid vigorous bumping. It is important to maximally remove DMSO and failure to do so will 
complicate the remainder of the procedure. 
19. The flask is heated with an oil bath at a bath temperature of 60 °C. 
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20. After addition of acetonitrile, the solution is placed in a 60 °C water bath with 
agitation for 20 minutes to give a light-brown suspension. The Celite is then added, and the 
suspension is mixed and allowed to settle before filtration. 
21. A 600-mL glass fritted funnel is packed with 40 g of silica gel and 25 g of Celite is 
then layered on top of the silica gel. 
22. The indicated product is in the filtrate. 
1
HNMR of the celite/silica mix indicated the 
absence of product, ensuring quantitative transfer. 
23. Diethyl ether is added (slowly down the side of the Erlenmeyer flask) from a 2-L 
separatory funnel. Adding the diethyl ether too quickly will result in formation of an oil. 
24. Activated carbon (100 mesh size) was obtained from Sigma-Aldrich (Lot No. 
MKBH7471V) and used as received. 
25. A 150-mL glass fritted funnel is packed with 30 g of silica gel. After rinsing with 
acetonitrile, 
1
HNMR of the obtained silica gel/charcoal mix indicated absence of product. 
26. The physical and spectral data for 3.3 are as follows: mp 176-180 °C, uncorrected; 
TLC (MeCN) Rf = 0.41, visualized by UV (λ = 254 nm) and KMnO4 stain; 
1
HNMR (500 MHz, 
CD3CN) δ 8.67 (ddd, J = 4.8, 1.6, 1.1 Hz, 1H), 7.70 (td, J = 7.6, 1.7 Hz, 1H) 7.63 (dt, J = 7.6, 1.1 
Hz, 1H), 7.28 (ddd, J = 7.6, 4.8, 1.4 Hz, 1H), 4.11 (d, J = 16.8 Hz, 2H), 4.00 (d, J = 16.8 Hz, 
2H), 2.56 (s, 3H); 
13
CNMR (125 MHz, CD3CN) δ 169.6, 150.9, 135.8, 128.1, 124.3, 63.0, 47.6; 
11
BNMR (96 MHz, CD3CN) δ 10.3; HRMS (CI+) Calculated for C10H12BN2O4 (M+H)
+ 
: 
235.0890 Found : 235.0895; FTIR (KBr, cm
-1
) 3004, 2956, 1774, 1749, 1663, 1590, 1466, 1340, 
1289, 1279, 1214, 1152, 1095, 1054, 1045, 998, 964, 894, 866, 775, 754, 708, 683. Anal. calcd. 
for C10H11BN2O4 : C, 51.32; H, 4.74; N, 11.97; Found : C, 51.07; H, 4.52; N, 11.63 (Note 27, 
Part A). 
27. An analytically pure sample for CHN analysis can be obtained via any of three 
methods. A) Recrystallization through vapor diffusion: 2-pyridylboronic acid MIDA ester (70 
mg) in a 7 mL scintillation vial is partially dissolved with anhydrous acetone (2 mL), and the 
suspension swirled for 10 minutes. The saturated solution is then taken up into a 5 mL 
polypropylene syringe, and filtered through a 0.45 μm Iso-DiscTM filter into a 7 mL scintillation 
vial. The vial is then placed into a 40 mL scintillation vial containing anhydrous diethyl ether (9 
mL), and the 40 mL vial capped. The system is allowed to sit undisturbed for 24 hours, upon 
which white crystals form. The remaining solvent is removed and the product is dried over P2O5 
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at 150 mTorr overnight immediately before analysis. B) Recrystallization through liquid/liquid 
diffusion: To 2-pyridylboronic acid MIDA ester (70 mg) in a 7 mL scintillation vial is added 
anhydrous acetone (2 mL), and the saturated suspension swirled for 10 minutes. The suspension 
is then taken up into a 5 mL polypropylene syringe, and filtered through a 0.45 μm Iso-DiscTM 
filter into a 7 mL scintillation vial. Then anhydrous diethyl ether (4 mL) is slowly added on top 
of the acetone layer, and the vial is capped. The solution is allowed to sit undisturbed for 24 
hours, upon which white crystals form. The remaining solvent is removed and the product is 
dried over P2O5 at 150 mTorr overnight immediately before analysis. C) Column 
chromatography: 2-pyridylboronic acid MIDA ester (140 mg) is purified by flash column 
chromatography (10.0 g silica gel) with anhydrous acetonitrile as eluent. The fractions 
containing product (as indicated by TLC) are collected into a 100 mL round-bottomed flask, and 
concentrated in vacuo. The product is transferred via acetonitrile (4 mL) into a 7 mL scintillation 
vial, and concentrated in vacuo. The white crystals are then dried over P2O5 at 150 mTorr 
overnight immediately before analysis. 
28. If the method is not performed effectively, a pyridinium species may form: 
1
HNMR 
(500 MHz, CD3CN): δ 8.81 (ddd, J = 5.8, 1.4, 0.7 Hz, 1H), 8.48 (td, J = 7.8, 1.5 Hz, 1H), 8.17 
(d, J = 7.8 Hz, 1H), 8.02 (ddd, J = 7.2, 5.8, 1.4 Hz, 1H), 4.34 (d, J = 17.2 Hz, 2H), 4.23 (d, J = 
17.2, 2H), 2.96 (s, 3H). Other shifts have been observed, however they are always downfield 
from the expected shifts (Note 23). A free-base procedure can be performed to convert this 
material into 2-pyridyl MIDA boronate. This involves stirring the isolated material with 
anhydrous K2CO3 (1.5 g/g) in boiling acetonitrile (20 mL/g) for 20 minutes, then adding 
activated carbon (50 mg/g) and MgSO4 (200 mg/g). The suspension is then stirred for 20 
minutes, and filtered while hot through a pad of Celite. The solvent is then removed in vacuo to 
yield pure 2-pyridylboronic acid MIDA ester. 
29. Additional 2-pyridylboronic acid MIDA ester (5% additional product) can be 
obtained from the final filtrate. Diethyl ether (1 L) is carefully layered on top of the filtrate and 
this biphasic solution is allowed to sit undisturbed for 48 hours. The suspension is stirred, and the 
resulting solid is collected by vacuum filtration. 
30. The purity of the product is found to be >95% by 
1
HNMR. The impurity (<5%) is n-
butyl MIDA boronate. Higher purity material can be obtained by triturating with acetone/ether 
with a loss of yield or through column chromatography. 
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CHAPTER 4 
SYNTHESIS OF MOST POLYENE NATURAL PRODUCT MOTIFS USING JUST TWELVE 
BUILDING BLOCKS AND ONE REACTION 
 
Eric M. Woerly, Jahnabi Roy, and Martin D. Burke 
 
In order to expedite synthetic access to functional molecules, we aim to identify common 
substructural motifs that are prevalent in a wide range of natural products and transform them 
into shelf-stable building blocks that are compatible with iterative assembly using, ideally, a 
single reaction and a general set of reaction conditions. We identified polyene natural products as 
an excellent opportunity for testing this concept, because of their prevalence across a wide range 
of biosynthetic classes of natural products. We specifically decided to ask the question: if 
restricted to the use of only the Suzuki-Miyaura reaction, how many bifunctional MIDA 
boronate building blocks would be required to make most polyene natural product motifs? To 
address this question, we devised an algorithm for systematically retrosynthesizing polyene core 
motifs into bifunctional building blocks. Remarkably, this analysis resulted in a collection of just 
12 bifunctional haloalkenyl MIDA boronate building blocks with which >75% of all polyene 
motifs found in Nature can be prepared using a single reaction iteratively. Applying this same 
approach to other classes of small molecule natural products, pharmaceuticals, and materials 
represents a promising roadmap towards a universal approach to the synthesis of small 
molecules. 
Jahnabi Roy contributed to the synthesis of building blocks and to the preparation of 
polyene motifs. 
 
 
Adapted from Woerly, E. M.; Roy, J.; Burke, M. D. manuscript in preparation.
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4-1 INTRODUCTION 
The vast majority of molecules found in living systems are biosynthesized via a common 
systematic strategy involving the iterative assembly of bifunctional building blocks.
1
 In the case 
of polypeptides, oligonucleotides, and increasingly oligosaccharides, this strategy has been 
successfully replicated in the laboratory to enable efficient, flexible, and even fully-automated 
access to these molecules.
2
 As a result, the function, not the synthesis, of these molecules is now 
the main focus of research in these areas.  
In contrast, despite also being biosynthesized primarily via iterative building block 
assembly, the laboratory synthesis of small molecule natural products remains a relatively 
inefficient, inflexible, and unsystematized process practiced almost exclusively by specialists.
3
 
The substantial level of inherent modularity that results from the common biosynthetic origins of 
most natural products suggests that a generalized building block based approach may also be 
applicable to the laboratory synthesis of many of these compounds. Customized iterative 
strategies have been developed for the synthesis of substructures of particular biosynthetic 
origins (see Chapter 1). However, a generalized strategy that is potentially applicable to most 
classes of natural products has yet to emerge. As a result, synthesis remains the rate-limiting step 
in small molecule science, and the functional capacity of many small molecules remains 
untapped. 
As a roadmap for creating a general strategy for small molecule synthesis, we aim to 
identify common substructural motifs that are prevalent in a wide range of natural products and 
transform them into shelf-stable building blocks that are compatible with iterative assembly 
using, ideally, a single reaction and a general set of reaction conditions. As described throughout 
this thesis, iterative cross-coupling (ICC) with N-methyliminodiacetic acid (MIDA) boronates 
has emerged as a potentially general platform for enabling such an approach.
4
 In this type of 
synthesis, MIDA boronate building blocks having all of the required functional groups 
preinstalled in the correct oxidation states and with the desired stereochemical relationships are 
iteratively united using only the stereospecific Suzuki-Miyaura cross-coupling reaction. These 
building blocks are remarkably convenient to prepare, analyze, purify, and store and more than 
130 are now commercially available.
5
 The MIDA boronate functional group is inert to anhydrous 
cross-coupling conditions, yet can be readily transformed into a fully reactive boronic acid using 
mild reagents. These features have enabled the simple, efficient, and flexible synthesis of a range 
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of complex small molecules, including polyketide, polyterpene, fatty acid, and phenylpropanoid 
derived natural products, as well as pharmaceutical agents, via the ICC of MIDA protected 
haloboronic acids.
4 
Emboldened by the accelerating success of the ICC strategy, we have begun to question 
whether this approach could provide a pathway to systematize and ultimately automate the total 
synthesis of most natural products. We identified polyene natural products as an excellent 
opportunity for testing this concept, because of their prevalence across a wide range of 
biosynthetic classes of natural products (Figure 4-1).
6
 The synthesis of polyenes is challenging 
due to sensitivities to light, oxygen, and many common reagents including protic and Lewis 
acids.
7
 Controlling the stereochemistry during the formation of each double bond is also a critical 
issue. Common strategies for the synthesis of polyenes include olefination reactions (Wittig, 
Horner-Wadsworth-Emmons, Julia), which suffer from lack of stereocontrol, and transition 
metal based reactions (organozinc and organostannane cross-couplings), which often suffer from 
challenges in synthesis, instability to long-term storage, difficulty in handing, and the generation 
of toxic byproducts.
8
 Due to the instability of polyenylboronic acid intermediates, it had been 
challenging to similarly prepare polyenes via organoboron cross-couplings, yet some progress 
has been made using the MIDA boronate platform. However, none of these approaches have 
previously proven to be universally applicable to most polyene frameworks found in Nature. 
 
 
Figure 4-1. The polyene motif is present in natural products across a range of biosynthetic classes. 
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With this goal in mind, together with Jahnabi Roy, we specifically decided to ask the 
question: if restricted to the use of only the Suzuki-Miyaura reaction, how many bifunctional 
MIDA boronate building blocks would be required to make most polyene natural product 
motifs? To address this question, we devised an algorithm for systematically retrosynthesizing 
polyene core motifs into bifunctional building blocks. Remarkably, this analysis resulted in a 
collection of just 12 bifunctional haloalkenyl MIDA boronate building blocks with which >75% 
of all polyene motifs found in Nature can be prepared using a single reaction iteratively. 
Applying this same approach to other classes of small molecule natural products, 
pharmaceuticals, and materials represents a promising roadmap towards a universal approach to 
the synthesis of small molecules. 
 
4-2 IDENTIFYING POLYENE NATURAL PRODUCTS 
We first utilized the CRC Dictionary of Natural Products, a comprehensive searchable 
database of over 238,000 compounds, to identify all known polyene natural products.
9
 
Specifically, a substructure search for a polyene motif, which we defined as three or more 
carbon-carbon double bonds in conjugation, none of which are contained in a <12-membered 
ring, returned 2,839 compounds, or 1.2% of all known natural products. Importantly, this set 
includes natural products derived from all major biosynthetic classes, including polyterpenes, 
polyketides, hybrid peptide/polyketides, fatty acids, and polyphenylpropanoids.  
 
4-3 A SYSTEMATIC RETROSYNTHESIS OF POLYENE NATURAL PRODUCTS 
To determine how many bifunctional MIDA boronate building blocks would be required 
to access the core polyene motif found in >75% of these natural products, we developed an 
algorithm for systematically retrosynthesizing these motifs into a collection of bifunctional 
haloalkenyl MIDA boronate building blocks (Figure 4-2). Based on a wide range of experiences 
with MIDA boronates in our own laboratories, this algorithm was designed to maximize the 
potential that the resultant forward synthetic pathways would prove to be viable in the 
laboratory. To achieve this goal, the following specific guidelines were employed: First, the 
polyenyl halo MIDA boronate building blocks cannot be longer than a triene. Our experience has 
shown that increasing the polyene length in a single building block beyond a triene leads to 
increased challenges in stereospecific synthesis and/or decreased ICC efficiency. Second, using 
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mono-, di-, and triene building blocks, the polyene cores are dissected into the number of 
building blocks such that the fewest number of couplings would be needed for the targeted 
synthesis, thus maximizing the overall efficiency. Third, disconnections are chosen such that the 
length of the longest polyenyl borane intermediate in each pathway is minimized. This is because 
increasing the length of polyenyl borane intermediates can decrease their stability.  Applying this 
algorithm to the polyene motifs found in >75% of all polyene natural products yielded a 
collection of just 12 bifunctional MIDA boronate building blocks (4.1 – 4.12) from which, in 
theory, any of these polyene motifs can be prepared via ICC (Figure 4-3). 
 
 
Figure 4-2. A set of guidelines to systematically retrosynthesize polyene natural products into a collection of 
bifunctional MIDA boronate building blocks. 
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Figure 4-3. A collection of 12 MIDA boronate building blocks that can be used to access >75% of all known 
polyene natural products. 
 
The following three examples demonstrate the systematic application of this algorithm. 
First, the hybrid polyketide/polyphenylpropanoid derived natural product asnipyrone A was 
originally isolated and structurally assigned in 1989 by Li and coworkers and reisolated in 2011 
by Liu and coworkers (Figure 4-4).
10
 Detailed NMR analysis led Liu to reassign the structure of 
asnipyrone A to 4.13. Applying the algorithm, the polyene core, defined as the polyene motif 
minus the terminal olefins, was identified as a monoene. As a result, three building blocks 4.14, 
4.3, and 4.15 were identified as being required to complete the synthesis of this natural product. 
 
 
Figure 4-4. Systematic retrosynthesis of asnipyrone A. 
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Second, the fatty acid derived natural product α-parinaric acid 4.16 was first discovered 
in 1933 by Tsujimoto and Koyanagi (Figure 4-5).
11
 This tetraene has important fluorescent 
properties and is commonly used for the study of biomembranes. The polyene core of α-parinaric 
acid was identified as a diene. Following our second guideline, this motif can be accessed with 
one building block (4.5) instead of dissecting into two building blocks (4.1 + 4.1). Therefore, 
three building blocks 4.17, 4.5, and 4.18 were identified as being required to complete the 
synthesis of this natural product. 
 
 
Figure 4-5. Systematic retrosynthesis of α-parinaric acid. 
 
Third, the polyterpene derived natural product neurosporaxanthin β-D-glucopyranoside 
4.19 was isolated by Sakaki and coworkers in 2002 (Figure 4-6).
12
 In order to determine the 
building blocks that would be necessary to complete the synthesis of 4.19, we applied the 
standardized retrosynthetic algorithm. First, the polyene core for 4.19 was identified as an 
octaene. Second, we dissected this octaene core into the fewest number of building blocks, a 
diene and two trienes. In order to minimize the length of the polyenyl borane intermediates, we 
would first couple the diene building block, followed by couplings of the trienes. As a result, five 
building blocks 4.20, 4.6, 4.11, 4.9, and 4.21 were identified from this analysis. 
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Figure 4-6. Systematic retrosynthesis of neurosporaxanthin β-D-glucopyranoside. 
 
4-4 SYNTHESIS OF THE TWELVE MIDA BORONATE BUILDING BLOCKS 
Efficient access to these 12 building blocks was accomplished by taking advantage of 
many of the enabling features of the MIDA boronate platform, including the capacity to carry 
MIDA boronates through multistep synthesis pathways. We recognized that many of the di- and 
trienyl building blocks can be prepared using the monoene building blocks as a starting material. 
Thus, we first developed robust and scalable syntheses of each of these single olefin building 
blocks 4.1, 4.2, 4.3, and 4.4 (Figure 4-7). 
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Figure 4-7. Robust and scalable syntheses of single olefin building blocks. 
 
Our group has developed several routes to building block 4.1. First reported by Dr. Suk 
Joong Lee and Dr. Kaitlyn Gray, the bromoborylation of acetylene followed by complexation 
with MIDA provided a first generation route to 4.1.
13
 Later, Brice Uno and Dr. Eric Gillis 
reported that 4.1 can be prepared from the silane precursor through a transmetalation/trap 
sequence with boron tribromide and the bis-sodium salt of MIDA (MIDA
2-
 Na
+
2).
14
 
Alternatively, 4.1 can be accessed through a bromodestannylation reaction from commercially 
available trans-2-(tributyltin)vinyl MIDA boronate.
15
 
As described in Chapter 3, MIDA boronate 4.2 can be obtained from a 
bromination/elimination sequence starting from commercially available trans-2-(pinacol 
boronate)vinyl MIDA boronate.
16
  
As described in Chapter 2 in the context of the total synthesis of peridinin, MIDA 
boronate 4.3 can be synthesized from a bromination/elimination sequence starting from 
commercially available isoprenyl MIDA boronate.
17
 
Finally, as originally developed in collaboration with undergraduate Sean O’Hara, MIDA 
boronate 4.4 can be prepared through a bromination/elimination sequence starting from 4.5. 
Building block 4.5, in turn, is obtained from a Miyaura borylation of 4.3. All of these building 
blocks (4.1-4.4) can be readily accessed on larger than 10 gram scale without the need for 
265 
 
purification by column chromatography. Moreover, all four of these building blocks are now 
commercially available.  
The di- and triene building blocks 4.6-4.12 were accessed through couplings with a range of 
different bis-metalated fragments followed by halodemetalation of the resulting 
polyenylgermanium or polyenylsilicon precursors (Figure 4-8). While halodesilylation reactions 
have been used on dienylsilane systems,
18
 to the best of our knowledge, the halodesilylation of a 
trienylsilane has not been reported. The development of this methodology was instrumental in 
the preparation of building blocks 4.10 and 4.11. Interestingly, in contrast to halodegermylation 
and halodestannylation reactions, the methyl substitution pattern of the polyene plays an 
important role in the stereo outcome of the halodesilylation reaction. For example, while 4.11 
can be prepared by treating the silane precursor with NIS in MeCN, building block 4.12 could 
not be prepared by this method. Specifically, treatment of the silane precursor with NIS in 
MeCN produced trace amounts of the desired product and numerous decomposition products. As 
a result, an alternative route to 4.12 was developed involving the iododegermylation of the 
germane precursor. In all, the halodegermylation and halodesilylation approach provides a mild 
and highly stereocontrolled way to access a variety of substituted polyene frameworks. 
 
 
Figure 4-8. Preparation of building blocks 4.5-4.12 from 4.1-4.4. 
266 
 
 
4-5 IDENTIFYING GENERAL REACTION CONDITIONS 
With building blocks 4.1-4.12 in hand we sought to combine them in an iterative fashion 
to prepare a collection of common polyene motifs that collectively represent those found in 
2,131 natural products, or >75% of all polyene natural products that have been isolated and 
characterized to date (Figure 4-9). This collection of motifs include both trans- and cis-olefins, 
various methyl substituted olefins, as well as a variety of chain lengths, from three to ten olefins. 
Thus, this diverse collection of targets represents a substantial challenge for the development of a 
general synthesis strategy, especially one that is restricted to only the use of common reaction 
conditions. 
 
 
Figure 4-9. The polyene motifs that are present in >75% of all known polyene natural products. 
 
In this vein, we encountered important limitations when we first attempted to apply our 
established ICC strategy (Chapters 1-3) to the synthesis of some of the more complex members 
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of our collection of targeted polyene motifs. Specifically, instability of the polyenyl boronic acid 
intermediates required for the synthesis of the longer motifs resulted in poor yields of the desired 
final products. As described above, polyenylboronic acids are notoriously unstable, and this 
precluded their general utilization to achieve our stated goals.  
In contrast, polyenylboronic esters are typically more stable than their boronic acid 
counterparts. Moreover, we have found that when using DMSO as the solvent, polyenyl boronic 
esters can be cross-coupled under anhydrous Suzuki-Miyaura cross-coupling reaction conditions, 
as required for ICC with MIDA boronates. We envisioned a new ICC cycle involving the 
coupling of a pinacol ester to a bifunctional MIDA boronate building block under anhydrous 
conditions followed by a transesterification of the resulting MIDA boronate to a pinacol ester, 
thus generating a new boronic ester to continue the cycle (Figure 4-10). 
 
 
Figure 4-10. A new ICC cycle involving the coupling of pinacol esters and bifunctional MIDA boronate building 
blocks. 
 
With the goal of developing a general platform, we further sought to identify a single set 
of reaction conditions for both the coupling of polyenyl pinacol esters with polyenyl bifunctional 
MIDA boronate building blocks and for deprotection of MIDA boronates to pinacol esters. Such 
general conditions can greatly enable utilization of the ICC approach, removing the need for ad 
hoc optimization and potentially facilitating automation of the synthesis process. In this vein, we 
found that a wide range of polyenyl MIDA boronates of varying length and with varying methyl 
substitution patterns can be transesterified to the corresponding pinacol ester using the same set 
of general conditions: pinacol (1.5 eq.) and NaHCO3 (5.0 eq.) in MeOH at room temperature for 
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3 h. The resulting pinacol esters were found to be quite stable, and could be isolated without 
special precautions. Moreover, we found that these polyenyl pinacol esters of varying length, 
stereochemistry, and methyl substitution patterns can be coupled to mono-, di- and trienyl 
chloride, bromide, and iodide bifunctional MIDA boronate building blocks using a general set of 
cross-coupling conditions: 2
nd
 generation XPhos palladacycle pre-catalyst (10 mol%), Cs2CO3 (4 
eq.), and DMSO. Furthermore, a final coupling between the polyenyl MIDA boronate and a 
capping group, also under a common set of conditions (2
nd
 generation XPhos palladacycle 
catalyst, NaOH, and THF:H2O), provides the final polyene motifs. These conditions promote the 
in situ release of unstable polyenyl boronic acids directly from the corresponding much more 
stable polyenyl MIDA boronates and thereby promote the final coupling reactions in the ICC 
sequence with maximized efficiency.  
 
4-6 ACCESSING >75% OF KNOWN POLYENE NATURAL PRODUCTS 
With this new ICC cycle in hand, we attempted to synthesize all of the targeted polyene 
motifs 4.22-4.36, representing the structures found in >75% of all polyene natural products, 
using only our twelve building blocks and the general set of cross-coupling conditions in an 
iterative fashion (Figure 4-11). MIDA boronate 4.37 and vinyl iodide 4.38 were chosen as 
representative natural product-like capping groups for the polyene motifs. Remarkably, without 
any optimizations to the general reaction conditions described above, all of the targeted polyene 
motifs were successfully prepared in multimilligram quantities. These syntheses ranged from a 
single iteration of ICC to generate triene 4.22 to four iterations to generate highly complex 
decaene 4.36. Moreover, all of the targets, including those that contain cis-olefins (4.23 and 4.24) 
were formed with complete stereocontrol. The successful preparation of all of these targets 
validates the effectiveness and scope for this systematized approach for polyene synthesis. 
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Figure 4-11. The synthesis of motifs that are present in >75% of all polyene natural products from a collection of 12 
building blocks and a common set of reaction conditions. The isolated yields for the deprotection and cross-coupling 
reactions are located below the corresponding bolded bond. 
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Figure 4-11 continued. 
 
4-7 TOTAL SYNTHESIS OF NEUROSPORAXANTHIN β-D-GLUCOPYANOSIDE 
As a final test of this platform, we targeted the first total synthesis of the complex 
polyene natural product neurosporaxanthin β-D-glucopyranoside 4.19 (Figure 4-12). Using the 
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general set of deprotection and cross-coupling reactions identified above, the synthesis 
commenced with the deprotection of 4.20 and coupling with diene 4.6 to provide tetraene 4.39. 
Deprotection of 4.39 and coupling with 4.11 provided heptaene 4.40. This framework could be 
accessed using the general reaction conditions despite the varying methyl substitution pattern. A 
third iteration of deprotection and coupling with 4.9 provided decaene 4.41. Importantly, the 
polyenyl pinacol ester intermediate could be isolated without difficulty. Furthermore, the general 
reaction conditions are compatible with the coupling of this pinacol ester with a polyenyl 
bromide without modification, providing access to the very complex boronate framework of 
4.41. A final coupling with 4.21 utilizing the general in situ deprotection/coupling conditions 
provided 4.42. Current efforts are focused on global deprotection to complete the first total 
synthesis of 4.19. 
 
 
Figure 4.12. The first total synthesis of neurosporaxanthin β-D-glucopyranoside. 
 
4-8 SUMMARY AND CONCLUSIONS 
Although natural products are very diverse at their cores, they are inherently modular and 
lend themselves to iterative synthesis. We envision that the systematic and automated synthesis 
of most natural products can be achieved using a limited number of building blocks that are 
united under common reaction conditions. Toward this broader goal, we have demonstrated that 
the polyene motifs present in >75% of all polyene natural products can be generated from a 
collection of just 12 bifunctional MIDA boronate building blocks that are united using one 
reaction and a general set of reaction conditions. Furthermore, these building blocks and general 
conditions were applied en route to the first total synthesis of the polyene natural product 
neurosporaxanthin β-D-glucopyanoside.  
The identification of general reaction conditions is central to the execution of this 
synthesis strategy. A robust and general set of conditions that can reliably provide the targeted 
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product is highly amenable to automation and removes the need for a specialist to perform 
screening and optimization studies. 
Ultimately, we envision that this same strategy may represent a general approach to the 
preparation of other classes of small molecule natural products, pharmaceuticals, and materials. 
For example, polyketide derived natural products contain the stereotetrad substructural motif, 
consisting of four contiguous stereogenic centers in any diastereomeric combination. Recent 
advances in sp
2
-sp
3
 and sp
3
-sp
3
 Suzuki-Miyaura cross-coupling methodology would enable the 
iterative union of building blocks containing these motifs, potentially using a general set of 
reaction conditions. 
Furthermore, cyclic natural products (for example amphotericin B and steroids) are 
biosynthesized via the covalent folding of linear precursors. A single cyclization can lead to 
macrocycles, which often have superior physical and/or functional properties relative to their 
linear counterparts. Moreover, in the same fashion, linear frameworks can be constructed 
through the iterative assembly of bifunctional building blocks and then cyclized to form complex 
molecular frameworks.  
It is interesting to consider how many building blocks would be required to access most 
of the structural motifs found in known natural products. Collectively, such a synthesis strategy 
seeks to promote a move away from specialized synthesis routes and reaction conditions toward 
a more systematic approach that has the potential to enable the efficient, flexible, and even fully 
automated access to many classes of small molecules.  
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CHAPTER 4 
EXPERIMENTAL SECTION 
 
Materials. Commercial reagents were purchased from Sigma-Aldrich, Fisher Scientific, Alfa 
Aesar, TCI America, Strem Chemicals Inc., or Frontier Scientific and were used without further 
purification unless otherwise noted. Solvents and amines were dried as noted in Chapter 2.  
 
General Experimental Procedures. The general experimental procedures followed in these 
studies are the same as those detailed in Chapter 2, except where noted.  
 
Structural analysis. Structural analysis was preformed and described as detailed in Chapter 2. 
 
Experimental Procedures. 
 
 
MIDA boronate 1.  MIDA boronate 4.1 was prepared according to literature precedent.
1
 MIDA 
boronate 4.1 is commercially available from Sigma-Aldrich (product number 703478). 
 
 
MIDA boronate 4.2.  MIDA boronate 4.2 was prepared according to literature precedent.
2
 
 
 
MIDA boronate 4.3.  MIDA boronate 4.3 was prepared according to literature precedent
3
 by the 
following modified procedure: 
To a 2 L round bottom flask equipped with a stir bar and charged with isoprenyl MIDA 
boronate 4.43 (25.12 g, 127.5 mmol) was added CH2Cl2 (1.2 L).  The resulting clear, colorless 
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solution was cooled to 0 
o
C in an ice bath.  Neat bromine (13.0 mL, 253.8 mmol) was added 
dropwise over 10 minutes to give a cloudy orange solution.  The solution was warmed to 23 
o
C 
over 1 hr.  An aliquot was removed, concentrated in vacuo, and analyzed by NMR to ensure full 
conversion of the isoprenyl MIDA boronate starting material.  If full conversion is not observed, 
an additional 0.5 eq. of neat bromine can be added.  Ensuring full conversion, the resulting 
orange solution was concentrated in vacuo to give a yellow solid.  This solid was azeotroped 
with CH2Cl2 (2 x 100 mL) to remove residual bromine. 
The resulting white solid was suspended in MeCN (1 L).  1,8-Diazabicyclo[5.4.0]undec-
7-ene (DBU, 56.9 mL, 380.7 mmol) was added in one portion.  The resulting mixture stirred at 
23 
o
C for 1 hr to give a clear, yellow/brown solution.  The solution was poured into a separatory 
funnel containing EtOAc:acetone (4:1, 1 L) and 1 M aq. HCl (1 L).  After shaking, the layers 
were separated.  The organic layer was washed with saturated aqueous sodium bisulfite:brine 
(3:2, 1 x 500 mL) and then brine (1 x 250 mL).  The organic layer was dried over MgSO4, 
filtered, and concentrated in vacuo.  The resulting crude material was pushed through a plug of 
silica, eluting with acetone.  The filtrate was concentrated and resuspended in a minimum 
volume of 3:1 EtOAc:acetone.  Et2O was added in portions to precipitate the product.  The 
resulting solid was collected by vacuum filtration to afford MIDA boronate 4.3 as a white solid 
(24.58 g, 70%). 
 
 
MIDA Boronate 4.44.  To a 40 mL vial containing brominated MIDA boronate 4.3 (1.04 g, 3.8 
mmol) and a stir bar, in a glovebox, was added B2pin2 (1.37 g, 5.4 mmol), KOAc (1.20 g, 12.2 
mmol), and PdCl2dppf•CH2Cl2 (151.8 mg, 0.19 mmol).  The vial was capped with a septum cap, 
removed from the glovebox, and placed under N2.  DMSO (30 mL) was added in one portion.  
The reaction was sealed under N2 and stirred at 75 
o
C for 25 h.  The solution was poured into a 
separatory funnel containing EtOAc (200 mL) and H2O (150 mL).  After shaking, the layers 
were separated.  The organic layer was washed with H2O (2 x 150 mL).  The aqueous layer from 
the initial extraction was back extracted with EtOAc (100 mL).  The combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo.  The resulting residue was dry 
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loaded onto celite and purified by column chromatography on silica gel (Et2O:Acetone 100:0  
3:1) to afford bis-borylated 4.44 as a pale yellow solid (537.6 mg, 44%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.47, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 5.78 (s, 1H), 4.21 (d, J = 17.0 Hz, 2H), 4.05 (d, J = 17.0 Hz, 2H), 2.97 (s, 3H), 2.01 (s, 
3H), 1.25 (s, 12H).  
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 83.2, 62.6, 47.0, 25.1, 20.2 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 30.0, 11.1 
 
HRMS (ESI+) 
Calculated for C14H24B2NO6 (M+H)
+
: 324.1790 
Found:      324.1788 
 
MIDA Boronate 4.4.  To a 100 mL round bottom flask containing bis-borylated MIDA boronate 
4.44 (537 mg, 1.66 mmol) and a stir bar, was added CH2Cl2 (20 mL) followed by neat bromine 
(0.13 mL, 2.5 mmol).  The solution was stirred at 23 
o
C for 1 h and then concentrated in vacuo to 
give a yellow solid.  This solid was azeotroped with CH2Cl2 (3 x 20 mL) to remove residual 
bromine.  To the resulting solid was added finely ground K3PO4 (3.68 g, 17.3 mmol) and MeCN 
(20 mL).  The resulting suspension was stirred at 23 
o
C for 4.5 h.  The resulting suspension was 
poured into 35 mL EtOAc and 30 mL pH 7 phosphate buffer (0.5 M).  The mixture was shaken 
and the aqueous layer was removed.  The organic layer was washed with pH 7 phosphate buffer 
(0.5 M, 1 x 35 mL).  The combined aqueous layers were back extracted with 9:1 EtOAc:Acetone 
(1 x 50 mL).  The combined organic layers were dried over MgSO4, filtered, and concentrated in 
vacuo.  The resulting residue was azeotroped with CH2Cl2 (2 x 50 mL) and then suspended in 
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Et2O (75 mL).  This suspension was placed in a sonicator bath for 30 min.  The resulting solid 
was collected by vacuum filtration and rinsed with Et2O (15 mL) to yield MIDA boronate 4.4 as 
a tan solid (369.7 mg, 81%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.53, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.71 (s, 1H), 4.31 (d, J = 17.0 Hz, 2H), 4.11 (d, J = 17.0 Hz, 2H), 3.19 (s, 3H), 1.83 (d, 
J = 1.5 Hz, 3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 168.9, 112.0, 64.5, 47.9, 24.4 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.1 
 
HRMS (ESI+) 
Calculated for C8H12BBrNO4 (M+H)
+
: 276.0043 
Found:      276.0045 
 
X-ray quality crystals were grown by layering petroleum ether onto a dissolved solution of 4.4 in 
acetonitrile. 
 
 
MIDA boronate 4.5.  MIDA boronate 4.5 was prepared according to literature precedent.
4
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Aldehyde 4.46. To a 500 mL round bottom flask charged with a stir bar and allylic alcohol 4.45
5
 
(10.0 g, 69.3 mmol) was added CH2Cl2 (270 mL). To the stirring solution, at 23 
o
C was added 
activated MnO2 (122.1 g, 1404 mmol). The suspension was stirred vigorously at 23 
o
C under air 
for 30 min. The suspension was filtered through celite, rinsing the filter cake with CH2Cl2 (4 x 
50 mL then 1 x 100 mL). The filtrate was concentrated in vacuo (the bath was maintained at 23 
o
C because the product is volatile) to yield aldehyde 4.46 (9.9 g, 99%) as a pale yellow oil. This 
material was used immediately in the next reaction. 
 
TLC (hexane:EtOAc 4:1) 
Rf = 0.66, stained by KMnO4 
 
1
H-NMR (500 MHz, CDCl3) 
δ 10.12 (d, J = 8.0 Hz, 1H), 6.21 (dq, J = 8.0, 2.0 Hz, 1H), 2.26 (d, J = 2.0 Hz, 3H), 0.15 
(s, 9H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 190.2, 165.8, 136.5, 15.5, -2.8 
 
HRMS (EI+) 
Calculated for C7H14OSi:   142.0814 
Found:      142.0814 
 
Alkyne 4.47. To a 500 mL Schlenk flask charged with a stir bar was added TMS diazomethane 
solution (2.0 M in Et2O, 52 mL, 104 mmol). The solution was cooled to -78 
o
C. To the stirring 
solution was dropwise added nBuLi solution (2.5 M in hexanes, 36 mL, 90 mmol) over 45 min. 
After the addition was complete, the solution was stirred at -78 
o
C for an additional 30 min. A 
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solution of aldehyde 4.46 (9.9 g, 69.3 mmol) in THF (120 mL) was prepared and dropwise added 
to the cooled reaction solution over 1 h 15 min. After the addition was complete, the solution 
was stirred at -78 
o
C for an additional 1 h then at 0 
o
C for 30 min. The solution was transferred to 
a separatory funnel and diluted with saturated aqueous NH4Cl (200 mL), H2O (200 mL) and 
Et2O (100 mL). After shaking, the layers were separated and the aqueous layer was extracted 
with Et2O (2 x 100 mL). The combined organics were dried over MgSO4, filtered, and 
concentrated in vacuo (the bath was maintained at 23 
o
C because the product is volatile) to 
provide a brown oil. The resulting residue was purified by column chromatography on silica gel 
(petroleum ether) to afford alkyne 4.47 as a pale orange oil (6.6 g, 69%). This material was used 
immediately in the next reaction. 
 
TLC (hexane) 
Rf = 0.68, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 5.76 (s, 1H), 3.69 (s, 1H), 1.96 (s, 3H), 0.10 (s, 9H). 
 
MIDA boronate 4.48. To a 300 mL round bottom flask charged with a stir bar and 
dicyclohexylborane (900 mg, 5.0 mmol), under an inert atmosphere, was added THF (25 mL). 
The solution was cooled to 0 
o
C and catecholborane (5.1 mL, 47.6 mmol) was added in one 
portion. The solution was stirred at 0 
o
C for an additional 5 min. A solution of alkyne 4.47 (6.58 
g, 47.6 mmol) in THF (25 mL) was prepared and dropwise added to the cooled reaction solution 
over 15 min. The solution was warmed to 23 
o
C and stirred at this temperature for 4 h. After this 
time, to the solution was added N-methyliminodiacetic acid (MIDA, 10.5 g, 71.3 mmol) and 
DMSO (90 mL). The suspension was sealed under N2 and placed in a 60 
o
C oil bath with stirring 
for 16 h. After this time, the solution was cooled to 23 
o
C and transferred to a separatory funnel 
and diluted with H2O (400 mL) and EtOAc:acetone (4:1, 500 mL). After shaking, the layers were 
separated and the organic layer was washed with brine:H2O (1:1, 2 x 400 mL). The combined 
aqueous layers were back extracted with EtOAc:acetone (3:1, 2 x 400 mL). The combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo. The resulting residue 
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was dry loaded onto celite and purified by column chromatography on silica gel (Et2O:MeCN 
100:0  50:50) to afford MIDA boronate 4.48 as a white solid (6.84 g, 49%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.39, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.00 (dd, J = 17.0, 11.0 Hz, 1H), 6.39 (d, J = 11 Hz, 1H), 5.72 (d, J = 17.0 Hz, 1H), 
4.22 (d, J = 17.0 Hz, 2H), 4.05 (d, J = 17.0 Hz, 2H), 3.01 (s, 3H), 1.85 (d, J = 2.0 Hz, 
3H), 0.09 (s, 9H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.0, 140.5, 140.0, 138.3, 62.3, 47.3, 15.2, -2.2 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.5 
 
HRMS (ESI+) 
Calculated for C13H23BNO4Si (M+H)
+
: 296.1489 
Found:      296.1486 
 
MIDA boronate 4.6. To a 40 mL vial charged with a stir bar and MIDA boronate 4.48 (600 mg, 
2.0 mmol) was added MeCN (10 mL). The solution was cooled to 0 
o
C. To a second 40 mL vial 
charged with a stir bar and N-iodosuccinimide (NIS, 915 mg, 4.1 mmol) was added MeCN (10 
mL). The solution was cooled to 0 
o
C. The cooled NIS solution was transferred to the cooled 
reaction solution in one portion. The solution continued to stir at 0 
o
C for 4 h 30 min. After this 
time, saturated aq. Na2S2O3 (10 mL) and EtOAc (10 mL) were added to the reaction solution. 
The reaction solution was warmed to 23 
o
C with vigorous stirring. The solution was poured into 
a separatory funnel and diluted with saturated aq. Na2S2O3 (50 mL) and EtOAc (50 mL). After 
shaking, the layers were separated and the aqueous layer was extracted with EtOAc (2 x 50 mL). 
The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The 
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resulting residue was dry loaded onto celite and purified by column chromatography on silica gel 
(hexanes:EtOAc 100:0  0:100) to afford MIDA boronate 4.6 as a white solid (534 mg, 76%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.53, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.89 (d, J = 11.0 Hz, 1H), 6.74 (dd, J = 17.0, 11.0 Hz, 1H), 5.71 (d, J = 17.0 Hz, 1H), 
4.23 (d, J = 17.0 Hz, 2H), 4.05 (d, J = 17.0 Hz, 2H), 3.02 (s, 3H), 2.56 (d, J = 1.5 Hz, 
3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.0, 143.6, 137.3, 99.6, 62.2, 47.4, 28.5 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.1 
 
HRMS (ESI+) 
Calculated for C10H14BINO4 (M+H)
+
: 350.0061 
Found:      350.0070 
 
 
MIDA boronate 4.51.
6
 In a glovebox, to a 20 mL vial charged with a stir bar, 1-
triethylgermanium-2-tributytin ethylene 4.50
7
 (443 mg, 0.93 mmol) and vinyl iodide 4.49
8
 (200 
mg, 0.62 mmol) was added Pd2dba3 (14 mg, 0.016 mmol), Ph3As (18.0 mg, 0.059 mmol), DMF 
(9.3 mL), and THF (3.0 mL). The vial was sealed with a PTFE-lined cap, removed from the 
glovebox, and placed in a 60 
o
C heating block and maintained at that temperature with stirring 
for 15 h. The reaction was cooled to 23 
o
C and transferred to a separatory funnel, diluted with 
EtOAc (20 mL) and brine (20 mL). After shaking, the layers were separated. The aqueous layer 
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was extracted with EtOAc (3 x 20 mL), dried over MgSO4, filtered and concentrated in vacuo. 
The resulting residue was dry loaded onto celite and purified by column chromatography on 
silica gel (1:1 petroleum ether:EtOAc  EtOAc  9:1 EtOAc:MeCN) to afford MIDA boronate 
4.51 as a white solid (205 mg, 86%). 
 
TLC (EtOAc) 
Rf = 0.38, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.61 (d, J = 18.5 Hz, 1H), 6.04 (d, J = 18.5 Hz, 1H), 5.42 (s, 1H), 4.21 (d, J = 17.0 Hz, 
2H), 4.05 (d, J = 17.0 Hz, 2H), 3.03 (s, 3H), 1.92 (s, 3H), 1.03 (t, J = 8.0 Hz, 9H), 0.88 
(q, J = 8.0 Hz, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 152.0, 149.5, 126.5, 62.6, 47.2, 15.1, 9.4, 5.1 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 10.9 
 
HRMS (ESI+) 
Calculated for C16H29BGeNO4 (M+H)
+
: 384.1401 
Found:      384.1404 
 
MIDA boronate 4.7. To a 250 mL round bottom flask charged with a stir bar and MIDA 
boronate 4.51 (1.41 g, 3.7 mmol) was added MeCN (70 mL). The solution was cooled to 0 
o
C. A 
solution of N-iodosuccinimide (NIS, 2.49 g, 11.1 mmol) in MeCN (60 mL) was prepared and 
this solution was added dropwise to the cooled reaction solution over 30 min. After the addition 
was complete, the mixture was stirred at 0 
o
C for an additional 2 h. After this time, saturated 
aqueous Na2S2O3 (100 mL) was added to the reaction solution. The reaction solution was 
warmed to 23 
o
C with vigorous stirring. The solution was transferred to a separatory funnel and 
diluted with EtOAc (100 mL). After shaking, the layers were separated and the aqueous layer 
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was extracted with EtOAc (2 x 100 mL). The combined organic layers were dried over MgSO4, 
filtered, and concentrated in vacuo. The resulting residue was dry loaded onto celite and purified 
by column chromatography on silica gel (1:1 petroleum ether:EtOAc  EtOAc) to afford MIDA 
boronate 4.7 as a white solid (1.07 g, 83%). 
 
TLC (EtOAc) 
Rf = 0.38, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.16 (d, J = 15.0 Hz, 1H), 6.56 (d, J = 15.0 Hz, 1H), 5.42 (s, 1H), 4.24 (d, J = 17.0 Hz, 
2H), 4.05 (d, J = 17.0 Hz, 2H), 3.04 (s, 3H), 1.92 (s, 3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 168.7, 152.8, 148.3, 77.6, 62.2, 46.9, 14.8 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 10.5 
 
HRMS (ESI+) 
Calculated for C10H14BINO4 (M+H)
+
: 350.0061 
Found:      350.0066 
 
 
MIDA boronate 8.  MIDA boronate 8 was prepared according to literature precedent.
4
  
 
284 
 
 
Pinacol ester 4.53. To a 40 mL vial charged with a stir bar and MIDA boronate 4.52
3
 (998 mg, 
2.6 mmol) was added solid NaHCO3 (1.27 g, 15.1 mmol), pinacol (500 mg, 4.2 mmol), and 
MeOH (13 mL). The suspension was stirred at 45 
o
C for 3 h. The suspension was cooled to 23 
o
C 
and filtered through celite, eluting with acetone. The solution was concentrated in vacuo and 
residual MeOH was azeotropically removed with toluene (1 x 10 mL). To the resulting residue 
was added solid NaHCO3 (1.11 g, 13.1 mmol), finely ground CaCl2 (1.49 g, 13.4 mmol), and 
toluene (13 mL). The suspension was stirred at 23 
o
C for 1 h. The suspension was filtered 
through celite, eluting with acetone. The solution was concentrated in vacuo and residual toluene 
was azeotropically removed with MeCN (3 x 10 mL) to provide pinacol ester 4.53 as a clear, 
colorless oil (920.5 mg, 99%) that was used immediately in the next reaction. 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.95 (dd, J = 18.0, 11.0 Hz, 1H), 6.73 (d, J = 11.0 Hz, 1H), 6.24 (d, J = 18.0 Hz, 1H), 
1.80 (d, J = 1.5 Hz, 3H), 1.25 (s, 12H), 1.05 (t, J = 8.0 Hz, 9H), 0.85 (q, J = 8.0 Hz, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 144.9, 140.6, 136.5, 83.9, 25.1, 14.4, 9.2, 4.8 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 31.1 
 
HRMS (EI+) 
Calculated for C17H33BGeO2:   354.1786 
Found:      354.1790 
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MIDA boronate 4.54. In a glovebox, to a 40 mL vial charged with a stir bar, pinacol ester 4.53 
(920 mg, 2.6 mmol), and MIDA boronate 4.1 (559 mg, 2.1 mmol) was added 2
nd
 generation 
XPhosPd cycle (170 mg, 0.22 mmol), Cs2CO3 (2.5 g, 7.7 mmol), and DMSO (15 mL). The vial 
was capped, removed from the glovebox, and stirred at 45 
o
C for 14.5 h. After this time, the 
solution was cooled to 23 
o
C and poured into a separatory funnel. The solution was diluted with 
H2O:brine (1:1, 60 mL) and EtOAc (60 mL). After shaking, the layers were separated, and the 
aqueous layer was extracted with EtOAc (2 x 50 mL). The combined organic layers were washed 
with H2O:brine (1:1, 1 x 50 mL). The organic layer was dried over MgSO4, filtered, and 
concentrated in vacuo. The resulting residue was dry loaded onto celite and purified by reverse 
phase column chromatography on C18 silica gel (H2O:MeCN 90:10  0:100) to afford MIDA 
boronate 4.54 as a pale yellow solid (402 mg, 46%). 
 
TLC (Et2O:MeCN 6:1) 
Rf = 0.30, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.94 (dd, J = 18.0, 11.0 Hz, 1H), 6.23 (d, J = 18.0 Hz, 1H), 6.17 (d, J = 11.0 Hz, 1H), 
6.16 (d, J = 18.0 Hz, 1H), 5.79 (d, J = 18.0 Hz, 1H), 4.22 (d, J = 17.0 Hz, 2H), 4.04 (d, J 
= 17.0 Hz, 2H), 3.01 (s, 3H), 1.92 (d, J = 1.0 Hz, 3H), 1.05 (t, J = 8.0 Hz, 9H), 0.85 (q, J 
= 8.0 Hz, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.2, 147.3, 141.1, 136.0, 135.0, 134.3, 62.1, 47.2, 12.6, 9.1, 4.8 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.7 
 
HRMS (ESI+) 
Calculated for C18H31BGeNO4 (M+H)
+
: 410.1558 
Found:      410.1557 
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MIDA boronate 4.9. To a 40 mL vial charged with a stir bar and MIDA boronate 4.54 (400 mg, 
0.98 mmol) was added MeCN (10 mL). The solution was cooled to 0 
o
C. To a second 40 mL vial 
charged with a stir bar and N-bromosuccinimide (NBS, 265 mg, 1.5 mmol) was added MeCN 
(10 mL). The solution was cooled to 0 
o
C. The cooled NBS solution was dropwise transferred to 
the cooled reaction solution. The solution continued to stir at 0 
o
C for 1 h. After this time, 
saturated aq. Na2S2O3 (8 mL) and EtOAc (8 mL) were added to the reaction solution. The 
reaction solution was warmed to 23 
o
C with vigorous stirring. The solution was poured into a 
separatory funnel and diluted with saturated aq. Na2S2O3:H2O (1:1, 30 mL) and EtOAc (30 mL). 
After shaking, the layers were separated and the aqueous layer was extracted with EtOAc (30 
mL). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
The resulting residue was dry loaded onto celite and purified by reverse phase column 
chromatography on C18 silica gel (H2O:MeCN 95:5  0:100) to afford MIDA boronate 4.9 as a 
pale yellow solid (238 mg, 74%). 
 
TLC (Et2O:MeCN 6:1) 
Rf = 0.30, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.16 (dd, J = 13.0, 11.0 Hz, 1H), 6.63 (d, J = 13.0 Hz, 1H), 6.60 (d, J = 18.0 Hz, 1H), 
6.16 (d, J = 11.0 Hz, 1H), 5.89 (d, J = 18.0 Hz, 1H), 4.23 (d, J = 17.0 Hz, 2H), 4.05 (d, J 
= 17.0 Hz, 2H), 3.01 (s, 3H), 1.89 (d, J = 1.0 Hz, 3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 146.5, 137.9, 135.2, 129.5, 110.5, 62.2, 47.3, 12.6 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.5 
 
HRMS (ESI+) 
Calculated for C12H15BBrNaNO4 (M+Na)
+
: 350.0175 
Found:      350.0180 
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MIDA boronate 4.55. In a glovebox, to a 500 mL Schlenk flask charged with a stir bar and 
MIDA boronate 4.1 (15.3 g, 58.3 mmol) was added Pd2dba3 (2.7 g, 2.9 mmol) and Ph3As (1.8 g, 
5.8 mmol). The flask was sealed, removed from the glovebox, and placed under a N2 
atmosphere. THF (300 mL) was added to the reaction flask, followed by stannane 4.56
9
 (30.6 g, 
75.8 mmol). The solution was stirred at 50 
o
C for 13.5 h. After this time, the reaction solution 
was cooled to 23 
o
C and filtered through a pad of celite/silica, rinsing the filter cake with 
acetone. The filtrate was concentrated in vacuo and the resulting residue was dry loaded onto 
celite and purified by column chromatography on silica gel (Et2O:MeCN 100:0  6:1  5:1  
3:1) to afford MIDA boronate 4.55. This material was dissolved in acetone and the product was 
precipitated by addition of Et2O. The material was collected by vacuum filtration to provide 
MIDA boronate 4.55 as a white solid (5.23 g, 30%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.64, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.60 (d, J = 18.0 Hz, 1H), 5.71 (d, J = 18.0 Hz, 1H), 5.59 (s, 1H), 4.22 (d, J = 17.0 Hz, 
2H), 4.05 (d, J = 17.0 Hz, 2H), 3.01 (s, 3H), 1.94 (s, 3H), 0.14 (s, 9H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 149.3, 133.0, 62.3, 47.3, 17.5, 2.0, 0.0 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.6 
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HRMS (ESI+) 
Calculated for C13H23BNO4Si (M+H)
+
: 296.1489 
Found:      296.1488 
 
Pinacol ester 4.57. To a 20 mL vial charged with a stir bar and MIDA boronate 4.55 (120 mg, 
0.41 mmol) was added solid NaHCO3 (171 mg, 2.0 mmol), pinacol (72 mg, 0.6 mmol), and 
MeOH (4 mL). The suspension was stirred at 45 
o
C for 3 h. The suspension was cooled to 23 
o
C 
and filtered through celite, eluting with acetone. The solution was concentrated in vacuo and 
residual MeOH was azeotropically removed with toluene (1 x 5 mL). To the resulting residue 
was added solid NaHCO3 (172 mg, 2.0 mmol), finely ground CaCl2 (225 mg, 2.0 mmol), and 
toluene (4 mL). The suspension was stirred at 23 
o
C for 1 h. The suspension was filtered through 
celite, eluting with acetone. The solution was concentrated in vacuo and residual toluene was 
azeotropically removed with MeCN (3 x 10 mL) to provide pinacol ester 4.57 as a clear, 
colorless oil (107 mg, 99%) that was used immediately in the next reaction. 
 
1
H-NMR (400 MHz, d6-acetone) 
δ 6.98 (d, J = 18.0 Hz, 1H), 5.76 (s, 1H), 5.49 (d, J = 18.0 Hz, 1H), 1.92 (s, 3H), 1.24 (s, 
12H), 0.15 (s, 9H). 
 
13
C-NMR (100 MHz, d6-acetone) 
δ 156.2, 151.6, 136.7, 83.7, 25.1, 17.0, -0.2 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 30.8 
 
HRMS (ESI+) 
Calculated for C14H27BNaO2Si (M+Na)
+
: 289.1771 
Found:      289.1773 
 
MIDA boronate 4.58. In a glovebox, to a 20 mL vial charged with a stir bar, pinacol ester 4.57 
(134 mg, 0.5 mmol), and MIDA boronate 4.3 (116 mg, 0.42 mmol) was added 2
nd
 generation 
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XPhosPd cycle (33 mg, 0.04 mmol), Cs2CO3 (547 mg, 1.7 mmol), and DMSO (8 mL). The vial 
was capped, removed from the glovebox, and stirred at 40 
o
C for 14 h. After this time, the 
solution was cooled to 23 
o
C and poured into a separatory funnel. The solution was diluted with 
H2O:brine (1:1, 20 mL) and EtOAc (20 mL). After shaking, the layers were separated, and the 
aqueous layer was extracted with EtOAc (2 x 20 mL). The combined organic layers were washed 
with H2O:brine (1:1, 1 x 20 mL). The organic layer was dried over MgSO4, filtered, and 
concentrated in vacuo. The resulting residue was dry loaded onto celite and purified by column 
chromatography on florisil (hexanes:EtOAc 95:5  0:100) to afford MIDA boronate 4.58 as a 
pale yellow solid (102 mg, 73%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.63, stained by KMnO4 
 
1
H-NMR (400 MHz, d6-acetone) 
δ 6.67 (dd, J = 15.5, 11.0 Hz, 1H), 6.45 (d, J = 11.0 Hz, 1H), 6.34 (d, J = 15.5 Hz, 1H), 
5.61 (s, 1H), 4.23 (d, J = 17.0 Hz, 2H), 4.06 (d, J = 17.0 Hz, 2H), 2.97 (s, 3H), 1.98 (s, 
3H), 1.83 (d, J = 1.0 Hz, 3H), 0.14 (s, 9H). 
 
13
C-NMR (100 MHz, d6-acetone) 
δ 169.2, 151.4, 140.6, 137.2, 133.1, 125.4, 62.6, 47.1, 17.9, 15.3, 0.1 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.6 
 
HRMS (ESI+) 
Calculated for C16H27BNO4Si (M+H)
+
: 336.1802 
Found:      336.1813 
 
MIDA boronate 4.10. To a 40 mL vial charged with a stir bar and MIDA boronate 4.58 (102 
mg, 0.3 mmol) was added EtCN (4 mL). The solution was cooled to -78 
o
C. To a second 40 mL 
vial charged with a stir bar and N-iodosuccinimide (NIS, 137 mg, 0.6 mmol) was added EtCN (4 
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mL). The solution was cooled to -78 
o
C. The cooled NIS solution was dropwise transferred to the 
cooled reaction solution. The solution continued to stir at -78 
o
C for 5 h 30 min. After this time, 
saturated aq. Na2S2O3 (10 mL) and EtOAc (10 mL) were added to the reaction solution. The 
reaction solution was warmed to 23 
o
C with vigorous stirring. The solution was poured into a 
separatory funnel and diluted with saturated aq. Na2S2O3 (10 mL) and EtOAc (10 mL). After 
shaking, the layers were separated and the aqueous layer was extracted with EtOAc (2 x 20 mL). 
The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The 
resulting residue was dry loaded onto celite and purified by reverse phase column 
chromatography on C18 silica gel (H2O:MeCN 95:5  0:100) to afford MIDA boronate 4.10 as 
a pale yellow solid (99 mg, 83%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.47, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.78 (dd, J = 15.0, 11.0 Hz, 1H), 6.57 (s, 1H), 6.47 (d, J = 15.0 Hz, 1H), 6.42 (d, J = 
11.0 Hz, 1H), 4.23 (d, J = 17.0 Hz, 2H), 4.06 (d, J = 17.0 Hz, 2H), 2.97 (s, 3H), 2.03 (d, J 
= 1.0 Hz, 3H), 1.82 (d, J = 1.0 Hz, 3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 146.5, 136.8, 134.7, 126.3, 84.5, 62.6, 47.1, 20.1, 15.4 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.6 
 
HRMS (ESI+) 
Calculated for C13H18BINO4 (M+H)
+
: 390.0374 
Found:      390.0381 
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Pinacol ester 4.59. To a 40 mL vial charged with a stir bar and MIDA boronate 4.48 (1.4 g, 4.7 
mmol) was added solid NaHCO3 (2.0 g, 23.7 mmol), pinacol (841 mg, 7.1 mmol), and MeOH 
(24 mL). The suspension was stirred at 45 
o
C for 3 h. The suspension was cooled to 23 
o
C and 
filtered through celite, eluting with acetone. The solution was concentrated in vacuo and residual 
MeOH was azeotropically removed with toluene (1 x 10 mL). To the resulting residue was added 
solid NaHCO3 (2.0 g, 23.7 mmol), finely ground CaCl2 (2.6 g, 23.7 mmol), and toluene (24 mL). 
The suspension was stirred at 23 
o
C for 1 h. The suspension was filtered through celite, eluting 
with acetone. The solution was concentrated in vacuo and residual toluene was azeotropically 
removed with MeCN (3 x 10 mL) to provide pinacol ester 4.59 as a clear, colorless oil (1.22 g, 
97%) that was used immediately in the next reaction. 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.37 (dd, J = 18.0, 11.0 Hz, 1H), 6.40 (d, J = 11.0 Hz, 1H), 5.53 (d, J = 18.0 Hz, 1H), 
1.91 (d, J = 1.5 Hz, 3H), 1.25 (s, 12H), 0.10 (s, 9H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 145.1, 144.9, 139.5, 83.7, 25.1, 15.5, -2.3 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 30.7 
 
HRMS (ESI+) 
Calculated for C14H28BO2Si (M+H)
+
:  267.1952 
Found:      267.1964 
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MIDA boronate 4.60. In a glovebox, to a 40 mL vial charged with a stir bar, pinacol ester 4.59 
(532 mg, 2.0 mmol), and MIDA boronate 4.3 (459 mg, 1.7 mmol) was added 2
nd
 generation 
XPhosPd cycle (65.5 mg, 0.08 mmol), Cs2CO3 (2.2 g, 6.7 mmol), and DMSO (30 mL). The vial 
was capped, removed from the glovebox, and stirred at 35 
o
C for 14 h. After this time, the 
solution was cooled to 23 
o
C and poured into a separatory funnel. The solution was diluted with 
H2O:brine (1:1, 100 mL) and EtOAc (100 mL). After shaking, the layers were separated, and the 
aqueous layer was extracted with EtOAc (100 mL). The combined organic layers were washed 
with H2O:brine (1:1, 100 mL). The organic layer was dried over MgSO4, filtered, and 
concentrated in vacuo. The resulting residue was dry loaded onto celite and purified by column 
chromatography on florisil (hexanes:EtOAc 90:10  0:100) to afford MIDA boronate 4.60 as a 
pale yellow solid (459 mg, 82%). 
 
TLC (Et2O:MeCN 6:1) 
Rf = 0.39, stained by KMnO4 
 
1
H-NMR (400 MHz, d6-acetone) 
δ 6.70-6.62 (m, 2H), 6.52-6.42 (m, 2H), 4.22 (d, J = 17.0 Hz, 2H), 4.04 (d, J = 17.0 Hz, 
2H), 2.96 (s, 3H), 1.86 (d, J = 1.0 Hz, 3H), 1.81 (d, J = 1.0 Hz, 3H), 0.08 (s, 9H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.2, 140.8, 138.3, 137.5, 130.4, 129.9, 62.7, 47.1, 15.3, 15.2, -2.1 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.7 
 
HRMS (ESI+) 
Calculated for C16H27BNO4Si (M+H)
+
: 336.1802 
Found:      336.1805 
 
MIDA boronate 4.11. To a 40 mL vial charged with a stir bar and MIDA boronate 4.60 (500 
mg, 1.5 mmol) was added EtCN (7.5 mL). The solution was cooled to -78 
o
C. To a second 40 
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mL vial charged with a stir bar and N-iodosuccinimide (NIS, 670 mg, 3.0 mmol) was added 
EtCN (7.5 mL). The solution was cooled to -78 
o
C. The cooled NIS solution was dropwise 
transferred to the cooled reaction solution. The solution continued to stir at -78 
o
C for 6 h. After 
this time, the solution was poured into a separatory funnel and diluted with saturated aq. Na2S2O3 
(50 mL) and EtOAc (50 mL). After shaking, the layers were separated and the organic layer was 
washed with saturated aq. Na2S2O3 (50 mL). The combined aqueous layers were extracted with 
EtOAc (50 mL). The combined organic layers were dried over MgSO4, filtered and concentrated 
in vacuo. The resulting residue was dry loaded onto celite and purified by column 
chromatography on silica gel (hexanes:EtOAc 90:10  0:100) to afford MIDA boronate 4.11 as 
a pale yellow solid (456 mg, 79%). 
 
TLC (Et2O:MeCN 4:1) 
Rf = 0.47, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.92 (d, J = 11.0 Hz, 1H), 6.69 (dd, J = 15.0, 11.0 Hz, 1H), 6.48 (dd, J = 15.0, 11.0 Hz, 
1H), 6.45 (d, J = 11.0 Hz, 1H), 4.23 (d, J = 17.0 Hz, 2H), 4.06 (d, J = 17.0 Hz, 2H), 2.97 
(s, 3H), 2.57 (s, 3H), 1.80 (s, 3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 142.1, 136.7, 130.3, 128.9, 97.7, 62.7, 47.1, 28.4, 15.4 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.8 
 
HRMS (ESI+) 
Calculated for C13H18BINO4 (M+H)
+
: 390.0374 
Found:      390.0374 
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MIDA boronate 4.61. In a glovebox, to a 40 mL vial charged with a stir bar, 1-
triethylgermanium-2-tributytin ethylene 4.50
7
 (850 mg, 1.8 mmol) and vinyl iodide 4.6 (480 mg, 
1.4 mmol) was added PdCl2(MeCN)2 (18 mg, 0.07 mmol), DMF (10.5 mL), and THF (3.5 mL). 
The vial was sealed with a PTFE-lined cap, removed from the glovebox, and placed in a 45 
o
C 
heating block and maintained at that temperature with stirring for 4 h 30 min. The reaction was 
cooled to 23 
o
C and concentrated in vacuo, azeotropically removing residual DMF with toluene 
(3 x 30 mL). The resulting residue was dry loaded onto celite and purified by column 
chromatography on florisil (Et2O:MeCN 100:0  60:40) to afford MIDA boronate 4.61 as a pale 
yellow solid (280 mg, 50%). 
 
TLC (Et2O:MeCN 6:1) 
Rf = 0.33, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.98 (dd, J = 17.0, 11.0 Hz, 1H), 6.59 (d, J = 18.5 Hz, 1H), 6.18 (d, J = 11.0 Hz, 1H), 
6.11 (d, J = 18.5 Hz, 1H), 5.78 (d, J = 17.0 Hz, 1H), 4.21 (d, J = 17.0 Hz, 2H), 4.02 (d, J 
= 17.0 Hz, 2H), 2.98 (s, 3H), 1.89 (s, 3H), 1.04 (t, J = 8.0 Hz, 9H), 0.83 (q, J = 8.0 Hz, 
6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 148.9, 139.2, 137.1, 134.3, 127.2, 62.1, 47.3, 12.3, 9.1, 4.7 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.1 
 
HRMS (ESI+) 
Calculated for C18H31BGeNO4 (M+H)
+
: 410.1558 
Found:      410.1560 
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MIDA boronate 4.12. To a 40 mL vial charged with a stir bar and MIDA boronate 4.61 (280 
mg, 0.69 mmol) was added EtCN (7 mL). The solution was cooled to -78 
o
C. To a second 40 mL 
vial charged with a stir bar and N-iodosuccinimide (NIS, 310 mg, 1.4 mmol) was added EtCN (7 
mL). The solution was cooled to -78 
o
C. The cooled NIS solution was dropwise transferred to the 
cooled reaction solution. The solution continued to stir at -78 
o
C for 3 h. After this time, 
saturated aq. Na2S2O3 (8 mL) and EtOAc (8 mL) were added to the reaction solution. The 
reaction solution was warmed to 23 
o
C with vigorous stirring. The solution was poured into a 
separatory funnel and diluted with saturated aq. Na2S2O3:H2O (1:1, 30 mL) and EtOAc (30 mL). 
After shaking, the layers were separated and the aqueous layer was extracted with EtOAc (30 
mL). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
The resulting residue triturated with Et2O (2 x 10 mL) to afford MIDA boronate 4.12 as a pale 
yellow solid (231.3 mg, 90%). 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.15 (d, J = 15.0 Hz, 1H), 6.94 (dd, J = 17.0, 11.0 Hz, 1H), 6.56 (d, J = 15.0 Hz, 1H), 
6.20 (d, J = 11.0 Hz, 1H), 5.88 (d, J = 17.0 Hz, 1H), 4.23 (d, J = 17.0 Hz, 2H), 4.05 (d, J 
= 17.0 Hz, 2H), 3.01 (s, 3H), 1.90 (s, 3H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.0, 138.3, 137.3, 136.5, 134.9, 77.0, 62.3, 47.4, 12.2 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.2 
 
HRMS (ESI+) 
Calculated for C12H16BINO4 (M+H)
+
: 376.0217 
Found:      376.0220 
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General deprotection condition. To a vial charged with a stir bar and MIDA boronate (1.0 eq.) 
was added solid NaHCO3 (5.0 eq.), pinacol (1.5 eq.), and MeOH (0.2 M). The suspension was 
stirred at 45 
o
C for 3 h. The suspension was cooled to 23 
o
C and filtered through celite, eluting 
with acetone. The solution was concentrated in vacuo and residual MeOH was azeotropically 
removed with toluene. To the resulting residue was added solid NaHCO3 (5.0 eq.), finely ground 
CaCl2 (5.0 eq.), and toluene (0.2 M). The suspension was stirred at 23 
o
C for 1 h. The suspension 
was filtered through celite, eluting with acetone. The solution was concentrated in vacuo and 
residual toluene was azeotropically removed with MeCN to provide the pinacol ester, which was 
used immediately in the next reaction. 
 
 
General pinacol ester cross-coupling reaction condition. In a glovebox, to a vial charged with 
a stir bar, pinacol ester (1.1-1.3 eq.), and MIDA boronate (1.0 eq.) was added 2
nd
 generation 
XPhosPd cycle (10 mol %), anhydrous Cs2CO3 (4.0 eq.), and DMSO (0.05 M). The vial was 
capped, removed from the glovebox, and stirred at 35 
o
C for 12-16 h. After this time, the solution 
was cooled to 23 
o
C and poured into a separatory funnel. The solution was diluted with 
H2O:brine (1:1, at least 3 times the volume of DMSO used in the reaction) and EtOAc (equal 
volume to H2O:brine). After shaking, the layers were separated, and the aqueous layer was 
extracted with EtOAc (same volume as above). The combined organic layers were washed with 
H2O:brine (1:1, same volume as above). The organic layer was dried over MgSO4, filtered, and 
concentrated in vacuo. The resulting residue was dry loaded onto celite and purified by column 
chromatography on silica, florisil, or C18 silica to afford the MIDA boronate. 
 
 
General MIDA boronate cross-coupling reaction condition. In a glovebox, to a vial charged 
with a stir bar, MIDA boronate (1.0 eq.) and halide (1.5 eq) was added 2
nd
 generation XPhosPd 
cycle (10 mol %), finely ground NaOH (7.5 eq.), and THF (0.05 M total concentration, 5:1 
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THF:H2O, see below for water). The vial was capped with a septum cap, removed from the 
glovebox, and degassed H2O (5:1 THF:H2O) was added in one portion. The solution was stirred 
at 23 
o
C for 1-4 h. The reaction solution was diluted with Et2O and H2O. After shaking, the 
aqueous layer was removed and extracted with Et2O (2 times). The combined organic layers 
were dried over MgSO4, filtered, and concentrated in vacuo. The resulting residue was dry 
loaded onto celite and purified by column chromatography on florisil or C18 silica to afford the 
polyene product. 
 
 
Pinacol ester 4.62. Following the general deprotection condition, MIDA boronate 4.37
10
 (1.5 g, 
5.7 mmol), NaHCO3 (2.4 g, 28.3 mmol), pinacol (1.0 g, 8.5 mmol), and MeOH (28 mL) were 
stirred at 45 
o
C for 3 h. After filtration and concentration, to the residue was added NaHCO3 (2.4 
g, 28.3 mmol), CaCl2 (3.1 g, 28.3 mmol), and toluene (28 mL). After stirring at 23 
o
C for 1 h, 
filtering, and concentrating, pinacol ester 4.62 was obtained as a clear, colorless oil (1.3 g, 95%). 
Characterization was consistent with literature precedent.
11
 
 
 
MIDA boronate 4.63. In a glovebox, to a 20 mL vial charged with boronic acid 4.63 (103.9 mg, 
0.67 mmol) was added MIDA boronate 4.1 (135.9 mg, 0.52 mmol), Pd(OAc)2 (5.7 mg, 0.025 
mmol), XPhos (26.3 mg, 0.055 mmol), anhydrous Cs2CO3 (543.8 mg, 1.7 mmol) and THF (10.4 
mL).  The vial was sealed with a cap and removed from the glovebox. The solution was stirred in 
a subdued light environment at 45 
o
C for 19 hr. The reaction mixture was filtered through a pad 
of Celite, concentrated in vacuo, dry loaded onto Celite from an acetone solution, and purified 
via flash chromatography on silica (Et2O:acetone 100:0 → 80:20) to afford MIDA boronate 4.64 
as a white solid (69.1 mg, 46%). 
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TLC (Et2O:MeCN 4:1) 
Rf = 0.51, stained by KMnO4 
 
1
H-NMR (400 MHz, d6-acetone) 
δ 6.52 (dd, J = 17.4, 10.0 Hz, 1H), 6.09 (dd, J = 15.0, 10.0 Hz, 1H), 5.70 (dd, J = 15.0, 
7.0 Hz, 1H), 5.53 (d, J = 17.4 Hz, 1H), 4.17 (d, J = 17.0 Hz, 2H), 3.99 (d, J = 17.0 Hz, 
2H), 2.98 (s, 3H), 2.01 (m, 1H), 1.77-1.57 (m, 5H), 1.36-1.03 (m, 5H).  
 
13
C-NMR (100 MHz, d6-acetone) 
δ 169.1, 143.9, 142.0, 130.9, 62.1, 47.2, 41.4, 33.4, 26.7, 26.5 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.4 
 
HRMS (ESI+) 
Calculated for C15H23BNO4 (M+H)
+
:  292.1720 
Found:      292.1718 
 
 
MIDA boronate #. In a glovebox, to a 20 mL vial charged with boronic acid 4.63 (97.8 mg, 0.64 
mmol) was added MIDA boronate 4.2 (130.1 mg, 0.50 mmol), Pd(OAc)2 (8.7 mg, 0.039 mmol), 
XPhos (28.8 mg, 0.060 mmol), anhydrous Cs2CO3 (493.2 mg, 1.5 mmol) and THF (6.7 mL).  
The vial was sealed with a cap and removed from the glovebox. The solution was stirred in a 
subdued light environment at 35 
o
C for 20.5 hr. The reaction mixture was filtered through a pad 
of Celite, concentrated in vacuo, dry loaded onto Celite from an acetone solution, and purified 
via flash chromatography on silica (Et2O:acetone 100:0 → 80:20) to afford MIDA boronate 4.65 
as a pale yellow solid (81.2 mg, 56%). 
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TLC (Et2O:MeCN 4:1) 
Rf = 0.57, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.68-6.56 (m, 2H), 5.66 (dd, J = 14.5, 7.0 Hz, 1H), 5.25 (d, J = 13.0 Hz, 1H), 4.20 (d, J 
= 17.0 Hz, 2H), 4.00 (d, J = 17.0 Hz, 2H), 3.01 (s, 3H), 2.02 (m, 1H), 1.77-1.58 (m, 5H), 
1.37-1.02 (m, 5H).  
 
13
C-NMR (125 MHz, d6-acetone) 
δ 168.9, 145.1, 144.0, 127.9, 62.3, 47.2, 41.6, 33.4, 26.7, 26.6 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.2 
 
HRMS (ESI+) 
Calculated for C15H23BNO4 (M+H)
+
:  292.1720 
Found:      292.1720 
 
 
MIDA boronate #.  In a glovebox, to a 20 mL vial charged with boronic acid 4.63 (100.1 mg, 
0.65 mmol) was added MIDA boronate 4.3 (143.0 mg, 0.52 mmol), Pd(OAc)2 (5.7 mg, 0.025 
mmol), XPhos (24.8 mg, 0.052 mmol), anhydrous Cs2CO3 (509.2 mg, 1.6 mmol) and THF (6.7 
mL).  The vial was sealed with a cap and removed from the glovebox. The solution was stirred in 
a subdued light environment at 45 
o
C for 21 hr. The reaction mixture was filtered through a pad 
of Celite, concentrated in vacuo, dry loaded onto Celite from an acetone solution, and purified 
via flash chromatography on silica (Et2O:acetone 100:0 → 80:20) to afford MIDA boronate 4.66 
as a white solid (108.2 mg, 68%). 
 
TLC (Et2O:MeCN 4:1) 
Rf =0.46, stained by KMnO4 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.42 (ddd, J = 15.0, 11.0, 1.0 Hz, 1H), 6.32 (dd, J = 11.0, 1.5 Hz, 1H), 5.68 (dd, J = 
15.0, 7.0 Hz, 1H), 4.19 (d, J = 17.0 Hz, 2H), 4.02 (d, J = 17.0 Hz, 2H), 2.96 (s, 3H), 2.07 
(m, 1H), 1.76 (d, J = 1.5 Hz, 3H), 1.75-1.61 (m, 5H), 1.36-1.06 (m, 5H).  
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.2, 142.2, 137.6, 124.9, 62.6, 47.0, 41.8, 33.6, 26.7, 26.5, 15.0 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.8 
 
HRMS (ESI+) 
Calculated for C16H24BNO4Na (M+Na)
+
: 328.1696 
Found:      328.1704 
 
 
MIDA boronate #.  In a glovebox, to a 20 mL vial charged with boronic acid 4.63 (105.2 mg, 
0.68 mmol) was added MIDA boronate 4.4 (135.1 mg, 0.49 mmol), Pd(OAc)2 (5.8 mg, 0.026 
mmol), XPhos (23.8 mg, 0.050 mmol), anhydrous Cs2CO3 (488.7 mg, 1.5 mmol) and THF (6.7 
mL).  The vial was sealed with a cap and removed from the glovebox. The solution was stirred in 
a subdued light environment at 45 
o
C for 21 hr. The reaction mixture was filtered through a pad 
of Celite, concentrated in vacuo, dry loaded onto Celite from an acetone solution, and purified 
via flash chromatography on silica (Et2O:acetone 100:0 → 80:20) to afford MIDA boronate 4.67 
as a white solid (43.3 mg, 29%). 
 
TLC (Et2O:MeCN 4:1) 
Rf =0.58, stained by KMnO4 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.55-6.47 (m, 2H), 5.56 (dd, J = 14.0, 7.0 Hz, 1H), 4.24 (d, J = 17.0 Hz, 2H), 4.03 (d, J 
= 17.0 Hz, 2H), 2.96 (s, 3H), 1.98 (m, 1H), 1.76 (s, 3H), 1.73-1.59 (m, 5H), 1.34-1.01 (m, 
5H).  
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.0, 142.2, 142.1, 127.3, 63.0, 47.3, 41.6, 33.6, 26.8, 26.6, 24.7 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.6 
 
HRMS (ESI+) 
Calculated for C16H24BNO4 Na(M+Na)
+
: 328.1696 
Found:      328.1694 
 
 
MIDA boronate 4.68. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.62 (135 mg, 0.57 mmol), MIDA boronate 4.5 (135 mg, 0.40 mmol), 2
nd
 generation 
XPhosPd cycle (35 mg, 0.05 mmol), Cs2CO3 (580 mg, 1.8 mmol), and DMSO (9 mL) were 
combined and stirred at 35 
o
C for 15 h, the reaction was worked up using H2O:brine (1:1, 30 mL) 
and EtOAc (30 mL). After drying, filtering, and concentrating, the residue was dry loaded onto 
celite and purified by column chromatography on florisil (Et2O:MeCN 100:0  60:40) to afford 
MIDA boronate 4.68 as a pale yellow solid (99.2 mg, 78%). 
 
TLC (Et2O:MeCN 6:1) 
Rf =0.49, stained by KMnO4 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.59 (dd, J = 17.0, 10.0 Hz, 1H), 6.27 (dd, J = 15.0, 10.0 Hz, 1H), 6.21 (dd, J = 15.0, 
10.0 Hz, 1H), 6.09 (dd, J = 15.0, 10.0 Hz, 1H), 5.73 (dd, J = 15.0, 7.0 Hz, 1H), 5.65 (d, J 
= 17.0 Hz, 1H), 4.20 (d, J = 17.0 Hz, 2H), 4.01 (d, J = 17.0 Hz, 2H), 2.98 (s, 3H), 2.03 
(m, 1H), 1.80-1.55 (m, 5H), 1.36-1.00 (m, 5H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 143.5, 142.4, 135.0, 133.6, 128.7, 62.1, 47.3, 41.6, 33.4, 26.6, 26.5 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.3 
 
HRMS (ESI+) 
Calculated for C17H25BNO4 (M+H)
+
:  318.1877 
Found:      318.1878 
 
 
MIDA boronate 4.69. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.62 (220 mg, 0.93 mmol), MIDA boronate 4.6 (250 mg, 0.72 mmol), 2
nd
 generation 
XPhosPd cycle (56 mg, 0.07 mmol), Cs2CO3 (934 mg, 2.9 mmol), and DMSO (14 mL) were 
combined and stirred at 35 
o
C for 14 h 30 min, the reaction was worked up using H2O:brine (1:1, 
30 mL) and EtOAc (30 mL). After drying, filtering, and concentrating, the residue was dry 
loaded onto celite and purified by column chromatography on florisil (Et2O:MeCN 100:0  
60:40) to afford MIDA boronate 4.69 as a pale yellow solid (176.5 mg, 74%). 
 
TLC (Et2O:MeCN 6:1) 
Rf =0.49, stained by KMnO4 
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1
H-NMR (400 MHz, d6-acetone) 
δ 6.95 (dd, J = 17.0, 11.0 Hz, 1H), 6.11 (d, J = 16.0 Hz, 1H), 6.08 (d, J = 11.0 Hz, 1H), 
5.73 (dd, J = 16.0, 7.0 Hz, 1H), 5.68 (d, J = 17.0 Hz, 1H), 4.22 (d, J = 17.0 Hz, 2H), 4.03 
(d, J = 17.0 Hz, 2H), 3.00 (s, 3H), 1.86 (s, 3H), 2.07 (m, 1H), 1.78-1.58 (m, 5H), 1.38-
1.05 (m, 5H). 
 
13
C-NMR (100 MHz, d6-acetone) 
δ 169.1, 139.2, 137.1, 136.5, 133.1, 132.4, 62.2, 47.3, 41.9, 33.8, 26.7, 26.6, 12.9 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.4 
 
HRMS (ESI+) 
Calculated for C18H27BNO4 (M+H)
+
:  332.2033 
Found:      332.2043 
 
 
MIDA boronate 4.70. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.62 (88 mg, 0.37 mmol), MIDA boronate 4.7 (100 mg, 0.29 mmol), 2
nd
 generation 
XPhosPd cycle (23 mg, 0.03 mmol), Cs2CO3 (374 mg, 1.1 mmol), and DMSO (6 mL) were 
combined and stirred at 35 
o
C for 13 h, the reaction was worked up using H2O:brine (1:1, 30 mL) 
and EtOAc (30 mL). After drying, filtering, and concentrating, the residue was dry loaded onto 
celite and purified by column chromatography on florisil (Et2O:MeCN 100:0  60:40) to afford 
MIDA boronate 4.70 as a pale yellow solid (71 mg, 75%). 
 
TLC (Et2O:MeCN 6:1) 
Rf =0.50, stained by KMnO4 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.28-6.24 (m, 2H), 6.09 (dd, J = 16.0, 8.0 Hz, 1H), 5.73 (dd, J = 15.0, 7.0 Hz, 1H), 5.36 
(s, 1H), 4.20 (d, J = 17.0 Hz, 2H), 4.03 (d, J = 17.0 Hz, 2H), 3.00 (s, 3H), 2.02 (m, 1H), 
1.93 (s, 3H), 1.76-1.59 (m, 5H), 1.35-1.05 (m, 5H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.0, 148.6, 141.8, 138.6, 129.8, 129.1, 62.3, 47.0, 41.6, 33.5, 26.7, 26.5, 15.5 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.3 
 
HRMS (ESI+) 
Calculated for C18H27BNO4 (M+H)
+
:  332.2033 
Found:      332.2038 
 
 
MIDA boronate 4.71. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.62 (26 mg, 0.11 mmol), MIDA boronate 4.8 (30 mg, 0.08 mmol), 2
nd
 generation XPhosPd 
cycle (6.5 mg, 0.008 mmol), Cs2CO3 (108 mg, 0.33 mmol), and DMSO (2 mL) were combined 
and stirred at 35 
o
C for 14 h, the reaction was worked up using H2O:brine (1:1, 15 mL) and 
EtOAc (15 mL). After drying, filtering, and concentrating, the residue was dry loaded onto celite 
and purified by column chromatography on florisil (Et2O:MeCN 100:0  60:40) to afford 
MIDA boronate 4.71 as a pale yellow solid (23 mg, 81%). 
 
TLC (Et2O:MeCN 4:1) 
Rf =0.67, stained by KMnO4 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.61 (dd, J = 17.0, 10.0 Hz, 1H), 6.38-6.18 (m, 4H), 6.11 (dd, J = 15.0, 10.0 Hz, 1H), 
5.72 (dd, J = 15.0, 7.0 Hz, 1H), 5.68 (d, J = 17.0 Hz, 1H), 4.21 (d, J = 17.0 Hz, 2H), 4.03 
(d, J = 17.0 Hz, 2H), 2.99 (s, 3H), 2.02 (m, 1H), 1.77-1.59 (m, 5H), 1.35-1.05 (m, 5H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.0, 143.5, 142.1, 135.4, 134.9, 134.8, 131.6, 129.0, 62.3, 47.3, 41.7, 33.5, 26.7, 26.6 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.4 
 
HRMS (ESI+) 
Calculated for C19H27BNO4 (M+H)
+
:  344.2033 
Found:      344.2030 
 
 
MIDA boronate 4.72. Following a modified version of the general pinacol ester cross-coupling 
condition, boronic acid 4.63 (15.3 mg, 0.10 mmol), MIDA boronate 4.9 (27.1 mg, 0.08 mmol), 
2
nd
 generation XPhosPd cycle (6.5 mg, 0.008 mmol), Cs2CO3 (108 mg, 0.33 mmol), and THF (2 
mL) were combined and stirred at 35 
o
C for 15 h, the reaction was worked up by filtering 
through celite and concentrating. The residue was dry loaded onto celite and purified by column 
chromatography on florisil (Et2O:MeCN 100:0  60:40) to afford MIDA boronate 4.72 as a pale 
yellow solid (14.7 mg, 50%). 
 
TLC (Et2O:MeCN 4:1) 
Rf =0.68, stained by KMnO4 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.63 (d, J = 17.5 Hz, 1H), 6.55 (dd, J = 14.0, 11.0 Hz, 1H), 6.32 (dd, J =15.0, 11.0 Hz, 
1H), 6.22-6.15 (m, 2H), 5.72 (dd, J = 15.0, 7.0 Hz, 1H), 5.71 (d, J = 17.5 Hz, 1H), 4.21 
(d, J = 17.0 Hz, 2H), 4.04 (d, J = 17.0 Hz, 2H), 3.00 (s, 3H), 2.07 (m, 1H), 1.89 (s, 3H), 
1.77-1.60 (m, 5H), 1.36-1.06 (m, 5H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.0, 147.4, 142.0, 136.3, 135.6, 133.4, 129.4, 128.2, 62.3, 47.3, 41.7, 33.6, 26.8, 26.6, 
12.5 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.4 
 
HRMS (ESI+) 
Calculated for C20H29BNO4 (M+H)
+
:  358.2190 
Found:      358.2188 
 
 
MIDA boronate 4.73. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.62 (205 mg, 0.87 mmol), MIDA boronate 4.12 (250 mg, 0.67 mmol), 2
nd
 generation 
XPhosPd cycle (52.5 mg, 0.07 mmol), Cs2CO3 (869 mg, 2.7 mmol), and DMSO (13 mL) were 
combined and stirred at 35 
o
C for 14 h, the reaction was worked up using H2O:brine (1:1, 40 mL) 
and EtOAc (40 mL). After drying, filtering, and concentrating, the residue was dry loaded onto 
celite and purified by reverse phase column chromatography on C18 silica gel (H2O:MeCN 
90:10  0:100) to afford MIDA boronate 4.73 as a pale yellow solid (76 mg, 32%). 
 
TLC (Et2O:MeCN 6:1) 
Rf =0.32, stained by KMnO4 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.97 (dd, J = 17.0, 11.0 Hz, 1H), 6.34 (dd, J = 15.0, 10.0 Hz, 1H), 6.24 (d, J = 15.5 Hz, 
1H), 6.15 (d, J = 11.0 Hz, 1H), 6.12 (dd, J = 15.0, 10.0 Hz, 1H), 5.74 (d, J = 15.5 Hz, 
1H), 5.72 (d, J = 17.0 Hz, 1H), 4.21 (d, J = 17.0 Hz, 2H), 4.04 (d, J = 17.0 Hz, 2H), 2.99 
(s, 3H), 2.05 (m, 1H), 1.90 (s, 3H), 1.76-1.60 (m, 5H), 1.35-1.05 (m, 5H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 141.6, 139.2, 136.7, 136.0, 133.6, 130.5, 129.3, 62.2, 47.3, 41.7, 33.5, 26.7, 26.5, 
12.8 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.4 
 
HRMS (ESI+) 
Calculated for C20H29BNO4 (M+H)
+
:  358.2190 
Found:      358.2189 
 
 
Pinacol ester 4.74. Following the general deprotection condition, MIDA boronate 4.68 (50 mg, 
0.16 mmol), NaHCO3 (66 mg, 0.79 mmol), pinacol (28 mg, 0.24 mmol), and MeOH (1 mL) were 
stirred at 45 
o
C for 3 h. After filtration and concentration, to the residue was added NaHCO3 (66 
mg, 0.79 mmol), CaCl2 (87 mg, 0.79 mmol), and toluene (1 mL). After stirring at 23 
o
C for 1 h, 
filtering, and concentrating, pinacol ester 4.74 was obtained as a clear, colorless oil (44 mg, 
98%). 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.97 (dd, J = 17.5, 11.0 Hz, 1H), 6.41 (dd, J = 15.0, 10.0 Hz, 1H), 6.24 (dd, J = 15.0, 
11.0 Hz, 1H), 6.12 (dd, J = 15.0, 11.0 Hz, 1H), 5.81 (dd, J = 15.0, 7.0 Hz, 1H), 5.46 (d, J 
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= 17.5 Hz, 1H), 2.07 (m, 1H), 2.05 (s, 3H), 1.77-1.60 (m, 5H), 1.34-1.03 (m, 5H), 1.23 (s, 
12H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 150.6, 144.2, 138.0, 133.2, 128.7, 83.6, 41.7, 33.4, 26.7, 26.6, 25.1 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 30.6 
 
HRMS (ESI+) 
Calculated for C18H30BO2 (M+H)
+
:  289.2339 
Found:      289.2342 
 
 
Pinacol ester 4.75. Following the general deprotection condition, MIDA boronate 4.69 (134 mg, 
0.40 mmol), NaHCO3 (170 mg, 2.0 mmol), pinacol (72 mg, 0.60 mmol), and MeOH (4 mL) were 
stirred at 45 
o
C for 3 h. After filtration and concentration, to the residue was added NaHCO3 (170 
mg, 2.0 mmol), CaCl2 (224 mg, 2.0 mmol), and toluene (4 mL). After stirring at 23 
o
C for 1 h, 
filtering, and concentrating, pinacol ester 4.75 was obtained as a clear, colorless oil (119 mg, 
97%). 
 
1
H-NMR (400 MHz, d6-acetone) 
δ 7.34 (dd, J = 17.0, 11.0 Hz, 1H), 6.13 (d, J = 15.5 Hz, 1H), 6.10 (d, J = 11.0 Hz, 1H), 
5.82 (dd, J = 15.5, 7.0 Hz, 1H), 5.49 (d, J = 17.0 Hz, 1H), 2.07 (m, 1H), 1.91 (s, 3H), 
1.79-1.59 (m, 5H), 1.37-1.05 (m, 5H), 1.24 (s, 12H). 
 
13
C-NMR (100 MHz, d6-acetone) 
δ 146.1, 139.7, 138.6, 132.9, 131.9, 83.6, 41.9, 33.6, 26.7, 26.6, 25.2, 13.0 
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11
B-NMR (128 MHz, d6-acetone) 
δ 30.6 
 
HRMS (ESI+) 
Calculated for C19H32BO2 (M+H)
+
:  303.2495 
Found:      303.2493 
 
 
Pinacol ester 4.76. Following the general deprotection condition, MIDA boronate 4.70 (71 mg, 
0.21 mmol), NaHCO3 (90 mg, 1.1 mmol), pinacol (38 mg, 0.32 mmol), and MeOH (1.1 mL) 
were stirred at 45 
o
C for 3 h. After filtration and concentration, to the residue was added 
NaHCO3 (90 mg, 1.1 mmol), CaCl2 (119 mg, 1.1 mmol), and toluene (1.1 mL). After stirring at 
23 
o
C for 1 h, filtering, and concentrating, pinacol ester 4.76 was obtained as a clear, colorless oil 
(59 mg, 91%). 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.40 (dd, J = 15.0, 11.0 Hz, 1H), 6.25 (d, J = 15.0 Hz, 1H), 6.12 (dd, J = 15.0, 11.0 Hz, 
1H), 5.81 (dd, J = 15.0, 7.0 Hz, 1H), 5.25 (s, 1H), 2.01 (s, 3H), 2.06 (m, 1H), 1.77-1.61 
(m, 5H), 1.36-1.05 (m, 5H), 1.25 (s, 12H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 156.1, 143.3, 137.3, 132.8, 128.9, 83.3, 41.7, 33.4, 26.7, 26.6, 25.2, 16.6 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 30.6 
 
HRMS (ESI+) 
Calculated for C19H32BO2 (M+H)
+
:  303.2495 
Found:      303.2495 
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Pinacol ester 4.77. Following the general deprotection condition, MIDA boronate 4.73 (76 mg, 
0.21 mmol), NaHCO3 (88 mg, 1.1 mmol), pinacol (38 mg, 0.32 mmol), and MeOH (1.0 mL) 
were stirred at 45 
o
C for 3 h. After filtration and concentration, to the residue was added 
NaHCO3 (89 mg, 1.1 mmol), CaCl2 (117 mg, 1.1 mmol), and toluene (1.0 mL). After stirring at 
23 
o
C for 1 h, filtering, and concentrating, pinacol ester 4.77 was obtained as a clear, colorless oil 
(67 mg, 96%). 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.35 (dd, J = 17.0, 11.0 Hz, 1H), 6.42 (dd, J = 15.0, 10.0 Hz, 1H), 6.26 (d, J = 15.5 Hz, 
1H), 6.17 (d, J = 11.0 Hz, 1H), 6.14 (dd, J = 15.0, 10.0 Hz, 1H), 5.78 (dd, J = 15.0, 7.0 
Hz, 1H), 5.52 (d, J = 17.0 Hz, 1H), 2.06 (m, 1H), 1.95 (s, 3H), 1.77-1.60 (m, 5H), 1.38-
1.06 (m, 5H), 1.25 (s, 12H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 146.0, 142.5, 139.9, 135.6, 133.1, 131.9, 129.3, 83.6, 41.7, 33.5, 26.7, 26.6, 25.2, 12.9 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 30.5 
 
HRMS (ESI+) 
Calculated for C21H34BO2 (M+H)
+
:  329.2652 
Found:      329.2656 
 
 
MIDA boronate 4.78. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.74 (44 mg, 0.15 mmol), MIDA boronate 4.8 (46 mg, 0.13 mmol), 2
nd
 generation XPhosPd 
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cycle (10.0 mg, 0.01 mmol), Cs2CO3 (166 mg, 0.5 mmol), and DMSO (2.5 mL) were combined 
and stirred at 35 
o
C for 14 h, the reaction was worked up using H2O:brine (1:1, 15 mL) and 
EtOAc (15 mL). After drying, filtering, and concentrating, the residue was dry loaded onto celite 
and purified by column chromatography on florisil (hexanes:EtOAc 80:20  0:100) to afford 
MIDA boronate 4.78 as a pale yellow solid (30 mg, 60%). 
 
TLC (Et2O:MeCN 6:1) 
Rf =0.57, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-DMSO) 
δ 6.51 (dd, J = 17.0, 10.0 Hz, 1H), 6.40-6.21 (m, 8H), 6.08 (dd, J = 16.0, 11.0 Hz, 1H), 
5.72 (dd, J = 15.0, 7.0 Hz, 1H), 5.64 (d, J = 17.0 Hz, 1H), 4.21 (d, J = 17.0 Hz, 2H), 4.00 
(d, J = 17.0 Hz, 2H), 2.74 (s, 3H), 2.02 (m, 1H), 1.76-1.56 (m, 5H), 1.30-1.00 (m, 5H). 
 
13
C-NMR (125 MHz, d6-DMSO) 
δ 169.3, 142.0, 141.6, 141.0, 134.9, 134.3, 134.2, 134.0, 132.8, 132.5, 131.3, 128.5, 61.5, 
46.9, 40.5, 32.5, 35.8, 25.6 
 
11
B-NMR (128 MHz, d6-DMSO) 
δ 10.4 
 
HRMS (ESI+) 
Calculated for C23H31BNO4 (M+H)
+
:  396.2346 
Found:      396.2343 
 
 
MIDA boronate 4.79. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.75 (51 mg, 0.17 mmol), MIDA boronate 4.11 (50 mg, 0.13 mmol), 2
nd
 generation 
XPhosPd cycle (10.1 mg, 0.01 mmol), Cs2CO3 (168 mg, 0.5 mmol), and DMSO (2.5 mL) were 
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combined and stirred at 35 
o
C for 14 h 30 min, the reaction was worked up using H2O:brine (1:1, 
15 mL) and EtOAc (15 mL). After drying, filtering, and concentrating, the residue was dry 
loaded onto celite and purified by column chromatography on florisil (hexanes:EtOAc 90:10  
0:100) to afford MIDA boronate 4.79 as a pale yellow solid (29 mg, 51%). 
 
TLC (Et2O:MeCN 6:1) 
Rf =0.50, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.75-6.65 (m, 3H), 6.56-6.50 (m, 1H), 6.38 (d, J = 15.0 Hz, 1H), 6.32-6.26 (m, 1H), 
6.15 (d, J = 16.0 Hz, 1H), 6.14 (d, J = 11.0 Hz, 1H), 5.71 (dd, J = 15.0, 7.0 Hz, 1H), 4.23 
(d, J = 17.0 Hz, 2H), 4.06 (d, J = 17.0 Hz, 2H), 2.97 (s, 3H), 2.07 (m, 1H), 1.98 (s, 3H), 
1.89 (s, 3H), 1.83 (s, 3H), 1.77-1.60 (m, 5H), 1.37-1.06 (m, 5H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 137.9, 137.7, 137.4, 136.4, 136.3, 133.4, 132.9, 131.2, 131.1, 130.3, 125.9, 62.7, 
47.1, 42.0, 33.9, 26.8, 26.7, 15.4, 13.0, 12.8 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.7 
 
HRMS (ESI+) 
Calculated for C26H37BNO4 (M+H)
+
:  438.2816 
Found:      438.2808 
 
 
MIDA boronate 4.80. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.76 (83 mg, 0.27 mmol), MIDA boronate 4.9 (69 mg, 0.21 mmol), 2
nd
 generation XPhosPd 
cycle (16.5 mg, 0.02 mmol), Cs2CO3 (274 mg, 0.8 mmol), and DMSO (4 mL) were combined 
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and stirred at 35 
o
C for 15 h, the reaction was worked up using H2O:brine (1:1, 25 mL) and 
EtOAc (25 mL). After drying, filtering, and concentrating, the residue was dry loaded onto celite 
and purified by reverse phase column chromatography on C18 silica gel (H2O:MeCN 95:5  
0:100) to afford MIDA boronate 4.80 as a yellow solid (16 mg, 18%). 
 
TLC (Et2O:MeCN 6:1) 
Rf =0.43, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.76 (dd, J = 15.0, 11.0 Hz, 1H), 6.69 (d, J = 11.0 Hz, 1H), 6.67 (d, J = 17.0 Hz, 1H), 
6.39-6.22 (m, 4H), 6.14 (dd, J = 15.0, 10.0 Hz, 1H), 5.75 (d, J = 17.5 Hz, 1H), 5.73 (dd, J 
= 15.0, 7.0 Hz, 1H), 4.22 (d, J = 17.0 Hz, 2H), 4.04 (d, J = 17.0 Hz, 2H), 3.01 (s, 3H), 
2.02 (m, 1H), 1.92 (s, 3H), 1.85 (s, 3H), 1.77-1.60 (m, 5H), 1.36-1.06 (m, 5H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.0, 147.3, 141.6, 137.0, 136.9, 136.1, 133.9, 132.4, 131.6, 130.4, 130.3, 129.6, 62.3, 
47.3, 41.8, 33.6, 26.8, 26.6, 12.8, 12.6 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.8 
 
HRMS (ESI+) 
Calculated for C25H35BNO4 (M+H)
+
:  424.2659 
Found:      424.2663 
 
 
MIDA boronate 4.81. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.77 (65 mg, 0.20 mmol), MIDA boronate 4.10 (92.4 mg, 0.24 mmol), 2
nd
 generation 
XPhosPd cycle (15.6 mg, 0.02 mmol), Cs2CO3 (258 mg, 0.8 mmol), and DMSO (4 mL) were 
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combined and stirred at 35 
o
C for 15 h, the reaction was worked up using H2O:brine (1:1, 20 mL) 
and EtOAc (20 mL). After drying, filtering, and concentrating, the residue was dry loaded onto 
celite and purified by reverse phase column chromatography on C18 silica gel (H2O:MeCN 
90:10  0:100) to afford MIDA boronate 4.81 as a yellow solid (28.4 mg, 31%). 
 
TLC (Et2O:MeCN 6:1) 
Rf =0.32, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.77-6.67 (m, 3H), 6.50 (d, J = 11.0 Hz, 1H), 6.41 (d, J = 15.0 Hz, 1H), 6.38-6.24 (m, 
4H), 6.14 (dd, J = 15.0, 10.0 Hz, 1H), 5.73 (dd, J = 15.0, 7.0 Hz, 1H), 4.23 (d, J = 17.0 
Hz, 2H), 4.06 (d, J = 17.0 Hz, 2H), 2.97 (s, 3H), 2.04 (m, 1H), 1.97 (s, 3H), 1.92 (s, 3H), 
1.84 (s, 3H), 1.79-1.59 (m, 5H), 1.37-1.06 (m, 5H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.2, 141.5, 139.1, 137.8, 136.9, 136.7, 136.1, 133.7, 132.5, 131.2, 130.5, 130.2, 
129.6, 125.2, 62.7, 47.1, 41.8, 33.6, 26.7, 26.6, 15.4, 12.8, 12.7 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.8 
 
HRMS (ESI+) 
Calculated for C28H39BNO4 (M+H)
+
:  464.2972 
Found:      464.2970 
 
 
MIDA boronate 4.82. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.75 (159 mg, 0.53 mmol), MIDA boronate 4.12 (153 mg, 0.44 mmol), 2
nd
 generation 
XPhosPd cycle (34.5 mg, 0.04 mmol), Cs2CO3 (571 mg, 1.8 mmol), and DMSO (9 mL) were 
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combined and stirred at 35 
o
C for 15 h, the reaction was worked up using H2O:brine (1:1, 25 mL) 
and EtOAc (25 mL). After drying, filtering, and concentrating, the residue was dry loaded onto 
celite and purified by column chromatography on florisil (Et2O:MeCN 100:0  55:45) to afford 
MIDA boronate 4.82 as a yellow solid (128 mg, 74%). 
 
TLC (Et2O:MeCN 4:1) 
Rf =0.64, stained by KMnO4 
 
1
H-NMR (400 MHz, d6-acetone) 
δ 7.00 (dd, J = 17.0, 11.0 Hz, 1H), 6.72 (dd, J = 15.0, 11.0 Hz,1H), 6.35 (d, J = 15.0 Hz, 
1H), 6.20 (d, J = 11.0 Hz, 1H), 6.14 (d, J = 15.0 Hz, 1H), 6.13 (d, J = 11.0 Hz, 1H), 5.75 
(d, J = 17.0 Hz, 1H), 5.70 (dd, J = 15.0, 7.0 Hz, 1H), 4.22 (d, J = 17.0 Hz, 2H), 4.04 (d, J 
= 17.0 Hz, 2H), 3.00 (s, 3H), 2.07 (m, 1H), 1.96 (s, 3H), 1.89 (s, 3H), 1.80-1.60 (m, 5H), 
1.38-1.05 (m, 5H). 
 
13
C-NMR (100 MHz, d6-acetone) 
δ 169.1, 139.2, 137.7, 137.0, 136.5, 136.4, 134.2, 133.3, 130.9, 126.4, 62.2, 47.4, 41.9, 
33.8, 26.7, 26.6, 12.9, 12.8 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.2 
 
HRMS (ESI+) 
Calculated for C23H33BNO4 (M+H)
+
:  398.2503 
Found:      398.2505 
 
 
MIDA boronate 4.83. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.75 (180 mg, 0.60 mmol), MIDA boronate 4.10 (210 mg, 0.54 mmol), 2
nd
 generation 
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XPhosPd cycle (43 mg, 0.05 mmol), Cs2CO3 (706 mg, 2.2 mmol), and DMSO (11 mL) were 
combined and stirred at 35 
o
C for 13 h 30 min, the reaction was worked up using H2O:brine (1:1, 
50 mL) and EtOAc (50 mL). After drying, filtering, and concentrating, the residue was dry 
loaded onto celite and purified by reverse phase column chromatography on C18 silica gel 
(H2O:MeCN 90:10  0:100) to afford MIDA boronate 4.83 as a yellow solid (100 mg, 48%). 
 
TLC (Et2O:MeCN 4:1) 
Rf =0.60, stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.75-6.65 (m, 3H), 6.50 (d, J = 11.0 Hz, 1H), 6.40 (d, J = 15.0 Hz, 1H), 6.33 (d, J = 
10.0 Hz, 1H), 6.18 (d, J = 10.0 Hz, 1H), 6.14 (d, J = 15.0 Hz, 1H), 5.72 (dd, J = 15.0, 7.0 
Hz, 1H), 4.23 (d, J = 17.0 Hz, 2H), 4.06 (d, J = 17.0 Hz, 2H), 2.97 (s, 3H), 2.07 (m, 1H), 
1.96 (s, 3H), 1.88 (s, 3H), 1.84 (s, 3H), 1.77-1.61 (m, 5H), 1.37-1.06 (m, 5H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.2, 139.1, 137.7, 136.8, 136.7, 136.3, 133.7, 133.3, 131.2, 131.1, 130.0, 125.0, 62.2, 
47.1, 42.0, 33.8, 26.7, 26.6, 15.3, 12.9, 12.8 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.9 
 
HRMS (ESI+) 
Calculated for C26H37BNO4 (M+H)
+
:  438.2816 
Found:      438.2818 
 
 
Pinacol ester 4.84. Following the general deprotection condition, MIDA boronate 4.82 (49 mg, 
0.12 mmol), NaHCO3 (51 mg, 0.61 mmol), pinacol (22 mg, 0.18 mmol), and MeOH (1.2 mL) 
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were stirred at 45 
o
C for 3 h. After filtration and concentration, to the residue was added 
NaHCO3 (51 mg, 0.61 mmol), CaCl2 (68 mg, 0.61 mmol), and toluene (1.2 mL). After stirring at 
23 
o
C for 1 h, filtering, and concentrating, pinacol ester 4.84 was obtained as a clear, colorless oil 
(44 mg, 97%). 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.36 (dd, J = 17.0, 11.0 Hz, 1H), 6.81 (dd, J = 15.0, 11.0 Hz, 1H), 6.36 (d, J = 15.0 Hz, 
1H), 6.21 (d, J = 11.0 Hz, 1H), 6.15 (d, J = 15.0 Hz, 1H), 6.14 (d, J = 11.0 Hz, 1H), 5.74 
(d, J = 16.0, 7.0 Hz, 1H), 5.54 (d, J = 17.0 Hz, 1H), 2.07 (m, 1H), 2.01 (s, 3H), 1.91 (s, 
3H), 1.78-1.59 (m, 5H), 1.35-1.09 (m, 5H), 1.25 (s, 12H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 146.0, 140.3, 137.3, 137.0, 133.6, 133.3, 130.8, 129.0, 127.7, 83.7, 42.0, 33.8, 26.8, 
26.7, 25.1, 13.0, 12.9  
 
11
B-NMR (128 MHz, d6-acetone) 
δ 30.4 
 
HRMS (ESI+) 
Calculated for C24H38BO2 (M+H)
+
:  369.2965 
Found:      369.2957 
 
 
Pinacol ester 4.85. Following the general deprotection condition, MIDA boronate 4.83 (30 mg, 
0.07 mmol), NaHCO3 (29 mg, 0.35 mmol), pinacol (12 mg, 0.10 mmol), and MeOH (0.5 mL) 
were stirred at 45 
o
C for 3 h. After filtration and concentration, to the residue was added 
NaHCO3 (29 mg, 0.35 mmol), CaCl2 (39 mg, 0.35 mmol), and toluene (0.5 mL). After stirring at 
23 
o
C for 1 h, filtering, and concentrating, pinacol ester 4.85 was obtained as a clear, colorless oil 
(28 mg, 99%). 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.89 (d, J = 11.0 Hz, 1H), 6.87-6.63 (m, 3H), 6.38 (d, J = 15.0 Hz, 1H), 6.30 (d, J = 
11.0 Hz, 1H), 6.15 (d, J = 15.0 Hz, 1H), 6.15 (d, J = 11.0 Hz, 1H), 5.72 (dd, J = 15.0, 7.0 
Hz, 1H), 2.07 (m, 1H), 2.01 (s, 3H), 1.90 (s, 3H), 1.80 (s, 3H), 1.77-1.59 (m, 5H), 1.33-
1.04 (m, 5H), 1.25 (s, 12H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 143.5, 138.8, 137.7, 136.7, 136.6, 133.4, 133.3, 132.6, 131.1, 129.7, 126.5, 83.9, 42.0, 
33.9, 26.8, 26.7, 25.2, 14.6, 13.0, 12.9 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 30.7 
 
HRMS (ESI+) 
Calculated for C27H41BO2 (M+H)
+
:  408.3200 
Found:      408.3193 
 
 
MIDA boronate 4.86. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.84 (76 mg, 0.21 mmol), MIDA boronate 4.10 (81 mg, 0.21 mmol), 2
nd
 generation 
XPhosPd cycle (16 mg, 0.02 mmol), Cs2CO3 (270 mg, 0.83 mmol), and DMSO (4 mL) were 
combined and stirred at 35 
o
C for 13 h, the reaction was worked up using H2O:brine (1:1, 20 mL) 
and EtOAc (20 mL). After drying, filtering, and concentrating, the residue was dry loaded onto 
celite and purified by column chromatography on florisil (Et2O:MeCN 100:0  60:40) to afford 
MIDA boronate 4.86 as a yellow solid (54 mg, 52%). 
 
TLC (Et2O:MeCN 6:1) 
Rf =0.48 stained by KMnO4 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.76-6.67 (m, 4H), 6.50 (d, J = 11.0 Hz, 1H), 6.41 (d, J = 15.0 Hz, 1H), 6.38 (d, J = 
15.0 Hz, 1H), 6.36-6.28 (m, 2H), 6.15 (d, J = 17.0 Hz, 1H), 6.14 (d, J = 11.0 Hz, 1H), 
5.71 (dd, J = 15.0, 7.0 Hz, 1H), 4.23 (d, J = 17.0 Hz, 2H), 4.06 (d, J = 17.0 Hz, 2H), 2.98 
(s, 3H), 2.03 (m, 1H), 1.98 (s, 6H), 1.90 (s, 3H), 1.85 (s, 3H), 1.78-1.60 (m, 5H), 1.36-
1.07 (m, 5H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.2, 139.1, 137.9, 137.8, 137.3, 137.0, 136.5, 136.4, 133.8, 133.5, 133.2, 131.3, 
131.2, 130.9, 126.1, 125.4, 62.7, 47.1, 42.0, 33.9, 26.8, 26.7, 15.4, 13.0, 12.8, 12.8 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.8 
 
HRMS (ESI+) 
Calculated for C31H43BNO4 (M+H)
+
:  504.3285 
Found:      504.3287 
 
 
MIDA boronate 4.87. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.85 (26.0 mg, 0.06 mmol), MIDA boronate 4.9 (17.4 mg, 0.05 mmol), 2
nd
 generation 
XPhosPd cycle (4.2 mg, 0.005 mmol), Cs2CO3 (69.1 mg, 0.21 mmol), and DMSO (1.1 mL) were 
combined and stirred at 35 
o
C for 13 h, the reaction was worked up using H2O:brine (1:1, 10 mL) 
and EtOAc (10 mL). After drying, filtering, and concentrating, the residue was dry loaded onto 
celite and purified by reverse phase column chromatography on C18 silica gel (H2O:MeCN 95:5 
 0:100) to afford MIDA boronate 4.87 as an orange solid (10.7 mg, 38%). 
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TLC (Et2O:MeCN 6:1) 
Rf =0.40 stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.81-6.62 (m, 5H), 6.48 (d, J = 15.0 Hz, 1H), 6.38 (d, J = 15.0 Hz, 1H), 6.32 (dd, J = 
18.0, 10.0 Hz, 1H), 6.29 (d, J = 11.0 Hz, 1H), 6.15 (d, J = 15.0 Hz, 1H), 6.14 (d, J = 11.0 
Hz, 1H), 6.14 (m, 1H), 5.75 (d, J = 18.0 Hz, 1H), 5.71 (dd, J = 15.0, 7.0 Hz, 1H), 4.22 (d, 
J = 17.0 Hz, 2H), 4.04 (d, J = 17.0 Hz, 2H), 3.01 (s, 3H), 2.01 (m, 1H), 1.98 (s, 6H), 1.95 
(s, 3H), 1.90 (s, 3H), 1.77-1.60 (m, 5H), 1.35-1.04 (m, 5H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.0, 139.4, 137.6, 137.0, 136.9, 134.4, 134.2, 133.4, 133.3, 133.0, 132.4, 132.3, 
132.0, 131.3, 130.7, 130.6, 127.0, 126.9, 62.3, 47.3, 42.1, 33.9, 26.8, 26.6, 15.1, 13.0, 
12.8, 12.7 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.5 
 
HRMS (ESI+) 
Calculated for C33H45BNO4 (M+H)
+
:  530.3442 
Found:      530.3441 
 
 
Triene 4.22. In a glovebox, to a 20 mL vial charged with MIDA boronate 4.64 (69.1 mg, 0.24 
mmol) was added vinyl iodide 4.38 (38.7 mg, 0.18 mmol), Pd(OAc)2 (3.8 mg, 0.017 mmol), 
XPhos (10.4 mg, 0.022 mmol), finely ground NaOH (55.7 mg, 1.4 mmol) and THF (3.0 mL).  
The vial was sealed with a septum cap and removed from the glovebox.  To the reaction was 
added degassed DI H2O (0.6 mL).  The solution was stirred in a subdued light environment at 23 
o
C for 4.5 hr. The reaction mixture was filtered through a pad of MgSO4/Celite, concentrated in 
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vacuo, dry loaded onto Celite from an acetone solution, and purified via flash chromatography 
on silica (Hexanes/EtOAc 100:0 → 70:30) to afford triene 4.22 as a yellow oil (20.3 mg, 51%). 
 
TLC (Hexanes:EtOAc 4:1) 
Rf = 0.19, stained by KMnO4 
 
1
H-NMR (500 MHz, CDCl3) 
δ 6.12-5.97 (m, 4H), 5.65 (dd, J = 15.0, 7.0 Hz, 1H), 5.63 (dd, J = 15.0, 7.0 Hz, 1H), 3.65 
(t, J = 6.5 Hz, 2H), 2.18 (q, J = 7.5 Hz, 2H), 2.00 (m, 1H), 1.77-1.60 (m, 6H), 1.38 (bs, 
1H), 1.32-1.00 (m, 6H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 140.6, 133.0, 131.6, 131.1, 130.6, 127.7, 62.4, 40.8, 32.8, 32.2, 29.1, 26.1, 26.0 
 
HRMS (ESI+) 
Calculated for C15H25O (M+H)
+
:  221.1905 
Found:      221.1907 
 
 
Triene 4.23. In a glovebox, to a 20 mL vial charged with MIDA boronate 4.65 (58.2 mg, 0.20 
mmol) was added vinyl iodide 4.38 (37.6 mg, 0.18 mmol), Pd(OAc)2 (7.1 mg, 0.032 mmol), 
XPhos (21.7 mg, 0.046 mmol), finely ground NaOH (47.4 mg, 1.2 mmol) and THF (2.5 mL).  
The vial was sealed with a septum cap and removed from the glovebox.  To the reaction was 
added degassed DI H2O (0.5 mL).  The solution was stirred in a subdued light environment at 23 
o
C for 4 hr. The reaction mixture was filtered through a pad of MgSO4/Celite, concentrated in 
vacuo, dry loaded onto Celite from an acetone solution, and purified via flash chromatography 
on silica (Hexanes/EtOAc 100:0 → 70:30) to afford triene 4.23 as a yellow oil (19.7 mg, 51%). 
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TLC (Hexanes:EtOAc 4:1) 
Rf = 0.21, stained by KMnO4 
 
1
H-NMR (500 MHz, CDCl3) 
δ 6.52 (dd, J = 15.0, 9.0 Hz, 1H), 6.44 (dd, J = 15.0, 7.5 Hz, 1H), 5.90-5.80 (m, 2H), 5.69 
(dd, J = 15.0, 7.5 Hz, 1H), 5.65 (dd, J = 15.0, 7.0 Hz, 1H), 3.67 (t, J = 6.5 Hz, 2H), 2.23 
(q, J = 7.5 Hz, 2H), 2.04 (m, 1H), 1.78-1.60 (m, 6H), 1.35 (bs, 1H), 1.32-1.02 (m, 6H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 141.5, 134.1, 128.4, 127.4, 126.4, 123.1, 62.4, 41.1, 32.9, 32.3, 29.2, 26.1, 26.0 
 
HRMS (ESI+) 
Calculated for C15H24ONa (M+Na)
+
:  243.1725 
Found:      243.1733 
 
 
Triene 4.25. In a glovebox, to a 20 mL vial charged with MIDA boronate 4.66 (108.2 mg, 0.35 
mmol) was added vinyl iodide 4.38 (60.0 mg, 0.28 mmol), Pd(OAc)2 (3.3 mg, 0.015 mmol), 
XPhos (14.1 mg, 0.030 mmol), finely ground NaOH (84.6 mg, 2.1 mmol) and THF (5.0 mL).  
The vial was sealed with a septum cap and removed from the glovebox.  To the reaction was 
added degassed DI H2O (0.9 mL).  The solution was stirred in a subdued light environment at 23 
o
C for 4 hr. The reaction mixture was filtered through a pad of MgSO4/Celite, concentrated in 
vacuo, dry loaded onto Celite from an acetone solution, and purified via flash chromatography 
on silica (Hexanes/EtOAc 100:0 → 70:30) to afford triene 4.25 as a yellow oil (27.8 mg, 42%). 
 
TLC (Hexanes:EtOAc 4:1) 
Rf = 0.24, visualized by short wave UV 
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1
H-NMR (500 MHz, CDCl3) 
δ 6.32 (ddd, J = 15.0, 11.0, 1.0 Hz, 1H), 6.09 (d, J = 15.5 Hz, 1H), 5.93 (d, J = 11.0 Hz, 
1H), 5.65 (dd, J = 15.0, 7.0 Hz, 1H), 5.64 (dt, J = 15.0, 7.0 Hz, 1H), 3.66 (t, J = 6.5 Hz, 
2H), 2.21 (q, J = 7.0 Hz, 2H), 2.04 (m, 1H), 1.83 (s, 3H), 1.77-1.60 (m, 6H), 1.42 (bs, 
1H), 1.33-1.03 (m, 6H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 141.0, 135.4, 132.9, 129.8, 127.9, 124.1, 62.4, 41.2, 33.0, 32.5, 29.3, 26.1, 26.0, 12.7 
 
HRMS (ESI+) 
Calculated for C16H27O (M+H)
+
:  235.2062 
Found:      235.2052 
 
 
Triene 4.24. In a glovebox, to a 20 mL vial charged with MIDA boronate 4.67 (43.3 mg, 0.14 
mmol) was added vinyl iodide 4.38 (24.5 mg, 0.12 mmol), Pd(OAc)2 (2.2 mg, 0.010 mmol), 
XPhos (6.2 mg, 0.013 mmol), finely ground NaOH (32.1 mg, 0.80 mmol) and THF (2.0 mL).  
The vial was sealed with a septum cap and removed from the glovebox.  To the reaction was 
added degassed DI H2O (0.4 mL).  The solution was stirred in a subdued light environment at 23 
o
C for 4 hr. The reaction mixture was filtered through a pad of MgSO4/Celite, concentrated in 
vacuo, dry loaded onto Celite from an acetone solution, and purified via flash chromatography 
on silica (Hexanes/EtOAc 100:0 → 70:30) to afford triene 4.24 as a yellow oil (15.4 mg, 57%). 
 
TLC (Hexanes:EtOAc 4:1) 
Rf = 0.23, visualized by short wave UV 
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1
H-NMR (500 MHz, CDCl3) 
δ 6.63 (d, J = 15.5 Hz, 1H), 6.46 (ddd, J = 15.0, 11.0, 1.0 Hz, 1H), 5.84 (d, J = 11.0 Hz, 
1H), 5.69, (dt, J = 15.5, 7.0 Hz, 1H), 5.59 (dd, J = 15.0, 7.0 Hz, 1H), 3.68 (t, J = 6.5 Hz, 
2H), 2.26 (q, J = 7.0 Hz, 2H), 2.03 (m, 1H), 1.84 (s, 3H), 1.77-1.60 (m, 6H), 1.34 (bs, 
1H), 1.33-1.03 (m, 6H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 140.2, 131.5, 130.0, 128.4, 127.7, 122.9, 62.5, 41.1, 33.0, 32.5, 29.6, 26.1, 26.0, 20.6 
 
HRMS (ESI+) 
Calculated for C16H27O (M+H)
+
:  235.2062 
Found:      235.2066 
 
 
Tetraene 4.26. Following the general MIDA boronate cross-coupling reaction condition, MIDA 
boronate 4.68 (40.0 mg, 0.13 mmol), vinyl iodide 4.38 (34.8 mg, 0.16 mmol), 2
nd
 generation 
XPhosPd cycle (9.9 mg, 0.013 mmol), NaOH (37.8 mg, 0.95 mmol), THF (2.1 mL), and 
degassed H2O (0.4 mL) were combined and stirred at 23 
o
C for 4 h. The reaction was worked up 
using Et2O (4.0 mL) and H2O (4.0 mL) and the aqueous layer was extracted with Et2O (2 x 4.0 
mL). After drying, filtering, and concentrating, the residue was dry loaded onto celite and 
purified by column chromatography on florisil (hexanes:EtOAc 100:0  70:30) to afford 
tetraene 4.26 as a pale yellow solid (9.5 mg, 31%). 
 
TLC (hexanes:EtOAc 4:1) 
Rf =0.29 stained by KMnO4 
 
1
H-NMR (500 MHz, CDCl3) 
δ 6.22-6.07 (m, 5H), 6.04 (ddd, J = 15.0, 10.0, 1.0 Hz, 1H), 5.68 (dt, J = 15.0, 7.0 Hz, 
1H), 5.66 (dd, J = 15.0, 7.0 Hz, 1H), 3.66 (t, J = 6.5 Hz, 2H), 2.20 (q, J = 7.0 Hz, 2H), 
2.01 (m, 1H), 1.80-1.60 (m, 6H), 1.30 (bs, 1H), 1.29-1.00 (m, 6H). 
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13
C-NMR (125 MHz, CDCl3) 
δ 141.1, 133.7, 133.1, 131.9, 131.3, 131.2, 130.8, 128.0, 62.4, 40.9, 32.8, 32.2, 29.1, 26.1, 
26.0 
 
HRMS (EI+) 
Calculated for C17H26O:   246.1984 
Found:      246.1975 
 
 
Tetraene 4.27. Following the general MIDA boronate cross-coupling reaction condition, MIDA 
boronate 4.69 (22.5 mg, 0.07 mmol), vinyl iodide 4.38 (11.1 mg, 0.05 mmol), 2
nd
 generation 
XPhosPd cycle (2.1 mg, 0.003 mmol), NaOH (15.7 mg, 0.39 mmol), THF (0.9 mL), and 
degassed H2O (0.2 mL) were combined and stirred at 23 
o
C for 4 h. The reaction was worked up 
using Et2O (2.0 mL) and H2O (2.0 mL) and the aqueous layer was extracted with Et2O (2 x 2.0 
mL). After drying, filtering, and concentrating, the residue was dry loaded onto celite and 
purified by column chromatography on florisil (hexanes:EtOAc 100:0  80:20) to afford 
tetraene 4.27 as a pale yellow solid (7.5 mg, 55%). 
 
TLC (hexanes:EtOAc 4:1) 
Rf =0.24 stained by KMnO4 
 
1
H-NMR (500 MHz, CDCl3) 
δ 6.50-6.40 (m, 1H), 6.24-6.18 (m, 2H), 6.08 (d, J = 15.5 Hz, 1H), 6.00 (d, J = 11.0 Hz, 
1H), 5.69 (dt, J = 15.0, 7.0 Hz, 1H), 5.64 (dd, J = 15.0, 7.0 Hz, 1H), 3.67 (t, J = 6.5 Hz, 
2H), 2.21 (q, J = 7.0 Hz, 2H), 2.03 (m, 1H), 1.85 (s, 3H), 1.78-1.61 (m, 6H), 1.57 (bs, 
1H), 1.37-1.02 (m, 6H). 
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13
C-NMR (125 MHz, CDCl3) 
δ 135.9, 135.4, 133.5, 132.2, 132.2, 131.6, 129.3, 127.7, 62.4, 41.2, 33.1, 32.2, 29.1, 26.2, 
26.1, 12.7 
 
HRMS (ESI+) 
Calculated for C18H29O (M+H)
+
:  261.2218 
Found:      261.2211 
 
 
Pentaene 4.28. Following the general MIDA boronate cross-coupling reaction condition, MIDA 
boronate 4.71 (20.0 mg, 0.058 mmol), vinyl iodide 4.38 (16.0 mg, 0.076 mmol), 2
nd
 generation 
XPhosPd cycle (4.6 mg, 0.006 mmol), NaOH (17.5 mg, 0.43 mmol), THF (1.0 mL), and 
degassed H2O (0.2 mL) were combined and stirred at 23 
o
C for 1 h. The reaction was worked up 
using Et2O (2.0 mL) and H2O (2.0 mL) and the aqueous layer was extracted with Et2O (2 x 2.0 
mL). After drying, filtering, and concentrating, the residue was dry loaded onto celite and 
purified by column chromatography on florisil (hexanes:EtOAc 100:0  70:30) to afford 
pentaene 4.28 as a pale yellow solid (7.0 mg, 44%). 
 
TLC (hexanes:EtOAc 4:1) 
Rf =0.26 stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.32-6.06 (m, 8H), 5.76 (dt, J = 15.0, 7.0 Hz, 1H), 5.68 (dd, J = 15.0, 7.0 Hz, 1H), 3.55 
(q, J = 6.0 Hz, 2H), 3.29 (t, J = 6.0 Hz, 1H), 2.18 (q, J = 7.0 Hz, 2H), 2.03 (m, 1H), 1.79-
1.51 (m, 6H), 1.37-1.03 (m, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 141.6, 135.7, 134.2, 133.9, 133.4, 133.3, 132.0, 131.9, 131.8, 129.2, 61.8, 41.7, 33.5, 
33.3, 29.9, 26.7, 26.6 
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HRMS (EI+) 
Calculated for C19H28O:   272.2140 
Found:      272.2144 
 
 
Pentaene 4.29. Following the general MIDA boronate cross-coupling reaction condition, MIDA 
boronate 4.72 (30.0 mg, 0.083 mmol), vinyl iodide 4.38 (36.0 mg, 0.17 mmol), 2
nd
 generation 
XPhosPd cycle (6.6 mg, 0.008 mmol), NaOH (25.2 mg, 0.63 mmol), THF (1.4 mL), and 
degassed H2O (0.3 mL) were combined and stirred at 23 
o
C for 1 h. The reaction was worked up 
by diluting with acetone, drying the organic layer over MgSO4, filtering, and concentrating. The 
resulting residue was dry loaded onto celite and purified by column chromatography on florisil 
(hexanes:EtOAc 100:0  60:40) to afford pentaene 4.29 as a pale yellow solid (21.1 mg, 88%). 
 
TLC (hexanes:EtOAc 4:1) 
Rf =0.18 stained by KMnO4 
 
1
H-NMR (500 MHz, CDCl3) 
δ 6.53 (dd, J = 15.0, 7.0 Hz, 1H), 6.46 (dd, J = 15.0, 11.0 Hz, 1H), 6.27-6.05 (m, 5H), 
5.73 (dt, J = 15.0, 7.0 Hz, 1H), 5.69 (dd, J = 15.0, 7.0 Hz, 1H), 3.68 (t, J = 6.5 Hz, 2H), 
2.21 (q, J = 7.0 Hz, 2H), 2.03 (m, 1H), 1.87 (s, 3H), 1.78-1.57 (m, 6H), 1.29 (bs, 1H), 
1.28-1.00 (m, 6H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 141.3, 135.8, 134.8, 133.8, 133.5, 131.6, 131.4, 128.3, 127.8, 127.3, 62.4, 41.0, 32.8, 
32.3, 29.2, 26.2, 26.0, 12.6 
 
HRMS (EI+) 
Calculated for C20H30O:   286.2297 
Found:      286.2301 
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Hexaene 4.30. Following the general MIDA boronate cross-coupling reaction condition, MIDA 
boronate 4.82 (19.9 mg, 0.05 mmol), vinyl iodide 4.38 (8.8 mg, 0.04 mmol), 2
nd
 generation 
XPhosPd cycle (1.6 mg, 0.002 mmol), NaOH (12.5 mg, 0.31 mmol), THF (0.9 mL), and 
degassed H2O (0.2 mL) were combined and stirred at 23 
o
C for 4 h. The reaction was worked up 
using Et2O (2.0 mL) and H2O (2.0 mL) and the aqueous layer was extracted with Et2O (2 x 2.0 
mL). After drying, filtering, and concentrating, the residue was dry loaded onto celite and 
purified by column chromatography on florisil (hexanes:EtOAc 100:0  80:20) to afford 
hexaene 4.30 as a yellow solid (9.1 mg, 52%). 
 
TLC (hexanes:EtOAc 4:1) 
Rf =0.24 stained by KMnO4 
 
1
H-NMR (500 MHz, CDCl3) 
δ 6.57 (dd, J = 15.0, 11.0 Hz, 1H), 6.48 (dd, J = 14.0, 11.0 Hz, 1H), 6.30 (d, J = 15.0 Hz, 
1H), 6.24 (dd, J = 15.0, 11.0 Hz, 1H), 6.20 (dd, J = 15.0, 11.0 Hz, 1H), 6.11 (d, J = 11.0 
Hz, 1H), 6.10 (d, J = 15.5 Hz, 1H), 6.08 (d, J = 11.0 Hz, 1H), 5.73 (dt, J = 14.0, 7.0 Hz, 
1H), 5.65 (dd, J = 15.5, 7.0 Hz, 1H), 3.67 (t, J = 6.5 Hz, 2H), 2.22 (q, J = 7.0 Hz, 2H), 
2.05 (m, 1H), 1.92 (s, 3H), 1.89 (s, 3H), 1.80-1.61 (m, 6H), 1.57 (bs, 1H), 1.34-1.05 (m, 
6H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 136.9, 136.0, 135.8, 135.5, 134.2, 133.1, 132.4, 131.6, 131.4, 130.1, 127.8, 124.7, 62.4, 
41.2, 33.2, 32.2, 29.2, 26.2, 26.1, 12.9, 12.7 
 
HRMS (ESI+) 
Calculated for C23H35O (M+H)
+
:  327.2688 
Found:      327.2687 
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Heptaene 4.31. Following the general MIDA boronate cross-coupling reaction condition, MIDA 
boronate 4.78 (30.0 mg, 0.08 mmol), vinyl iodide 4.38 (24.1 mg, 0.11 mmol), 2
nd
 generation 
XPhosPd cycle (6.0 mg, 0.008 mmol), NaOH (23.0 mg, 0.6 mmol), THF (1.3 mL), and degassed 
H2O (0.3 mL) were combined and stirred at 23 
o
C for 1 h. The reaction was worked up using 
Et2O (3.0 mL) and H2O (3.0 mL) and the aqueous layer was extracted with Et2O (2 x 3.0 mL). 
After drying, filtering, and concentrating, the residue was dry loaded onto celite and purified by 
column chromatography on florisil (hexanes:EtOAc 100:0  70:30) to afford heptaene 4.31 as 
an orange solid (7.8 mg, 32%). 
 
TLC (hexanes:EtOAc 4:1) 
Rf = 0.23 stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.40-6.21 (m, 8H), 6.19-6.07 (m, 2H), 6.05 (dd, J = 15.0, 11.0 Hz, 1H), 5.98 (dd, J = 
8.0, 6.0 Hz, 1H), 5.79 (dt, J = 14.0, 7.0 Hz, 1H), 5.71 (dd, J = 15.0, 7.0 Hz, 1H), 3.55 (t, J 
= 6.5 Hz, 2H), 2.19 (q, J = 7.5 Hz, 2H), 2.09 (bs, 1H), 2.02 (m, 1H), 1.78-1.54 (m, 6H), 
1.36-1.01 (m, 6H). 
 
HRMS (EI+) 
Calculated for C23H32O:   324.2453 
Found:      324.2445 
 
 
Heptaene 4.32. Following the general MIDA boronate cross-coupling reaction condition, MIDA 
boronate 4.83 (53.8 mg, 0.12 mmol), vinyl iodide 4.38 (39.1 mg, 0.18 mmol), 2
nd
 generation 
XPhosPd cycle (9.7 mg, 0.012 mmol), NaOH (37.0 mg, 0.92 mmol), THF (2.0 mL), and 
degassed H2O (0.5 mL) were combined and stirred at 23 
o
C for 4 h. The reaction was worked up 
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using Et2O (4.0 mL) and H2O (4.0 mL) and the aqueous layer was extracted with Et2O (2 x 4.0 
mL). After drying, filtering, and concentrating, the residue was dry loaded onto celite and 
purified by reverse phase column chromatography on C18 silica gel (H2O:MeCN 85:15  
0:100) to afford heptaene 4.32 as an orange solid (12.9 mg, 29%). 
 
TLC (hexanes:EtOAc 4:1) 
Rf =0.26 stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.72-6.62 (m, 3H), 6.37 (d, J = 15.0 Hz, 1H), 6.28 (d, J = 11.0 Hz, 1H), 6.22-6.09 (m, 
4H), 5.78 (dt, J = 15.0, 7.0 Hz, 1H), 5.71 (dd, J = 15.5, 7.0 Hz, 1H), 3.56 (q, J = 6.0 Hz, 
2H), 3.51 (t, J = 6.0 Hz, 1H), 2.22 (q, J = 7.5 Hz, 2H), 2.07 (m, 1H), 1.96 (s, 3H), 1.90 (s, 
3H), 1.87 (s, 3H), 1.78-1.57 (m, 6H), 1.36-1.08 (m, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 146.6, 138.0, 136.7, 136.5, 136.0, 133.3, 133.2, 131.2, 131.1, 130.9, 130.4, 130.1, 
125.6, 120.5, 61.8, 42.0, 33.8, 31.5, 30.2, 26.8, 26.7, 13.0, 12.9, 12.8 
 
HRMS (EI+) 
Calculated for C26H38O:   366.2923 
Found:      366.2917 
 
 
Heptaene 4.33. Following the general MIDA boronate cross-coupling reaction condition, MIDA 
boronate 4.80 (10.7 mg, 0.025 mmol), vinyl iodide 4.38 (8.0 mg, 0.038 mmol), 2
nd
 generation 
XPhosPd cycle (2.0 mg, 0.003 mmol), NaOH (7.6 mg, 0.19 mmol), THF (0.5 mL), and degassed 
H2O (0.1 mL) were combined and stirred at 23 
o
C for 2 h. The reaction was worked up using 
Et2O (2.0 mL) and H2O (2.0 mL) and the aqueous layer was extracted with Et2O (2 x 2.0 mL). 
After drying, filtering, and concentrating, the residue was dry loaded onto celite and purified by 
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reverse phase column chromatography on C18 silica gel (H2O:MeCN 95:5  0:100) to afford 
heptaene 4.33 as an orange solid (5.3 mg, 60%). 
 
TLC (hexanes:EtOAc 4:1) 
Rf =0.26 stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.74-6.64 (m, 2H), 6.38-6.09 (m, 8H), 5.80 (dt, J = 15.0, 7.0 Hz, 1H), 5.72 (dd, J = 
15.0, 7.0 Hz, 1H), 3.55 (q, J = 6.5 Hz, 2H), 3.49 (t, J = 6.5 Hz, 1H), 2.19 (q, 7.0 Hz, 2H), 
2.02 (m, 1H), 1.91 (s, 6H), 1.79-1.56 (m, 6H), 1.40-1.04 (m, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 146.6, 141.4, 136.4, 136.2, 136.1, 135.5, 132.6, 132.6, 132.2, 130.6, 130.5, 130.0, 
129.7, 129.6, 61.8, 41.8, 38.9, 33.6, 31.5, 26.8, 26.6, 13.9, 12.7 
 
HRMS (EI+) 
Calculated for C26H36O:   352.2766 
Found:      352.2764 
 
 
Octaene 4.34. Following the general MIDA boronate cross-coupling reaction condition, MIDA 
boronate 4.81 (28.4 mg, 0.061 mmol), vinyl iodide 4.38 (19.5 mg, 0.092 mmol), 2
nd
 generation 
XPhosPd cycle (4.8 mg, 0.006 mmol), NaOH (18.4 mg, 0.46 mmol), THF (1.0 mL), and 
degassed H2O (0.2 mL) were combined and stirred at 23 
o
C for 1 h 30 min. The reaction was 
worked up using Et2O (2.0 mL) and H2O (2.0 mL) and the aqueous layer was extracted with 
Et2O (2 x 2.0 mL). After drying, filtering, and concentrating, the residue was dry loaded onto 
celite and purified by reverse phase column chromatography on C18 silica gel (H2O:MeCN 
90:10  0:100) to afford octaene 4.34 as an orange solid (6.9 mg, 29%). 
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TLC (hexanes:EtOAc 4:1) 
Rf =0.27 stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.91-6.59 (m, 3H), 6.41-6.06 (m, 9H), 5.79 (dt, J = 15.0, 7.0 Hz, 1H), 5.73 (dd, J = 
15.0, 7.0 Hz, 1H), 3.55 (t, J = 6.5 Hz, 2H), 2.21 (q, J = 7.0 Hz, 2H), 2.01 (m, 1H), 1.97 
(bs, 1H), 1.92 (s, 3H), 1.90 (s, 3H), 1.83 (s, 3H), 1.78-1.56 (m, 6H), 1.43-1.10 (m, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 146.6, 141.5, 137.6, 134.5, 134.4, 132.6, 132.4, 132.3, 132.0, 130.8, 130.7, 127.0, 
126.9, 125.7, 120.6, 120.5, 61.8, 42.7, 39.0, 38.4, 31.5, 26.0, 24.5, 13.2, 13.0, 12.5 
 
HRMS (ESI+) 
Calculated for C26H36O (M+H)
+
:  393.3157 
Found:      393.3152 
 
 
Nonaene 4.35. Following the general MIDA boronate cross-coupling reaction condition, MIDA 
boronate 4.86 (13.7 mg, 0.027 mmol), vinyl iodide 4.38 (4.8 mg, 0.023 mmol), 2
nd
 generation 
XPhosPd cycle (0.9 mg, 0.001 mmol), NaOH (6.8 mg, 0.17 mmol), THF (0.5 mL), and degassed 
H2O (0.1 mL) were combined and stirred at 23 
o
C for 4 h. The reaction was worked up using 
Et2O (2.0 mL) and H2O (2.0 mL) and the aqueous layer was extracted with Et2O (2 x 2.0 mL). 
After drying, filtering, and concentrating, the residue was dry loaded onto celite and purified by 
column chromatography on florisil (hexanes:EtOAc 100:0  70:30) to afford nonaene 4.35 as 
an orange solid (4.3 mg, 36%). 
 
TLC (hexanes:EtOAc 4:1) 
Rf =0.28 stained by KMnO4 
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1
H-NMR (500 MHz, CDCl3) 
δ 6.67-6.56 (m, 4H), 6.34 (d, J = 15.0 Hz, 1H), 6.32 (d, J = 15.0 Hz, 1H), 6.26-6.21 (m, 
2H), 6.18 (d, J = 15.0 Hz, 1H), 6.14-6.07 (m, 3H), 5.72 (dt, J = 15.0, 7.0 Hz, 1H), 5.67 
(dd, J = 15.0, 7.0 Hz, 1H), 3.68 (t, J = 6.0 Hz, 2H), 2.25 (q, J = 7.5 Hz, 2H), 2.05 (m, 
1H), 1.96 (s, 6H), 1.91 (s, 3H), 1.90 (s, 3H), 1.75 (bs, 1H), 1.74-1.63 (m, 6H), 1.34-1.07 
(m, 6H). 
 
13
C-NMR (125 MHz, CDCl3) 
δ 137.4, 137.0, 136.5, 136.3, 136.1, 135.8, 135.6, 132.5, 132.4, 132.3, 132.2, 130.5, 
130.2, 130.6, 129.8, 129.0, 125.0, 124.8, 62.5, 41.2, 33.2, 32.5, 29.4, 26.2, 26.1, 13.0, 
12.9, 12.8, 11.4 
 
HRMS (ESI+) 
Calculated for C31H45O (M+H)
+
:  433.3470 
Found:      433.3478 
 
 
Decaene 4.36. Following the general MIDA boronate cross-coupling reaction condition, MIDA 
boronate 4.87 (30.0 mg, 0.057 mmol), vinyl iodide 4.38 (18.0 mg, 0.085 mmol), 2
nd
 generation 
XPhosPd cycle (4.5 mg, 0.006 mmol), NaOH (17.0 mg, 0.42 mmol), THF (1.0 mL), and 
degassed H2O (0.2 mL) were combined and stirred at 23 
o
C for 1 h 30 min. The reaction was 
worked up using Et2O (2.0 mL) and H2O (2.0 mL) and the aqueous layer was extracted with 
Et2O (2 x 2.0 mL). After drying, filtering, and concentrating, the residue was dry loaded onto 
celite and purified by reverse phase column chromatography on C18 silica (H2O:MeCN 95:5  
0:100) to afford decaene 4.36 as an orange solid (mass ND). 
 
TLC (hexanes:EtOAc 4:1) 
Rf =0.29 stained by KMnO4 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.80-6.67 (m, 4H), 6.41 (d, J = 15.0 Hz, 1H), 6.38 (d, J = 15.0 Hz, 1H), 6.37-6.27 (m, 
4H), 6.26-6.11 (m, 4H), 5.81 (dd, J = 15.0, 7.5 Hz, 1H), 5.71 (dd, J = 15.0, 7.0 Hz, 1H), 
3.80 (bs, 1H), 3.55 (t, J = 6.0 Hz, 2H), 2.20 (q, J = 7.5 Hz, 2H), 2.03 (m, 1H), 1.98 (s, 
6H), 1.93 (s, 3H), 1.89 (s, 3H), 1.79-1.58 (m, 6H), 1.36-1.10 (m, 6H). 
 
 
MIDA boronate 4.20. To a 200 mL round bottom flask charged with a stir bar and 
dicyclohexylborane (503 mg, 2.8 mmol), under an inert atmosphere, was added THF (28 mL). 
The solution was cooled to 0 
o
C and catecholborane (3.0 mL, 28.2 mmol) was added in one 
portion. The solution was stirred at 0 
o
C for an additional 5 min. A solution of alkyne 4.88 (4.18 
g, 28.2 mmol) in THF (28 mL) was prepared and dropwise added to the cooled reaction solution 
over 15 min. The solution was warmed to 23 
o
C and stirred at this temperature for 15.5 h. After 
this time, to the solution was added N-methyliminodiacetic acid (MIDA, 6.31 g, 42.3 mmol) and 
DMSO (56 mL). The suspension was sealed under N2 and placed in a 60 
o
C oil bath with stirring 
for 4.5 h. After this time, the solution was cooled to 23 
o
C and transferred to a separatory funnel 
and diluted with H2O (300 mL) and EtOAc (300 mL). After shaking, the layers were separated 
and the aqueous layer was extracted with EtOAc (250 mL). The combined organic layers were 
washed with brine:H2O (1:1, 250 mL). The organic layer were dried over MgSO4, filtered and 
concentrated in vacuo. The resulting residue was dry loaded onto celite and purified by column 
chromatography on silica gel (Et2O:MeCN 100:0  60:40) to afford MIDA boronate 4.20 as a 
white solid (5.43 g, 63%). 
 
TLC (Et2O:MeCN 6:1) 
Rf = 0.41, stained by KMnO4 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.53 (d, J = 18.0 Hz, 1H), 5.48 (d, J = 18.0 Hz, 1H), 4.23 (d, J = 17.0 Hz, 2H), 4.05 (d, 
J = 17.0 Hz, 2H), 3.06 (s, 3H), 1.99 (ap t, J = 6.0 Hz, 2H), 1.69 (d, J = 1.0 Hz, 3H), 1.61 
(m, 2H), 1.45 (m, 2H), 1.01 (s, 6H). 
 
HRMS (ESI+) 
Calculated for C16H25BNO4 (M+H)
+
:  306.1877 
Found:      306.1870 
 
 
Vinyl bromide 4.21. To a 300 mL round bottom flask charged with a stir bar was added vinyl 
bromide 4.89
12
 (602 mg, 3.6 mmol), powdered mol sieves (3.0 g), silver carbonate (3.0 g, 10.9 
mmol), sugar 4.90 (3.0 g, 7.3 mmol), hexanes (100 mL), and CH2Cl2 (20 mL). The suspension 
was stirred at 23 
o
C for 48 h. After this time, the suspension was filtered through a pad of celite, 
rinsing the filter cake with hexanes. The filtrate was concentrated in vacuo and the resulting 
residue was dry loaded onto celite and purified by reverse phase chromatography on C18 silica 
(H2O:MeCN 90:10  0:100) to afford vinyl bromide 4.21 as a white solid (932 mg, 52%). 
 
TLC (CH2Cl2:EtOAc 2:1) 
Rf =0.47 stained by KMnO4 
 
1
H-NMR (500 MHz, CDCl3) 
δ 7.53 (q, J = 1.5 Hz, 1H), 5.66 (d, J = 8.0 Hz, 1H), 5.20 (t, J = 9.5 Hz, 1H), 5.09 (dd, J = 
10.0, 8.0 Hz, 1H), 5.03 (t, J = 9.5 Hz, 1H), 4.19 (dd, J = 12.5, 4.5 Hz, 1H), 3.99 (dd, J = 
12.5, 1.5 Hz, 1H), 3.82 (m, 1H), 1.96 (s, 3H), 1.92 (s, 3H), 1.91 (s, 6H), 1.88 (s, 3H). 
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13
C-NMR (125 MHz, CDCl3) 
δ 170.1 , 169.6, 169.0, 168.9, 162.4, 132.4, 125.9, 92.1, 72.4, 72.1, 69.8, 67.5, 61.1, 20.4, 
20.3, 20.2, 20.2, 15.3 
 
HRMS (ESI+) 
Calculated for C18H23BrNaO11 (M+H)
+
: 517.0321 
Found:      517.0322 
 
 
Pinacol ester 4.91. Following the general deprotection condition, MIDA boronate 4.20 (763 mg, 
2.5 mmol), NaHCO3 (1.1 g, 12.5 mmol), pinacol (443 mg, 3.8 mmol), and MeOH (13 mL) were 
stirred at 45 
o
C for 3 h. After filtration and concentration, to the residue was added NaHCO3 (1.1 
g, 12.5 mmol), CaCl2 (1.4 g, 12.5 mmol), and toluene (13 mL). After stirring at 23 
o
C for 1 h, 
filtering, and concentrating, pinacol ester 4.91 was obtained as a clear, colorless oil (686 mg, 
99%). Characterization of this compound was consistent with previously reported data.
13
 
 
 
MIDA boronate 4.39. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.91 (545 mg, 2.0 mmol), MIDA boronate 4.6 (530 mg, 1.5 mmol), 2
nd
 generation XPhosPd 
cycle (120 mg, 0.15 mmol), Cs2CO3 (2.0 mg, 6.1 mmol), and DMSO (30 mL) were combined 
and stirred at 35 
o
C for 12 h 30 min, the reaction was worked up using H2O:brine (1:1, 150 mL) 
and EtOAc (150 mL). After drying, filtering, and concentrating, the residue was dry loaded onto 
celite and purified by column chromatography on florisil (Et2O:MeCN 100:0  60:40) to afford 
MIDA boronate 4.39 as a pale yellow solid (370 mg, 66%). 
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TLC (Et2O:MeCN 6:1) 
Rf =0.31 stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.00 (dd, J = 17.0, 11.0 Hz, 1H), 6.24 (d, J = 16.5 Hz, 1H), 6.14 (d, J = 11.0 Hz, 1H), 
6.11 (d, J = 16.5 Hz, 1H), 5.72 (d, J = 17.0 Hz, 1H), 4.21 (d, J = 17.0 Hz, 2H), 4.03 (d, J 
= 17.0 Hz, 2H), 3.00 (s, 3H), 2.02 (m, 2H), 1.95 (s, 3H), 1.70 (s, 3H), 1.61 (m, 2H), 1.48 
(m, 2H), 1.02 (s, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 139.2, 138.5, 137.3, 136.6, 133.0, 129.5, 127.8, 62.2, 47.3, 40.1, 34.5, 33.1, 29.1, 
21.8, 19.8, 12.7 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.1 
 
HRMS (ESI+) 
Calculated for C21H31BNO4 (M+H)
+
:  372.2346 
Found:      372.2346 
 
 
Pinacol ester 4.92. Following the general deprotection condition, MIDA boronate 4.39 (370 mg, 
1.0 mmol), NaHCO3 (420 mg, 5.0 mmol), pinacol (177 mg, 1.5 mmol), and MeOH (5.0 mL) 
were stirred at 45 
o
C for 3 h. After filtration and concentration, to the residue was added 
NaHCO3 (420 mg, 5.0 mmol), CaCl2 (555 mg, 5.0 mmol), and toluene (5.0 mL). After stirring at 
23 
o
C for 1 h, filtering, and concentrating, pinacol ester 4.92 was obtained as a clear, colorless oil 
(341 mg, 99%). 
 
 
338 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 7.38 (dd, J = 17.0, 11.0 Hz, 1H), 6.34 (d, J = 16.0 Hz, 1H), 6.17 (d, J = 11.0 Hz, 1H), 
6.15 (d, J = 16.0 Hz, 1H), 5.53 (d, J = 17.0 Hz, 1H), 2.02 (m, 2H), 2.00 (s, 3H), 1.71 (s, 
3H), 1.66-1.58 (m, 2H), 1.50-1.44 (m, 2H), 1.25 (s, 12H), 1.03 (s, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 146.0, 139.8, 138.4, 138.2, 132.6, 130.1, 129.3, 83.6, 40.2, 34.8, 33.5, 30.5, 29.2, 25.1, 
21.9, 19.8, 12.8 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 30.4 
 
HRMS (ESI+) 
Calculated for C22H36BO2 (M+H)
+
:  343.2808 
Found:      343.2809 
 
 
MIDA boronate 4.40. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.92 (341 mg, 1.0 mmol), MIDA boronate 4.11 (425 mg, 1.1 mmol), 2
nd
 generation 
XPhosPd cycle (78 mg, 0.01 mmol), Cs2CO3 (1.3 mg, 4.0 mmol), and DMSO (20 mL) were 
combined and stirred at 35 
o
C for 16 h, the reaction was worked up using H2O:brine (1:1, 100 
mL) and EtOAc (100 mL). After drying, filtering, and concentrating, the residue was dry loaded 
onto celite and purified by reverse phase column chromatography on C18 silica (H2O:MeCN 
90:10  0:100) to afford MIDA boronate 4.40 as a pale yellow solid (174 mg, 37%). 
 
TLC (Et2O:MeCN 6:1) 
Rf =0.38 stained by KMnO4 
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1
H-NMR (500 MHz, d6-acetone) 
δ 6.76 (dd, J = 15.0, 11.0 Hz, 1H), 6.75-6.70 (m, 2H), 6.57-6.52 (m, 1H), 6.42 (d, J = 
15.0 Hz, 1H), 6.33-6.29 (m, 1H), 6.26-6.15 (m, 3H), 4.24 (d, J = 17.0 Hz, 2H), 4.07 (d, J 
= 17.0 Hz, 2H), 2.99 (s, 3H), 2.04 (m, 2H), 2.01 (s, 3H), 2.00 (s, 3H), 1.84 (s, 3H), 1.72 
(s, 3H), 1.66-1.58 (m, 2H), 1.52-1.45 (m, 2H), 1.04 (s, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 138.8, 138.7, 138.3, 137.7, 137.4, 136.4, 133.1, 132.0, 131.2, 130.4, 129.7, 
127.1, 125.9, 83.6, 62.6, 47.1, 40.4, 34.9, 33.6, 33.5, 29.3, 25.1, 19.9, 12.8, 12.7 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.8 
 
HRMS (ESI+) 
Calculated for C29H41BNO4 (M+H)
+
:  478.3129 
Found:      478.3127 
 
 
Pinacol ester 4.93. Following the general deprotection condition, MIDA boronate 4.40 (174 mg, 
0.4 mmol), NaHCO3 (150 mg, 1.8 mmol), pinacol (63 mg, 0.5 mmol), and MeOH (2.0 mL) were 
stirred at 45 
o
C for 3 h. After filtration and concentration, to the residue was added NaHCO3 (150 
mg, 1.8 mmol), CaCl2 (200 mg, 1.8 mmol), and toluene (2.0 mL). After stirring at 23 
o
C for 1 h, 
filtering, and concentrating, pinacol ester 4.93 was obtained as a clear, colorless oil (160 mg, 
99%). 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.90 (d, J = 11.0 Hz, 1H), 6.85 (d, J = 12.0 Hz, 1H), 6.82 (d, J = 11.0 Hz, 1H), 6.78 (dd, 
J = 15.0, 11.0 Hz, 1H), 6.68 (dd, J = 12.0, 15.0 Hz, 1H), 6.42 (d, J = 15.0 Hz, 1H), 6.31 
(d, J = 12.0 Hz, 1H), 6.22 (dd, J = 17.0, 12.0 Hz, 1H), 6.17 (d, J = 17.0 Hz, 1H), 2.04 (m, 
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2H), 2.03 (s, 3H), 1.99 (s, 3H), 1.81 (s, 3H), 1.71 (s, 3H), 1.66-1.58 (m, 2H), 1.51-1.45 
(m, 2H), 1.25 (s, 12H), 1.04 (s, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 143.5, 138.7, 138.7, 138.6, 138.0, 136.8, 133.2, 132.7, 131.9, 129.7, 129.6, 127.3, 
126.5, 83.8, 40.2, 34.8, 33.5, 29.2, 29.1, 25.1, 21.9, 19.8, 14.6, 12.8, 12.8 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 30.5 
 
HRMS (ESI+) 
Calculated for C30H46BO2 (M+H)
+
:  449.3591 
Found:      449.3591 
 
 
MIDA boronate 4.41. Following the general pinacol ester cross-coupling condition, pinacol 
ester 4.93 (160 mg, 0.4 mmol), MIDA boronate 4.9 (141 mg, 0.4 mmol), 2
nd
 generation XPhosPd 
cycle (28 mg, 0.04 mmol), Cs2CO3 (469 mg, 1.4 mmol), and DMSO (7 mL) were combined and 
stirred at 35 
o
C for 13 h, the reaction was worked up using H2O:brine (1:1, 50 mL) and EtOAc 
(50 mL). After drying, filtering, and concentrating, the residue was dry loaded onto celite and 
purified by reverse phase column chromatography on C18 silica (H2O:MeCN 90:10  0:100) to 
afford MIDA boronate 4.41 as a pale yellow solid (61 mg, 30%). 
 
TLC (Et2O:MeCN 6:1) 
Rf =0.29 stained by KMnO4 
 
1
H-NMR (500 MHz, d6-acetone) 
δ 6.77-6.71 (m, 4H), 6.67 (d, J = 18.0 Hz, 1H), 6.48 (d, J = 15.0 Hz, 1H), 6.41 (d, J = 
16.0 Hz, 1H), 6.36 (d, J = 11.0 Hz, 1H), 6.34 (d, J = 11.0 Hz, 1H), 6.29 (d, J = 11.0 Hz, 
341 
 
1H), 6.25-6.12 (m, 4H), 4.21 (d, J = 17.0 Hz, 2H), 4.04 (d, J = 17.0 Hz, 2H), 3.00 (s, 3H), 
2.03 (m, 2H), 2.00 (s, 3H), 1.99 (s, 6H), 1.95 (s, 3H), 1.71 (s, 3H), 1.66-1.59 (m, 2H), 
1.51-1.45 (m, 2H), 1.03 (s, 6H). 
 
13
C-NMR (125 MHz, d6-acetone) 
δ 169.1, 146.6, 144.1, 141.5, 138.8, 138.7, 137.7, 137.0, 136.6, 134.1, 132.0, 130.7, 
127.3, 127.0, 126.6, 125.9, 125.0, 124.9, 124.5, 120.6, 62.3, 48.0, 40.3, 34.9, 33.6, 31.5, 
29.3, 26.0, 19.9, 12.8, 12.7, 12.7, 12.6 
 
11
B-NMR (128 MHz, d6-acetone) 
δ 11.5 
 
HRMS (ESI+) 
Calculated for C36H49BNO4 (M+H)
+
:  570.3755 
Found:      570.3752 
 
 
Neurosporaxanthin β-D-glucopyranoside tetraacetate 4.42. Following the general MIDA 
boronate cross-coupling reaction condition, MIDA boronate 4.41 (15.0 mg, 0.026 mmol), vinyl 
bromide 4.21 (19.6 mg, 0.040 mmol), 2
nd
 generation XPhosPd cycle (2.1 mg, 0.003 mmol), 
NaOH (7.9 mg, 0.20 mmol), THF (0.5 mL), and degassed H2O (0.1 mL) were combined and 
stirred at 23 
o
C for 1 h 15 min. The reaction was worked up using Et2O (2.0 mL) and H2O (2.0 
mL) and the aqueous layer was extracted with Et2O (2 x 2.0 mL). After drying, filtering, and 
concentrating, the residue was dry loaded onto celite and purified by column chromatography on 
silica (hexanes:EtOAc 100:0  90:10  60:40) to afford Neurosporaxanthin β-D-
glucopyranoside tetraacetate 4.42 as an orange solid (12.8 mg, 59%). 
 
TLC (hexanes:EtOAc 3:2) 
Rf =0.47 stained by KMnO4 
 
342 
 
1
H-NMR (500 MHz, CDCl3) 
δ 7.33 (d, J = 11.0 Hz, 1H), 6.68 (dd, J = 15.0, 11.0 Hz, 1H), 6.68-6.65 (m, 3H), 6.62 (dd, 
J = 15.0, 11.0 Hz, 1H), 6.48 (dd, J = 15.0, 11.0 Hz, 1H), 6.48 (d, J = 15.0 Hz, 1H), 6.40 
(d, J = 11.0 Hz, 1H), 6.35 (d, J = 15.0 Hz, 1H), 6.33 (d, J = 11.0 Hz, 1H), 6.26 (d, J = 
11.0 Hz, 1H), 6.18 (d, J = 16.0 Hz, 1H), 6.16 (d, J = 11.0 Hz, 1H), 6.13 (d, J = 16.0 Hz, 
1H), 5.78 (d, J = 8.0 Hz, 1H), 5.30 (t, J = 9.0 Hz, 1H), 5.27 (dd, J = 9.5, 8.0 Hz, 1H), 
5.17 (t, J = 9.5 Hz, 1H), 4.32 (m, 1H), 4.13 (m, 1H), 3.89 (ddd, J = 9.5, 4.5, 2.5, 1H), 
2.09 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.03 (s, 3H), 2.02 (m, 2H), 2.01 (s, 3H), 1.99 (s, 
6H), 1.98 (s, 6H), 1.72 (s, 3H), 1.61 (m, 2H), 1.47 (m, 2H), 1.03 (s, 6H).
 
 
1
H-NMR for Neurosporaxanthin β-D-glucopyranoside tetraacetate 4.42 
Literature reference
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(500 MHz, CDCl3) 
Synthetic material 4.42 
(500 MHz, CDCl3) 
7.35 7.33 
6.69 6.68-6.65 
6.68 6.68-6.65 
6.68 6.68 
6.67 6.68-6.65 
6.63 6.62 
6.48 6.48 
6.48 6.48 
6.40 6.40 
6.36 6.35 
6.34 6.33 
6.26 6.26 
6.19 6.18 
6.16 6.16 
6.13 6.13 
5.78 5.78 
5.30 5.30 
5.26 5.27 
5.17 5.17 
4.32 4.32 
4.12 4.13 
3.89 3.89 
2.10-2.01 2.10-2.01 
2.02 2.03 
2.02 2.02 
1.99 1.99 
1.99 1.99 
343 
 
1.98 1.98 
1.98 1.98 
1.72 1.72 
1.61 1.61 
1.47 1.47 
1.03 1.03 
1.03 1.03 
 
HRMS (ESI+) 
Calculated for C49H64NaO11 (M+H)
+
:  851.4346 
Found:      851.4343 
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